<SEC-DOCUMENT>0001564590-21-026559.txt : 20210511
<SEC-HEADER>0001564590-21-026559.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210511161706
ACCESSION NUMBER:		0001564590-21-026559
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Taysha Gene Therapies, Inc.
		CENTRAL INDEX KEY:			0001806310
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				843199512
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39536
		FILM NUMBER:		21911528

	BUSINESS ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1430
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
		BUSINESS PHONE:		(214) 612-0000

	MAIL ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1430
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tsha-10q_20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
tsha-10q_20210331.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended March 31, 2021</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from ___________ to ___________</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: 001-39536</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">84-3199512</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">( State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3000 Pegasus Park Drive Ste 1430</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dallas, Texas </p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">75247</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (214) 612-0000</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, par value&#160;$0.00001 per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TSHA</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;&#160;</font>&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;&#160;</font>&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;&#160;</font>&#160;&#160;&#160;No&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of May 11, 2021, the registrant had 37,917,473  shares of common stock, $0.00001 par value per share, outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IFINANCIAL_INFORMATION"><font style="text-decoration:underline;">FINANCIAL INFORMATION</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Condensed Consolidated Financial Statements (Unaudited)</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;"> Balance Sheets</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"><font style="text-decoration:underline;"> Statements of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CONVER"><font style="text-decoration:underline;"> Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"><font style="text-decoration:underline;"> Statements of Cash Flows</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"><font style="text-decoration:underline;">Notes to Financial Statements</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IIOR_INFORMATION"><font style="text-decoration:underline;">OTHER INFORMATION</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><font style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><font style="text-decoration:underline;">Defaults Upon Senior Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><font style="text-decoration:underline;">Exhibits</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><a name="PART_IFINANCIAL_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IFINANCIAL_INFORMATION"></a>PART I&#8212;FINANCI</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AL INFORMATION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1. Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONDENSED_CONSOLIDATED_BALANCE_SHEETS"></a>Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399967"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,817</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,626</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239,629</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,879</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred lease asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">242,829</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">258,881</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,083</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,958</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,129</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,957</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies - Note 10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2021 and December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.00001 par value per share; 200,000,000 shares authorized and 37,761,435 issued and outstanding as of March 31, 2021 and December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316,022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">312,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,150</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,126</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,872</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">242,829</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">258,881</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"></a><a name="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"></a>Condensed Consolidated Statements of Operations </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399968"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,854</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,514</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,090</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.87</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,992,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,894,999</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CONVER"></a>Condensed Consolidated Statements<a name="CONDENSED_CONSOLIDATED_STATEMENTS_CONVER"></a> of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share data) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54374284"></a>For the Three Months Ended March 31, 2021</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399969"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">37,761,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">312,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(61,126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">251,302</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">37,761,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">316,022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(93,150</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">222,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share data) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399970"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,894,999</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A convertible preferred stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of offering costs of $430 and issuance of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock tranche liability of $1,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10,894,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6,546</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5,566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a><a name="CONDENSED_CONSOLIDATED_STATEMENTS_CASH_F"></a>Condensed Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development license expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,184</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">907</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,035</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,699</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property, plant and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(534</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuances of Series A convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from note payable to related party</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of note payable to related party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,646</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,027</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash at the beginning of the period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">251,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash at the end of the period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">228,684</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of research and development license not yet paid</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment in accounts payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of property, plant and equipment funded by landlord</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs not yet paid</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of preferred stock tranche liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A issuance costs not yet paid</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><a name="NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"></a>Note 1&#8212;Organization and Descr</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">iption of Business Operations </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc. (the &#8220;Company&#8221; or &#8220;Taysha&#8221;) was originally formed under the laws of the State of Texas on September 20, 2019 (&#8220;Inception&#8221;). Taysha converted to a Delaware corporation on February 13, 2020, which had no impact to the Company&#8217;s par value or issued and authorized capital structure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taysha is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Split </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2020, the Company effected a 1.0895-for-one stock split of its authorized, issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s convertible preferred stock as discussed in Note 5. Accordingly, all share and per share amounts for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the convertible preferred stock conversion ratios. On September 16, 2020, the Company also increased the number of shares of common stock authorized for issuance under the 2020 Equity Incentive Plan (the &#8220;Existing Plan&#8221;) to 3,845,294. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54613033"></a>On September 23, 2020, the Company&#8217;s registration statement on Form S-1 (File No. 333-248559) related to the initial public offering (&#8220;IPO&#8221;) of its common stock became effective and on September 28, 2020, the IPO closed. Pursuant to the IPO, the Company issued and sold 9,050,000 shares of common stock at a public offering price of $20.00 per share, which included 1,180,434 shares of common stock issued upon the exercise in full of the underwriters&#8217; option to purchase additional shares<a name="_Hlk54613033"></a>. The Company received net proceeds of $165.9 million after <font style="color:#000000;">deducting underwriting discounts and commissions and other offering costs of $2.5&#160;million. The shares began trading on the Nasdaq Global Select Market on September 24, 2020.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54375096"></a>On September 28, 2020, in connection with the closing of the IPO, 10,000,000 shares of Series A and 5,647,048 shares of Series B convertible preferred stock automatically converted into an aggregate of 17,047,378 shares of common stock with a conversion ratio of 1.0895 shares of common stock for each share of Series A and Series B convertible preferred stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the IPO, including the underwriters&#8217; exercise in full of their option to purchase additional shares, and the conversions of the Series A and B convertible preferred stock, the Company&#8217;s total number of outstanding shares increased by 26,097,378 immediately following the closing of the IPO.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the effectiveness of the Company&#8217;s registration statement related to the IPO, the Company&#8217;s 2020 Stock Incentive Plan (the &#8220;New Plan&#8221;) and 2020 Employee Stock Purchase Plan became effective. At that time, all shares reserved for issuance under the Existing Plan ceased to be available for issuance under such plan and became available for issuance under the New Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2021, the Company had an accumulated deficit of $93.2 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of the Company&#8217;s IPO, between March and July 2020, the Company closed on the sale of an aggregate of 10,000,000 shares of Series A convertible preferred stock for gross proceeds of $30.0 million. Between July and August 2020, the Company closed on the sale of an aggregate of 5,647,048 shares of Series B convertible preferred stock for gross proceeds of $96.0 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future capital requirements will depend on many factors, including the timing and extent of spending on research and development and the market acceptance of the Company&#8217;s products. The Company will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable to the Company.<font style="color:#000000;"> As of March 31, 2021, the Company had cash of</font> $228.7 <font style="color:#000000;">million which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">novel</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> coronavirus </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">global </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandemic</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> resulting in federal, state and local governments and private entities implementing various restrictions, includ</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing travel restrictions, restrictions on public gatherings, stay at home orders, and advisories and quarantining people who may have been exposed to the virus. The Company has been actively monitoring COVID</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> its impact globally. Management believes t</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he financial results for the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> months ended </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were not significantly impacted by COVID-19. In addition, management believes the remote working arrangements and travel restrictions imposed by various governmental jurisdictions have had limi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ted impact on the Company&#8217;s ability to maintain internal operations during the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> months ended </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31, 2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2&#8212;Summary of Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X and are consistent in all material respects with those included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission ("SEC") on March 3, 2021 (the &#8220;2020 Annual Report&#8221;). In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The consolidated balance sheet as of December 31, 2020 is derived from audited financial statements, however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes in the Company&#8217;s 2020 Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated financial statements include the accounts of Taysha and its inactive wholly owned U.S. subsidiaries that were incorporated during 2020. All intercompany transactions and balances have been eliminated in consolidation. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company&#8217;s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company&#8217;s critical and significant accounting estimates, including assessment of impairment of long-lived assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in the Company&#8217;s significant accounting policies as disclosed in Note 2 to the audited consolidated financial statements included in the 2020 Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as amended, with guidance regarding the accounting for and disclosure of leases. This update requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheets. This update also requires lessees and lessors to disclose </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">key information about their leasing transactions. This guidance will become effective for the Company for annual reporting periods beginning after December 15, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 and interim periods within fiscal years beginning after December 15, 2022. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new standard requires the use of one of the following two approaches, either (1) retrospectively to each prior reporting period presented in the financial statements with t</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he cumulative effect recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company has not yet concluded which approach will b</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e utilized to adopt the new standard</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and is currently evaluating the impact of this standard on its consolidated financial statements</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3&#8212;Balance Sheet Components </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk71527842"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,462</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical trial</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">331</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,817</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,626</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment consisted of the following (in thousands):<font style="margin-left:36pt;"></font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399973"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,889</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $32,000 for the three months ended March 31, 2021. There was no depreciation expense for the three months ended March 31, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399974"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,672</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued license fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,766</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4&#8212;Research, Collaboration and License Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">UT Southwestern Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>On November 19, 2019, the Company entered into a research, collaboration and license agreement (&#8220;UT Southwestern Agreement&#8221;) with the Board of Regents of the University of Texas System on behalf of The University of Texas Southwestern </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Center (&#8220;UT Southwestern&#8221;). Under the UT Southw</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estern Agreement, UT Southwestern is primarily responsible for preclinical development activities with respect to licensed products for use in certain specified indications (up to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigational new drug application</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-enabling studies), and the Company is r</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">esponsible for all subsequent clinical development and commercialization activities with respect to the licensed products. UT Southwestern will conduct such preclinical activities for a two-year period under mutually agreed upon sponsored research agreemen</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts that were entered into beginning in April 2020. During the initial research phase, the Company has the right to expand the scope of specified indications under the UT Southwestern Agreement. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the UT Southwestern Agreement, the Company obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern and a non-exclusive, worldwide, royalty-free license under certain know-how of UT Southwestern, in each case to make, have made, use, sell, offer for sale and import licensed products for use in certain specified indications. Additionally, the Company obtained a non-exclusive, worldwide, royalty-free license under certain patents and know-how of UT Southwestern for use in all human uses, with a right of first refusal to obtain an exclusive license under certain of such patent rights and an option to negotiate an exclusive license under other of such patent rights. The Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2020, the Company amended the UT Southwestern Agreement to include the addition of another licensed product and certain indications, and a right of first refusal to the Company over certain patient dosing patents. No additional consideration was transferred in connection with this amendment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UT Southwestern Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last valid claim of a licensed patent in such country for such licensed product. After the initial research term, the Company may terminate the agreement, on an indication-by-indication and licensed product-by-licensed product basis, at any time upon specified written notice to UT Southwestern. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, as partial consideration for the license rights granted under the UT Southwestern Agreement, the Company issued 2,179,000 shares of its common stock, or 20% of its then outstanding fully-diluted common stock, to UT Southwestern. As additional consideration, UT Southwestern was entitled to receive additional shares if their holdings fell below 10% on a fully-diluted basis before or as a result of the completion of a qualified financing. In March 2020, following the initial closing of the Series A convertible preferred stock agreement, which met the definition of such qualified financing, the anti-dilution feature expired and no additional shares were issued. The Company does not have any future milestone or royalty obligations to UT Southwestern under the UT Southwestern Agreement other than costs related to maintenance of patents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Queen&#8217;s Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2019, the Company entered into a research grant agreement (&#8220;RGA&#8221;) with Queen&#8217;s University at Kingston (&#8220;Queen&#8217;s&#8221;), for certain research and development activities related to the generation of AAV9 vector. The Company committed to fund $3.8 million under the RGA with Queen&#8217;s. The Company issued Queen&#8217;s a promise-to-pay note whereby any amounts paid directly by Queen&#8217;s for the manufacture of the vector for use in the funded research activities, to the extent such amounts had not already been funded by the Company to Queen&#8217;s, would become a loan obligation for the Company (the &#8220;Note&#8221;), subject to an interest rate of 6%. Any amounts outstanding under the Note were required to be repaid, along with any accrued interest, by or before June 30, 2020. In the event of default, any amount outstanding was deemed immediately payable by RA Session II, the Company&#8217;s President and Chief Executive Officer, as a personal guarantor (see Note 8). For the period from Inception through December 31, 2019, the Company did not incur any expenses associated with the Queen&#8217;s RGA, and no amounts were due or outstanding under the Note as of December 31, 2019. <font style="color:#000000;">For the year ended December 31, 2020, the Company paid all expenses associated with the Queen&#8217;s RGA, thus no amounts were due or outstanding under the Note as of December 31, 2020, and the promise-to-pay has therefore expired.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>On February 21, 2020, the Company entered into a license agreement with Queen&#8217;s (the &#8220;Queen&#8217;s Agreement&#8221;) to obtain the exclusive perpetual, royalty-bearing license, with the right to sublicense through multiple tiers, under certain patent rights and know-how of Queen&#8217;s, including certain improvements to such patent rights and know-how, to develop products in any field which use one or more valid claims of the patents licensed under the Queen&#8217;s Agreement (the &#8220;Licensed Patents&#8221;), or the technology, information and intellectual property related to the patents licensed under the Queen&#8217;s Agreement (together with the Licensed Patents, the &#8220;Licensed Products&#8221;), and to make, have made, use, sell, offer for sale, import and export Licensed Products and otherwise exploit such patents and know-how for use in certain specified indications. In exchange for the rights granted to the Company, the Company made a cash payment of $3.0 million in April 2020 which is recorded in research and development expenses in the condensed consolidated statements of operations for the three months ended March 31, 2020. The Company is obligated to make aggregate cash payments of up to $10.0 million upon the completion of a combination of regulatory milestones and up to $10.0 million upon the completion of a combination of commercial milestones. In further consideration of the rights granted, beginning with the Company&#8217;s first commercial sale of the Licensed Products, the Company will also pay an annual earned royalty in the low single digits on net </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales of Licensed Products, subject to certain customary reductio</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ns, and a percentage of non-royalty sublicensing revenue ranging in the low double digits. Royalties are payable, on a Licensed Products-by-Licensed Products and a country-by-country basis, until expiration of the last valid claim of a Licensed Patent cove</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ring such Licensed Products in such country and the expiration of any regulatory exclusivity for such Licensed Products in such country. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abeona CLN1 Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into license and inventory purchase agreements with Abeona Therapeutics Inc. (&#8220;Abeona&#8221;) for worldwide exclusive rights to certain intellectual property rights and know-how relating to the research, development and manufacture of ABO-202, an AAV-based gene therapy for CLN1 disease (also known as infantile Batten disease). Under the terms of the agreements, the Company made initial cash payments to Abeona of $3.0 million for the license fee and $4.0 million for purchase of clinical materials and reimbursement for previously incurred development costs in October 2020. In exchange for the license rights, the Company recorded an aggregate of $7.0 million within research and development expenses in the consolidated statements of operations for the year ended December 31, 2020 since the acquired license or acquired inventory do not have an alternative future use. The Company is obligated to make up to $26.0 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed CLN1 product. The Company will also pay an annual earned royalty in the high single digits on net sales of any licensed CLN1 products. The license agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. The Company may terminate the license agreement for convenience upon specified prior written notice to Abeona.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No additional milestone payments were made in connection with this agreement during the three months ended March 31, 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abeona Rett Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 29, 2020, the Company entered into a license agreement (the &#8220;Abeona Rett Agreement&#8221;) with Abeona pursuant to which the Company obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain obligations of Abeona, the Company is required to use commercially reasonable efforts to develop at least one licensed product and commercialize at least one licensed product in the United States.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Abeona Rett Agreement, the Company paid Abeona a one-time upfront license fee of $3.0 million which is recorded in research and development expenses in the consolidated statements of operations for the year ended December 31, 2020 since the acquired license does not have an alternative future use. The Company is obligated to pay Abeona up to $26.5 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed Rett product and high single-digit royalties on net sales of licensed Rett products. Royalties are payable on a licensed product-by-licensed product and country-by-country basis until the latest of the expiration or revocation or complete rejection of the last licensed patent covering such licensed product in the country where the licensed product is sold, the loss of market exclusivity in such country where the product is sold, or, if no licensed product exists in such country and no market exclusivity exists in such country, ten years from first commercial sale of such licensed product in such country.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Abeona Rett Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. The Company may terminate the agreement for convenience upon specified prior written notice to Abeona.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No additional milestone payments were made in connection with the Abeona Rett Agreement during the three months ended March 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Acquisition of Worldwide Rights for TSHA-120 for the treatment of GAN </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>In March 2021, the Company acquired the exclusive worldwide rights to a clinical-stage AAV9 gene therapy program, now known as TSHA-120, for the treatment of Giant Axonal Neuropathy (&#8220;GAN&#8221;). TSHA-120 is an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health in close collaboration with a leading patient advocacy group focused on finding treatments and cures for GAN. TSHA-120 has received rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration for the treatment of GAN. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The worldwide rights was acquired through </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">icense </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> effective March 29, 2021</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> between Hannah&#8217;s Hope Fund for Giant Axonal Neuropathy, Inc. (&#8220;HHF&#8221;).</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, in exchange for granting the Company the exclusive worldwide rights to TSHA-120, HHF will receive an upfront payment of $5.5 million and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3 million, as well as a low, single-digit royalty on net sales upon commercialization of the product. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the license rights, the Company recorded an aggregate of $5.5 million within research and development expenses in the condensed consolidated statements of operations since the acquired license does not have an alternative future use. This license fee was not paid as of March 31, 2021 and has been recorded in accrued expenses and other current liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5&#8212;Stockholders&#8217; Equity (Deficit), Convertible Preferred Stock and Tranche Liability </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Authorized Shares</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company amended its certificate of incorporation on March 4, 2020, July 2, 2020 and again on July 28, 2020 such that the total number of shares of common stock authorized to be issued was increased to 32,685,000, and the total number of shares of preferred stock authorized to be issued was increased to 15,647,052, of which 10,000,000 preferred shares were designated Series A convertible preferred stock and 5,647,052 were designated Series B convertible preferred stock. On September 28, 2020, the Company amended its certificate of incorporation such that the total number of shares of common stock authorized to be issued was increased to 200,000,000, and the total number of shares of new preferred stock authorized to be issued was 10,000,000. As of March 31, 2021 and December 31, 2020, no shares of preferred stock were issued or outstanding.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IPO</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2020, the Company issued an aggregate of 7,869,566 shares of common stock in the IPO, and on September 29, 2020, the Company issued an aggregate of 1,180,434 shares of common stock upon the underwriters&#8217; exercise in full of their option to purchase additional shares, each at the public offering price of $20.00 per share less underwriting discounts and commissions. In connection with the IPO, the Company received gross proceeds of $181.0 million, which was offset by issuance costs, including underwriters&#8217; discounts and commissions, of approximately $15.1 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series A and B convertible preferred stock</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2020, the Company entered into a purchase agreement (the &#8220;Series A Purchase Agreement&#8221;) providing for a private placement of up to 10,000,000 shares of Series A convertible preferred stock at an original issuance price of $3.00 per share, subject to separate closings, including: (1) 6,000,000 shares at the initial closing on March 4, 2020, and (2) 2,000,000 shares at each of two subsequent closings triggered by the achievement of specific clinical milestones. The Series A Purchase Agreement obligated the Company to issue and sell and the Series A investors to purchase up to a total of 4,000,000 additional shares of Series A convertible preferred stock (the &#8220;Milestone Shares&#8221;) at the same price per share upon the achievement of certain defined clinical milestones (the &#8220;tranche liability&#8221;). The determination as to whether the milestone events had been met was subject to certification by the Board of Directors. Each Series A investor had the right, but not the obligation, to purchase all or any portion of the Milestone Shares at any time in its sole option and in its sole and absolute discretion, whether or not the Company had achieved the applicable clinical milestone.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2020, several affiliated Series A investors elected to exercise in full their options to purchase 200,000 shares, representing all of their remaining pro-rata portion of the Milestone Shares, prior to the Company&#8217;s achievement of the clinical milestones for gross proceeds of $0.6 million. The remainder of the Series A investors exercised in full their options to purchase 3,800,000 shares, representing all of their remaining pro-rata portion of the Milestone Shares, prior to the Company&#8217;s achievement of the clinical milestones, for gross proceeds of $11.4 million between July 1, 2020 and July 2, 2020. As part of this issuance, the Company issued and sold 3,266,667 shares to PBM TGT Holdings, LLC and 400,000 shares to Nolan Capital, LLC, which stockholders are controlled by certain members of the Company&#8217;s board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>On July 2, 2020, the Company entered into a purchase agreement (the &#8220;Series B Purchase Agreement&#8221;), as later amended on July 28, 2020, providing for a private placement of up to 5,647,052 shares of Series B convertible preferred stock. The Company sold </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,647</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,048 shares of Series B convertible preferred stock at a price of $17.00 per share in multiple closings in July and August 2020 for gross proceeds of $96.0 million. The majority of investors that participated in the Series B Purchase Agreement were new inv</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estors.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described above, in connection with the closing of the IPO, all shares of Series A and Series B convertible preferred stock were automatically converted into an aggregate of 17,047,378 shares of common stock with a conversion ratio, which was adjusted for the stock split, of 1.0895 shares of common stock for each share of Series A and Series B convertible preferred stock then outstanding.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock tranche liability</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that the tranche liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable from the initial closing of the Series A convertible preferred stock. The estimated fair value of the tranche liability was determined using a Monte Carlo simulation at the initial issuance date. As of March 4, 2020, the simulations occurred based on the implied aggregate equity value of the Company derived from the Series A convertible preferred stock offering price of $3.00 per share, along with, in part, the following subjective assumptions: risk-free rate of 0.59%, an expected volatility of 80%, the expected term to a liquidity event of 1 year, and a 60% probability of achieving the clinical milestones and timing thereof. Subsequently, the estimated fair value of the tranche liability was determined using a backsolve approach at June 30, 2020, immediately prior to the issuance of the Milestone Shares, which was calculated based on the aggregate equity value of the Company derived from the Series B convertible preferred stock offering price of $17.00 per share. The subsequent remeasurement also considered, in part, a risk-free rate of 0.17%, an expected volatility of 80%, and the expected term to a liquidity event of 0.5 years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the analysis, the Company recorded a preferred stock tranche liability of $1.1 million at the issue date to account for the obligation to issue the Milestone Shares at a predetermined fixed price at a future settlement date. The Company remeasured the tranche liability at March 31, 2020, resulting in a gain of $0.2 million that was recorded in other income, net in the condensed consolidated statements of operations. The tranche liability was again later remeasured to fair value and reclassified to convertible preferred stock when the remaining Milestone Shares were sold to the investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6&#8212;Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2020, the Company&#8217;s board of directors approved the Existing Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, RSAs, RSUs and other stock-based awards to employees, directors, officers and consultants. On July 1, 2020, 3,529,412 shares of common stock were authorized for issuance under the Existing Plan. On September 16, 2020, the Company increased the number of shares of common stock authorized for issuance under the Existing Plan to 3,845,294. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55279911"></a>On September 16, 2020, the Company&#8217;s stockholders approved the New Plan, which became effective upon the execution of the underwriting agreement in connection with the IPO. The number of shares available for future issuance under the New Plan is the sum of (1) 3,390,168 new shares of common stock,&nbsp;&nbsp;(2) 209,841 remaining shares of common stock reserved under the Existing Plan that became available for issuance upon the effectiveness of the New Plan and (3) the number of shares of common stock subject to outstanding awards under the Existing Plan when the New Plan became effective that thereafter expire or are forfeited, canceled, withheld to satisfy tax withholding or to purchase or exercise an award, repurchased by the Company or are otherwise terminated. At December 31, 2020, there were 2,941,509 shares available for future grant under the New Plan. The number of shares of common stock reserved for issuance under the New Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2021 continuing through January 1, 2030, by 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors.&nbsp;&nbsp;On January 1, 2021 the board of directors increased the number of common stock reserved for issuance under the New Plan by 1,434,934 shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, on September 16, 2020, the Company&#8217;s stockholders approved the Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective upon the execution of the underwriting agreement in connection with the IPO. The maximum number of shares of common stock that may be issued under the ESPP will not exceed 362,000 shares of common stock, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the IPO Date and ending on (and including) January 1, 2030, in an amount equal to the lesser of (i) one percent (1.0%) of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year, and (ii) 724,000 shares of common stock. No shares have been added to the ESPP as of January 1, 2021 and no issuances have been made under the ESPP as of March 31, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Options </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2020, options to purchase 2,896,782 shares of common stock under the Existing Plan were awarded to certain employees and consultants of the Company with an exercise price per share of $0.80, which were expected to vest over a four-year period, all of which were subsequently cancelled (the &#8220;Cancelled Options&#8221;). The grant date fair value of the Cancelled Options was $13.8 million at the original grant date. In exchange, the Company awarded 2,518,932 RSUs on September 2, 2020, which are expected to vest over a four-year term. The Company accounted for the changes in award terms as a modification in accordance with ASC 718 Compensation &#8211; Stock Compensation. The modification was accounted for as an exchange of the original award for a new award with total compensation cost equal to the grant-date fair value of the original award plus any incremental value measured on the modification date. The Company determined that there was no incremental value as the fair value of the original award immediately before the modification was greater than the fair value of the new award immediately after the modification. Accordingly, the Company continues to recognize the remaining compensation cost of the Cancelled Options over the vesting period of the RSUs.&nbsp;&nbsp; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, 1,621,900 shares of common stock under the New Plan were awarded with a weighted-average grant date fair value per share of $18.75. The stock options vest over four years and have a ten-year contractual term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The following weighted-average assumptions were used to estimate the fair value of stock options that were granted during the three months ended March&#160;31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399975"></a>Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity, during the three months ended March&#160;31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399976"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,842</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.68</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,953</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.81</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled or forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,552</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value in the above table is calculated as the difference between the fair value of the Company&#8217;s common stock as of March&#160;31, 2021 and the exercise price of the stock options. As of March&#160;31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $37.0&#160;million, which the Company expects to recognize over a weighted-average period of approximately 3.7 years.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">R</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">estricted </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">S</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tock </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">nit</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 2, 2020, the Company issued 331,121 RSUs to an employee under the Existing Plan; 25% of the shares of common stock underlying the RSUs vest at each anniversary over a four-year period. The RSUs are subject to a service-based vesting condition. The RSUs were also subject to a liquidity-based performance vesting condition that was met upon the closing of the IPO. The Company at any time may accelerate the vesting of the RSUs. Such shares are not accounted for as outstanding until they vest.<font style="color:#000000;"> As of March 31, 2021, the total unrecognized compensation related to unvested RSUs granted, including the remaining compensation cost associated with the RSUs granted on September 2, 2020 in exchange for the Cancelled Options, was $15.4 million which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 1.7 years. The Company&#8217;s RSU activity for the three months ended March&#160;31, 2021 was as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399977"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at January 1, 2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted units granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Awards</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Session II, the Company&#8217;s President and Chief Executive Officer, was awarded 769,058 RSAs under the Existing Plan on July 1, 2020, which are expected to vest over a three-year term, subject to continuous employment. As of March 31, 2021, the total unrecognized compensation related to unvested RSAs granted was $3.0 million which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 2.0 years. The fair value of these RSAs at the grant date of July 1, 2020 was $5.28 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s RSA activity for the three months ended March&#160;31, 2021 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399978"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the total stock-based compensation expense for the stock options, RSAs and RSUs recorded in the condensed consolidated statements of operations for the three months ended March&#160;31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399979"></a>Research and development expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7&#8212;Net Loss Per Common Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Since the Company had a net loss in all periods presented, basic and diluted net loss per common share are the same. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represent</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s the calculation of basic and diluted net loss per common share (in thousands, except share and per share data):</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399980"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding used to compute net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,992,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,894,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following common stock equivalents outstanding as of March 31, 2021 and 2020 were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti&#8209;dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk71521167"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSAs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,905,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8&#8212;Related Party Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Session II, President and Chief Executive Officer and a member of the Company&#8217;s board of directors, was a guarantor under the Guaranty and Security Agreement between himself, Queen&#8217;s and the Company, and in the event of the Company&#8217;s failure to fund its obligations under the RGA with Queen&#8217;s, had personally guaranteed payments due by the Company to Queen&#8217;s. In addition, the Company entered into two secured promissory notes with Mr. Session in January 2020 for an aggregate of $1.67 million, with 10% interest. The Company secured the notes with a first priority security interest in certain assets of the Company. During March 2020, the Company repaid $1.65&#160;million of the notes, and the remaining balance was repaid in July 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company entered into a services agreement with PBM Capital Group, LLC (&#8220;PBM&#8221;), an affiliate of PBM TGT Holdings, LLC whereby PBM provides accounting and other administrative and management services related to payroll administration, human resources, bookkeeping, preparation of financial statements and tax returns, accounts payable and receivable, and other similar functions for a fee of $2,500 per month. Paul B. Manning, a member of the Company&#8217;s board of directors and a holder of more than 5% of the Company&#8217;s capital stock, is the Chief Executive Officer of PBM Capital Group, LLC and has sole voting and investment power with respect to the shares held by PBM TGT Holdings, LLC. In September 2020, PBM TGT Holdings, LLC distributed all of the shares of Series A convertible preferred stock it previously held to its beneficial owners, including Mr. Manning and entities controlled by Mr. Manning, for no additional consideration in accordance with the terms of its operating agreement. As of March 31, 2021, and December 31, 2020, the Company had recorded an immaterial amount due to PBM in the consolidated balance sheets.&nbsp;&nbsp; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9&#8212;Income Taxes </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. There is no provision for income taxes because the Company has incurred operating losses and capitalized certain items for income tax purposes since its inception and maintains a full valuation allowance against its net deferred tax assets. The </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reported amount of income tax expense for the period differs from the amount that would result from applying the fede</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ral statutory tax rate to net loss before taxes primarily because of the change in valuation allowance.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, there were no material changes to either the nature or the amounts of the uncertain tax positions previously determined for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10&#8212;Commitments and Contingencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commitments </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. The Company&#8217;s maximum exposure under these arrangements is unknown at March 31, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Durham Lease</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2020, the Company entered into a lease agreement (the &#8220;Durham Lease&#8221;) with Patriot Park Partners II, LLC, a Delaware limited liability company (the &#8220;Durham Landlord&#8221;), pursuant to which the Company agreed to lease approximately 187,500 square feet of a manufacturing facility located at 5 National Way, Durham, North Carolina (the &#8220;Facility&#8221;). The Durham Lease commenced on April 1, 2021 and is expected to have a term of approximately fifteen years and six months. The Company has two options to extend the term of the Durham Lease, each for a period of an additional five years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was not required to provide a security deposit in connection with its entry into the Durham Lease. The Company will be responsible for constructing interior improvements within the Facility. The Durham Landlord has the right to terminate the Durham Lease upon specified events of default, including the Company&#8217;s failure to pay rent in a timely manner and upon the occurrence of certain events of insolvency with respect to the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the Durham Lease if construction of the base building shell of the Facility is not complete by May 16, 2021. The Company incurred initial direct costs to enter into the Durham Lease of approximately $0.8 million. The costs have been recorded on the consolidated balance sheets as a deferred lease asset and will be amortized into earnings over the term of the Durham Lease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dallas Lease</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 11, 2021, the Company entered into a lease agreement (the &#8220;Dallas Lease&#8221;) with Pegasus Park, LLC, a Delaware limited liability company (the &#8220;Dallas Landlord&#8221;), pursuant to which the Company will lease approximately 15,000 square feet of office space at 3000 Pegasus Park Drive, Dallas, Texas 75247 (the &#8220;Office Space&#8221;).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70330750"></a><a name="_Hlk70330731"></a>The Lease commences on the date on which certain improvements to the Office Space have been made and the Office Space is tendered to the Company for possession, which the Company and the Dallas Landlord presently anticipate to be delivered on or about May 15, 2021, and will have a term of approximately ten years. The Company has an option to extend the term of the Lease for one additional period of five years. The Company&#8217;s obligation for the payment of base rent for the Office Space will initially be approximately $32,500 per month and will increase annually, up to an estimated monthly base rent of $50,000 during the term of the Lease. The Company is obligated<a name="_Hlk70330750"></a><a name="_Hlk70330731"></a> to pay operating costs and utilities applicable to the Office Space. The Company was required to provide a security deposit of $32,500 in connection with its entry into the Lease. <font style="color:#000000;">Total future minimum lease payments under the Dallas Lease over the initial 10 year term are approximately $4.9 million. </font>The Company will be responsible for costs of constructing interior improvements within the Office Space that exceed a construction allowance provided by the Dallas Landlord not to exceed $40.00 per rentable square foot.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a right of first refusal with respect to certain additional adjacent office space before the Dallas Landlord accepts any offer for such space.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Landlord has the right to terminate the Lease, or the Company&#8217;s right to possess th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Office Space without terminating the Lease, upon specified events of default, including the Company&#8217;s failure to pay rent in a timely manner and upon the occurrence of certain events of insolvency with respect to the Company. The Company may terminate th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Lease if the Office Space is not delivered will all improvements to be made by the Landlord pursuant to the Lease substantially completed by May 31, 2021.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the Company recognized approximately $0.6 million of lease construction incentive based on the construction allowance provided. The construction incentive has been recorded on the consolidated balance sheets as a deferred lease incentive obligation and will be amortized into earnings as a deduction of rent expense over the term of the Dallas Lease.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 2. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations.</font><font style="text-transform:uppercase;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December&#160;31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2020, or Annual Report, filed with the Securities and Exchange Commission, or the SEC, on March 3, 2021. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Taysha Gene Therapies, Inc. together with its consolidated subsidiaries.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note Regarding Trademarks</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise, references in this report to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Taysha Gene Therapies, Inc.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70325986"></a>We are a patient-centric gene therapy company focused on developing and commercializing&#160;AAV-based&#160;gene therapies for the treatment of monogenic diseases of the central nervous system, or CNS, in both rare and large patient populations. We were founded in partnership with The University of Texas Southwestern Medical Center, or UT Southwestern, to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we are advancing a deep and sustainable product portfolio of 26 gene therapy product candidates, with exclusive options to acquire four additional development programs at no cost. By combining our management team&#8217;s proven experience in gene therapy drug development and commercialization with UT Southwestern&#8217;s world-class <a name="_Hlk70325986"></a>gene therapy research capabilities, we believe we have created a powerful engine to develop transformative therapies to dramatically improve patients&#8217; lives. We recently acquired exclusive worldwide rights to a clinical-stage, intrathecally dosed AAV9 gene therapy program, now known as TSHA-120, for the treatment of giant axonal neuropathy, or GAN. A Phase 1/2 clinical trial of TSHA-120 is being conducted by the National Institutes of Health under an accepted investigational new drug application, or IND, and we expect to provide a regulatory and clinical update by the end of 2021. A Phase 1/2 clinical trial of TSHA-101 was initiated by Queen&#8217;s University at Kingston, or Queen&#8217;s University, under an accepted Clinical Trial Application, or CTA, in Canada, and Queen&#8217;s University expects to report preliminary safety and biomarker data in the second half of 2021 and preliminary clinical data by the end of 2021. We plan to submit an IND for TSHA-101 for the treatment of GM2 gangliosidosis to the U.S. Food and Drug Administration, or FDA, and initiate a Phase 1/2 clinical trial in the United States, each in the second half of 2021. In addition, we plan to submit INDs / CTAs for each of TSHA-102 in Rett syndrome and TSHA-104 in SURF1-associated Leigh syndrome in the second half of 2021 and one of the following programs in 2021: TSHA-103 in SLC6A1 haploinsufficiency, TSHA-105 in SLC13A5 deficiency, TSHA-111-LAFORIN and TSHA-111-MALIN for two different forms of Lafora disease, TSHA-112 in APBD and TSHA-119 in GM2 AB variant. We are also developing TSHA-118 for the treatment of CLN1 disease (one of the forms of Batten disease) and intend to initiate a Phase 1/2 clinical trial of TSHA-118 in the second half of 2021 under a currently open IND. In addition to our product pipeline candidates, we are building a platform of next-generation technologies to optimize key components of our&#160;AAV-based&#160;gene therapies, including redosing, transgene regulation and capsid development.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>We have a limited operating history. Since our inception, our operations have focused on organizing and staffing our company, business planning, raising capital and entering into collaboration agreements for conducting preclinical research and development activities for our product candidates. All of our lead product candidates are still in the clinical or preclinical development stage.&#160;We do not have any product candidates approved for sale and have not generated any revenue from product sales. We have </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funded our operations through the sale of equity, raising </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an aggregate of $307.0&#160;million of gross proceeds from our initial public offering and private placements of our convertible preferred stock. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. Our net losses were $32.0 million for the three months ended March 31, 2021 and $5.4 million for the three months ended March 31, 2020. As of March 31, 2021, we had an accumulated deficit of $93.2 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to advance the preclinical and clinical development of our product candidates and preclinical and discovery programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct our ongoing clinical trial of TSHA-101 and TSHA-120, as well as initiate and complete additional clinical trials of TSHA-101, TSHA-118, TSHA-102, TSHA-104 and any other current and future product candidates that we advance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approval for any product candidates that successfully complete clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to develop our gene therapy product candidate pipeline and next-generation platforms; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">scale up our clinical and regulatory capabilities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacture current Good Manufacturing Practice, or cGMP material for clinical trials or potential commercial sales; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish and validate a commercial-scale cGMP manufacturing facility; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a commercialization infrastructure and scale up internal and external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire additional clinical, manufacturing quality control, regulatory, manufacturing and scientific and administrative personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur additional legal, accounting and other expenses in operating as a public company. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing a deep and sustainable product portfolio of 26 gene therapy product candidates for monogenic diseases of the CNS in both rare and large patient populations, with exclusive options to acquire four additional development programs at no cost. Our portfolio of gene therapy candidates targets broad neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Our current pipeline, including the stage of development of each of our product candidates, is represented in the table below.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000001.jpg" title="" alt="" style="width:719px;height:362px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Developments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we acquired the exclusive worldwide rights to a clinical-stage AAV9 gene therapy program, now known as TSHA-120, for the treatment of GAN, pursuant to a license agreement with Hannah&#8217;s Hope Fund for Giant Axonal Neuropathy, Inc., or HHF. Under the terms of the agreement, HHF will receive an upfront payment of $5.5 million and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3 million, as well as a low, single-digit royalty on net sales upon commercialization of TSHA-120.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">TSHA-120 for Giant Axonal Neuropathy</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">We recently acquired exclusive worldwide rights to a clinical-stage, intrathecally dosed AAV9 gene therapy program, now known as TSHA-120, for the treatment of giant axonal neuropathy, or GAN. GAN is a rare autosomal recessive disease of the central and peripheral nervous systems caused by loss-of-function gigaxonin gene mutations. The estimated prevalence of GAN is 2,400 patients in the Unites States and European Union.</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>Symptoms and features of children with GAN usually develop around the age of five years and include an abnormal, wide based, unsteady gait, weakness and some sensory loss. There is often associated dull, tightly curled, coarse hair, giant axons seen on a nerve biopsy, and spinal cord atrophy and white matter abnormality seen on MRI. Symptoms progress and as the children grow older they develop progressive scoliosis and contractures, their weakness progresses to the point where they will need a wheelchair for mobility, respiratory muscle strength diminishes to the point where the child will need a ventilator (usually in the early to mid teens) and the children often die during their late teens or early twenties, typically due to respiratory failure. There is an early- and late-onset phenotype associated with the disease, with shared physiology. The late-onset phenotype is often categorized as Charcot-Marie-Tooth Type 2, or CMT2, with a lack of tightly curled hair and CNS symptoms with relatively slow progression of disease. This phenotype represents up to 6% of all CMT2 diagnosis. In the late-onset population, patients have poor quality of life but the disease is not life-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limiting. I</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n early-onset disease, symptomatic treatments attempt to maximize physical development and minimize the rate of deterioration. Currently, there are no approved disease-modifying treatments available. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TSHA-120 is an AAV9 self-complementary viral vector encoding the full length human gigaxonin protein. The construct was invented by Dr. Steven Gray and is the first AAV9 gene therapy candidate to deliver a functional copy of the GAN gene under the control of a JeT promoter that drives ubiquitous expression.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000002.jpg" title="" alt="" style="width:632px;height:203px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received orphan drug designation and rare pediatric disease designation from the FDA for TSHA-120 for the treatment of GAN.</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is an ongoing natural history study being led by the NIH, that has already identified and followed a number of patients with GAN for over five years with disease progression characterized by a number of clinical assessments. The GAN natural history study was initiated in 2013 and included 45 GAN patients, aged 3 to 21 years. As would be expected for a neurodegenerative disease, younger patients have higher baseline scores. However, the rate of decline in the MFM32 scores demonstrated consistency across patients of all ages, with most demonstrating an average 8-point decline per year regardless of age and/or baseline MFM32 score, as shown in the natural history plot below. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000003.jpg" title="" alt="" style="width:412px;height:334px;"></p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A 4-point score change in the MFM32 is considered clinically meaningful, suggesting that GAN patients lose significant function annually.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Data</font></p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">TSHA-120 performed well across <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies, and demonstrated improved motor function and nerve pathology, and long-term safety across several animal models. Of note, improved dorsal root ganglia, or DRG, pathology was demonstrated in TSHA-120-treated GAN knockout mice. These preclinical results have been published in a number of peer-reviewed journals.</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">Additional preclinical data from a GAN knockout rodent model that had received AAV9-mediated GAN gene therapy demonstrated that GAN rodents treated at 16 months performed significantly better than 18-month old untreated GAN rodents and equivalently to controls. These rodents were evaluated using a rotarod performance test which is designed to evaluate endurance, balance, grip strength and motor coordination in rodents. The time to fall off the rotarod, known as latency, was also evaluated and the data below demonstrate the clear difference in latency in treated versus untreated GAN rodents.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000004.jpg" title="" alt="" style="width:542px;height:283px;"></p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A result is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. The conventional method for determining the statistical significance of a result is known as the &#8220;p-value,&#8221; which represents the probability that random chance caused the result (e.g., a p-value = 0.01 means that there is a 1% probability that the difference between the control group and the treatment group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant.</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>With respect to dorsal root ganglia, or DRG, inflammation that has been a topic of considerable interest within the gene therapy circles, in GAN and in the majority of diseases in our neurodegenerative franchise, the DRG have a significantly abnormal histological appearance and function as a consequence of underlying disease pathophysiology. Treatment with TSHA-120 resulted in considerable improvements in the pathological appearance of the DRG in the GAN knockout mice. Shown below is tissue from a GAN knockout mouse model with numerous abnormal neuronal inclusions containing aggregates of damaged neurofilament in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRG</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indicated by the yellow arrows. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> image C, the tissue from the GAN knockout mice treated with an intrathecal inj</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ection of TSHA-120 had a notable improvement in the reduction of these neuronal inclusions in the DRG.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000005.jpg" title="" alt="" style="width:661px;height:249px;"></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a quantitative approach to the reduction in inclusions in the DRG was applied, it was observed that TSHA-120 treated mice experienced a statistically significant reduction in the average number of neuronal inclusions versus the GAN knockout mice that received vehicle as illustrated below. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000006.jpg" title="" alt="" style="width:363px;height:365px;"></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Results of Ongoing Phase 1/2 Clinical Trial</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>A Phase 1/2 clinical trial of TSHA-120 is being conducted by the NIH under an accepted IND. The ongoing trial is a single-site, open-label, non-randomized dose-escalation trial, in which patients are intrathecally dosed with one of 4 dose levels of TSHA-120 &#8211; 3.5x10<sup style="font-size:85%;line-height:120%;vertical-align:top">13</sup> total vg, 1.2x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg, 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg or 3.5x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg. The primary endpoint is to assess safety, with secondary endpoints measuring efficacy using pathologic, physiologic, functional, and clinical markers. To date, 14 patients have been intrathecally dosed and six patients have at least three years&#8217; worth of long-term follow up data. The 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg dose and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2x10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> total vg cohorts demonstrated dose-related and meaningful slowing of disease progression in the first year post dosing</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as illustrated below</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he 1.8x10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> total vg dose effected a statistically significant 8-point improvement versus the historical control</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> over the course of a year</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the 1.2x10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> total vg dose effected a statistically significant 6-point improvement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> over the course of a year</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000007.jpg" title="" alt="" style="width:409px;height:339px;"></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Six patients in the trial have been followed for more than three years. Patients dosed with 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg and 1.2x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg have shown sustained dose-dependent improvements in MFM32 scores for more than three years, as illustrated below. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000008.jpg" title="" alt="" style="width:719px;height:264px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> TSHA-120 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has been</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> well-tolerated at multiple doses with no signs of significant acute or subacute inflammation, no sudden sensory changes and no drug-related or persistent elevation of transam</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inases.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to report</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> additional data from this </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> later this year, including results from the highest dose cohort of 3.5x10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> total vg.</font></p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Bayesian Analysis of TSHA-120</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>To gain further insight into the impact of TSHA-120 treatment on GAN disease progression and to add more robustness to the data, an additional analysis utilizing Bayesian statistical methodology was performed. Bayesian analysis is a useful method that enables direct probability statements about any unknown quantity of interest to be m<a name="_AEIOULastRenderedPageBreakAEIOU27"></a>ade, in this case, a statement around the probability of a clinically meaningful improvement in MFM32. Bayesian analysis also enables immediate incorporation into the analysis of data gathered as the trial progresses. It is a particularly appropriate approach for a clinical trial in a rare disease and is a way of statistically increasing the power of a clinical trial in a small patient population when used to incorporate auxiliary information such as historical data, or data that are being accumulated as the trial progresses. Importantly, it has been accepted by regulatory agencies in such cases. Below are the results of the Bayesian analysis of patient data from cohorts treated at 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg and 1.2x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg. As seen in the table, the analysis confirmed both the natural history data of an 8-point decline in the MFM32 total percent score per year, and importantly, that patients treated with 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg experienced an arrest of disease progression that was statistically significant. The Bayesian analysis confirms the positive findings that were seen with the frequentist approach.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000009.jpg" title="" alt="" style="width:502px;height:470px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>As shown below, the Bayesian efficacy analysis confirmed that TSHA-120 halted patients&#8217; pre-treatment rate of decline when compared to individual historical data. As shown on these graphs, the 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg dose halted patient pre-treatment rate of decline with an average annual slope improvement of 7.78 points while the 1.2x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg dose resulted in a clinically meaningful </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">slowing of disease progression with an average annual slope improvement of 6.09 points. These results are consistent with a dose respo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nse relationship.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000010.jpg" title="" alt="" style="width:697px;height:223px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>Further analyses confirmed that there was a nearly 100% probability of clinically meaningful slowing of disease progression. As shown below, the 1.8x10<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> total vg dose confirmed a virtually 100% probability of clinically meaningful slowing of disease </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compared to natural history decline of GAN patients while the 1.2x10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> total vg dose confirmed an approximat</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ely 85% probability of clinically meaningful slowing of disease and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a virtually</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 100% probability of any slowing of disease.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000011.jpg" title="" alt="" style="width:499px;height:631px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to engage with the FDA, European Medicines Agency, Medicines and Healthcare products Regulatory Agency in the United Kingdom and the Pharmaceuticals and Medical Devices Agency in Japan to discuss the regulatory pathway for TSHA-120 and will provide an update by year-end.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Program Updates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Vagus Nerve Redosing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>Proof-of-concept research in the preclinical setting has supported that direct injection into the vagus nerve of TSHA-120 following an intrathecal administration of TSHA-120 may ameliorate autonomic nervous system dysfunction. At either four or sixteen weeks after wild-type rats were injected intrathecally with TSHA-120, they received a second dose via direct injection of the AAV9 vector into the vagus nerve. Four weeks after the second injection, tissues were assessed for expression of our re-dosed virus by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">staining for the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">green fluorescent protein, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GFP</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arried by the second AAV9 vector. Examination of the injected vagus nerve and associated nodose ganglia showed a robust expression of GFP (as represented by the brown staining</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), indicating that in rats, AAV9 can be re-dosed through a direct nerve inj</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ection following intrathecal delivery.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000012.jpg" title="" alt="" style="width:719px;height:325px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with single-dosing studies, re-dosed animals showed expression in the medulla vagus nerve nuclei. As shown below, GFP expression was seen in the nucleus ambiguous, which controls motor functions critical for vocalization, swallowing and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peristalsis and in the Pre-Botzinger complex, which contains respiratory rhythm generating neurons &#8211; all of which are autonomic functions compromised in GAN and many other neurological diseases.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000013.jpg" title="" alt="" style="width:719px;height:352px;"><font style="font-size:10pt;margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>As illustrated below, further support<a name="_AEIOULastRenderedPageBreakAEIOU31"></a> of how vagus nerve injection permits AAV9 redosing was demonstrated in the brain of a na&#239;ve animal shown on the left compared to an intrathecally AAV9-immunized rat on the right. Efficient GFP transduction was observed in vagal nerve fibers and in brain neurons. In the area postrema, which has a reduced blood-barrier and is a target for vagal afferent fiber trafficking, there was reduced GFP expression in pre-immunized animals, at four and sixteen weeks, as compared to na&#239;ve animals. This suggests that pre-existing neutralization antibodies may dampen the overall transduction of vagal nerve delivered </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AAV9, but efficient transduction of autonomic relevant neurons can still be achieved.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These results support that the vagus nerve space is immune </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">privileged enough to allow for redosing.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000014.jpg" title="" alt="" style="width:719px;height:335px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">TSHA-102 for Rett Syndrome</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TSHA-102, a neurodevelopmental disorder product candidate, is being developed for the treatment of Rett syndrome, one of the most common genetic causes of severe intellectual disability, characterized by rapid developmental regression and in many cases caused by heterozygous loss of function mutations in MECP2, a gene essential for neuronal and synaptic function in the brain. We designed TSHA-102 to prevent gene overexpression-related toxicity by inserting microRNA, or miRNA target binding sites into the 3&#8217; untranslated region of viral genomes. This overexpression of MECP2 is seen in the clinic in patients with a condition known as MECP2 duplication syndrome, where elevated levels of MECP2 result in a clinical phenotype similar to Rett syndrome both in terms of symptoms and severity. TSHA-102 is constructed from a neuronal specific promoter, MeP426, coupled with the miniMECP2 transgene, a truncated version of MECP2, and miRNA-Responsive Auto-Regulatory Element, or miRARE, our novel miRNA target panel, packaged in self-complementary AAV9.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently, preclinical data from the ongoing natural history study for TSHA-102 were published online in Brain, a highly esteemed neurological science peer-reviewed journal. The preclinical study was conducted by the UT Southwestern Medical Center (UT Southwestern) laboratory of Sarah Sinnett, Ph.D., and evaluated the safety and efficacy of regulated miniMECP2 gene transfer, TSHA-102 (AAV9/miniMECP2-miRARE), via intrathecal (IT) administration in adolescent mice between four and five weeks of age. TSHA-102 was compared to unregulated full length MECP2 (AAV9/MECP2) and unregulated miniMECP2 (AAV9/miniMECP2).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TSHA-102 extended knockout survival by 56% via IT delivery. In contrast, the unregulated miniMECP2 gene transfer failed to significantly extend knockout survival at either dose tested. Additionally, the unregulated full-length MECP2 construct did not demonstrate a significant extension in survival and was associated with an unacceptable toxicity profile in wild type mice.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to survival, behavioral side effects were explored. Mice were subjected to phenotypic scoring and a battery of tests including gait, hindlimb clasping, tremor and others to comprise an aggregate behavioral score. miRARE attenuated miniMECP2-mediated aggravation in wild type aggregate phenotype severity scores. Mice were scored on an aggregate severity scale using an established protocol. AAV9/MECP2- and AAV9/miniMECP2-treated wild type mice had a significantly higher mean (worse) aggregate behavioral severity score versus that observed for saline-treated mice (p &lt;0.05; at 6&#8211;30 and 7&#8211;27 weeks of age, respectively). TSHA-102-treated wild type mice had a significantly lower (better) mean aggregate severity score versus those of AAV9/MECP2- and AAV9/miniMECP2-treated mice at most timepoints from 11&#8211;19 and 9&#8211;20 weeks of age, respectively. No significant difference was observed between saline- and TSHA-102-treated wild type mice.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>miRARE-mediated genotype-dependent gene regulation was demonstrated by analyzing tissue sections from wild type and knockout mice treated with AAV9 vectors given intrathecally. TSHA-102 demonstrated regulated expression in different regions of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the brain. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the graph and photos below, i</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n the pons and midbrain, miRARE inhibited mean </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MECP2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expression in a genotype-dependent manner as indicated by significantly fewer myc(+) cells observed in wild type mice compared to knockout mice (p&lt;0.05), thereby dem</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onstrating that TSHA-102 achieved MECP2 expression levels similar to normal physiological parameters.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000015.jpg" title="" alt="" style="width:543px;height:333px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000016.jpg" title="" alt="" style="width:558px;height:269px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to submit an IND / CTA for TSHA-102 in the second half of 2021 and initiate a clinical trial by the end of 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">TSHA-104 for SURF1-Associated Leigh Syndrome</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing&#160;TSHA-104,&#160;a neurodegenerative product candidate, for the treatment of SURF1-associated Leigh syndrome. The&#160;<font style="font-style:italic;">SURF1</font>&#160;gene encodes the SURF1 protein, which plays a critical role in mitochondrial translation and is involved in the assembly of the cytochrome c oxidase complex. Mutations in&#160;<font style="font-style:italic;">SURF1&#160;</font>lead to SURF1-associated Leigh syndrome, a recessively inherited mitochondrial disease, and are the most frequent cause of Leigh syndrome, a rapidly progressive neurological condition characterized by the degeneration of the CNS. To date over 100&#160;<font style="font-style:italic;">SURF1</font>&#160;mutations, including&#160;non-sense,&#160;frame shift and missense variants have been described in literature. The incidence of SURF1-associated Leigh syndrome is estimated to be approximately 1 in 100,000 live births. The estimated prevalence of SURF1 deficiency is 300 to 400 patients in the United States and European Union.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SURF1-associated Leigh syndrome</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> can lead to difficulty swallowing in infancy, with subsequent failure to thrive. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severely diseased muscle tone leading to respiratory failure, movement disorders and balance abnormalities are common. According to the literature, only a few patients have been reported to survive beyond 10 years of age. In the majority of SURF1-deficient</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patients, serum lactate is elevated, and elevated levels of serum lactate have been reported in the CSF as well, indicative of mitochondrial dysfunction. We are pursuing a gene replacement strategy with the goal of restoring mitochondrial function in pati</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents with </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SURF1-associated Leigh syndrome</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> caused by&#160;loss-of-function&#160;mutations.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are constructing&#160;TSHA-104&#160;from a codon-optimized version of the human<font style="font-style:italic;">&#160;SURF1&#160;</font>gene packaged within a self-complementary AAV9 viral vector under the control of a CBh promoter. We plan to submit an IND / CTA for TSHA-104 in the second half of 2021 and initiate a Phase 1/2 clinical trial by the end of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received orphan drug designation and rare pediatric disease designation from the FDA for TSHA-104 for the treatment of SURF1-associated Leigh Syndrome.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data from preclinical studies suggest that functional gene replacement strategy could restore mitochondrial functions in SURF1-associated Leigh syndrome caused by SURF1 loss-of-function mutations, which we believe supports continued development of&#160;TSHA-104.&#160;In these studies,&#160;TSHA-104&#160;was administered at two dose levels via intrathecal lumbar puncture to a knock-out mouse model of SURF1-associated Leigh syndrome. Intrathecal treatment with&#160;TSHA-104&#160;was observed to be well tolerated. TSHA-104 also induced SURF1 expression in the brain and partially rescued COX activity in a tissue specific manner as shown below.</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000017.jpg" title="" alt="" style="width:552px;height:435px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown below, TSHA-104 restored elevation of blood lactate on exhaustive exercise in the SURF1 knock-out mice.</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000018.jpg" title="" alt="" style="width:450px;height:423px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">TSHA-113 for Tauopathies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing&#160;TSHA-113&#160;for the treatment of tauopathies. Tau accumulation predicts neurodegeneration in Alzheimer&#8217;s disease, and the propagation of tau aggregates is thought to mediate the progression of several neurodegenerative diseases, including progressive supranuclear palsy, corticobasal degeneration, behavioral variant frontotemporal degeneration, chronic traumatic encephalopathy, frontotemporal dementia and parkinsonism linked to chromosome 17.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, multiple strategies are currently being tested to reduce tau and ameliorate the effects of these diseases. Preclinical studies testing tau anti-sense oligonucleotides, or ASOs, in the PS19 tauopathy mouse model prevented neuronal loss and showed a reversal of pathological tau deposition and seeding. This treatment in being tested in clinical trials. While promising, ASOs only reduced tau protein levels by approximately 50% in mice, and they required repeated, life-long intrathecal administration to reach this maximum effect.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing&#160;TSHA-113&#160;to utilize&#160;AAV-mediated&#160;gene silencing to deliver life-long reduction of tau protein levels in neurons following administration of a single dose. We are developing&#160;tau-specific&#160;miRNA shuttles that have been designed to target mRNA for all six isoforms of tau found in the human brain and/or mouse brain. Our preliminary data in cells has shown that our tau miRNA selectively reduced some human and mouse tau expression&#160;<font style="font-style:italic;">in vitro</font>&#160;and we have packaged our miRNA shuttles in AAV9 capsids for further evaluation in mouse models of human tauopathies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In transgenic mouse models carrying human tau, TSHA-113 significantly reduced tau mRNA and protein levels, as shown in the three figures below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gmtxzzgtjwwl000019.jpg" title="" alt="" style="width:381px;height:400px;"><font style="font-size:12pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gmtxzzgtjwwl000020.jpg" title="" alt="" style="width:552px;height:343px;"><font style="font-size:12pt;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><img src="gmtxzzgtjwwl000021.jpg" title="" alt="" style="width:503px;height:323px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mice dosed with TSHA-113 demonstrated widespread function and GFP expression in neurons and glia, as illustrated below.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;border-top:Solid 0.75pt #7F7F7F;padding-top:0pt;border-bottom:Solid 0.75pt #7F7F7F;padding-bottom:0pt;border-left:Solid 0.75pt #7F7F7F;padding-left:0pt;border-right:Solid 0.75pt #7F7F7F;padding-right:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000022.jpg" title="" alt="" style="width:719px;height:357px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together with previous <font style="font-style:italic;">in vitro</font> findings, we believe that these data further validate selective reduction of tau mRNA and protein levels and warrant further preclinical development.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">TSHA-105 for SLC13A5 Deficiency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>We are developing&#160;TSHA-105&#160;for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy characterized by the onset of seizures within the first few days of life. The estimated prevalence of SLC13A5 deficiency is 1,900 patients in the United States and European Union. Affected children have impairments in gross motor function and speech production with relative preservation of fine motor skills and receptive speech. SLC13A5 deficiency is caused by&#160;bi-allelic&#160;loss-of&#160;function </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utations in the&#160;</font><font style="font-style:italic;">SLC13A5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;gene, which codes for a sodium dependent citrate transporter, or NaCT, that is largely expressed in the brain and liver. To date, all tested mutations result in no or a greatly reduced amount of the citrate in the cells.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diminished NaCT function leads to loss of neuronal uptake of citrate and other metabolites such as succinate that are critical to brain energy metabolism and function. Currently, there are no approved therapies for SLC13A5 deficiency, and treatment is largely to address symptoms.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing TSHA-105 as a gene replacement therapy for SLC13A5 deficiency. TSHA-105 is constructed from a codon-optimized human&#160;<font style="font-style:italic;">SLC13A5</font>&#160;gene packaged in a self-complementary AAV9 capsid. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received orphan drug designation and rare pediatric disease designation from the FDA for TSHA-105 for the treatment of epilepsy caused by caused by SLC13A5 deficiency.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preliminary safety studies conducted in wildtype mice, vehicle or TSHA-105 was administered via CSF delivery. Weight and survival in the control and treatment group were the same and no overt toxicities were observed for up to one-year post-treatment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70607215"></a>Studies to evaluate TSHA-105 were conducted using SLC13A5 knockout mice. In comparison to age-matched, wildtype controls, SLC13A5 knockout mice exhibit altered citrate metabolism along with abnormal electroencephalogram, or EEG, activity and increased seizure susceptibility. At 3 months of age, SLC13A5 knockout mice were treated with TSHA-105 via CSF delivery. Administration of TSHA-105 resulted in a significant, sustainable decrease of plasma citrate levels up to 3-months post-injection, as shown below. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000023.jpg" title="" alt="" style="width:516px;height:260px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in ongoing EEG studies, TSHA-105 normalized EEG activity and decreased the number of seizures in knockout mice in comparison vehicle-treated controls as shown below.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000024.jpg" title="" alt="" style="width:402px;height:288px;"></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000025.jpg" title="" alt="" style="width:445px;height:308px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TSHA-105 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also reduced seizure susceptibility </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SLC13A5 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">knockout mice </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as shown below.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000026.jpg" title="" alt="" style="width:621px;height:328px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">TSHA-103 for SLC6A1 Haploinsufficiency Disorder</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SLC6A1 haploinsufficiency disorder is caused by&#160;loss-of-function&#160;mutations in the&#160;<font style="font-style:italic;">SLC6A1</font>&#160;gene. Loss&#160;of-function&#160;mutations in the&#160;<font style="font-style:italic;">SLC6A1</font>&#160;gene have been identified as one of the most common monogenic causes of epilepsy with myoclonic atonic seizures, or brief and abrupt seizures followed by loss of muscle strength, as well as autism spectrum disorder and intellectual disability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients diagnosed with SLC6A1 haploinsufficiency disorder typically present with developmental delay, varying degrees of intellectual disability, seizures and abnormal EEG characterized by generalized spike-wave discharges. Most patients are refractory to pharmacological seizure control although a portion of patients become seizure free during the course of disease progression. Importantly, seizure control is not associated with improved cognitive outcomes, which highlights the complexity of the disease as well as the need for novel therapies directed at its underlying pathology.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 81% of patients with SLC6A1 haploinsufficiency disorder have epilepsy, with typical absence seizures, which are abrupt and followed by lack of awareness, being the predominant form observed. In addition, 91% of individuals exhibit developmental delays, with more than 80% characterized as mild or moderate intellectual disability. Ataxia, or tremors, is present in approximately 29% of individuals, while autism or autistic features are observed in approximately 24% of individuals diagnosed with SLC6A1 haploinsufficiency disorder.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The&#160;<font style="font-style:italic;">SLC6A1</font>&#160;gene encodes the gamma-aminobutyric acid, or GABA, transporter 1, or GAT1. GAT1 is a voltage-dependent transporter responsible for the reuptake of GABA, a&#160;non-protein&#160;amino acid that is well characterized for its role as a major inhibitory neurotransmitter within the mammalian CNS. GAT1 plays a critical role in the reuptake of GABA from neuronal synapses and extracellular spaces and as a result, a critical role in balancing neuronal excitations. When GABA transport is disrupted, brain development is negatively impacted resulting in deficits in attention and cognition as well as seizures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exact incidence and prevalence of SLC6A1 haploinsufficiency disorder is unknown but we believe the estimated prevalence is 17,000 patients in the United States and European Union. According to recently published data, the incidence of SLC6A1 haploinsufficiency disorder is approximately 1 in 36,000 live births. We believe that SLC6A1 haploinsufficiency disorder is underdiagnosed as the underlying biology was only recently elucidated and the gene had not been part of commercially available genetic epilepsy screening panels. Clinician education and expanded use of genetic screening panels that include SLC6A1 will likely lead to increased identification of individuals with these mutations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our Solution:&#160;TSHA-103</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing TSHA-103, a genetic epilepsy product candidate, for the treatment of SLC6A1 haploinsufficiency disorder. TSHA-103 is a gene replacement therapy constructed from a codon-optimized version of the human&#160;<font style="font-style:italic;">SLC6A1</font>&#160;gene packaged within a self-complementary AAV9 viral vector. We are currently conducting preclinical studies of&#160;TSHA-103. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received orphan drug designation and rare pediatric disease designation from the FDA for TSHA-103 for the treatment of epilepsy caused by SLC6A1 haploinsufficiency disorder.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting preclinical studies of&#160;TSHA-103. In the SLC6A1 knockout mouse model, TSHA-103 improved nesting and EEG, activity, as shown below.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000027.jpg" title="" alt="" style="width:657px;height:240px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;border-top:Solid 0.75pt #7F7F7F;padding-top:1pt;border-bottom:Solid 0.75pt #7F7F7F;padding-bottom:1pt;border-left:Solid 0.75pt #7F7F7F;padding-left:4pt;border-right:Solid 0.75pt #7F7F7F;padding-right:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In SLC6A1 knockout and heterozygous mouse models, TSHA-103 reduced spike train activity, which is a recording of abnormal neuronal activity associated with seizures, as shown below.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;border-top:Solid 0.75pt #7F7F7F;padding-top:1pt;border-bottom:Solid 0.75pt #7F7F7F;padding-bottom:1pt;border-left:Solid 0.75pt #7F7F7F;padding-left:4pt;border-right:Solid 0.75pt #7F7F7F;padding-right:4pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmtxzzgtjwwl000028.jpg" title="" alt="" style="width:552px;height:287px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License Agreements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research, Collaboration and License Agreement with The University of Texas Southwestern Medical Center </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, we entered into a research, collaboration and license agreement, or the UT Southwestern Agreement with The Board of Regents of the University of Texas System on behalf of UT Southwestern, as amended in April 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the UT Southwestern Agreement, we obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern and a non-exclusive, worldwide, royalty-free license under certain know-how of UT Southwestern, in each case to make, have made, use, sell, offer for sale and import licensed products for use in certain specified indications. Additionally, we obtained a non-exclusive, worldwide, royalty-free license under certain patents and know-how of UT Southwestern for use in all human uses, with a right of first refusal to obtain an exclusive license under certain of such patent rights and an option to negotiate an exclusive license under other of such patent rights. We are required to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the entry into the UT Southwestern Agreement, we issued to UT Southwestern 2,179,000 shares of our common stock. We do not have any future milestone or royalty obligations to UT Southwestern under the UT Southwestern Agreement, other than costs related to the maintenance of patents. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with Queen&#8217;s University </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, we entered into a license agreement, or the Queen&#8217;s University Agreement with Queen&#8217;s University. In connection with the Queen&#8217;s University Agreement, we obtained an exclusive, perpetual, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain patent rights and know-how of Queen&#8217;s University, including certain improvements to the foregoing, to make, have made, use, offer for sale, sell and import licensed products and otherwise exploit such patents and know-how for use in certain specified indications. We also obtained an exclusive right of first negotiation to license certain next generation technology and improvements of Queen&#8217;s University that do not constitute an already-licensed improvement to the licensed technology. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Queen&#8217;s University Agreement, we paid Queen&#8217;s University a one-time fee of $3.0&#160;million as an upfront fee and approximately $0.2 million to reimburse Queen&#8217;s University for certain plasmid production costs. We are obligated to pay Queen&#8217;s University up to $10.0&#160;million in the aggregate upon achievement of certain regulatory milestones and up to $10.0&#160;million in the aggregate upon achievement of certain commercial milestones, a low single digit royalty on net sales of licensed products, subject to certain customary reductions, and a percentage of non-royalty sublicensing revenue ranging in the low double digits. Royalties are payable on a licensed product-by-licensed product basis and country-by-country basis until expiration of the last valid claim of a licensed patent covering such licensed product in such country and the expiration of any regulatory exclusivity for such licensed product in such country. Additionally, we are obligated to pay Queen&#8217;s University a low double-digit portion of any amounts received by us in connection with the sale of a priority review voucher related to a licensed product, not to exceed a low eight-figure amount. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with a separate research grant agreement with Queen&#8217;s University, we reimbursed Queen&#8217;s University for certain manufacturing production costs totaling $3.8 million in fiscal year 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with Abeona (CLN1 Disease)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we entered into a license agreement, or the Abeona CLN1 Agreement, with Abeona Therapeutics Inc., or Abeona.&#160;In connection with the Abeona CLN1 Agreement, we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy for the prevention, treatment, or diagnosis of CLN1 Disease (one of the forms of Batten disease) in humans. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>In connection with the license grant, we paid Abeona a one-time upfront license fee of $3.0 million during fiscal year 2020. We are obligated to pay Abeona up to $26.0 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed product and high single-digit royalties on net sales of licensed products. Royalties are payable on a licensed product-by-licensed product and country-by-country basis until the latest of the expiration or revocation or complete rejection of the last licensed patent covering such licensed product in the country where the licensed product is sold, the loss of market exclusivity in such country where the product is sold, or, if no licensed product exists in such country and no market exclusivity exists in such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">country, ten years from first commercial sale of such licensed product in such country. In addition, concurrent with the Abeona C</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LN1 Agreement we entered into a purchase and reimbursement agreement with Abeona, pursuant to which we purchased specified inventory from Abeona and reimbursed Abeona for certain research and development costs previously incurred for total consideration of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $4.0 million paid in fiscal year 2020. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Abeona CLN1 Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. We may terminate the agreement for convenience upon specified prior written notice to Abeona. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with Abeona (Rett Syndrome)</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we entered into a license agreement, or the Abeona Rett Agreement with Abeona pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents,&#160;know-how&#160;and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain obligations of Abeona, we are required to use commercially reasonable efforts to develop at least one licensed product and commercialize at least one licensed product in the United States.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Abeona Rett Agreement, we paid Abeona a&#160;one-time&#160;upfront license fee of $3.0&#160;million during fiscal year 2020. We are obligated to pay Abeona up to $26.5&#160;million in regulatory-related milestones and up to $30.0&#160;million in sales-related milestones per licensed product and high single-digit royalties on net sales of licensed products. Royalties are payable on a licensed&#160;product-by-licensed&#160;product and&#160;country-by-country&#160;basis until the latest of the expiration or revocation or complete rejection of the last licensed patent covering such licensed product in the country where the licensed product is sold, the loss of market exclusivity in such country where the product is sold, or, if no licensed product exists in such country and no market exclusivity exists in such country, ten years from first commercial sale of such licensed product in such country.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Abeona Rett Agreement expires on a&#160;country-by-country&#160;and licensed&#160;product-by-licensed&#160;product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. We may terminate the agreement for convenience.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19 on Our Business </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been actively monitoring the COVID-19 situation and its impact globally. Our financial results for the quarter ended March 31, 2021 were not impacted by COVID-19. We believe the remote working arrangements and travel restrictions imposed by various governmental jurisdictions have had limited impact on our ability to maintain internal operations during the quarter ended March 31, 2021. The extent to which COVID-19 may impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the effectiveness of actions to contain and treat COVID-19 and the efficacy, availability and adoption of vaccines, both domestically and globally. Although we have not experienced any material business shutdowns or interruptions due to the COVID-19 pandemic, we cannot predict the scope and severity of any potential business shutdowns or disruptions in the future, including to our planned clinical trials and preclinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to our ability to conduct our business in the manner and on the timelines presently planned, which could have a material adverse impact on our business, results of operation and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not recognized any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products, if approved, in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses primarily consist of preclinical development of our product candidates and discovery efforts, including conducting preclinical studies, manufacturing development efforts, preparing for clinical trials and activities related to regulatory filings for our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Costs incurred in obtaining technology licenses through asset acquisitions are charged to research and development expense if the licensed technology has not reached technological feasibility and has no alternative future use. Research and development expenses include or could include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, other related costs for those employees involved in research and development efforts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">external research and development expenses incurred under agreements with consultants, contract research organizations, or CROs, investigative sites and consultants to conduct our preclinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs related to manufacturing material for our preclinical studies and clinical trials, including fees paid to contract manufacturing organizations, or CMOs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">laboratory supplies and research materials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs related to compliance with regulatory requirements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance and equipment. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our preclinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly as we commence clinical trials. Our future expenses may vary significantly each period based on factors such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred to conduct preclinical studies required to advance our product candidates into clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">per patient trial costs, including based on the number of doses that patients received; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of patients who enroll in each trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of trials required for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number of sites included in the trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the countries in which the trials are conducted; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the length of time required to enroll eligible patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the drop-out or discontinuation rates of patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential additional safety monitoring requested by regulatory agencies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the duration of patient participation in the trials and follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the phase of development of the product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the ability</font><font style="font-family:Times New Roman;"> to manufacture of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulators or institutional review boards, or IRBs requiring that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the efficacy and safety profile of our product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist or will consist principally of salaries and related costs for personnel in executive and administrative functions, including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include professional fees for legal, consulting, accounting and&#160;audit and tax-related&#160;services and insurance costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our expanded infrastructure, as well as the initiation and continuation of our preclinical studies and clinical trials for our product candidates. We also anticipate that our general and administrative expenses will increase as a result of payments for accounting, audit, legal, consulting services, as well as costs associated with maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. We anticipate the additional costs for these services will increase our general and administrative expenses by between $6.0&#160;million and $7.0&#160;million on an annual basis, including the cost of director and officer liability insurance.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Results of Operations for the Three Months Ended March 31, 2021 and for the Three Months Ended March 31, 2020 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the three months ended March&#160;31, 2021 and the three months ended March 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399982"></a>Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,854</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,514</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,090</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $23.9&#160;million for the three months ended March 31, 2021, compared to $5.5 million for the <font style="Background-color:#FFFFFF;color:#000000;">three months ended March 31, 2020. </font><font style="color:#000000;">The $18.4 million increase was primarily attributable to an increase of $3.1 million of expenses incurred in research and development manufacturing and other raw material purchases, which included cGMP batches produced by Catalent and UT Southwestern. Additionally, we incurred a year-over-year increase of $3.1 million in research and development licensing fees driven by the acquisition of exclusive worldwide rights to TSHA-120, for the treatment of GAN. We incurred an increase in employee compensation and expenses of $5.2 million, which included $1.6 million of non-cash stock-based compensation. We also incurred an increase of $2.4 million in sponsored research agreement expenses for our various product candidates. Additionally, we incurred an increase of $2.7 million for research and development consulting fees including technical operations support and translational sciences, $0.9 million for regulatory and clinical consulting, and other research and development of $1.0 million.  </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $8.2&#160;million for the three months ended March 31, 2021, compared to less than $0.1 million for the <font style="Background-color:#FFFFFF;color:#000000;">three months ended March 31, 2020. The increase of approximately $8.1 million was</font> primarily attributable to $4.2&#160;million of incremental compensation expense, which included $2.0 million of non-cash stock-based compensation, $1.5 million of additional consulting and professional fees, including patient advocacy consulting fees and personnel recruiting expenses. We also incurred an increase of $0.9 million of professional fees, which included $0.7 million in legal expenses related to general corporate matters, $0.8 million related to insurance expenses, $0.3 million of marketing expenses, and other general and administrative expenses of $0.5 million.&nbsp;&nbsp;<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Preferred Stock Tranche Liability </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that our obligation to issue, and the investors&#8217; right to purchase, additional shares of Series A convertible preferred stock pursuant to the milestone closings represented a freestanding financial instrument, or the tranche liability. The tranche liability was initially recorded at fair value. We concluded that the tranche liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable from the initial closing of the Series A convertible preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2020 the tranche liability was remeasured and a non-cash gain of $0.2 million was recorded in other income, net.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not generated any revenue and have incurred significant operating losses. As of March 31, 2021, we had cash and cash equivalents of $228.7 million. We have funded our operations through equity financings, raising an aggregate of $307.0 million in gross proceeds from our initial public offering and private placements of convertible preferred stock. Specifically, between March and July 2020, we closed on the sale of an aggregate of 10,000,000 shares of Series A convertible preferred stock for gross proceeds of $30.0 million. In July and August 2020, we closed on the sale of an aggregate of 5,647,048 shares of Series B convertible preferred stock for gross proceeds of $96.0 million. In September 2020, we raised gross proceeds of $181.0 million in our initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next few years.&#160;If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be compromised. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate significant revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of and seek marketing approval for our product candidates, as well as build out of our cGMP manufacturing facility in Durham, North Carolina. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital requirements into 2023. We intend to devote our existing cash and cash equivalents to the clinical and preclinical development of our product candidates.&#160;We have based this estimate on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and commercialization of biological products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, costs and results of discovery, preclinical development, laboratory testing and clinical trials for TSHA-101, TSHA-118, TSHA-102, TSHA-104, and TSHA-120 and any current and future product candidates that we advance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we develop, in-license or acquire other product candidates and technologies in our gene therapy product candidate pipeline; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number and development requirements of product candidates that we may pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our headcount growth and associated costs as we expand our research and development capabilities and establish a commercial infrastructure; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of establishing and maintaining our own commercial-scale cGMP manufacturing facility; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of operating as a public company. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available in the near term, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict our ability to operate. Any future debt financing and equity financing, if available, may involve agreements that include covenants limiting and restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a>We are continuing to assess the effect that the COVID-19 pandemic may have on our business and operations. The extent to which COVID-19 may impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease and the efficacy, availability and adoption of vaccines, both domestically and globally. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a continued and growing pandemic could result in significant disruption of global financial markets, reducing our ability to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access capital, which could in the future negatively affect our liquidity. In addition, a recession or marke</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows a summary of our cash flows for the three months ended March&#160;30, 2021 and 2020 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk70399983"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months Ended March&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,035</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,699</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,027</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, our net cash used in operating activities of $22.0 million primarily consisted of a net loss of $32.0 million, primarily attributable to our spending on research and development expenses.&#160;The net loss of $32.0 million was partially offset by adjustments for non-cash items, primarily the up-front license fee of $5.5 million to HHF related to the acquisition of TSHA-120 and stock-based compensation of $3.6 million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> For the three months ended March 31, 2020, our net cash used in operating activities of $1.7 million primarily consisted of a net loss of $5.4 million, primarily attributable to spending on research and development expenses.&nbsp;&nbsp;The net loss of $5.4 million was partially offset by the upfront fee to acquire the license rights pursuant to the Queen&#8217;s University Agreement for $3.0 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2021, investing activities used $0.5 million of cash attributable to capital expenditures related to computer and lab equipment.&nbsp;&nbsp;No investing activities took place in the three months ended March 31, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2020, financing activities provided $18.0 million attributable to the net proceeds from the sale of our Series A convertible preferred stock.&nbsp;&nbsp;No financing activities took place during the three months ended March 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no material changes to our critical accounting policies that are disclosed in our audited consolidated financial statements for the <font style="Background-color:#FFFFFF;color:#000000;">year ended December&#160;31, 2020 </font>filed with the SEC on March 3, 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note&#160;2 to our unaudited condensed consolidated financial statements located in &#8220;Part I &#8211; Financial Information, Item 1. Financial Statements&#8221; in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company and Smaller Reporting Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>In April 2012, the Jumpstart Our Business Startups Act of 2012, or JOBS Act, was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accou</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nting standards until they would apply to private companies. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an exception from compliance with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on financial statements. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may take advantage of these provisions until we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&#160;December&#160;31, 2025, (ii)&#160;the last day of the fiscal year in which we have more than $1.07&#160;billion in total annual gross revenues, (iii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June&#160;30th, or (iv)&#160;the date on which we have issued more than $1.0&#160;billion of non-convertible debt over the prior three-year period. We may choose to take advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this Quarterly Report on Form 10-Q and our other filings with the SEC. Accordingly, the information contained herein may be different than you might obtain from other public companies in which you hold equity interests. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by&#160;non-affiliates is less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our shares held by&#160;non-affiliates&#160;is less than $250&#160;million or (ii)&#160;our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our shares held by&#160;non-affiliates&#160;is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on&#160;Form&#160;10-K&#160;and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this Item.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_CONTROLS_PROCEDURES"></a><a name="ITEM_4_CONTROLS_PROCEDURES"></a>Item 4. Controls and Procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act ), as of the end of the period covered by this Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of&#160;March 31, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in this Form 10-Q was (a) reported<font style="Background-color:#FFFFFF;color:#000000;font-family:Arial;"> </font>within the time periods specified by SEC rules and regulations, and (b) communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Internal Controls</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><a name="PART_IIOR_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IIOR_INFORMATION"></a>PART II&#8212;OTHER</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> INFORMATION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_LEGAL_PROCEEDINGS"></a><a name="ITEM_1_LEGAL_PROCEEDINGS"></a>Item 1. Legal Proceedings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55917815"></a>We are not subject to any material legal proceedings. From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission on March 3, 2021. There have been no material changes to the risk factors described in that report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a>It<a name="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a>em 2. Unregistered Sales of Equity Securities and Use of Proceeds.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a) Recent Sales of Unregistered Equity Securities</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.<font style="font-weight:bold;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b) Use of Proceeds</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 23, 2020, our Registration Statement on Form S-1, as amended (File No. 333-248559), was declared effective in connection with our initial public offering, pursuant to which we sold an aggregate of 9,050,000 shares of our common stock, including the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $20.00 per share. Goldman Sachs&#160;&amp; Co. LLC, Morgan Stanley&#160;&amp; Co. LLC and Jefferies LLC acted as joint book-running managers and Chardan Capital Markets, LLC acted as lead manager for the offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial public offering closed on September 28, 2020 with respect to 7,869,566 shares of common stock. On September 29, 2020, the offering closed with respect to an additional 1,180,434 shares purchased by the underwriters pursuant to the underwriters&#8217; option to purchase additional shares. The aggregate net proceeds from our initial public offering, after underwriting discounts and commissions, and other offering expenses of $2.5 million, were $165.9&#160;million. In connection with our initial public offering, no payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates or to our affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our prospectus filed pursuant to Rule&#160;424(b)(4) under the Securities Act with the SEC on September 25, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>(c) Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"></a><a name="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"></a>Item 3. Defaults Upon Senior Securities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_OR_INFORMATION"></a><a name="ITEM_5_OR_INFORMATION"></a>Item 5. Other Information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><a name="ITEM_6_EXHIBITS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_EXHIBITS"></a>Item 6. E</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">xhibits.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibits listed on the Exhibit Index are either filed or furnished with this report or incorporated herein by reference.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1806310/000119312520257858/d78879dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39536), filed with the </font><font style="Background-color:#FFFFFF;text-decoration:underline;">Securities and Exchange Commission on September 29, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1806310/000119312520247565/d938924dex34.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39536), filed with the </font><font style="Background-color:#FFFFFF;text-decoration:underline;">Securities and Exchange Commission on September 29, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="tsha-ex311_10.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="tsha-ex312_7.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1*#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="tsha-ex321_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.2*#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="tsha-ex322_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:16.8pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:77.78%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section&#160;1350, and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.&#160;</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNA</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company Name</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ RA Session II</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RA Session II</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kamran Alam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kamran Alam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tsha-ex311_10.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
tsha-ex311_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, RA Session II, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Taysha Gene Therapies, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;RA Session II</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RA Session II</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tsha-ex312_7.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
tsha-ex312_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kamran Alam, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Taysha Gene Therapies, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Kamran Alam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kamran Alam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tsha-ex321_9.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
tsha-ex321_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of Taysha Gene Therapies, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;RA Session II</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RA Session II</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tsha-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
tsha-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of Taysha Gene Therapies, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Kamran Alam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kamran Alam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gmtxzzgtjwwl000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %8 BD# 2(  A$! Q$!_\0
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M ,31X$_Y)YX9_P"P5:_^BEKH* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)K9N
MKZTL45[NZ@MU8X#32! 3^-5X]=TB:18XM5L7D8X55N$))] ,T 9W_"">#_\
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M_P %T/\ \31_P@G@_P#Z%30__!=#_P#$UT%% '/_ /"">#_^A4T/_P %T/\
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M]9URX-M#!.Y\J-U.'8D<E<D>G6LG2I=<D_:#LU\06]G%>QZ4Z[[)V:*5><,
MW(],'TKHO$7@#6=5TG0;FUU"PA\0:-.;B-U@\NV<D@E=J\@<#GZ^M&D>"_$_
M_"R;;Q=KM_ILK"S>"2WM%=5B)Z!-P^8=R20>>E5IS7\W^6G]?\ 3^&WI^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3'\+-(3X?2>#VNKN2T:4S+.Q7S$?.01@8X^E+^;SM^95UIZ_H<-X+\6:XOQ
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M4 %%%% !1110 5\ 5]_U\ 4 ?;_@3_DGGAG_ +!5K_Z*6N@KG_ G_)//#/\
MV"K7_P!%+704 %%%% !1110 4444 %%%% !1110 4444 %%%% !116?;:U8W
M%Y]C,HAO,%A;3?+(5#$;@O<<'F@#0HHHH **0$'H0<'!Q2T %%%)D9QD9':@
M!:*** "BD) (!(&>GO2T %%%4+[6+/3) +YS;PE03<2#$0). "W8T 7Z*165
MT#HP96&00<@BEH **3(SC(R>U+0 444A( R2!]: %HHHH **.@R: 01D'(-
M!115:\O$LHUDE21D+89D7(08R6;T QUH LT57LKZUU&TCNK*XBN+>0962)@R
MG\15B@ HI"0.I ^M+0 444$@#)X H ** 01D<@T4 %%%("#G!!P<'% "T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7P!7W_7P!0!]O^!/^2>>&
M?^P5:_\ HI:Z"N?\"?\ )//#/_8*M?\ T4M=!0 4444 %%%% !1110 4444
M%%%% !1110 444V21(8GED8)&BEF8G@ =30!'=W4-E:2W,\L<44:[F>5PBCZ
ML>!7FM[*GB#5K2..*Y:>YN%,NGWL1D2-.\T%PGW, 9RK<^@J7_A((_$,6S5I
MWTTS7GVK3$OK<"">(+B,;NA)/SX//(XK;\!^')M"M)WGM#9&0(@M5N3*GRCY
MI./E!8Y/ ],T ==&@CC5 20H !)R>/>JFL7DVGZ->7D%M)<S0PLZ0QC+.0.
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MBN1D4 >@6OVC[+%]K,1N-H\PQ9V[N^,\XJ6BB@ HHHH **** "BBB@ HHHH
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MRC'4J.<?3-<MI-W=>)M+M(K_ $K2-4T6[ !^Q-C['QPKH_ITRI!![4 3> -
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MO^O@"@#[?\"?\D\\,_\ 8*M?_12UT%<_X$_Y)YX9_P"P5:_^BEKH* "BBB@
MHHHH **** "BBB@ HHHH *HZSJ2Z/HUYJ+1-*+:)I/+4X+8'3-7JPO&?_(EZ
MQ_UZO_*@!HU7Q"0#_P ([%S_ -/Z_P#Q-5;]M5U2U>VOO"MO/"XPR-?KR,YQ
M]WI72#[J_044 8<>HZ]%&L<?AN%$4855OE  ]!\M._M3Q#_T+L7_ ('K_P#$
MUM9I: ,"XN];N[=X+GPO;30N,/')>JRL/<%:CL)-7TNRCL[+PO##;QC"1C4
M0OTRM='2T 8G]J>(?^A=B_\  ]?_ (FD.I^(2,'P[%_X'K_\36Y24 <OI\6H
M:5)</8>$K6V-R^^417RA6;UQMP#]*O?VIXA_Z%V+_P #U_\ B:VJ* ,7^U/$
M/_0NQ?\ @>O_ ,35#RM0&KC51X1M5OPA0SK?*&93V.%Y_&NIHH Q/[4\0_\
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M9M2\(VMS%G($E\N5/J#MR#[BKBZEX@10J^'8@ ,#_3U_^)K<HH Q/[4\0_\
M0NQ?^!Z__$U%/>:W=0/!<>&+>6%QAXY+U65AZ$%:Z"B@#FM/;5M*LDL['PM!
M!;1YV1KJ PN>>,K5K^U/$/\ T+L7_@>O_P 36W10!S\OB#5;.6U^W:$L,$\Z
M0&1+Q7*EC@'&!D9KHZY_Q3_QYV'_ &$;?_T.N@H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O@"OO^O@"@#[?\"?\ )//#/_8*M?\ T4M=!7/^!/\
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M.?\ A,]%_P#!>W_QVNR\J#_GC%_WP*3RX/\ GC%_WP* .1_X2";_ *'31?\
MP7-_\=H_X2";_H=-%_\ !>W_ ,=KKQ%!_P \8O\ O@4&*#_GC%_WP* .0_X2
M";_H=-%_\%[?_':/^$@F_P"ATT7_ ,%[?_':Z[RX/^>,7_? I1%!_P \8O\
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M !1110 4444 %%%% !6)XQ1Y?!6MI&C.[6,P55&23L/ %;=% '.+XOT':O\
MIW8?\L)/_B:7_A+M _Y_O_($G_Q-=#@>@HP/04 <]_PE^@X_X_\ _P @R?\
MQ-'_  EV@_\ /_\ ^0)/_B:Z' ]!1@>@H Y[_A+M!S_Q_P#_ ) D_P#B:/\
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M#SSMJ$#!%A?H&R3R.@%=G28'I2T %%%% !1110 4444 %%%% !1110 4444
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M!L/^-']LZ]_T*LW_ (&P_P"-;>:7- &'_;.O?]"K-_X&P_XT?VSKW_0JS?\
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M &JN:)K$=U=NJR!LGC!KY-ET[7(Y2VRXR#U!->B_""^U23Q*\-VTA15_C[4
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M_P# J[_^*KNU/RK]!2YH X+_ (0W4_\ GTT;_P "KO\ ^*H_X0W4O^?31O\
MP*N__BJ[W/%)D4 <'_PAFI?\^FC?^!-W_P#%4?\ "&ZE_P ^FC?^!5W_ /%5
MWF1FER* ."_X0W4_^?31O_ J[_\ BJ/^$,U+_GTT;_P)N_\ XJN\W"C<* .#
M_P"$-U+_ )]-&_\  J[_ /BJ/^$-U(];31O_  )N_P#XJN\W"D+@#K0!P?\
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M %\ 4 ?;_@3_ ))YX9_[!5K_ .BEKH*Y_P "?\D\\,_]@JU_]%+704 %%%%
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M#WH 7Q5_QYV'_81M_P#T,5OUSZ^$;3[1!+-J&JW(@E65(Y[QW3<O0D=\5T%
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M!_\ T->A_P#@QA_^*HHH /\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
MX,8?_BJ** #_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJBB@
M_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*HHH /\ A._!_P#T
M->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ** #_ (3OP?\ ]#7H?_@QA_\
MBJ/^$[\'_P#0UZ'_ .#&'_XJBB@ _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\
MT->A_P#@QA_^*HHH /\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?
M_BJ** #_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJBB@ _P"$
M[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*HHH /\ A._!_P#T->A_
M^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ** #_ (3OP?\ ]#7H?_@QA_\ BJ/^
M$[\'_P#0UZ'_ .#&'_XJBB@ _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A
M_P#@QA_^*HHH /\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ*
M* #_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJBB@ _P"$[\'_
M /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*HHH /\ A._!_P#T->A_^#&'
M_P"*H_X3OP?_ -#7H?\ X,8?_BJ** #_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'
M_P#0UZ'_ .#&'_XJBB@ _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@
MQA_^*HHH /\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ** #_
M (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJBB@ _P"$[\'_ /0U
MZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*HHH /\ A._!_P#T->A_^#&'_P"*
MH_X3OP?_ -#7H?\ X,8?_BJ** #_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJBB@ _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^
M*HHH /\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ** #_ (3O
MP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJBB@ _P"$[\'_ /0UZ'_X
M,8?_ (JC_A._!_\ T->A_P#@QA_^*HHH /\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJ** #_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_
G .#&'_XJBB@ _P"$[\'_ /0UZ'_X,8?_ (JOB+RW_N-^5%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gmtxzzgtjwwl000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %. B # 2(  A$! Q$!_\0
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MDYY '))P*T;WQ[9:AI&D7MK=ZCIS2:]%ID]N+:-Y1-D[H) QPJ]RRG.,8ZT
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MLUMN6.-D#[RQ(& IZ9SP< X)KHGUBW_L./5[:.>\MYHXY85M8S(\BOC;@?\
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MP<$KE?8XHL_#^OZAX@;7-?;3H)X;"2RMK>QD>1/G(+.S,JG^$  #@=S79T4
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M7<Z@L8HY1OP.IV]<>]5Y?'.AQ:-8ZJ)+N2"^G-O;)'92M+*XW9 CV[OX6[4
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M9<XRVX@%B0!DD#I6Q10!PGA/1/%WAQ!I\D&@RZ<+FXE$RW$OG8D=G QY>.K
M=?SJ'PUX'UG0/$\>OM>6DMSJ2S?VX@9@C,6+1&'Y?X<[>=N1SUKT&B@#PWX;
M>'?$&O\ P\\-V4LMA#H=OJ#7DC8<7),4S'RMN-O+C.[/ XQQSW&D>!+F'0_&
M>EZA<PB/7]1N[B)X&+&..8 #(('S#N!D>]='-XDTZ'Q)'H'^D27[Q"9EBMW=
M(T)8 NX&U<E3C)_F*T6N[9+M+1KB(7,B&1(2XWLH(!8+U(!(R?<4 </H_A'4
M;9%6^T+PR\]K:M#;W0:1S(2FP[E9/D5APV"W4CFH])\%ZI8:7K4#V6D-:WWE
M"'0WN)9;2(+G?AV7*EL@X"8!4=>W7Z/K^G:ZVH+I\K2'3[M[*XRA7;*F-PYZ
M]>HK3H \QTGX=ZW9^(O#>I3WEK]ETR[O9S:">27[/'-$B)%$SC+@%2<G;C=P
M*FNO!'B+^SM9\.6EUIW]AZM=2W#W4I?[1 LK;I$5 NUCUPQ88STXKO[^_M-+
ML)KZ^G2"UA7=)*_11ZFL_1/%F@>)'E31M6M;UX@#(D3Y90>^.N/>@#A+KX9:
MM)X#\9:##<V(GUK6&OK5F=]B1&6-@'.W(;"'@ C..:ZKX@>&KSQ7X U#0;"6
M".ZN!$$>X8A!LD1SD@$]%/:NJJCJ>KV>CK:M>/(HNKE+6+9$SYD;. =H.!P>
M3P* .-F\#:D^I>/[A9[39XAT^*UM 6;*,MNT1,GR\#<1TSQ^57YO"^KCX767
MARTOTM]2MK.WA:6.5U1S'MW*' #*K!2NX#(!Z5V-% ''>$O"^H:/XBUC5;R+
M3[>*_@MHX[:SD=_+,>_.691NSN!SQW&.,GL:** "BBB@ HHHH **** "BBB@
M HHHH *\G\,WTFE/XTA6]L+/Q)_;,UPYU0;_ #+<X,6T!E)3;P.>#GV%>L5F
M:IX=T36WC?5='L+YXON-<VZ2%?8;@>* /-I/$FIZ_8>"(YBMG:ZQ;W%Q=)9W
M+6:R2* 5C$@)90<LV <G'7&:@DD\3P^(O!OA^]UZXB@O;K48VEM+SS9)+=$1
MXU=RO+CE=W7OD$\>K76C:7?:>NGWFFV=Q9+C%O+ K1C'3"D8XID&A:/;&S,&
ME6,1LMWV4I;H/(W##;,#Y<CKCK0!Y%:>(-631)M%EUF[ALX?%\FC2:B\I,T=
MH.0IESE6)^7?VS4OB"-VT/Q_HD&LZA>:3I]A%<0N]VTC1RE'+0F0G++@*2I)
MZXKUK^Q=*^S7=M_9EE]GO)&EN8O(7;.[?>9QC#$]R>M+9Z/IFGZ>;"RTZTM[
M-@0UO#"JQG/7*@8.: //=2O3X*M/"VO0ZO?76@Q[[;4!-<O< K*NZ.0DG^%P
M%!YX;' K$?5-9AF^'\.J:_>V">(&OKB];[05*!]DD40+YVX#!!W&XXP<8]#\
M0^"=/UGPBWAFT2#3=-DFC>2*WMP%*+()&50"-I8CK[]#1K_@NSU_7_#^HW#Q
M_9])%PC6<D DCG26,(5.3@ 8'8YZ4 >=KKVJP:-+I=MJ]U<Z:/$_]F)J+W)6
M0V^S=L\_G'S_ ";^O.!SBNLT4^+=&AU&*SLK?5[4W*&SBN-:+R01E/G5I&1B
M?F' )/#>W/8KHVEII7]E+IMH-.V[/LGD+Y6/39C&/PIVFZ3IVCVQMM,L+6R@
M+;C';0K&I/KA0.: .+L-2LK'XE>*I=5N;:S1M.L6<3S*%&!+NY. 0,]:XW2;
MW4=.\#P1V,C6FCZMXIEBM9(I#;^78N6*JCXS&&=2 W7#<'D5Z_>>&]"U&^6^
MOM%TZZO$QMN)[5'D&.F&(SQ5RYLK6]M'M+JVAGMG7:\,L89&'H5/!% 'CGB.
M_P#$'AC3;57UQK/3)O$-K#!/_:/VF6"!XI/-61W'*@C<-Q8>O Y?J.NZIX?A
M\:V>CZU=WUG:?8C'=SS><UHTSXEQ(<]%^;G[M=UKGP_TK4K#2K+3X;72[>PU
M2'4C%;VJA)2F<J5&!R&Z\_0UOV.C:7IED]E8:;:6MHY)>""!41B>N5 Q0!Y'
MXLG\1>%_"7B*^TW598[%;:V> OJS7D\4_P!H169689",C<C.,@\<FKE_J>L>
M%?%NN6%IJM_?A_"DFJK]LD\PBY5BH91@!00/NJ /:O1H?"?ARWLKBRAT#2X[
M6Y(,\"V<827!R-RXP<$ C/2K_P#9]E_:']H?8[?[;Y/D?:/*7S/+SG9NQG;G
MG'3- 'C%BL$7Q!^&\T'B*YUJZGL[RYG6>Z\W:[6V=R@Y,88@C;G V<#.[.GX
M/F\0ZO'H.OQZB6N[BY)U..XU1O+:(E@T:V^"J,AQ@#!^4@GDFO2[/P]HFGNC
MV6CV%NZ2M,K0VR(5=AM9@0."0<$^G%$?A[18M5;58](L$U%LDW:VR"4YX^_C
M- 'BV@ZSKD?A#P+XHGU_4[J\O]<33IXI9LQ- SR*5V #+?(#N.3GOT [3P)I
M=M:>.?%[KJ=])/'?A/(FO&=65H8VW,A/)!R W8#'05VZ:#HT=G:V::38+:VD
MHGMX5MD"0R DAT7&%;))R.>34BZ3IR:HVJ+86JZ@Z>6UT(5$I7^Z6QG' X]J
M /*/%T$T7C/Q/KUHN;S0H=-U%,'!9$\X2KGT,9>JRR+KOB7P_P",-K[=5\0K
M'9^8I#+:Q12*G!Z;FWO_ ,"'I7LGV"S\^XG^R0>=<((YY/+&Z51G"L>X&3P?
M4TQ=*TY(;2);"U6.S(:U00J! 0" 4&/EX)''8T >4:OK;MK%IJNF:CJ\17Q)
M'ISM<ZB!',#*5DC6V'RE "0"0&^4'GJ<C5M7UQ/"_C?Q&NOZF+G0O$4D%C )
ML0JGGHNUE RXPY&"2!@8 YS[,WAS0WOI;YM'T]KN5E>2<VR%V92"I+8R2" 0
M?8>E/?0='DM+JT?2;%K:\E,]S"ULA2>0D$NZXPS9 .3SP* /*]<N]5U+7_B2
M!KNJ6MOHMA!>64%M/Y:K)]F\S)(&<;E^[G!R<@\8DCUK5?%%_HMI>75Q%#-X
M=@OPMOJ#6)EN'.'?>O+;<#"YP-V3GBO4SI&F,]Z[:=:%[Y!'=L8%S<*%VA9.
M/G 4D8.>.*AN_#FAZA96]E>:/I]Q:VP"P02VR,D0 P JD87CCB@#S336\2:E
MX^T?P]K>O7$>SP^EY=?V=<X6>5+AU#;@!]X;2V ,[<<C.>E^)NHWVG0>%?L5
MW/;FX\1V<$WDN5,D9WDH<=0<#([UUL.E:=;W4=U!I]K%<1P"V29(55UB!R(P
M0,A<\[>E27=A9WXA%Y:07/D2K/#YT8?RY%^ZZYZ,,G!'(H \.U75]<3POXW\
M1KK^IBYT+Q%)!8P";$*IYZ+M90,N,.1@D@8& .<^D?$]M_PLU]L$9LR<'\*Z
M%]!T>2TNK1])L6MKR4SW,+6R%)Y"02[KC#-D Y// JU<VEM>VLEK=6\4]O(N
MUX94#(P]"#P10!YQXQO++5?%/@>#1KFUN-8AU))I&A</)':!3YVXC.%(XYZF
MN1T*"Z\4^%OAW>:IK&K/=7&I743S)>R(^ )R""#D,-H /8<=*]LTW1-)T9'3
M2]+LK%7.66UMTB#'WV@9I;?1=*M(+6"VTRRAAM',EM'';JJPL<Y9 !\I.YN1
MZGUH \@N8[OPU;^/]5TS4M1^TQ:C%;;Y;IG5$D$&^4@Y&Y0QPQ'RCV&*W9(]
M;T31_%=Q;:@_]FKHDTUOYFJM=SPW*HQWJS#(4C!Z\%>!S7I"V%FAN2EI OVI
MMUQB,#S3@#+?WC@ <]A5.S\-:%I]M<VUEHNG6UO=*4N(H;5$652,$, ,,,$C
M!]: /+()]5DMO!T5UK&I3P^(+5[V\:34&M]TBQ(4B21>47#$X!!;;DGKFQKM
MWXGTCPIX?M)=:DAGG\3Q64=U;70GD-H^_:KLRX9@.#D'.T$YKU"XT32;O3(]
M,N=,LIK"-55+62!6B4+T 4C QV]*1="T=+2UM%TJQ%M:2B:WA%NFR&09PZ#&
M%89/(YYH \@UH77]G?%#PY-JFI3V6E6\%U;/-=,T@,D)=T9NI0G^'I7I-G:P
M6?P]FBMKV>\B^PR,LT]P9V.4)QO))(YX]!6V-+T\3W<XL+437BJMU)Y*[IPH
MP YQ\P X&<\46>EZ?I^G_P!GV5C;6]F 1]GAB58\'K\H&.<G- 'CWALZBEU\
M.EUUX&L1IWFZ0UG R$S>0/W<Y8D<H>"N,D'BK_@^;Q#J\>@Z_'J):[N+DG4X
M[C5&\MHB6#1K;X*HR'& ,'Y2">2:]0;1],>WL[=].LVALG5[6,P*5@9?NE!C
M"D=B,8J*/P]HL6JMJL>D6":BV2;M;9!*<\??QF@#R^RN-1\3>+0B:GJ"&WUR
M=9YHM7\J!K:,N%A$"N&#YV9RG."<D$553Q%K$L.KVLVLW5O:W'C:73IKLR'=
M;6N.(T;/[O) 4$=-V>M=:OPT9KG9<:M'+8+?C4 /L2BZ,@D\P!I]QRN>.%!Q
M@9KL?[%TK[-=VW]F67V>\D:6YB^SKMG=OO,XQAB>Y/6@#R#Q1K6I^'=!\<6N
MB:[>SVNFI826US)<&:2WEDE >,2')(VX."3@-CO6OYFKZ7X]U/P]:^(KMA?>
M&C?)<ZA-O$-UYAC$@X 1>F0!CV[5Z&GAW1(](;24T?3QIKG+6@MD\ICD')3&
M"<@'IU%3RZ5IUQ=/=3:?:R7#P&V:5X5+M"3DQDD9*9YV]* .3^'U[B34M%N4
MOTU.P$+70N=0:]1BX.'CD8D@-M)*\8]*X_4M5O)M$\5>(IO$=[:ZYINI2V]C
M917!2-%1P(XS!G$A?KDC)W#'2O7--TG3='MS;Z986ME"3N,=M"L:D^N% YJ*
M70='GU2/5)M*L9-0C&$NGMT,J_1L9% '%:/I ;XQZK>R7>H+,FG6TYA^U/Y9
M9S*I4KG!48X4]#SUI/$.EVTOQBT&:?4[ZW,EA.ZK'>-&NY'BPH .,'G<O\6.
M>E>@K:6R7<EVMO$MS(@1Y@@#LHS@%NI R<#W-0WNDZ=J4EO)?6%K=/;.)(&G
MA5S$PZ,I(X/N* /!9VO=)\,_$+Q-I^K7]M=Z=XIF,$$4NV$DS1JQ=0/GRKXP
M21P, <YZW5[C6M>\3^)K6WOYK2XT](1IBKJ36J1%HMXE= ,2@L2#NR, C'6O
M27T'1Y+2ZM'TFQ:VO)3/<PM;(4GD)!+NN,,V0#D\\"FZAX>T75YHIM2TBPO)
M8?\ 5O<6R2,GT)'% '-?$-KE_@]K#7GE_:CIP,WE-N3?@;MIP,C.<' KAM8O
M[S3?%.I:A)J=GJ>J3^%;M8+G3%\G[ D2M(&==[?>8@!LYR.GI[5<VEM>6DEI
M=6\4]M(NQX94#(R^A4\$52M/#NAV%I<6EGHVG6]M<*5GAAM41)01@AE P01Q
MS0!YKI[M/H_AF*^U;Q!>:CKUF;UT34OLT*X1"27&&55! "J><DL">123Q%K#
M?#CP1<#6+J2:?Q/%9RW GR\\ EE4*[C&\$(N3_%CFO6;GP_HUY9VUG<Z38S6
MMJ0;>&2W1DBP,#:I&%P..*>=%TIH(8#IED88)_M,,9MUVQS9)\Q1CA\DG<.<
MDT >*:MJ^N)X6\;^(U\0:F+G0O$4D%C )L0JGGHNUE ^<8<C!) P, <Y]W1M
MZ*V",C.#5%]!T>2TNK1])L6MKR4SW,+6R%)Y"02[KC#-D Y// K0 P,#I0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&G_"C_A%!_T'M=_\#?\ ZU=#10!SW_"*#_H/:[_X&G_"C_A%!_T'M=_\#?\
MZU=#10!SW_"*#_H/:[_X&G_"C_A%!_T'M=_\#?\ ZU=#10!SW_"*#_H/:[_X
M&G_"C_A%!_T'M=_\#?\ ZU=#10!SW_"*#_H/:[_X&G_"C_A%!_T'M=_\#3_A
M70T4 <]_PB@_Z#VN_P#@;_\ 6H_X10?]![7?_ T_X5T-% '/?\(H/^@]KO\
MX&__ %J/^$4'_0>UW_P-/^%=#10!SW_"*#_H/:[_ .!O_P!:C_A%!_T'M=_\
M#3_A70T4 <]_PB@_Z#VN_P#@;_\ 6H_X10?]![7?_ T_X5T-% '/?\(H/^@]
MKO\ X&G_  H_X10?]![7?_ W_P"M70TC,$1G8X51DF@#G_\ A%!_T'M=_P#
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M):KODA\G<91$_'S _P 97MC\,UO:5#=1&]-TBJ9+DNFW;RNU>>/<'KS6C10
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M0 4444 %%%% !1110 4444 %%%(S!$9CT49- "T5X3X;\56-Y96WBWQ1%XF
MO+\LM]'<NEC9@2%8X]JNH*#: 6*$$GD\FNB:";QKX\\:V%YJ.H6]OHT%O#8I
M9W<D C>2-F:0[3AFR.,@C':@#U2N?\%_\B\__80O_P#TKFJE\,=<N_$?PXT;
M5+]R]U)$Z2.3RY1V3<?<[<GZU=\%_P#(O/\ ]A"__P#2N:@#H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:C_R#
M+O\ ZXO_ .@FK--D1)(G20 HRD,#Z=Z35U8&>&8%>P>&_P#D6]/_ .N*U6_X
M1WPWC_CVM_\ OZ?\:V;:&&WMHX;=0L*+A IR *X,'AW2DVVGZ&-.C*#NSA_/
M\1C4?+<7Y@\YM,"I&Q',F];DOCH(<#=TW$C).*Z/3D_LZ:\-Q-=LKW2PP">1
MWR"JXVY)XR6R?8^E;5)@'&1TZ5Z!L<O]NU>+Q3-<2V=X=*_>6Z*BE@=J!Q)M
M'S EA*N<$$%,'G%9EO?^)[*U:XNK*\DN5=93  9%83(5V*5[), <G!5&R0.M
M=Y10!Q.KS:YHVHV4L$LUY;VZ#SPQ8>:HAD4)R A=YC%@[@V3C[N:GFE\3:?>
M6.G66R:W!CAFN9;5Y"<PRLTF0P'WT0?\#^E=<0#U&:6@#D+O4?$?F,]E:^4\
MELDA,MM)*JOY3MM"[ACY@J\<\XZXJX][K45EJDD%EETD8P%][$\+C"'DKR>A
M'3I71T4 <A'?^)9-.OA>6P:13<K"(;>2,GRY]B'(<D[TPW&/:J<,GB2**\B:
M*]>2Z*I%AF.T&9P[!F&(V$>"!]T_+SS7=T4 <-)+XCF32I/+O4>"()=D @EU
MF1&<*/E?*AFQG&#D9XK5\)W-Q.+]+L7WVB.9@WVF&=%QO?;L,@"L, <H2,8S
MVKI** "N>\=?\B+K7_7H_P#*NAKGO'7_ "(NM?\ 7H_\J .AHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBL+5/%>G:/>7\%YYJ+8:>-0N)0!M
M6,LRJ!SDL2C<8[>XH W:*Y[PSXLC\1R75N^FWNFWELD4KV]XJAC'("4<%200
M=K#U!'-=#0 4444 ><)\+)%L?[ ;72WA07GVI=-%HOF8W;_*,N>8]W/W<]LU
M?U7P'?R>)-2UC0O$#:4=6A2'4(FM5F\S:-JNA)&Q@N1W'.<5W%% &=H.BVOA
MW0;'1[+=]GM(A$A;&YL=6..,DY)]S5#P7_R+S_\ 80O_ /TKFKH*Y_P7_P B
M\_\ V$+_ /\ 2N:@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *AN_\ CSG_ .N;?RJ:D90ZE6&5(P14R5XM#3L[
MGFM=]I'_ ""+7_KF*:-%TT=+2.KD<:0QK'&H5%& !VKR<NRZIA:CE)IW1W8O
M%QKQ2BCBX/$NH/!<M=7,=H$F1!(T8PL)E93-GIVV<_=(W-D$5T&A:D;VW<27
M,=P1*X@F7 \^)2!O '!&3C(X./>M>F>4GFF78/,*[2V.<>GZU[!P'#R>,KL7
M%U$5D1KUQ'I:^1EFQ(4=U[2@)MFP,G:2,<5;/B2^.GZ8^52?4(S9C*?ZN]5@
MI^4\D#$C$'M&:["B@#BK?7]89]8AD"-LC@BM94VNHN99)(]HV$_*H\ICNPP!
M)/&,37/BN^L]5DL4TZ*:"&.=C.]R0Q$/D[LC81N(FXY_A-=9)#%*8S)&KF-M
MZ%AG:V",CWP3^=/H Y5/$MXJVBQVL<WFDF5Y9MK*OV@1<!4P3ALXXZ8]ZGCU
M^[_LN&5+-I)9+D0*\\BJC9D*]5&>,?W?\:Z.B@#@)/&NI76B6MVED+.XN;-;
MI(TE$F \3, VY!R"I]!TJY<Z_J\>A*D".^JO=3Q*OD[W18]Q&]5]<(N5!'[P
M$<5V=% 'GMQXOU$QZA?0S".Q\B66WDE5 F%2)EP>QP[$[N,#CH:[+0[V+4-'
MM[J&]CO8Y-V+B*1)%;#$'#)\IQC''I6A10 5SWCK_D1=:_Z]'_E70USWCK_D
M1=:_Z]'_ )4 =#1110 4444 %%%% !1110 4444 %%%% !1110 4444 173S
M1V<SVT0FG6-C'$6VAVQP,]LGC->1:];^*?$]Y:W6L?".&ZEMAMC)U^)05W!M
MK $!URH.&R*]=NH!=6DUN9)(Q+&R%XFVNN1C*GL1V->,^*O#VF>%7,<GBKXB
MW]PENUW-'9:BK&"$9S(Y90%&00.<G!]* ._\'G6;J_U74=<\++HEU.(4##4%
MN3,JAN/EX0+GIW+$UUE<9X*TZST35M9TF+5]?U"ZB6WD<ZO<B8!&#%3%C&!G
M>#D Y7TP3V= !1110 4444 %<_X+_P"1>?\ ["%__P"E<U=!7/\ @O\ Y%Y_
M^PA?_P#I7-0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !117+>*O#V
MGRZ7JVJ,;M;M+62172^G10RH<':KA>P[4 =317/^'_#VGV5O9W\(N_M+0*6,
MMY-("649^5G(_2N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KGO'7_(BZU_UZ/_ "KH:Y[QU_R(NM?]>C_RH Z&BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#QOX>C\2ZRVE:;XC?2=7
MN]-:.[B%H)UGL]Q'S9QL^9FP<@G+ 9[=_7)>)_"6I:IJ\&LZ!XADT35$@^RR
MRBV6X2:'=N"E&XR&)(/N?6@"'P1IB:?J>LK>Z_+K/B >3'?2R6WV<1QA6,2J
MF,;<,QW#()SW%=G7,>$O"=SH$^H:AJFL2ZOK&H%/M%V\0B7:@(151>% R>G4
MFNGH **** "BBB@ KG_!?_(O/_V$+_\ ]*YJZ"N?\%_\B\__ &$+_P#]*YJ
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M_P#Z5S5?T'1;7P[H-CH]EN^SVD0B0MC<V.K''&2<D^YJAX+_ .1>?_L(7_\
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M_P"O7_VG76:!_P ARV_X%_Z":Y#Q_H^F7'C&[FGTZTEE=8RSO K,WR <DCT
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MRW,MTZ##33!0[^YV*JY^@%8MM_R4/5/^P39_^C;FN@H **** "BBB@ HHHH
M**** "N>\=?\B+K7_7H_\JZ&N>\=?\B+K7_7H_\ *@#H:*** "BBB@ HHHH
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MU\OG,U"$)6OJ?6Y=%RE)>18\#:E]MO;N/[#>P;8P=T\6T'GH.>M=O7+>$_\
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MJZ&N>\=?\B+K7_7H_P#*@#H:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH *Y[QU_R(NM?]>C_ ,JZ&N>\=?\ (BZU_P!>C_RH Z&BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M?\%_\B\__80O_P#TKFKH*Y_P7_R+S_\ 80O_ /TKFH Z"BBB@"AJFG2ZC'&D
M6IWMAL.2UH4!;V.Y6X^E<QI&DZC?7VM0R^*M;"V5\+>+:T&2ODQ/S^ZZY=O3
MC%:WBS44TZQ@9KU;4O)@,9=F>#[UY[HGB*./4-;)UE5\S4 V3=8W?N(1GKST
MQ^% KGJ&I:5-J A\O5]0LO+!!^RF,;\XY;<C>G;'4USOAS3-0U"UFN9_$^LE
MH;^Y@"YAVLL4[HN?W7HHS^-0_$;5Y-,33?*U%K0R&3.R?R]V-OOSU_6O//"/
MB.=+J*(ZS(J2:G*S)]J.&W3L22,\YS^.:[*>$=2"GS=_P/+Q&:1HU72<&[-?
MB>^T445QGJA1110 4444 %<=XF_Y"P_ZYC^M=C7'>)O^0L/^N8_K30F0:!_R
M'+;_ (%_Z":YWQS_ ,C7<_[B?^@BNBT#_D.6W_ O_037.^.?^1KN?]Q/_017
MH9;_ !GZ?Y'@\0?[HO\ $OR9-\/_ /D9O^V#_P!*Z/Q7I]_8:5?:I:^(]6BD
M5@R0AH?+7<X& /+S@ \<YKG/A_\ \C-_VP?^E==XXN8!X2OXS-%O'E_*6&?]
M8O:IS)VK?(OA_P#W/YO]#1TS1Y]/N&EDUO4KY67;Y=TT14<]1M13G\>]<KJO
M_(6NO^NK?SKNX[B&8D131N1R0K UPFJ_\A:Z_P"NK?SKY//7>E'U/K\L^.7H
M:WA/_CXNN/X%_F:ZFN6\)_\ 'Q=<?P+_ #-=377E'^Z1^?YF&/\ X[^7Y!4<
M_P#Q[R?[I_E4E,F_U$G^Z?Y5Z1QGF_;([BNAA_Y$?4O^N4W_ *#7/=1T[5T,
M7_(CZE_URF_]!K2G\:]3"O\ PI^C_(\LKU7PS=/9>!;.>.SN+ME+_N;?;O.9
M&'&Y@/UKRJO7?!;!?!]B6( 'F<D_]-&KV,S_ (*]?T9\EPY_O4O\+_-$"^,I
M'OY+%?#&N&YCB29TV0<(Q8*<^;CDHWY5>U:=[CPS),UO+ SA"8IL;T^8<':2
M,_0FJEM-%_PL/4SYB?\ (*LQG/\ TUN:T-?93H-PP8%3LP<]?F%?-8O_ '>I
M_A?Y'W.'_BQ]5^9Q%>@:7_R"K3/_ #Q7^5>?UZ!I?_(*M,_\\5_E7@Y%_%GZ
M'J9G\$?4MT445].>,%%%% !1110 4444 %<]XZ_Y$76O^O1_Y5T-<]XZ_P"1
M%UK_ *]'_E0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 45C#Q;X=;6?['&MV!U+?L^S"X7?N_NXSU]NM;- !7/\ @O\
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M@'&$X\WQ)K[SV</'V-13WL<M7H&E_P#(*M,_\\5_E6-_P@/A?_H%)_W]D_\
MBJ>/ WAL  :: !T_?2?_ !51@,N>$FY.5[^1Z&*Q:KQ2M:QT-%<]_P (/X<_
MZ!H_[_2?_%4?\(/X<_Z!H_[_ $G_ ,57J'$9OCG3+>_FL6FDNU**X'D7DL(/
M3J$89_&N9T?PSIUKJEGY+Z@H%RLFT:E<8+%]Q)&_!R22<]<G-=LW@/PR_P!_
M2D;'K*Y_]FIH\ >%@<C2(P0<@^8_^-,5CG?B'JWB'3]:MH])U"&WMVMPS(T;
M$EMS9.0P[8KGO NH>);;5-&TF7589+"$+"8_*;)15P!][VKT.3X?^%ICF72(
MG(& 6D<_UIJ_#SPFC!DT:%6'0AW!'ZUU1KTU3Y7'7N>74P.(E7]HJMHW3M8Z
M>BN>_P"$'\.?] T?]_I/_BJ/^$'\.?\ 0-'_ '^D_P#BJY#U3H:Y[QU_R(NM
M?]>C_P J/^$'\.?] T?]_I/_ (J@^!O#9&&TM&'HTCD'\,T =#1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<SXJ\:VGA.[T^&[M+F9+M9)'EAV[8(XR@=VR0<#S >,G -=-7)^)?#L
MNN>*='>2V\W2UL;^VO&W ;?.6(*,$Y.=K=!QB@"?7_&EIH&N:5I4EG<W$E_)
M&ADA"[( \BQH7)(ZLW&,GY6]*UAK>E-JQTD:E9G457<;03KYH'KMSFO.-/\
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MJ]7#0:5K%KX^^U:?97<%C<2!]2DGEA>WGQ%M#QC)E63(1>@7 /U/<T %%%%
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M)4DX)Z]373T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37
MC20J716*-N7<,[3ZCWIU% #7C20J716*-N7<,[3ZCWIU%% !1110 4444 %%
9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gmtxzzgtjwwl000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A 9,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBO,?B9
M<^+]&U'2;K1_%?V*SU/4K?35M/[.BD\DN&S)O;);[OW>.O6@#TZBO,/%NL^)
M_">FZ!IMUXCC07<TJ7WB2335*V_>(&)3M7)(7)XXSZU9USQK+X8M/"-]JNNV
MLFGW4\JWU[:0;HKB/RW,;* &(R=A^7OGM0!Z-17GGAGXBV/B+Q/XCN+/55G\
M/:?8PS*S0F,1M\YD)+*&Z*.O'%.\"Z_XAGUE['Q+.';4K"/5=/C\@1F!&8AX
M"0!N*;H^2 >3^ !Z#14%Y]J-I(+(PBY(Q&9L[ ?4XY/T_E7F]MXTUZS^&FI:
MI<307VL1ZI)I\#O&(H]QG$2DJO\ ",YQR>,9[T >GT5YQI^O>(]&\3:MX8UO
M58=3N%T9M4M+R.T6 KAF0H5!(.#C'L.:H_"KQ/=^(KA9;SQ_%K,QLP\VDG3$
MMG@D.TDAP 7"DE<@8.<T >JT5S5QJMZGQ+L=(6;%C+I4UP\6Q>9%EC4'.,]&
M/&<<UB1?&+PS+'9S^1JRVEWE8KHV+F(R#I$&&=TA]%SSQP>* /0**X^'XDZ(
M_AW4M:G@U"SBTVX2WN[>[M_+FB9V55)4GH=X/7I1:_$G1;@ZHKVVIVC6%F]]
MMO+-H6N($&6DB#8+#MSB@#L**X]?B3H9T9]6>'48K0S1P6I>T8->NXRH@7K)
MW&1QD'&1S4,7Q1T0Z5<WUS::G8M:3PPW=K>VXAFMQ*VU)'#'&SOD$\4 =M17
M/:AXSTC2[_4[6[>5/[-MHKBXE"94>8Q5$&#DN2.!CG(K/M_B7H3Z=J5Y?Q:C
MI1TZ-9IX-1M&AEV,Q5&53]X,1@8[]<4 =C17FGA_Q=<>(OC (8X]6L;%?#IE
M;3[^%H"LWV@#>4/!.T@!AGN,]:K_ !-\6WNA>*-+L5\7?\(W8S6<DKS_ -FB
M\WR!U 7;@D<$G/3B@#U.BO'?&7B[4M%NO#MI)X^_LNUN=,,\NI_V.L_VJ3*[
M3Y0!*9!)XX&,5MW6OZ_>WVG>&-&UJ!;@:2NHWWB">S!4(3M4K%D*K-RV#P!^
M- 'H]%<QX+O+JZL;A;GQ5IGB01N%6[L41"..0ZHS*#WXQUZ5E>/M9\1174>G
M^%KE(;VULI=4N=T*RB2-"%2$@]/,)?!!!_=G'? !WE%<KJ7C_1].T?2;\1WE
M[)JT0EL;.Q@,L\XV!SM3CH",YQBLFZ^),D7C/1])M]!U:>RO[7S6D6Q;>K%E
M /+#"ID[\C*DB@#T"BN#TCQW:)J=[:WM]=W*S>(9=)MW>UCA2WD5 1%D-EAD
M$!B-Q)QC'-/\0>-[9)X;:SO+RS>#7[;2Y94M8YEG=U#M&-S#:N#@MU!' - '
M<T5YSIWQ1>6^\4+?^']7CM=&,DBRK9[1Y:(I*N6?'F')8#C*X-=9#XITZZU;
M3-/MC)/)J-DU]#)& 46$;<,QSGG>,8![T ;5%<=J_BN+1_&\]K<7]S]EM-!E
MU*:S2U0J51_]8),[MV P"8QWS3]'^(VB:UK=KI<$.H0O>1&6SGN;5HXKH*,L
M(V/WMHY)''H30!UU%<#\2?$NJZ%+HUM9WT>D6-]+)'=ZS):_:%M" -@*=/F8
MXR>!BIVUO58;SP3 =5M;Q-2N)DN;BTC7RKE!"[H5SG;T4\'KGG% ';T5P_B3
M7-;OO&EOX.\/7D.FW)L&U"YU":W$WEQ[]BJB$@%MW)SQC'O1XHN/%N@_#R^N
MDU:QDU&S@EEDO1:8+JHRNV/)4,>Y)(&.AZ4 =Q17(>)M:N=/\ 0ZH=;@T@F.
M(W&H2V9N/+#@#*QKU8L5Z\#)K \*>.-5D^&>M:_J=S;ZB]I-+'87$2+&UX!A
M8BR*3L9W.-N >1QZ@'IU%<'X:UC7K>P\1Z1K]^EWK6E()H[I8%C\R*2+<C;1
M\IPZNO']T9]\;X5>)[OQ%<++>>/XM9F-F'FTDZ8EL\$AVDD. "X4DKD#!SF@
M#U6BN.\;^*6\+:GX?GFN_L^FRS7!O?W8;>B0.X XSG<!TP3TKGG\3^+O-T33
MOM%K!JGBBXFGM!) 'CTZTC0/M."#)(1@\G&21Q@4 >I45PFB:AXFT3QI;>&O
M$&J6^LPWMG)<V]\EJ+>171AN1D4E<888(K;\1>,--\,W=C:7L=W+<7ZRFWBM
M8#*\ACVY4*O))WC&!ZYP!0!T%%<%;_%SP]<BU*VFL*DLXMKAWL6"64I;:$F;
MHK9XP"3R*G?QI8Z7XD\7?VGJTHL='AM6>%[552 R*3\C@EI"V5X(&#@#.30!
MVU%<DGQ"TO\ L1]2N;#5[1A.+>.RN+%EN9G(RHCCZMD D8[ YQ@UI^&_$]EX
MGM9I;6&\M9K>017%I>P&&:%BH8!E/L0<C(H VJ*** "BBB@ KEO&_AF[\30Z
M$MI-#&VG:Q;ZA)YI(#)'NW 8!Y^;CM74T4 <]XGMO%%PL(\/3Z/Y; I<0:I
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M ("6W_QNC^Q=;_Z&V^_\!+;_ .-UOT4 8']BZW_T-M]_X"6W_P ;H_L76_\
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MUK>M$N4M8UO)H9K@#]Y)#$8T8^REF(_,U/10!YY% O\ PDS^#"BBW34/[:5
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MH 2BEHH 2BEHH 2BEHH 2BEHH 2D/WU_&G4A^^OXT %%+10 E%+10 E%+10
ME%+10 E%+10 E(O\7^\:=2+_ !?[QH **6B@!**6B@!**6B@!**6B@!**6B@
M#%\)_P#(&G_["5__ .E<U%'A/_D#3_\ 82O_ /TKFHH C\/?\ASQ9_V%4_\
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MBSM59&6WB!0;5P@&!D''Y@5-11SR[@5CIMB<_P"AP<H4.(P/E.,CZ<#\J?\
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M?^AG_P#)"/\ QH WZ*P/[(\0_P#0S_\ DA'_ (T?V1XA_P"AG_\ )"/_ !H
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M?^-']D>(?^AG_P#)"/\ QH WZ*P/[(\0_P#0S_\ DA'_ (T?V1XA_P"AG_\
M)"/_ !H E\)_\@:?_L)7_P#Z5S45;T33&TC3!:/<M<R&::9Y60+N:21I&X'
MY<T4 :-%<A::1#KGB#Q(][=ZK_HU^D$*6^J7,"(GV6W? 6.15^\['.,\U:G\
M'::D3R+>:Z-J$X_MV]P>/^NM '2T5Q:^"790PU;5,$9_Y#-]_P#'J7_A")/^
M@MJ?_@YOO_CU9>T?\K_#_,Q]K+^1_A_F=G17#Q>$/.DF1-6U7=$VQ\ZO?CG
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M!;4__!S??_'J/:/^5_A_F'MI?R/\/\SLZ*XS_A")/^@MJ?\ X.;[_P"/4?\
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M9VM%<6/!+D C5M4P>?\ D,7W_P >I?\ A")/^@MJ?_@YOO\ X]1[1_RO\/\
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MG17&?\(1)_T%M3_\'-]_\>H_X0B3_H+:G_X.;[_X]2]H_P"5_A_F'MI?R/\
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M_P"PE?\ _I7-10!'X>_Y#GBS_L*I_P"D5K6Q>2QI Z,P#/&VT'O@<UC^'O\
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MK?0T#H/I0 ZBDHH 6BDHH 6BDHH 6BDHH 6BDHH 1NJ_7^E.IC=5^O\ 2G4
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MPB-K_P!!37/_  :S_P#Q5;'V^S_Y^X/^_@H^WV?_ #]P?]_!0!C_ /"(VO\
MT%-<_P#!K/\ _%4?\(C:_P#04US_ ,&L_P#\56Q]OL_^?N#_ +^"C[?9_P#/
MW!_W\% &/_PB-K_T%-<_\&L__P 51_PB-K_T%-<_\&L__P 56Q]OL_\ G[@_
M[^"C[?9_\_<'_?P4 8__  B-K_T%-<_\&L__ ,51_P (C:_]!37/_!K/_P#%
M5L?;[/\ Y^X/^_@H^WV?_/W!_P!_!0!C_P#"(VO_ $%-<_\ !K/_ /%4?\(C
M:_\ 04US_P &L_\ \56Q]OL_^?N#_OX*/M]G_P _<'_?P4 8_P#PB%K_ -!3
M7/\ P:3_ /Q5'_"(VO\ T%-<_P#!K/\ _%5L?;[/_G[@_P"_@H^WV?\ S]P?
M]_!0!C_\(C:_]!37/_!K/_\ %4?\(C:_]!37/_!K/_\ %5L?;[/_ )^X/^_@
MH^WV?_/W!_W\% &/_P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\ Q5;'
MV^S_ .?N#_OX*/M]G_S]P?\ ?P4 8_\ PB-K_P!!37/_  :S_P#Q5'_"(VO_
M $%-<_\ !K/_ /%5L?;[/_G[@_[^"C[?9_\ /W!_W\% &/\ \(C:_P#04US_
M ,&L_P#\51_PB-K_ -!37/\ P:S_ /Q5;'V^S_Y^X/\ OX*/M]G_ ,_<'_?P
M4 8__"(VO_04US_P:S__ !5'_"(VO_04US_P:S__ !5;'V^S_P"?N#_OX*/M
M]G_S]P?]_!0!C_\ "(6G_04US_P:3_\ Q5'_  B-K_T%-<_\&L__ ,56Q]OL
M_P#G[@_[^"C[?9_\_<'_ '\% $>EZ9;Z/IZV5KYIB5WDS+(9&9G<NQ+'DDLQ
M/XT5:1TD0.C*RGH5.0:* .2TO1-)U/Q%XKFO]+LKN5=3C0//;H[!?L=L<9(Z
M9)_.KTGACPTUS$B:%I)*L0X6TCX^7//%+X>_Y#GBS_L*I_Z16M:CP1QWD;HN
M&D<LQR3D[<?ATIH"A_PB?AS_ *%_2O\ P#C_ ,*/^$3\.?\ 0OZ5_P" <?\
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MXY"X8<$C=6GJ]Y+JOQ*M_"WVN[MK6/1Y-0D-M,T1=S,L:?,I#?+ACCH<\YH
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MA?TK_P  X_\ "MFB@#&_X1/PY_T+^E?^ <?^%'_")^'/^A?TK_P#C_PK9HH
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M0 E%+10 E%+10 E%+10 E(?OCZ&G4T_?'T- "T4M% "44M% "44M% "44M%
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M@DCD'&. "/<5V%%)8J*5O9Q_'_,.7S.::[\9K%)MTK2'D )3-VZ@GC ^Z?\
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MX_["=_\ ^E<U%,\&S17&@2302)+%)J-^R.C!E8&[EP01U%% &_1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gmtxzzgtjwwl000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. B\# 2(  A$! Q$!_\0
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MP0-Z#S.7'RJ&Y&"3D8S6WJ'B*UTS7K'2[I'0WL$TL4Q(V9B ++]=I)^BGTH
MV**X_1?B%I^NVFB26UI=1S:M//"D$@4/#Y6[>SC/ &!^+J.]<UIGQ U-M(\'
M2Z78ZAJ\&K2W*22730)<2;/,^7AE0$;<YZ;1CK0!ZK17ETWCG4]#\<^.A/8W
M^IZ7IB6<HC@:,"TC,):1OF(SD\X&3P>F*] OX+C5M,C_ +.U6?3VDVR+<01Q
MNQ7'3$BL,'([4 :-%>1>'M>\:7OP=;Q5%J=QJ>K7"-LMA90D1!9RC.BHJEV"
M*3M).34VM^+Y[3X1ZYK>@>*[C4KJVEB1)[FVB2:V8RHC(R;%'0G[RYYX)XH
M]7HKS3_A88U?XA^$-*T>ZNEL[H7?V^*>R>+S"L.Z/!D0'@@GY3]>U(GB_6!\
M08;J2ZC7PK<ZC)HD43*JG[0B9$@;&3ND62/&0. 1G- 'IE%5FO(7DEMK>YMV
MO%4XB+@D'W YQTKD_!6L:Q/)XIBUN^CO9=-U!HD:* 1*$$2MA5R3C)/4D^]
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MZ,<8'! Z@5?T_P <06MIJI4:KJ=T/$$VEV]LXB#M*H!V(1@", $Y<YX.3TH
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M[I@<Y;)R37=W=[:V*1O=W$<"R2+$AD8*&=CA5'N3P*I_V_8?\)3_ ,(YN?\
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ME43DY\P 'AO?K6QX0ADL=?\ !=RE[?S2:UH4EQ?"XNY)5DD"PL&"L2%P7(&
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MUZ;28&<X&?6@#R+P)/->:CHC2Z[%'KD;2G5+.6YE:YG)#;U>(_*@5L%2!@
M#@\^O4F!DG R>II: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,=NN I(89:1PX!]%X!JS!\4=TFGWDMC-)975I9K]GM4#R_:[G>RH"2. J?\
MCPH ]+HK@(?BA9W]O,L>FZE9.;6ZEBFN(49/,MQ^\3 ?DKQZ ],US^K?$?6+
M:\O!;:C8HT-M:R6EI+ILDCWLDL0?8&5\(2> .>O?% 'K]%><>(/B!J&D:[HT
M#06EO:+;PW&M+,^9+<3.(U5>>JMDG@\#-9.K_$76[/Q-KEC;WECYEE=I;V.F
MM82/)>EE5M@D5L*QR>WO0!Z[17FA\7ZW<>-M4TM=0BM+>SNXH$C71IKHN&1&
M.Z5&VKRQ&2..M>ET %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5RVO:/X6US5K>?7)[.Z-FCQI:7,J
M&)2Q!+%#_%\H&>PS74U\=?$1+=OBAXC$^0/M;8('? I2=E<F4N57/H&V\">
M(+E'FGM+JUB\W[/8W-Q&]O;F1@S;$[<CN3@4Z'P7X'A&DK_:$;QZ3=/<V:/>
M(1'O8-L]T# $ ]^]?)A1=QX!_"D*KG[H_*ES"YS["U/1?#VJZHU]<>(Y?O>;
M';_;T,44NPH)$4YP0&.!G;GG&:9-X<\(SV4EHVJQK#)I\&G$+>("(H6+)C_:
MR3DU\@;5_NC\J3:O]T?E1S!SGV')H/A274'O6U:/SGOFOSB[3'F-#Y)_#;V]
M:HS>#/!<^GQ6+ZO^YBTW^S%Q>QY\GS%D_P"^LJ.?3M7R:8U^7 4D]@*66V>!
M]LD>UO0BESH.='W(-:TD #^T[+C_ *>$_P :/[;TG_H)V7_@0G^-?"^U<?=%
M)M7T'Y4^8.8^Z?[;TK_H)V7_ ($)_C1?WMAY,UI<:C%:O)&5SYRHZ@C&X9[^
MAKX755W#Y1U':O3OCHJGXC\@'_0(.H_WJ.;0?-I<]DC\!^ K6VL5L+JVL+JS
M!"WMM<QK/("A1M[$'=D,<\5;T[PCX%TJYTV?2WL;2YL1M66"= \ZE"I64_Q@
M@Y.>_-?)45N9R5CCW$#)P*6'?;2I/%A71L@X[U+J=B'5[;GUII7ACPMH?AR?
M0]+UN2TCEN/M)GCOU$RN,8YZ;0% VD$$<'-,3PGX/33KNR_M5"EW:R6TTAO$
MWMYC[Y'S_>9L9XQP,"OF"/6Y(KV:]-G;,\T?EL"O'UQ64GE*&S$I)Z<=*F-2
M3W1,:LW\43Z\'A_PF+^:\_M9/-FN+.X;_3$QNMAB/\,#GU]J%\/^$UC=!JR8
M>VN[8_Z8GW+F3S)/QST]!ZU\A>4 N2@_*F[5_NC\JOG+]H?9/A_3O#/AN6XD
ML=5A+7$-O"_FW:-\L,?EICWVCGWK<_MO2O\ H)V7_@0G^-?#6Q?[H_*DV+_=
M'Y4<X<Y]S?VUI7_03LO_  (3_&L[Q'9:%K]A:VNKWD/V(S)<"(SJJ7&TY ;/
MWDS@X]A7Q447'W1^5>F?$X ^#?AV,#_D$>GM'3YAJ9[++X%\ 273/'/:06DD
ML4LUA#<QK;3-'NVED[_?.1G!XI+GP)X"N++4[%+JWMK/47BDDM[>Z1$CDCZ/
M&/X21P?6OD_:F/NC\J0*O]T?E1S!SGV)K&C>&M9MK>TDUQK>QB@%L]I;WZI%
M-%Q\C+SZ 9&#C(S@TZVTCPQ;7=M=?VO&\]O<W-RK-=)R\X(?(] #@>F!7QZL
M092=J\>U,V+_ '1^5+G%SGUI<>#/!ESID=@^K?N4T]=.&+U,^4LJRCG^]N4<
M^E6I/#GA*2UO(?[517N=3.JB=;Q!)!<''S1GL.,8.>":^0E12/NK^5)L7/W1
M^5'./G/K6;P9X$N%N))KBT?4)[DW1U(W$?VE)-^X%7_A (  QC Q5N70/"DM
MK'%_:Z+)%J3:I%.EX@DCG9BS8/3:<D;<=#7Q_M7^Z/RHV+_='Y4<P<Y]@Z;H
MVB:1=R367BNYCADNGNGM/MD)B9W;<PQMS@D],UJ^(+?1O$?AV?3[W4433[DB
M.22&Y5=V"&*;O?'(],U\4[%/11^5>A3(&^ -B-HQ_P )!(>G_3(T^8.<]QN?
M _@*:9VMI[2PAFB$%Q;V5Q'''<('5\.._*CD8."1WJ=O"'@51J"6LME8P:A9
MFSN8+6>..-QG(?;_ 'QDX;WKY.LY((&D,MLLNY"JY_A/K3HX%>,YVC'M4.I;
MH0ZMGJCZUDT+P[_PC^GZ+:^(9;.UL8S$IM[Y TB,,,'SD-D$\XR#R,4Q/#7@
M^*.VCBU""..VOH+Z)4NT^5X8Q'&ONH4=.O7FODAXE0E0%/X5/:::][(R1*GR
M\DFAU4E=@ZT8KF>Q]7+X6\(K!'"-5&U!> ?Z8F?]*_UG_P!;T]Z=)X:\'S:=
MJ-A+J$4D&H1012AKQ,KY*A8V4]F& <^HKY,N)&EEPZ("GR_*/2BY@*"&0Q(J
MNN5QWH53N"J[7/JNZ\$>![T7S:O<6^H7=ZBJUW>7$;3( @0;&XVX S]>:>OA
M3PC_ &;?V4NLF;[;+%,\\EZGFI+$H5)$88VL-H.?K7RW#IPO-+NKUKF(- !B
M)S\S#VK,"+GA1^5$:J=_((5E*Z['U_'HVBP:K=:C;>+KJWEO)$EN$BO(0DCJ
MH7)!4]0HS@UU]M=VUXK-;7$4RJ<$Q.& /X5\(F,8SM&/I7T9^SB /"^LX&/]
M.'_H"U:E<T4KGM%%5--N7O-.@N) H>1<D+TJW5%!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\<_$:4P_%'
MQ$X4'_3&ZCV%?8U?&WQ-&/B9XA_Z_&_D*F:NK$32:LSEY6WR,^ -W84SM4J1
M>:,!@&]#3[>1;:YW/&L@7JIZ5E>RT,;V6A6I5&YL9Q3I6#RLZJ$#'(4=J95%
M="QYB"(1E!E3PXZT"0RW"-)NE53R,\D5"*=""9E&2,GJ#4V)LAUVL27#"'=Y
M?4!NU0"I9@?-;&2H. 348'/--;%1^$%^\OU%>F?'0X^)'_;A!_[-7F8^\/J*
M].^.*AOB3M"DL;&  #_@55T*^RSSGS'BDW(VTXZJ:C)).?7FK4<,5K<F/4(G
M("\*#CFH<>9(R1)D$_*.^*S31BFN@QHY$17*D*W2FA23P,TYBV-I8D#L>U(&
M(Z=13U*UL+R<*3CUIS1A1US21H9I .23Z=35^WL7N7>!  R#)W\5,I*.Y$YJ
M.YFX/7TI"<GI5@H\*/G!1CBHEDVQLFT'=W/452=]BT[[#*]*^)W_ ")WP[_[
M!'](Z\UKTOXFD#P?\/,_] C^D=6MBULSS+-*:0]:<.G-(0Y::1@T9 H;D<4A
M#D /4X_"FD<TZ/!R"2*3OB@.HVE6@C'- H&3VT22SA'D\L'^+%>CI,]I\"H4
MA591)KLL9+#MY?4?E7F95EP2",],BO0)G*_ .Q8''_%02?\ HHTG&Z9+CS)G
M D^7)E1C'8U/#,-Z>8@*AP3[CN*@8;B,<DU*8C"%+C#YY1A@U+LR79HVO$FH
M:=?+;"PM!"47YR$VY]JQ5N61!L)0]"RGK5FSGEM+M+T6RR+&V2LB93Z&EU6[
MCU+4)+N"UCMT8#,<8P :QIQY+4TM.]S"E!4TJ25TNM^O8H[E"MP22>#5B9WN
M+.-R%"P_+QU-,M5@:8B=)&!4A53KN[5$J-YHA9MN3@^U;:7]#9V;]"4>0(-X
M<B4=%(X-1*J'<22./E&.IJ:]M!9R!!*LC=]O2H@\8A:-HOWA/RMGI0G=70XN
MZNM;BK&PM6E.X#.!QP:^A/V<O^17UG_K^'_H"U\^.UQ'&+>4,J_>"D8KZ$_9
MS_Y%C6?^OX?^BUK2G>YI2O<]6T+_ ) EI_N?UK1K.T+_ ) EI_N?UK1K4W"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBN(\4>.SX>O=7M7%G ]IIZ75H+N0J;V0ELQQ@=<;0.,G+#C% ';U\;?$
MS_DIGB+_ *_&_D*^PK.=KJQM[AHGA:6)7,;]4)&<'W%?(_Q M%NOBAXD5ITB
M NG;+?0<5$VDKLSJ248W9Q0-31F+8RLN6/0U#QNJ<*L;!B-Z]QG%0S.1$H <
M;NG>E=2Q9E1MF>N.!2?>)(_"O0=,\9:!:>&X[&:Q=I$BV/$(P1(<<G/O6&(J
MSII.$.8YL56J44I4X.=^W3S//\+'*,D.H(/'>M&739+JRDU.")8K<-C;NZ5G
M/AF9D4*I.0/05/!'+(&@:5HUQNVL3@_A6D[Z-.QM.^C3M_D0Q2F'E"<GUJ(_
M>S4C1L$W@':#@FHZT5MS16O<E,818W$BMN/('45Z1\<6*?$H,"018P$$=OO5
MYHI7 !4[MPP<UZ5\=/\ DHW_ &X0?^S4^@U\+N>?2R_:"\DSLTF.":LZ='8O
M'+]KFEBD ^0H.*SXW"$Y4-QWJ_I6G2ZSJ,=G%*D3R9PSGBL9I1@[NR,*B48.
M[LD9[#YCR3SP:FCC\N7]X <#M4UWIES::A-8RH3<QN5*H-V?I5:&*::<0Q*6
MD)QM/%5S*2NGH7S*4;IZ$T$WDW7GIC*-E>*Z+5-!FLXH=4N;Z+;=Q[D,0^7=
MC.W\N]8LVC74&GK=N4^:4Q>6#E@11?W\4UC:P0P21M$I$FYR58^P[5A).<DZ
M;\F<TTZDXND]-GM_6Y&TR?8C"8E#AC\U4V1@%;;UZ5+Y:FU,OF#<&QL/I217
M!B1QL#%A@,>U;)6V.B*M?E(*]*^)Y_XH[X=_]@C^D=>;/UR*]*^)W_(F_#O_
M +!'](ZU6QM'8\SZTY: ..M'2D2!QM]Z0'BG*NX^U-8;7(I +2XI!S4F5V X
MY%#$QI/&*:IPW/:EH')YH LWE])>LADP-@P *[>;_D@5C_V,$G_HHUY^0,<5
MZ#+G_A0=CC_H8)/_ $4:(I)6012C&R.%AD:&6.9 -T;!AD<<5?O]2EUF\2:X
M6./"[<(.,5!YZ21+%Y()'3%5AE3TZ'D&L>5-\S6J,.52ES-:HWH-7U.V\,W=
ME#%$]@TFQY2OSC-8&&D'RC..:MWEW%(H2VB:"(@;TW9#,.]3Z=J%O;V%S!):
MK)+*/ED/\-1&/)%RC'5LSC'V<7*,=6_ZN4X[@16X58\3*^X2=Q[5#<7#W,S2
MR$&1NI Q3[B VTJCS%D5E#;E-5BA9CBMHJ/Q(Z(J-^9#B21TY]:7DC?GY@:(
MB4?D9S2,"C_6J\BBW>W\]^4:8+\@QE17T!^SH0?"^L8'_+\/_0%KYW9R(=@R
M 3DBOH;]G'_D5M9_Z_A_Z+6G2BEHBJ,5'1(]7T+_ ) EI_N?UK1K.T+_ ) E
MI_N?UK1K8W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O//&MKKLOB"&7PY!=&^CC0^=>-%]@3D\X<%M_J8\'IDUZ
M'7CWCD6$OQ#NX[^W\.S!=/@*#7[\Q*,M)GR@ ?3YL^@H ](\-76M7.DD:_:P
M6^H0RM$[6Y)BF Z2)GD CL?0U\K?%%(H_B3KQ#;R]RQ/^R<"OKNR"BPMP@C"
M^4N!$<H!@?=/<>E?'OQ-_P"2E^(O^OQOY"IDB)JYR-2AOW97/X4S!QG'%"'#
M@U#(>HHZXJS9RP)*%NDW0G[Q YJNH+S *,DG %2-;RBX\G83(?X1S4RLU9D2
MLU9B "2X(C!VEN![5>U1HQ=19B=2$&X$]15&2%X9=I(W=MIJ6Y^T1C%S$0S
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MD_PH.@:U_P! ;4?_  %D_P *Z5?BEXZ89'B.[..N$3_XFF?\+4\=?]#+=_\
M?*?_ !-5[%[G->)S?_"/ZUG_ ) VH_\ @))_A3_[ UK'_('U'_P$D_PKI?\
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M2F*74[U8Y'>E%TGNF_\ *Q6MM"WL@\E SMY\9^93T_"DFF^TWJ;]D0.%9D'
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M+3_<_K6C7$=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7=<L$SC/'-,=2,$]ZEC81[HV P>I/:EN2"5 )( [BJE&-2$JDGKVVLV_\O\
M(A/6PR"0I)R <\"FW"%93D'/?(I$#$G Z<U+(3*NXD9'&.]1&\Z3B]]U^H;2
MN0"I%8CH3FF *$SN^;/2E'!K%IQ:?S&R4JIB#,^9">:BY!P#4YMIO)^T%,1D
MXSF@_P#'KP%)SR>XKHE3E.3NN5I7];?Y]?O)31!STKT"3/\ PH6QZ_\ (P2?
M^BC7 HQ5M_7M7H,S.WP(L">#_P )!(/_ "$:QY8Z7;OZ=/4OHSAHW5)$<IN
M/(/0U*[0, J,P+G)ST6HC')N"X//3WJ:&*T:VD\Z8I,#PM=2E*G-Q:^_0YY6
M6I?@TZSDT>:X-WB4':J9^\:S8$502V=QX!SC%/2TD;S9(D)2'&\@]J6ZCMY9
M-]JVV/:.'/.:N?+!-35W'3?\O1W,XZ-IRO?\/(BO)'<Q"68OM7 [D"H<*K#G
M@]2*TK)?[62WTH+:02%SBZE;;^!-9I4Q%HV RI(R*S<Z4I7M;;O]QK!KX>J_
MJX-Q(-IS@\58:*$W<(N9=L3#+,G.*+6+SY1"9(XF8;@SG ^E0W#1MLVQA-JX
M.#G)]:SJ-V6OR'N[$MU9/;P)/*#Y<P)B;/)^M>]_LY_\BOK/_7\/_0%KY\::
M1[<1LQ94.0">%KZ#_9T_Y%C6?^OX?^BUK&LWR*_]:_B;45)?$>K:%_R!+3_<
M_K6C6=H7_($M/]S^M:-<ITA1110 4444 %%%% !1110 4444 %%%% !1110
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MR)DKH^85&"1FFXR>M?1W_#.OA_.3K.JGZ^7_ /$TG_#.?A[_ *#6J_\ D/\
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M5-J'*SY9+$-N7@'TIC-M;,;?E7T;_P ,\^']NTZQJA]/]7Q_X[3?^&=/#_\
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MVX<C/F_OFIV7" [ASZ5]$_\ #.OA[_H-:K_Y#_\ B:4?L[^'Q_S&=4_\A_\
MQ-.$X+1@X29\Y%LGGFA/OXS@&OHS_AG7P]_T&=5_\A__ !-'_#.OA[_H,ZK_
M .0__B:7M/>N]0]FSYZF@:'!)RK=#ZUV]R/^+"6(_P"IAD_]%&O47_9ZT*0
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C1%& H' I]8FH4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gmtxzzgtjwwl000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &1 7X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T3P;X-\+7
MG@;P_=77AO1Y[B;3;:2666QB9W8Q*2S$KDDGDDUM_P#"">#_ /H5-#_\%T/_
M ,31X$_Y)YX9_P"P5:_^BEK?=UC0N[!549))P!0!@?\ "">#_P#H5-#_ /!=
M#_\ $T?\()X/_P"A4T/_ ,%T/_Q-:O\ :NG?\_\ :_\ ?Y?\:E:[MDA69[B)
M8F^ZY<!3^- &+_P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-;;7
M-ND(F>>)8FZ.7 4_C2R3Q0Q^9+*D:?WF8 ?G0!A_\()X/_Z%30__  70_P#Q
M-'_"">#_ /H5-#_\%T/_ ,36Z\L<49DD=40#)9C@#\:(I8YHQ)%(DB'HR-D'
M\: ,+_A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH*C$\)G, EC,
MP&3&&&X#UQ0!A_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-
M;DT\-NF^:5(USC<[ #/XTYY$CC+NZJ@&2S' % &#_P ()X/_ .A4T/\ \%T/
M_P 31_P@G@__ *%30_\ P70__$UN0W$%PI:":.50<$HP8?I2RRQP1F261(T'
M5G; 'XT 87_"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 36S#>
MVEP^R"Z@E;&=J2!C^E3T <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30
M_P#P70__ !-=!5*[UC3;&^M+&[O8(;J[)6WA=P&E(Z[1WH S/^$$\'_]"IH?
M_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B
M:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!
M_P#T*FA_^"Z'_P")K?9E1"S$!5&23V%5-,U;3]:LQ>:9>0W=L6*B6%PRY'49
M% &7_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UN1SPRLZQR
MQN4.'"L#M/OZ413PSH7AECD4'!9&! _*@##_ .$$\'_]"IH?_@NA_P#B:/\
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MHK:012F[N%CD/\+;0 ?PKR99=.;2TT.6U$?BW^U/+/B$W68A\V<^;GTXQ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KQ_\ :._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\ HJ6@
M#T#P)_R3SPS_ -@JU_\ 12UT%<_X$_Y)YX9_[!5K_P"BEKH* "BBB@ HHHH
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MPGXKT_QCH@U/3EE1 [1213+M>-QU!%>9_$/_ (3?PUJ5C/;>,I?L^J:B+:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7C_P"T=_R3S3_^PK'_ .BI:]@KQ_\ :._Y)YI__85C_P#14M 'H'@3
M_DGGAG_L%6O_ **6N@KG_ G_ "3SPS_V"K7_ -%+704 %%%% !1110 4444
M%>4?$GPEXLUC7$O;9Y-4T!%7S-&BO#;,Y Y.0.<_G7J]>97T^J:W\4-:TI=6
MDM8M/TP?8[-7VK</*A!=O7:2.G3BI8U_7WF5\&Y]/TF_U70Y]'N-)U2:YDN(
M;>X@8,(!C"^81SC/K7L5>->!]*O_  E\0],T>XU2:_GN])>6_BEF\X6\BL,%
M2>0#7LM:/9?UMI^A*W?];ZA12!E;.T@X.#@]*0NH8*6 8] 3R:D8ZN%^'_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'_VCO\
MDGFG_P#85C_]%2U[!7C_ .T=_P D\T__ +"L?_HJ6@#T#P)_R3SPS_V"K7_T
M4M=!7/\ @3_DGGAG_L%6O_HI:Z"@ HHHH **** "BBB@ KSGXA::UFTFNS^,
M-;TVW<I#'96"AR[G@!%ZEC7HU>6?%7Q/HJS0:',^IQ:A:/'?K>V, D%B0<*[
M@]1R>*3Z#74B^'5]#/XAB5_$_B*ZFEM7D2RU2(*K -M8@C^)2.1VS7K%>*?#
M>."3Q]Y8UJY\0O903$7<5N([6W:1@S#/\3,3^%>UU3V1*W84444AA7"_#_\
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M $K9?QGXJ>-E_P"%=:GR"/\ C\@_QKDOAX_C#P5HUW8S^!;^Y:>[>X#1W4(
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M-@^$>^\LPIN(LV_R;AE>>AR/2N7\9^!;CQ)YMWIWPXU+2]0* *8KN 0DCNR
M_P L4 >[^'=:B\1>';#6((VCCO(5E"-U7/4?G6G7F'AK7O%>@>&=-TEOA[J,
MC6ENL1=+N$!B!U'-:P\:>*2P!^'>I@$]?MD/'ZT =S12 DJ"1@D=*6@ HHHH
M **** "BBB@ KQ_]H[_DGFG_ /85C_\ 14M>P5X_^T=_R3S3_P#L*Q_^BI:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'_P!H
M[_DGFG_]A6/_ -%2U[!7C_[1W_)/-/\ ^PK'_P"BI: /F*3_ %C?4TVBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *FMO
(]8?I110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gmtxzzgtjwwl000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N 6P# 2(  A$! Q$!_\0
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M22<9]:RY/AUKV@Z+X<GTO5KS4[O0YX9([#9;QH5)Q,%8A3RI;[S?CGFO6:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&H_]?/\ [(M7ZH:=_P ?&H_]?/\ [(M7Z;W%'8****0PHHHH **** "BBB@
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M8>-=JL,=0.PK23?+J8P24W8L4445F;!1110!0T[_ (^-1_Z^?_9%J_5#3O\
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M5!K,GFEO; 6"6,T<S!58LN$CQW![].,5MT5<9V(E#F#M1114%A1110 4444
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M6EX>M9[6RF$L;0QO,SPPN<F-#T'_ -:G2G-RM+M]VWE^HDV:]%%%=)84444
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M8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*;("T; =2"*=39.(G(_NFA@<\(M1;1K?3CISJR&,&0R+M^5@2>N>U='7&I-9
M?V1;3)J4K7Y:/*?:F))+#(VY],UV5<]!I_<B8A111704%%%% !1110 4444
M%%%% !1110!Q^K6UW:ZY-<VL>'=ED23[6(T"A<,"I/4^N/Y5<\(V\L-O*_E&
M.!UCVG?N$CX^9Q['BJVI:/#J6KW[+]D>YC,;*MU&>/E((SW4CTZ&NDT^![73
MK>"219'CC"EE& <#M6C?N6,5'W[EFBBBLS8**** *&G?\?&H_P#7S_[(M7ZH
M:=_Q\:C_ -?/_LBU?IO<4=@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M:X35)FO6:/*?:B<DL,C;GZUV%94ZG.).X4445J,**** "BBB@ HHHH ****
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M'_/&/_OD5)10%B/[/!_SQC_[Y%48+>+^V;S,*;?*BQ\@]7K2HIW%8C^SP?\
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M^SP?\\8_^^11]G@_YXQ_]\BI** L1_9X/^>,?_?(IX 4 *  .@%+10 4444
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gmtxzzgtjwwl000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ ?@# 2(  A$! Q$!_\0
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MXDU_XG)XU\3Z1'I L;0VMG:+<K,Q)W98LO&,2/U]>G&:U?AGX<U7P]_PDO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_"_/!7][4?_  %/^-%T!ZA17F'_  OSP5_>U'_P%/\ C2CX]>"L$[]1&/\
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M56 ?(5.TJ221SFE7/W:AS3U//'6AH"5,^E:.GV$EW((XU9F;@!1GFJ2S@0[
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M5>1C[$U<CN71P0Y'H:\_ZK*%[O4CEL;ES>W0MCIJ"-8@_F$MCJ!ZU@W%PC8
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MINGB>*25G 5!ZU-514;L'89!'YC #C/O6F-,G73VNW&(0VP'^\?:H?LJPSJ
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MG*>:SYMRJ1Y/^T4VVX\.D==MQ_[3KQ:ZO9[N&))9"PC7:H/85[1^T5G[3X=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gmtxzzgtjwwl000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $< A\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TOPSI>HZQ
MX4T?5+GQ/K(N+RQAN)1&T(4,Z!C@>5P,FM3_ (1FZ_Z&C7/^^X/_ (U1X$_Y
M)YX9_P"P5:_^BEKH* .?_P"$9NO^AHUS_ON#_P"-4?\ ",W7_0T:Y_WW!_\
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MSW(QWK4^('C_ %GPKJ$BVBZ#!:V\(F(U*[/G7G4E(8T)((P!N< 9/M0!U/\
MPC-U_P!#1KG_ 'W!_P#&J/\ A&;K_H:-<_[[@_\ C5>:ZSJT6J>+M0UG[*KP
MW7PXDNOL\Q.&5I"VQBI!Q@X."#Z&NG&H>)+7X<>&M1\.?\(Y8V::5%+>#56G
M$<*>4A4(5).!\P.XD].3S0!T?_",W7_0T:Y_WW!_\:H_X1FZ_P"AHUS_ +[@
M_P#C5<%J'Q.\1>'O!^G7GB"#1K/5=5N95M"Z7"P1VZJ"))$ :3))'R@ X=<X
M.:TK3XJ&_P# =KJ]G:VLVJ76IKI$$*R.(7N&;"MN*A@I3Y\$ ]NM '5_\(S=
M?]#1KG_?<'_QJC_A&;K_ *&C7/\ ON#_ .-5Q>@2:Z_QT(\106$5\GAC:382
M.T4B_:0=PW@%>21@YZ=>:P_B1;Z+<_&*!=>\.ZKKMHOA]66VTR-WD1_M#_.0
MK*=H&1G.,L* /4/^$9NO^AHUS_ON#_XU1_PC-U_T-&N?]]P?_&J\R\(ZS8>&
M]/U[Q;HFG7VG^#;>Q6.*QO+C>TEX)2#M!=S'U"D'J6!KK[?Q-XNM-6CT36[/
M1(=2U6VN)=(>WEE:(21J#Y<P(R<;@25Z@' H WO^$9NO^AHUS_ON#_XU1_PC
M-U_T-&N?]]P?_&J\Y^'WB/Q;8?")-6N3I=Y$\A%G/>7C1L@,T@EDN7<X(!Q@
M)DD<=:>OQ=U;_A"?%5\$T:ZU30GM0)[,R/9SK-(%^7)#9 W \]10!Z'_ ,(S
M=?\ 0T:Y_P!]P?\ QJC_ (1FZ_Z&C7/^^X/_ (U6/J?B;Q+IT&EZ8]EI/_"2
M:Q/*EG")I#;Q1HF\M(V S%1UP!DGBJQ^(L^D>&_$LVOVELNL>'O+6YAM)&,4
MS2JIB*DC<JL6QR#CF@#H?^$9NO\ H:-<_P"^X/\ XU1_PC-U_P!#1KG_ 'W!
M_P#&JX.YF\3R_%GP /$UKI<,G_$Q:%M/E=@08.58.!AEP.02#GM4?QCATZX\
M7^"(M6TB^U>Q;[?YEC8(S32_NX\;0K*>#AC@C@&@#T#_ (1FZ_Z&C7/^^X/_
M (U1_P (S=?]#1KG_?<'_P :KB/ UNN@7VLZS8Z+JV@>$8=-WFRU1F$AG1F9
MY%1G8H-HYSUR#1X#^+[>*O%$&DW0TP?;87EMTM&F\R JH;RY?,159L;CE#CY
M3]: .W_X1FZ_Z&C7/^^X/_C5'_",W7_0T:Y_WW!_\:KR77_&?CGQ#\$;GQ$T
M>D6-G-M21[9Y1.R^>8R4'1>=HY)R-YXX%=1I;:YX4L]-\#^'M.T"+7VMI=0N
M T]PUG#%YNT$;B9&+9 Y/!![4 =E_P (S=?]#1KG_?<'_P :H_X1FZ_Z&C7/
M^^X/_C5<EJ/Q)U5?#NF7.GZ?9'5I/$*Z%>6LTC&-9!N#!7&",X4AB#@-T-2W
MGBCQTGB^#PO967A^34&T7[?+)*\RQ1R><R<$9++@*,8!R<Y XH ZC_A&;K_H
M:-<_[[@_^-4?\(S=?]#1KG_?<'_QJN*TOXG:[?6OAC6Y]'L(="UJ]330%G=K
MD3L2N_& H0,CC&2<8/'2F^,OBCJWA36[CS(M"73K694:SDNR]_<H<?O$5"50
M<DX?!PIZ9H [?_A&;K_H:-<_[[@_^-4?\(S=?]#1KG_?<'_QJN:N?%/C34/&
M?B?0/#MCHCKI0M6CGOGE7'F1[R"%SN).<8V@8YS4</Q*OM:\-^%Y-#T^U76O
M$1G6"&]D80P^2&\QV*C) *C X)!]J .I_P"$9NO^AHUS_ON#_P"-4?\ ",W7
M_0T:Y_WW!_\ &JY_6?'.L^%/ C:IXDTVSM-6^V"S11,6MY23Q,-NYPFT,VTC
M=\I&.E6/AMX]_P"$WLK]96LGN["1$DELO,$,JLN0RB15=>0PP1_#UH V/^$9
MNO\ H:-<_P"^X/\ XU1_PC-U_P!#1KG_ 'W!_P#&JR=7\3>(KOQ/>Z)X3L]+
MFDTJ.&6_?4)77/F!BL<80<,57.3P,]*\\\::AJGQ'OO L6F1Z<^EZS;W$JV=
M[-,J-/$I,@E,1!*K@;=O\6[/% 'K/_",W7_0T:Y_WW!_\:H_X1FZ_P"AHUS_
M +[@_P#C54_B!JD_A;X;:M>Z8KI-:VPC@*#)CR50-S_=SGGTKB/$&F_#KP3J
M]K]M\0:II7B!EBNGO5FNIY+A Q'S_>0@[&&"/PQ0!Z'_ ,(S=?\ 0T:Y_P!]
MP?\ QJC_ (1FZ_Z&C7/^^X/_ (U7%?%"?2M=U^P\*ZGK5MIEM%:3:A+)-<B#
M,N/+MP&8@'#%VQS]T=.^7XMU,^-/ASX!N!=&*XO->LX)IX#S',!(CLO7HP)'
M4=.M 'I/_",W7_0T:Y_WW!_\:H_X1FZ_Z&C7/^^X/_C5<%XJU>YU&Q\'VFI(
M(]7T_P 76-O>H!@,V'(D7_8=<,/J1U!KK_'_ (FU3PQ9:*^DVUK<W.H:O!8&
M.Y+!2) W0K]TY4<X.,G@T 7O^$9NO^AHUS_ON#_XU1_PC-U_T-&N?]]P?_&J
MS=:\1Z]I5KHFDI;Z9-XHU=Y(XD,CBU38I=W)QO*@8XX)SVK(F^)&I:?87>FW
M]A9-XIM]1M=,6"&5_L\LMPNZ-PQ&Y5*AC@\_+C- '4_\(S=?]#1KG_?<'_QJ
MC_A&;K_H:-<_[[@_^-5P5AJ.KZ?\8KN^\516$-Q9^$GEE>PD=HGC6X#%AO *
M_P 0P<].O-3> _B^WBKQ1!I-T-,'VV%Y;=+1IO,@*J&\N7S$56;&XY0X^4_6
M@#M_^$9NO^AHUS_ON#_XU1_PC-U_T-&N?]]P?_&J\[L_B=XS_P"$#L_&U[I&
MBG14D*WB0RRB>13-Y0:-3E5P>Q9LX[5I?"6Z\67>I>*#K-QI\UE'J]U%*8WE
M:5+E3&"L>[@0!<[0?F% '9?\(S=?]#1KG_?<'_QJC_A&;K_H:-<_[[@_^-5T
M%% '/_\ ",W7_0T:Y_WW!_\ &J/^$9NO^AHUS_ON#_XU7044 <__ ,(S=?\
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MU)K7@#5+_P .>&]'T_Q-]@31HHU=FT]9UN7C151V1FP-NTD [AD@]5!KO:*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=-%_9UL/,3_5K_$/2KM9T$E33\D54=Y,****V("BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]=_Y#'AC_ +";_P#I)<5N
M5AZ[_P ACPQ_V$W_ /22XH C\"?\D\\,_P#8*M?_ $4M=!7/^!/^2>>&?^P5
M:_\ HI:Z"@ HHHH \3\8O>_\)?J*Q7GQ%5?,&$TNS#VX^4?<.X9']<UO_#$W
M7]JWPN+CQE(/(&%U^V$2#YOX.3EOZ5>^*5CJVIVFBV5A+J$5G<7PBO'L&(D4
M,I"$X_@#XS7+_!RUOK;Q)J"W$>M'RM/CBN7U$L52Y#D.L>>JD $4 >F^*=(L
M]7T&Z2ZLH[MX8I)8$>/?MDV, 0/7GBO+([+4-%T/X9ZW<:7?2V^DQR)>P16[
M-+%O3:"4Z]:]MHH ^==*TC6/"ZZ/KM_HVHRV]S9ZA%Y$-NTDD#2LQC#*.1N!
M'YUVVC^"=>7X9Z):GQ#J&BSVEE(9[>!5.\L2P#9Z$ XKU2JVH?\ (-NO^N+_
M ,C0!R?PD_Y)5X?_ .N#?^AM7:UQ7PC_ .25>'_^N#?^AM7:T %%%% !1110
M 4444 %%%% !1110 4ASM.T@''!(I::[K&C.[!449+,< "@#+NCJ=OY.+V!O
M,E6/_CWZ9[_>J[;Q7B2$SW4<J8^ZL.TY^NXUYOK7BK4;K4G\F8PP0RYB15'8
M\$Y[UV&A>)8K[2HY;UO+G!*L0APV.XXQ7%2Q-.=1Q39C&I%RL=#15'^VM+[Z
MA:K_ +TH&?SJ5=0LG^Y>6[?24'^M=:G%]36Z+-%(KJXRK!OH<TM4,***Q-?O
M=(L$6;4H/-<C$8\LDM[ ]/UJ)S4(W8F[*YMT5Q6@ZCH-_P"9 ]EMG,CNJF$L
M2I8D ;<]!79H%6-50;5   QC J:555%=6"+YE<=144MS!!_KIHX_]]@/YU6_
MMG3C]R[CE_ZY?O/_ $'-6Y16["Z+U%9TFLPHFX6]V5]3"4_]#Q3?MU_<1;K;
M36CR.#<N%Q^ )J'6@G;=^125]329@JEF( '4DUP_BB:T_M$3_)M,8R^W[QR>
MGK71+::G(P>?[(7'3>S2!?H,*/ZUQ_C>WG^T07$MW!<, 8W6)=NP]1D;B>]>
M?F/-5HV>BO\ /^OO-(5E1O.,>9K[A?"_V6XU&S3;&Y4?,K+W"G^M>C5Y;X*A
M+>(H9BZHD8;)8XW$C  ]3DUZE595#EI2UZ_HB'6=6,9-6TMZA1117IDA1110
M 445C^(=?BT*T5V3S)I"1''G&<=2?8<5,YQA'FEL)M)79L45Y]:?$&[%R/M=
MI"8">?*R& _$G-=]%*D\*31,&C=0RL.X/2LZ5>%7X&3&<9;#Z*RYO$.F6^J#
M3I)Y!/O6-G$$ABC=L;4>4+L1SN7"LP)WI@?,N=2MBPHJO<7UO:3VD,\FR2[E
M,, VD[W"-(1QT^5&//IZXJQ0 457M[ZWNY[N&"3?):2B&<;2-CE%D YZ_*ZG
MCU]<U8H **IZCJMCI*6[W]S' +BXCM8=QYDE=MJHHZDD_D 2> 30=5L5UE-(
M-S'_ &@]NUT+<'+>4K!2Y]!N8 9Z\XS@X +E%%% !1110 4444 %%%% !6'K
MO_(8\,?]A-__ $DN*W*P]=_Y#'AC_L)O_P"DEQ0!'X$_Y)YX9_[!5K_Z*6N@
MKG_ G_)//#/_ &"K7_T4M=!0 4444 >!>*OB#/X=U#X@V<>MSV^J&YM?[-C.
M7" !?,VY!5>":]7\+>.O#WBQFM](U(7=Q!$KS*(V7 /&>0.]6O$$_AK1+*75
M==2P@A! :::%26/8="2:@\)Z]X6\0P377AN2T?9A9A#%Y;KZ!A@&@#HZ***
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M?AWQIXEN?A?I%VGA^YUR>XMIDN+E+A(RFQF4%MWWB0,\>E '2?"/_DE7A_\
MZX-_Z&U=K7%?"/\ Y)5X?_ZX-_Z&U=K0 4444 %%%% &5XE<1>'KN0@D*%/'
M^\*\O&J2^?YA1<$8(]J]>O;2.^LIK67.R5"IQU'O7GD?@BY.M?87NXO+$8E,
MB@Y*Y(Z>O'K7CYAA'5J*=KW5@E7KP2C2=M;G6Z7BYL;;[&,$Q+YERW)7C[JY
M[_H/TK9@@CMXA'$N%'/7))[DGN?>B"&.VMXX(EVQQJ%4>@%25Z=*DJ<4ARDY
M/FEN%%%%:B"BBB@ HHHH **** "BH;BZAM8P\SXR<* ,ECZ #DGZ55\JZO\
MF<M;6Y_Y8JWSO_O,.@]A^?:J4>KV,Y3L[+5CY+XO(T%D@GF4X=B<1Q_[Q]?8
M<_3K67K7AZXU2P,2W2&X<C?-(IPJ_P!U%'W1G'N>Y-;T<4<,:QQ(J1J,*JC
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M!WR)NW(/5AL?(ZC:WH:XO4?#_B.Y\07/B"![0&"]@>UM7AS<-;PAD95D\T1
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MY^[[_I6]164Z,9N[_0=Y=&06B%+<!H$@.3E$;<!^.!4]%%:))*R%KU"BBBF
M4444 %%<]KUCI5II_G26T$;//&H;;C)+C/Z9J\UMI>F2),MK&DQ)$8C3+L?0
M 5KR*R:OKY?\$YO;24W%I:6Z][^7D:=46OGN',6GJLI!PTS?ZM#_ .S'V'XD
M4W[-<7W-X3% >ELC<M_OL.OT''J35]55$"(H55&  , "ITCYLTO*>VB_'_@?
MGZ%:WL4AD,SLTUP1@ROUQZ =%'L/UJU114MM[EQBHJR"BBBD4%%%% !1110
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M3@'(!'J<?A6=X+_M[5/B/J^OZMX=N='AFT^*WC69PVYE;)Y'UKTJB@ HHHH
M*K:A_P @VZ_ZXO\ R-6:K:A_R#;K_KB_\C0!R?PC_P"25>'_ /K@W_H;5VM<
M5\(_^25>'_\ K@W_ *&U=K0 4444 %%%% !7FGB/1]=UGQ)<.ED?D4>4OFH,
M1Y(!^]W()KT6YM+>\0)<PI*H.0&&<&JO]A:5G/V"#/\ N5TX>NJ+YEOZ?\$\
M_'X-XN*IO1)WWM^C&:%;/;:3 )[..UNMN)50+\S#OE>N>OXUIU'!;PVL0B@C
M6.,=%48%25A.7-)L[*4.2"CV_KR"BBBI- HHHH **** "BBB@ HHHH ****
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M"?\ 0M6?_CW^-<_=?!_0F\=V%S!H%F-!2RD6XCWGF8GY3C.3Q0!Z+_;&F?\
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M1?"#0!X[N;F3P_9G06T]$BCWGB?>23C.?NXYK>_X51X$_P"A:L__ ![_ !H
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MW9N;F,LS8?<B9/W4R =O?GN375T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8>N_P#(8\,?]A-__22XK<K#UW_D
M,>&/^PF__I)<4 1^!/\ DGGAG_L%6O\ Z*6N@KG_  )_R3SPS_V"K7_T4M=!
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\
MT,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^
M,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:
MK_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!
ML45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\
MT,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^
M,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:
MK_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!
ML45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\
MT,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^
M,T?V-?\ _0S:K_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:
MK_W[M?\ XS0!L45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!
ML45C_P!C7_\ T,VJ_P#?NU_^,T?V-?\ _0S:K_W[M?\ XS0!L5AZ[_R&/#'_
M &$W_P#22XJ3^QK_ /Z&;5?^_=K_ /&::N@2-J%E=W6M:C=_8Y6FBBE6!5W&
--X\G9&I^[(W>@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gmtxzzgtjwwl000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) FX# 2(  A$! Q$!_\0
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M_N^U=+>V.H:I\0H=9M]'OH+*7PW/"!-!L*2%CB-AV;VKU&BDUI;^MK%7UO\
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MM975Y%);,4VI)\AW%?7GK7/_ !)TJ/6K^X6Q\*:V/$D6Q;#5K,!(VZ$%I V
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MVBU>[C>P>(L\*2/E;F)>Y]3Z=*CE\/:RG@K5?!;^%[V?6;O46FCU7RE\A@9
MPE:7.00H(QUKWFBI2LDOZZ?Y%7UO_77_ #/);ZSUS0?&'B1X]"U#5$UC2H;>
MVGM@"GF)&5(D8D;>3G)K.M]#U;2M-^&VI3:%?7*Z5'-%>V\,&^:,NN%RA[9_
M*O:Z*:T_KU_S%_7Y?Y'"_%/3;_5_"=G#IUG-<3#4;:4QQIEE4-DDCT%<Q!X.
MUI?BL]@;=QX42^.N*^SY#.4 V9Z<.2<>U>PT4+1_UY?Y!_7]?>>(:?X;UN/P
M]X2CDTF[$EMXHDN9T,1S'$78[R.R\]:W/"=K>^']=UK2]4\,WMW<W^KO=PZG
M' LD/EL059G)^4KC..OI7J=%"T5OZZ?Y ]=?ZZ_YG@>@^#-0BD@T77;7Q2UQ
M#JGVI6M$A^QLV_(E\TKN'!.1G/:O?***%M8.MPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG]Y@\-0;NX+[D8__  BNA_\ 0,@_(T?\(KH?_0,@_(UL44>VJ?S/[Q?5,/\
MR+[D8_\ PBNA_P#0,@_(T?\ "*Z'_P! R#\C6Q11[:I_,_O#ZIA_Y%]R,?\
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M:?\ ()M?^OV+^=;4*M1U8IR?WG+C<-1CAYN,$G;LCHZ***Y3T0HHHH ****
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M%% !1110 4444 %%%% !7B.NW4&N>,KO1M-L(K*6\O'M9XOM)Q=O&N\22PJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <YI__(]ZS_UPA_E71URMU/-HOBJ\OFL;N[BNX8POV:(O
MM*\'=4W_  EO_4"UC_P&_P#KUU5*4YVE%:67Y'FT,32H\T*CL^:7?JVSI**Y
MO_A+?^H%K'_@-_\ 7H_X2W_J!:Q_X#?_ %ZS^KU.QM]?P_\ -^#_ ,CI**YO
M_A+?^H%K'_@-_P#7K9TZ^_M"S6X^S3V^21Y<Z;6&/:IG2G!7DC2EBJ567+!W
M?S+=%%%9G0%%%% !1110 4444 %%%% !12,2%) R0.GK65_:MX.ND7&/9@:R
MJ5H4[<WY-_D7"G*>WYHUJ*RTU:<R*K:9=+N(&<9 K4ITZT*GP_DU^83IRA\0
M45Y18Z_J4\$2W^J7%L3<+"")< VC2L&GW'JVX"/_ & ??-=EH<IC\2:E86M]
M->6$4$4@,LQF,4K%LJ'))Y4*<$\9]ZT6JN0=+16!HVL:E?ZQJ5K=Z7);06\@
M6.1I(SCY%.#AB23DFLJ>S=?$NLQPZM>6QBL$FA::]D:*&1S(-Q4MC P.#QQ2
MN!VE%>=Z?J^IB^TNQM5=[J&ZFAN8[C46DBF(A#!EEVL6'.<$9!)'%5YM;U>Y
MT>"SA>]?4?M%U<2"R;S&41RL(T)./D+87IT4C%/K8#TRF2Q1SPO#,BR1NI5D
M89# ]016#_; UO0Y6M9+JP$MJ)5O=B[5R 2%8\;AR.1P:Y8:K/=Z/I(N-7N(
M8QH#78N([DJTMP H^8@_,1G.WOGD4/K_ %W_ ,@6O]>G^9Z2JA%"J,*!@ =J
M6N%TS4+J#Q!:3:A,UPVHNB1QPWSYMF\D%E>#[H&58YY(R*T+J5+SQ1J%KJ.I
MSV4-M!$]M'%<F#>&SND)!&[!&,'(&.G--B1TOV>'[3]I\I//V>7YF/FVYSC/
MIFI:\SU;5+RPBUJ+[?/<S7$,D]I=6M]E!&)%&PIG]TX# !AP>><UT>K2W.G>
M [Z2.*\MI]A4"XN?.D3<P7=OW'H#GKQ2Z#ZG4T5R5QX@OM/U?['%;VIT^&[A
ML!EF,I+QA@?3@D#'?VK/U37]?&CS>;$;<O-##YOV9[;8KR!6.]F;'!ZXXSFC
MT#U.]HKB-,U'S=5T8QB6-A<7=C*K737 D"KOW!VY8 J.3TR17;T %<!J/PWE
MU'Q/)<RZN3H-Q>IJ%SIAA!,LZ*%&7S]SY5.W':N_HHZW#I8PO#F@/HEQK,SR
MQ-_:%^UTJ1)M6-=JJ!]<+DGU-;M%% !5.35=.AN9+:6_M4GCC,CQ-,H94')8
MC.0!ZU<K@];T&^U_Q--]NT>5=+@@FBMGMYHE,SRQ[7D<D[AQ\JC!YY/; !VE
MG?6FH0>?974%S%G&^&0.N?3(JQ7/^$;?6;739X=7R%2<K9JY0RK   HD,?RE
MN#T[8JC/X;\627$CQ>/+F*-G)2,:9;G8,\#)7)Q38(;\-/\ D5)O^PG??^E,
ME=A7%_"U)(O!9CEF,TBZA>J\I4*7(N),M@<#/7 KM*0!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 0-96CH$:UA9 K*%,8QAOO#Z'OZTMM:VUG#Y-K;Q01 YV1(%7/T%344 %,,
M,3,[-$A+KM8E1\P]#ZCDT^B@"""RM+9(TM[6")(R2BQQA0N>N,=,T^.WAB<O
M'#&C'J54 GG/\R:DHH @:SM7M3:O;0M;GK$4!0\YZ=.M1#2=-$,<(T^T$4;[
MT00KM5O4#'!]ZN44 0)96D=V]VEK"MRXP\PC =AZ$]3THN;&TO#&;JU@G,9R
MAEC#;3ZC/2IZ* *PT^R62:06=N'G_P!:PB&9,?WN.?QIU[:0ZA8SV=PNZ&>,
MQN/8C%3T4 0):0I&BLBR,NT[W4%F8# 8GU]ZDEBCGB:*:-9(W&&1UR&'H13Z
M* *(TFT2]M;F.,1_98WCAB0!40-C)  Z\8_.KU%% !1110 4444 %%%% !11
M10!Q_P -/^14F_["=]_Z4R5V%<?\-/\ D5)O^PG??^E,E=A0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% ''_#3_D5)O^PG??\ I3)785Q_PT_Y%2;_ +"=]_Z4R5V% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEGCGPK)X=\&:CJMCXI\4?:;=4*>9JTC+RZJ<CZ$UT/\ PKN#_H:/%G_@XDH
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M16'PSTNS8F74=4O?+M)+*T%U.&%I$XVL(\*.<<9.3@4WY>?Z_P# $O/^MO\
M@E3PO\0=2UG5=&MM2T2&R@UFR>ZLY(KKS6^0 D.-HQD'(ZUZ!7,Z?X(T[3KG
M0)XI[IFT2U>UMPS+AU8 $MQR>.V*Z:F[=!*X4444AA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gmtxzzgtjwwl000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ 9T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2 <].F01[UL5%;VMO:1>5;0101@YV1(%'Y"I:EN[+BK(****0PHHHH ****
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M]1M+F,O',N%&6#?*5QUR#TJ:&>*XC$D,J2(>C(P(_2NI23V+)****8!1110
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MLD-.Y9HHHK884444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ)!1115C"BBB@ HHHH **** "BBB@ HHHH **** "DP/04M% !1110 4444
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M.VNEG3S3Y;,T43.2D1;J5';.3^9JDU;4AJ5]#1HHHJ2PHHHH **** "BBB@
MK!N]6U&&[O;>.")FB,)B*(\A"NQ!+ <G 7M6]5&XTJ">:6;S)HYI0@+Q2%2-
MN<8_[Z--6ZDR3:T':7=_;;%93*DC[F5BD;)@@X(*MR"/>KE5[*RAL+?R8=V"
MQ=F9LLS$Y))[DU8H>^@U>VH4444AA1110 4444 %9&N7]YI\0EMVM0H4X24,
MSROV10/7UY^E:]9][I$-[=QW33W,4T:&-6ADVX!.335KZBE>VAG3ZW>HEU=K
M#"+6SE6*:-LF1B0I8@]!C=Z'.#TKH:S)-"LY;CSG,Q#%6DC\P[)67&&8=SP/
MR%:=-M=!13ZA1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(<9-LDHHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"*:W@N4"3PQRJ#D"10P_6I%4*H50 H&  .E+10 A /49I:** "BBB@ P#
MU'2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gmtxzzgtjwwl000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) M # 2(  A$! Q$!_\0
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M?[19SK-%DKN7U':K-3L4G?8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9\JY>5MR@'=P&4\ XZ8KM**3GY#5*UM0HHHK,U"BBB@ HHHH **** "BBB@
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MHJ"REFFM(Y;A$21QNVH<@ ].:GJ'H4G=7"BBB@84444 %%%% !1110 4444
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M,TL@(<-N;KN&#P/I4MKHD%L8#YLKM"Y=2Q'IC!Q[5IT4^9ARH****DH****
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M_O(=II14HJVX:D]%9U[)>V5JTD<B2@$#+K@KDXSQZ4NGW,DLLL33+.J!2)%
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M%(84444 %%%% %:>_MK>7RY),-C)PI.T>IQT_&K'!'J#6?=Z=)/)-Y<P2.<
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M3YA_C4L<T4RYC=6'L::DF!)13(Y8Y0?+D5\'!VG.*?3 **** "BBB@ HHHH
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M/43LXN(E$>58-N;^[Z4"9+1110,*0@,,$ @]C2T4 (  ,   =A2T44 %%%%
M!1110 4444 %%%% !52^L8[NWD0 +(RD*XX(_$5;HI-)JS S+"SEBN!(\*0J
MD?EX5LE^>I^G;ZUIT44HQ459 @HHHJ@"BBB@ HHHH **** "BBB@#*UFUN;Q
MK>*$VVS<682DACQ_"1S5O3H#:Z?#"S(Q08)087KVK%UI%?5QLMY9IQ -I0@&
M)MWRL"??K[5I:!_R!+<EMS$,6.,<[CG]:M_"9I^^:5%%%0:%2?\ Y"5I]'_E
M5NJD_P#R$K3Z/_*K=-B04444AA4<D$4OWXU;W(J2B@+7*_V4K_JII$]L[A^M
M&;I.T<H]OE-6**=R>5="O]K"_P"MBDC]RN1^8IQN[<1&0S)M'4@U-52\L4ND
M4@*LB,&5BO<>M-<K>H/F2T)X9XKA"T3;@#@\8(/N*DK/M[6YM6DEWK*TA&Y.
MF,=,'_&K<5PDIV\K(.J,,&AKL$9.VNY+1114E!1110 5#"@668B7>6;)7/W>
M.E35! 8?.N/+!#;_ )\^N*!$]5K^!KFRDA7&6'0]_:K-%-.SN#5U9F5964\<
MTDBEK:,J%$?RG)'?BH;C3KEYY>KM(P*3Y *#^?'M6W15^T=[F?LHVL4YM/6X
M@:.2:8[AUW=#]*CATYTF:9[AO,*[1LX 'T.:T**GG=K%<D;W*^+I.C1RCW&T
MUS6KP32:E))#;(I$/S[P"H]^.GUKK:AFM8+AE:6)7*]":NG4Y7<BK2YXVN9N
MGS3V6FP>9'Y\&T8DCZCZC^HK1CNX)<8< GH&XS33;;#NMV\L]UQ\I_#_  K(
MO(1]K87%JY1TPBJ?D#>N>Q]Z=E-BO*FK&\TB*RJSJ&;H">M.KG5LS.'6!HY7
M95!</_JR/8]OI6RIN85 95F &-RG!/X'_&HE!+9EQFWNBS15<7L&[:[^6W]V
M3BG&ZMP,^='_ -]"ILR^9=R:BJ_VVW[/N_W034%WJ'EI&(D;=(X0,R' IJ+8
MG.*5R_156SN'F\U)-I:)MI9.C5:I-6=AIW5S,\0)%)I$J2V]Q< D8CMVPY/;
M!JIX8MV@MY1+"T<A(^]&RG'8$G[Q]P!5K7UE.F;X8YWDBD5U$"AFX]CUJMX9
MFEEM75I7DCCPJ[]F0>X.T]?K5+X60_C1NTF]<@;ASTYZU3U2WN;JQ:&UE6-G
MX8L#RO<#'3ZUSZ:+J*VT44D"/)Y*1QNK\6Y#9)YYZ=Q223ZE2DULCH]2_P"0
M?-_NU83_ %:_050U*"0V<S_:9 -H^4 8_E5]/]6OT%+H-;CJ***0PHHHH **
M** "BBB@ HHHH **** "BBB@ J)Q*9XBK 1@'>/7TJ6H9%0W4+&3:RAMJ_WN
ME ,FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** .;\1W<UI>0-;WT:2,A7[,(U,D@SU4GI^/%;>GC&GP#
M=N^0<X4?^@\?E6#K]V+;58U;[&^]%(2=@&P&^;&0>HXK>T^1)K"&2.-(U9<A
M$/ ^E6_A1FOC99HK$UF^O[>[M4MH)?)\U/,D10=^3C;[?6HM,O;N;4$5Y7=F
M60W$3+@0D'Y<<?\ Z^M+E=KE.:3L:L__ "$K3Z/_ "JW6<3<'4[7SDB48?&Q
MB>WTK1I,:"BBBD,**** "BBB@ HHHH *9+#',,.N<=#W'T-/HH#<K8N(.F9X
M_0_>'^-2Q3QS [&Y'53P1]14E12V\<I!((<='4X(IW3W)LUL2T56WSP?ZQ?-
MC_O*/F'U'?\ "IHY4E7=&P8>U#0TQ]0PN6EF!BV!6P#_ 'N.M35%$)O,E\PC
M;N^3'IBD,EHJ*>XBMU#2MC)P !DGZ"G12I-&)(V#*>A%.SM<5U>P^BFB1&<H
M'4L.H!Y%.I#"BBB@ HHHH *ANH!=6LD#' =<9Q4U%"=M1-75F9MOIK"<2SD+
MM38JQNV#_GTJW]BM\Y,>?J2:GHJG-L2A%$/V6WQCR(_^^13!8PH<P9A/^QP/
MRZ59HI<S'RHK?Z5'V28>WRG_  J.XN[80,+M"B]UD7@_T-7:BN($N8&B?.#W
M':FFKZB:=M"*SFA93#%$82@SY97'![U:JM;6GD.TCRM)(1MW$ 8'H *LT2M?
M0(WMJ5K^T-]:-;BXF@W=7A;#?G46FZ8NF1M&DS.K'.&51SZ\#D_6KU%*[M8=
ME>X4444AE74O^0?-_NU83_5K]!5?4O\ D'S?[M6$_P!6OT%/H+J.HHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "H)#$+N ,I,A#;#Z=,U/43LXN(E$>Y2
M&W-_=]*!,EHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &)KFG7VH21);K;"%1EG8E90?]EL'%:MJDD=K
M$DHPZK@_,6_4]:FHIWTL+EUN%%%%(94G_P"0E:?1_P"56ZJ3_P#(2M/H_P#*
MK=-B04444AA1110 4444 %%%% !1110 4444 %0R6R.V]28Y/[Z_U]:FHIIV
M$TF4)[R:S"K+%YC.=J,G /U]*CL[F25IS'$Y<O\ ,'.%7CL>XJ]/;QW"!7SP
M<JRG!!]0:ALHX(6GCAW[@^9"Q));%5>-MM2+2YM]"*XL;B=XYOM $L><* 0N
M#^M.M].$$)7SY=[$LS*W&3[5>HI<[M8?LXWN8<5I<6DT+2(HCB8EY@06;/ZX
M]<UN @C(.0:.HP:QYKJ>SGFCA*"")0V'!)Y[#VJM:C)TIKR-BBJ@U*V^SB5Y
M N0"5/7GMBGP7D,X;!*,OWE<8(J.5E\T>Y8HJ(W$(ZRH/^!4W[9;_P#/9/P-
M%F/F1/16?<:FJR1Q6^UI'!.6S@ ?A5BSNA=VXD  .2I .1D>AIN+2NQ*<6[(
ML4445)04444 %%,:6-/O2*/J:KSZA#%#(Z$R%5SA 3FFDWL)R2W+=%9]I>32
M3QQRE'$D>\; 1M^O^-:%#33%&2DKH****10450U@L--DVV\MP20/+C)!/Y<X
MK!-G?K%&JK=R-Y:BV?E?+?=\VX>F/7M5*-R92L='J7_(/F_W:L)_JU^@JAJ4
M=P;.5A<*$VC*^7GZ\YJ^G^K7Z"ET&MQU%%12K,2/*D11WW+G^M)C):*QK:VU
M5;]GDF&W+;F/*L/X<+GC%:T8D"XD96;U Q41DY=+"3'Y%("&&00?I6//:7*7
MFH/!"S"YB"J?,P-V#^7X55TRRO[2QO%6*1)'"^420#NQCITQ[]ZCVKO;E[A<
MZ/.*3</4<=>:QI;2]N=,M!,&-Y'*K.=W3U/'&*@L-*N#,1-&T*B/;*^_/FON
MR&'^-'M)<UE$+G0]:*R+BRO+.RCCTV5V82G<'(Y5NIS[=:KZ3<W,NLW,4\TS
MK&"$!7Y3@]?8T_:VDHM;A<WZ***U&%%%% !43B4SQ%6 C .\>OI4M0R*ANH6
M,FUE#;5_O=,T R:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BL?5KZ>WN[>&VN(UE?GR67[PS
MR2<\#^M1:=JES<7T2NZ.)ED+1*N##M.!D^_O5<KM<ER5[&E/_P A*T^C_P J
MMUFF29]3M1+!Y8P^#O!SQ[5I4F-!1144C3!AY:*P[Y;%(;9+163;7&IM=LLD
M(V\[@W 7GC![\5J1ERF9%"MZ YJI1Y28S4AU%9,MQ);SWXEEG,>U3'M7)'!R
M%X]J@@O;J'2&FB+7$IEPD;@EL>A/KWS5>S;1#JI.S-VBL>_EO-MK+:N[,Z-E
M%7Y2=N0:99)/=K(JW,XB4J4E<?-N(.X4>STO</:^]9(VZ*RYYKRQ^RV\:B8.
MNPR,#P1W/MC-)HVHRZAYS2F,;2-JJ.1UZTN1VYN@_:+FY7N:M%%%0:!1110
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MCPO?"Z,CAPR-CM\H('\ZI6MJ0^:^@T>(=+:)Y5NE*ICL><],>M-O-<A@2R:
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gmtxzzgtjwwl000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %0 M # 2(  A$! Q$!_\0
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MBC_P$B_^.UG;".A^4=A2T_9H+FC_ ,+9M?\ H4O%/_@)%_\ ':3_ (6U:?\
M0I^*/_ 2+_X[6<6../SJ'=)YP7;^[(^_GH:/9A<U_P#A;5I_T*?BC_P$B_\
MCM=+X4\5VGB[3KB\M+6\M?L]RUM+#>1JDBN%5N@8C&&'>N%\HYW%F##CKP:U
M_A2"+'Q("<D:W)SZ_N(:F4;#3N<)X%2PG\&62S%O-C+\%>"?,;&#WI^K2RF:
MU5!<1PLS9RQZX...GN/<"LCPQH\-]X2TZ=KB2.1#(RA"1_RT:NJV3>1.OG12
M*5Q&DG\!_GFMJ4NC-'%6N,>UO[AX[BX@C2XNEC)(!7..3TR/3MVI(+3Q':WB
MB34$,93#3-\SXXQVZ\'GWI$T^[NK6SM[E;@JG+R0M@#V]_K4^IQR6ODWELA:
M6$X56<XYXY]:I)\UKDNU@30)8;=DF/FM*PW[CM#+DG&0,]\_I5$+<0S6UC!-
M:O"JJ"IG8DE2,X./KU]NG-:MC=2L?*O+T7-PHYR"#S3<S)/<K';11I$NY9@!
MP3U]S0HI28M;:E)?#4]P\4QD^5',WFK<956W9V@8.>.W%)*-7MQ*T=]Y,SN/
M+_>MP 6R=O0Y!4?A5RT5+FSDD-Z720??5M@3'H*O16T4\<4ZK$YB7:LG4TG)
M-V"UMS/M7NYK<P:A(TK.-Q 8L ,#C.!WR?QJ!B=/BD*7Z(S-^[!.?+7NHK3E
MO((K5E>$R/#RS+\N[O6'&B23M-/IF+=OFC=#N))]J4=GJ6EY$W[BWECU*YEE
MO,C@D\HOX5+<:@C$-'%*1(-P;=@8^E$@2"6.T-L\<8&]&"]?; J\SP6VEG4$
MMGE8YRDORD?AZ5G4;EN4K(RM(\2R0R,C+%+;@E0[+][V)[5LJ\=TTAL5>&><
M -EMR;1V4=JH+XHL)',<>GV> N22,;C["LZ[UW5KUW-N4BCA(RBIMP#Z>M+F
ML_=&Z=]6K%BVMPK3P75J+>6.3IM(4Y_B!_I3(].BL;98TF#7#.74OW_"F1RZ
MC//!YLLDXD7A778J^A.:MW6C3FXCN"\#.%Z!LGZU#DI+0K6.[*DF^WNO/9I'
M60<D+PN.O'K3[:_2-II#;O"FT%IE;*MSTV^M01Z;,?,2=IIC*#M5FR%/7(-.
MN?.:R-O"XMIEP%4=">_!JX*_0&:EKK-LVFG[59QQPER"[+GGUK.:R7[9+JD*
MJL90X4D\X[_2J4<^I(J1^; 0A+.\HW+]/K5^&ZNI8]T:I/O&79,;3ST'TISG
MIRV%&%G>YF/ TD,5[?7+"8'"PPKDGG_Z]:^G:=;[O,FC*PI\Q*MEL=>/>JEZ
MUR+I9KF&\CMU 41P*.2?]KTZ5?7=9QB,V=PT;CS7 ;Y/<%O6HC%VM8J4O,>^
MHQRLDT6G0(SDB(DAW_'WJIJ,EA*W^E6\+WBG]V8EVA5(Z,.YS6<)IF2Y%G;!
M#(VT;9,%%]L]*CMX;IKN.8!6=0RLC,<D>N35.R>C$HZ:HKP-#D_;,SRASNVH
M/W?US[=ZBD%M+J,PB2-5FA,L201E!Z<]\FM2_>TMOGN+?:TD:JQSDY'7VJFV
MH/9P*A2-6F?Y954;@O0 GTK.:Y58N.NI%96[22>9+)''; $O"0<DGH0.WXTY
M"Q#DLRGK#YB[B/7CWIHF-D\K1B3S'4/YBY.XXSP,>M++K%Q<-&L]D%?=Q(WW
ME'N*S6VI=G<G\J&2&/[0J&;:P5F3:,'T]ZKR?;TMH $>,;@55U.6'L?6IHKI
M8KAGN3NC^Y'C@D^N*25_[1G:.:>8K""8XW8@ 'BINK!9W'&YCO69XA"DRX&Z
M3^(CU]*DN-3(3#6J$.-HR/O$8R2/?M67'9Q:=*"J2?,WR1 EV=NQK82RMWC\
MV]NRDH'S6\*Y(;Z]/RJTG?783MT*L4@4N5MF7)W@-QM..A'I3"\ZLDIN)22<
M'R\+O)Z >U3O;MN:0"1XV.=KG)7([MWJ?3@LL_\ I2+'%N*JH/#>A'I4..I5
M]+F1<VMV^J0?;"XFC1_+4G&%;'!S_NBG:?HL=A:SQVA9DF<L5<] 0!@>V!6_
M=10.Q#(SQEN03G)_F*2:U^TVZ2%RA#+E4X;CMGN*M16Q%]F84.D.-,BC2YNH
M;6-!%L$BY<=.<KQ]1@U:DM85M(TM8YDC5-H19>$(X'Z5LBVM)$8%)'V$AR <
MKGV[U0GMD6Z\I\+9R$?*!@DBG[-V$I*YH6OV>+$94$H 3M&.O?-6(76)V=KL
MLC'*JG\ K)E@C>TCABNE6$G9(?7V-7;81P@VS+NC YD5N:2<EHP:3U-.SEN(
M(9#+,USN;*8Z@>E*G^F3123P.LL3':&_AXK.?5IA&);=HS;HP(&P\ =R>YJ]
M!=&:7SV=BQ')(QNKH]I[Q@Z;M>QG>),?\(EKFX@L;*;D*!_ :]DTG_D#6/\
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M;@>...M.OEM[IA=?9HXT+\AP?E],9[548KFLT#NK<K'?84NK!KJV5G+ ( B
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MM[FY]N%N_F^;L0@Y9SR<=JIK=2>9]HDFY<AFC7 QZ$UJZ3I\E["TSF)I=O\
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MH[Z*&2ZF1I,2R#?D,<EO4^E1)IRP/Y5NLV[;\TBL67=^/?FLYX:I4LZK_P#
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M-XX(TDD!=E&\CH3Z"K3HT^5,B HO(QDYI$MV0)YA9R.<CO4J#:;N-RU. O\
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M*T5V[[BD152"%##/2BVDF9@\D13'91Q5D(J*?*4;D'W5^Z*9$DV_S!)'N?D
M_P J%?>XW8F1E'WFR6/ /6FW'EI PV%5)YV\?C2LC$%I4!8<@@X_*J4\MU=6
MNTP^4[/@8.<?6KL[&:6IC7T>II=^5#&)+?<"7/(QBNN^$PQIWB(>FM/_ .B(
M*S;RS>XTYX&;/R_3)_"M+X2HT>F^(D;[RZRX.#W\B"LN3E=RYSYHI'F_@VT:
MY\*6SPEA-'OV^8OR'YVZ&NRT_P )O<6Z7D<H5;A!YL,WS8()R![&N8\&VTUS
MX*TT":6)5:3#1D<?O&SQWKJ;G4+^WLHK:&9AY0*L8@23D]?7/-<.8TL5*,/J
MDE%WUOKI;_,UIRTLS'U;2_[&EE2Z9&#G_1@P#*@^GI[5E-;7=JT21OI\ G^<
MS!"<'MD=?QK7NY[UKRSFEM3<F,;1+,?G+ Y''?N:<=9U6]O;B">^@LXXW5D
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M(R=QS5GR%C\L%E\K'5CSFJ\MM?WICC,OE1I\TCJ<;SZ?2I9+>W<Q27;QLR<
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M!^1J]:TG_D#6/_7O'_Z"*\I\7 ?\(;K9R,_89<C/^R:]6TG_ ) UC_U[Q_\
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M&>XJM%HT5M([K/)N;D' .*V5Y (Z'I41,HN540@Q8RSYZ'TQ24$'M);7&M"
M1Y;$K@=1SFH)X=T$@V@MMX&.*L70N#%BU,8DSUDZ 4VT,QC99XV5D.-Q(.[W
MI\BM<2DRA#A;$&2/RCMPW0$>],6T$<)=)79<99R^=PK5EAC9&6105/4&A8D1
M!&B +V J7'H5[3JC-M(TFB5X'<A^ASBIO(F\IA&5\S/#.*N^4%R H7'&*14E
M\_.5$07@=RQH4%<3FV4+NS\VU*R3O N 7>)MI_.IXX(/*1DYVC([Y]ZM[!C!
MY/H13D$:M\ZDCT%'*KBYW8Y+7]!TW5]1@^UVD\TB]XVV@+[UL-I5J-,6S@MX
MQ .%0CY?QK2P,D@8%.'3@ 4^6-[V'[25K7*EM:M H!*!?+V;47 'N*6:.=8E
M%OL+ @$OZ=_QJ>9O)B\QE8KTX&:K0W3RR[3!(J]F(JDM"+W=S!\:V2CPCKMR
M9'9OL4NU2>!\A[5ZCI/_ "!K'_KWC_\ 017G'C?_ )$77/\ KRE_]!->CZ3_
M ,@:Q_Z]X_\ T$5A5W+CL7*\8\#2^3X&TUW953:PR?\ ?:O9Z\;\![?^$'TO
M?TVMC_OMJF&XV="L\33>06'GA=Q7VIF^X:61?*953H3T>K(4#D<&G*RMD!LX
MXXK4SO8KVT8S)*T81Y#EC@9/UHF>:*/*1>9(6PB XX]S4Y]<97VI^U<#=^M)
MJZ'>SN587NUE5)8%*%<M*'&%/ICK^-2+*DDA&\C'R[2,#([BI.0^\9;(Q@=*
M:T\"SQ02,%FD4E5[GUH <1N W[<=1SWIL2R"WQ(%8D]%'&*60*2!(!@<@T\8
M1MQ<;3P![T /16"KN ! QQTI(XHX=VP ;F+-[D]ZJW$]S;NJB.26-SC=$N2G
MU]JE;"LJECN/5FX%*X^5DI1 1)CD55_TGSWE!18%& NWYC4\['R259$Z?,QX
MHQYT>"Q ]N*3&M$0VXW"0F$1 /\ *>[#U]J@G1X9&:.1U$K990NXGCMZ59D\
MTR*8D7 SG=ZT6LT\T/\ I 5) 2"JTK]"EIJ51%+/ \,I92_W2#@BIYRL<865
MCC'<\&H)K.*ZO89UGGC,/_+-6PK?6H-9@=H1)&69HOF1,]?P[U+;@O>1HDI-
M),O0(@!<QI& ,;@,#%9I2":]CNKF9FBC?]R-I SZGUJAIFL7=W>+;W$9,14A
M@1P/>M:6>TCG-L[1;D3(!<!CGT'6L_:JJKK8MTW3=GN6?LUJ7+""%6'.]5&3
M5>.7[*L<L]V95 V X&6)/'2L9=5AO+*$L##;%S&VUNK?W<^OM6OI M3;*(8(
MXXP3Y2D@MQU-5&HY.P2ARK4EGVLC1QEQ,XWH"=O0]*Q-0TC6;J8L]\H5^2F.
MGM716TD3I^_*O(S%DVD-@>OTJI'\MQ,9"PE<':LIP"/IZ4JL%.RD%*;C=Q,K
M3X-1T^/>+G,6,[67):M*19KH9N8U*%,(I..M/O;E()UB.(XMH ..,G^51R8$
M>TR;AP2XY">F36;A&"Y5<OF<WS-$$VI'PWH[/)#<R.#D*3OW$^A]JTHS]K@C
MFGF\IYXQ\F2!C&>GJ*SXIY9I$B\Q)HR-W*=*O7$EI%&$G"1Y7:NX=<\<55.5
M];Z$SCY:BV]FD2X$_G1]B#G!JT=WG+E%,>WKGY@:S[26"T/V2!H%(49^;^+T
MVU<,ACWS/+P!G&W@5K'2*1G)-N['.JB=2)0"O\(]Z;- )>7"D Y.[O\ A5"]
MTT:FL+R7)5T.5DA;!7T^M:#7<<7E6YE$DC# 8'J1ZT^?743C9:;D9@$D$?V8
M@1]L<8QTI%AO'9%N&3'\3)D9^E3M).N#"(R,=&XJM+=W)"@>3\W"G?C)]JI*
M^XKOH6E5=NU7W!.N>338IH79@KJS<9 ICQL]PNVYDBZ%@H!!]N:2WMX;5&08
M7:3M/.0#Z^M&HM!9(7-P)Q+*J(,&$!3O_'K4<MVT<4LL\#1QH,\')-67W;48
M?.2>2./QID@PKM'%YS#H,]?:FWI8%N.M97A/GK*S0R 'RF[>XK0^WV^Q6WGY
MN@QS6);K,&9Y/, =LB/AMOL*G,$S3AC@1@= V*46V*45?4=>,\ES,\42D",%
M">[=ZKV[F6T#,K0DMC!JQ*[1(6/(]NHI$D#JKJ"5/3CFFWJ-:1*6Z*"_,#JP
M><;@P)YQ_*II<P3(WS%&X9O0_P"%8WC2<:?H7VX.?M$$RM$QZY)Z5J:1J<6L
MZ5;WL:LJRCH1C!'6LT_?<?F:-/D4_D3L9&,B1D ,.'7J#ZU8^%H86OB8.Y=A
MKDF7/\1\F'FHB%^]$!GZXS4WPOX@\4#_ *CLO_HF&JEL9'*_#:'_ (HG3I2W
M_/7''3]Z]=3^^:9LD&,?=YY!KF_ANQ'@'30/^FN1Z_O7KIXY$?=L(.TX/L?2
MMX_"B&]1(K=T#;I"ZD_*".5_'O6#JGAN)KG[;;(Q?=N:$$8;\^E=%&[L6WQ%
M<' R<Y]Z?SBK$I.+NC@1JOE-+!)'+!*""H"X*8XSGN*Z7P9J%O(9H+B#9=R'
MS&DD4#S!V(IFM:=;/I]T_E-N(+$QCYB?;WK \/6<#:M9_;S*8,XCRVWY^OS?
MX5Q5(\E5..S.U.-2D[GK%+2#IQ2UU'F!5+4KVUMXA#<'_7'8!C/6KM<#XG^T
MB^EOY7V6\9V6^#D.WOZ$<UG5FXQNC:C34Y6;,PV8FUO^S[61Q''E6N$^N3UZ
M>E=K&NV,#D[1C)KEO#%IY"27DDL;/.<1\\&NF@\[RAY^SS.^S.W\,\TZ,;0-
M<0[RMV)1P#D9R/RI.2..I'%(1D$'H>U"*$4*!@#H*U,!ENDZQA)W$LF3R%Q3
M3:PF42^2AD'1L<BG+-%)(Z12*[(<, W*_6E#J79,@L.2*-;C(5NXVO/LZ*SD
M [W7E4/H?>K!&!G@_2HH+:&V,C1(%\QMSX[FI%7:".3D_C0[=!%:-;HNQ<J%
MS\H'I3[1[IX,W<:12[B-L;9&.U3\'OP#R*CD81R9WJL7^UUI%7).@]Z8T4;N
MLC1@R#H2.@I$,S7#_(ODA00V>2:>"-V,\T]A!C& !^5#*'RK ;6X(-/#LJ,H
MQANM(N2/8>M("I;6TJ2O([[5/RI"/NJ >#^-6^V*!D]>/2@D@G![4VP$P?K4
M,@C%R$> _-'YGF%>" <8SZTEH\^TI<X,@)Y P,=JM'D8)) [4;"V(F_>0'RF
MV$CY6]*5,JBJS;F Y.,9IGF0H1&&4$=JE5XRHDR"GKG@T@!@03W &>!34<-@
MG@GL>M.61)!E""/;M3/*7SO-/+8P,]OI3L 2SPP%!(X4R-M7)ZGTIV!2211R
M@"2-6 .1D9P?6G]S2 @,Q6Z6'RVP5SYG;Z5(Q EV;@6/3%.QW-&1TQSZT 5[
MFZ6W>%61CYK;!M&<'WJPRD ''6F<^9@J/8FH7N6:4Q0J'*$;R3T%.UP)'9P5
M"1@@]3FGXR<FJ]];RW<1C29H%R#N3J<=1]*L1ILC"]@,4:!T#+!N.@[YH8Y)
M)[U%BX:[QA1"!P<\DU*>O(Y%&@CG_&Y'_"#ZX #_ ,>,I_\ ':]'TG_D#6/_
M %[Q_P#H(KSGQQ_R(FN_]>4O_H)KT;2?^0-8_P#7O'_Z"*YZOQ&D-BY7CO@'
M_D1M,Z?<?_T-J]BKQWP /^*'TSG^!_\ T-JF&XY;&XUSFX:),C8,L^/E'MGU
MJ:-X\_(/O<Y X:D,.PEH]N6^]QUJ0+M &!BM"=+"L"RLJ'#XX--V3BW<KS-V
M#'C-/8!EZ\CN*BFC\YE3S&7/S!D;DTQ(>JNR R##8!8*>]-^SQN)#E]KIM.6
M/Y^U*TRQJVYP=@^;BEC;S 6W9B9>!2&.!W!HUQP.#FFBV8J5>0D=CWJ&VDQ.
MZ>2T<8X$A&-Q_K]:M>80AV$N V#[4O4K5;#0#!$T< RRD'YB3UJK>Z<+V&5&
M<LSE756)PI'TJ]G<RLO([4&5GC8QX+ [>>QH:3W!2:=T5EC!C*S$.J??4K\I
M-.G<?8WF$FQ0/E91G;2,EW()(S*$^8;608POX]:5Y6CA;R8O,9&QM.!GZ4M!
MZW.<U/Q-/8VK&.TD>;.Q693M/N?\*3POJ]UJ<]Y)<Q8E55V[00"/I74/&DT2
ME@!CG!%0JD ),497G#9[CU%8^SDJG-?3L;^T@X.*CKW PLV6XCRO('7-1;T@
MCEGN 8P_))/?IQ4LBJZB-FQNSG&02*AAB@'EH\SR>4<YD .:UDS-$;1@(K E
M/FS@)][CO7,ZCH\]WK$E[/Y @?R'.)&,JE&!*A ,$D# .X8ST-=JR* [G:JX
MSNSGCZ5BW]O+?V9>VNTM%D8%98UR63_&LYJVJ5S2#OI>QS%GX?GM[1&-U;"W
M%YYWEDG(D,F"3Z?)Q]36_HVB7.G:TC"6 6S+.TD0SGS6<$.O;!4<^X![FL)9
M+[3(&L;"PN-9>25EEE4@!!GC.?UK2L/%TMM<?V=>Z==O,A&6C3.%/0G%9TZB
M5G(TJ47*_*:NC:-<:5J%]-)) Z7;F0)&I'E$NQVCU7YL_P"\7/\ %@7=142V
MDH'DF51R[_PCUKA-4\53_P!LMHVGV-]'#))\]S$26.>ZYZ"NQM]/@TZQDCNK
MJ2X,@#DSD _3BK=3FNEL1[+DLWN4(+96MS*=5E>)UWE(\#>OU/.*IZ1J&DB)
MX+F\$+(YVP397!['/<5M+!&P7%M B*/]63T]JS?%-G;C1YKJT5=Q D)$0=<*
M>1[9K)QLN9=#:,DWROJ;+3(US&P D4)\SH_3Z#O5ELE5/E%XR.3CG\*\]TKQ
MSH%]JMNLD<UK,I"QQ*,QENA/_P"NNTGEDLI6^TWK>5*^$P!M4=E%:1G=7>QG
M*G9V0Y+.UOA]HBMA#,DGWBFUF^M6=ZS&6V\MMR+\V. <^AIKPB%&$4LPG08#
M==WX=ZDEE!@3S5RS8R$.*TO;1F>^PV*WB2,9B9>V%_STIDUI;CE(E:11QM.,
M'ZU-YFQ_-="T)X(/('O36,[WA$<*+:!.6[D^U%D^@KON-7**-[<GC-0S^098
MU>.-MIW*2.5]Z<9(XO+2/G.0H/L*E$0<X(7<>6!JUM876Y*%# 2J2K>HYIX?
MS5$B\*IP><9JO)'*=I&8V0Y0?PGCO5N-"8(U(!;'/.0*:=R&K(8(P(1$&*@=
M#Z4Z.W\EMWG,PQT.,5+MPI+?RIKQI,N&9MI&.#BG85RI*9(+H.JF2.0@$9P(
M_?WS5LG",H8>9M^4'U[5%%%)"V#)O&<8)Z"I# K2>9DYH2LP;N5VM_.BC^TL
M!*!SY9XS4IC*CY0 .YS0T"B82Y/'1:;.$D@99,A",'G%,+G)>-]#N]<M$%E,
M2]OEC >C_P#UZQ? UOXFM-1\BZAEBTU%)*R] >VVN^2ZCAMO,-O<(BG:<IDC
MW^E645<%AD!N>36,J"<^8W5=J'(5QN1F:4*BDX7GK5GX8?ZGQ1QC_B>R_P#H
MF&J]U;&6+ R2!@$=O>IOA8I6U\3*6+$:Y("3U/[F&KJ;&)RWP\M4E\$:1,6D
M#(9<8;C_ %K]177O$'1E)(R/X>#7+?#?/_"!:9_VU_\ 1KUU><<UT1?NHS;U
M(+B.Y,"K:RHCAAN:09!7O^-6&=1]YL#U:@$,,@Y]Q44\,%S&89PK*W\+'K3$
M+-&)8R">#W%<;+;7%GJYLRP-M<'.<C@]O?/O7:KEITACA2*%8^7S_%V&*P_$
M&F"XBAG!1KF,Y11U8^@K*K34D;4*G*[,['3MZ6<<4K[Y8P%9O6K5<KX<UA)0
MMM/,!=1Y#@G[Y^OK75#\*(NZ,*D7&5F1W#M' S(0&QP2.E>>^)9Y=3UR'3HU
M7R(V'FNO1F/4FNMUS45M+1I0R'8,A3U9NU<MX<AEGF>_D&5?...<U$[RERHW
MH+EBYLZ"*PM8;:%45/W7"J!PM+)).+B)(HE>,_ZQ]V"OX4EN9V>3SHT5 V(\
M')/UIZQ)'<,RJ=\GWV[<5T)&+>NI-^//:D'0CIZU6N)H7M\"[6/S&\M) ?XO
M0>].W&UMXUQ)*00N>I/N:+"%6WBMUD-O"BN_)P,;C[U)$6$:LX4/WQ0CB638
MGS.!G IJ0+%O #?.V2">])C"XE\B%Y65CM7=@#DU7_M+RMLFT@D<!ATJP\$<
MD31,OR,,$4PVL9Q\HXZ4GL-6ZD\=RDMOEH\'J"HJ.0!D*@*SXR$:C8Z1[8MN
M[_:Z4T62S2R^9(H\Y5!P,'(Y&#3274E^0S[2]O&OVC =ARJ'I5:^BNIHE-DP
M5F."QZJ/458O&,<T(-H\S,VTE3P@]35PQNJDB-]H'\(SFGMJ.]B.)62%5=B[
M*H!;U/K3&:0W'E>40A7(E# \^F*EB.]=QS'GLXP138UD0'S65SGJOI4B'?C0
M$7C'./6GD8QG R,_2JD<\INI(FA*HHRLF>#18"8(?.DD+<-C"XX7'I3^O':C
MTXZ4R65(8FE?A5&20*-P('L(S<"0D_2IS#&8O*"@)V IGV@&542-R&7<&QQ0
MLK1 _:GB4DX4J>#_ /7IZCU'I&D2[47:HJ;RF$?F-A5/3/>F@X.1CBAB7;+$
MGZFD(!L;"X(<\Y/2@GYN3DT <4FY5Z]:!"22+&A=N .M,BFBFCW1MD9XXI)H
MDN(C&^=I]ZA-B-T!CF>-(SRB]&^M/09:QSU&:8(E0DJH!8Y..]+N;=C9D'O3
MMI(Z=*0"XY!/3VJ&XN(;9-\L@1<XRQISS)&K;CC:-S>PJN9;75+;RP5EC(Z
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MC0D"U3(,8[^^1TK9M5B56AC0J8SM((Q^/N/>JVFVL5I$<QE)IVW.-V[G_"M
MY/)/YT*-@G*^BV&L6V'9C=CC/3-)%N$"B7'FG[^WI^%+O52 2,L<#/K1E2V,
MC(ZBF9F>FEE9)FBE>&*1"JHJC"D]6'O5F&*YBD4-,KPJH49'S'W)JWCY1\W3
M^'%)CCCC--R;'<:S+&"[$+M_B["DDFC$:R&4'=TP:) /*8.H<8Y7'6F&"-T4
M-&,+]T$=*0@CFW-P"#FING7/X4TQ@#*XS[T!#O+,Q(/0=J0]!QX.,@$^IZU'
M<1O);.D4ABD.-L@&=OX5&]I;O<I=/'^]C'RMG.T4]YHX]N]L;NE/T$2A3M )
MW$#D^M*2<8W$>V::71$+N2".@ ZTH[\46 JM#+Y^3G;4KW$,<J1/*JR/]U2>
M34H''( /US4+VT$DRRR0HTB?==AR/I220[W)F4MUR3CBF(A0$%O_ *U$K2#:
M8PK#=SGT]J;/*L:*KJS*YV_**=F(DX)X/Y4Y@HB9C\[=D'4U#!;16T96,-C.
M>N:=!*7A\QXFBYQM?K18"&6&[:Y0PSHEN#D@IEB/2F3VGVF]1IE!BB&4.>=W
MTJV2Q7./H*KSSK;0F28G82 -HR:=W?0$6L9)YQQUIBL=YXX'>F01B"  R,R]
M<L>:D4C&5Z'O2 <>/>JEV;E(3(+=UV]0PZ_2K1JS!,!:OYC*XS\H)S0(P-&%
M]Y4LE\!N=LISV^G:KT]TD)^<'.,\#BI\Y^M,E$<<+2RX6,=2U-N[N5<9;SB>
M+S N,^M38  R1SV[U"DBR*IC^X>5(Z$5+GG&>OZTA,"$&=QR,=<5$L*1MN1%
M4GJ0.M38.,8SGG IK*'7J5^AH 7'I4$%P9I9D:&1!&V S=']Q5J)0SA3T/<&
MF< G)_*@1S_CD?\ %"ZYS_RY2_\ H)KT;2?^0-8_]>\?_H(KSOQRQ/@/7 .G
MV*7M_LFO1-)_Y UC_P!>\?\ Z"*YZWQ&D-BY7CO@'_D1],X_@?\ ]#:O8J\8
M^'PE'@[3RSH8BC;5 Y'SMUJ:>XY;'4CUH8%D90<$]#1Q3AG;[>M:D$;I)) 8
MBREV&#D<'\*J:%A-3NHE9&$:A2%[5HK]X9/3K6)X=8-K>H%3A2_!SUYJ6[,T
MCK&1UU!SCCK12.<(2..*HQ.4E47?B&3R1%)*A"OO;.T=^/6MX@J[8^[C%8FF
MB0Z]?,J@V[')D &,_6MS))P3^-3'8VJ;V$SM0X!/<4(WFIN*%">S=:CFDDC*
M!(V?+8..WO4O;(JB"!$FDMU2XVB3.6,9XZ\58P#U4<4U2VYMV,?PT2R"*)I&
MSM49..:  .HGVG.]AT]J5XUD4HP)5N#@]JKI<N+(3NI;>?E51S[5%:PW4TQE
MO#@*VZ-$;@?7UIV'8NA!&JJHSM^4=SCZTR6&.2XCE;ET!VC/!SUXI,3F24%E
M"?P8'(^M'V9'FBF?)EC! 8'CF@"5,@?+D<\BFS1^<H5G88.<J<4D%Q'.'*$X
M1BIR,<T^25(HR[L%1>I- #LL._ I@+&4DE2,<#'2AF)D5#&2C#._/ I^/0T@
M$.U_DVY/0XJN+2.!=BQ9SZFK\$L<,?*_-Z^M1/(9FWG''0 YQ2!-HY?4O!OA
MF>02W6FP N<$@8)/X5?TO0-)T\3+9Z9%:[!A6VC+^^>M;&Q7 R ?K1M&[/I1
MRQ[%\\NY4>U Q)L!?CD=:E2S0LSS$R,QZ'H!Z8J< COP>U!8!<L<"CE0N9E2
M9)\A8QM'08Z"F$R[HXYE5T;@D#.__"KW!'2DR =I_ 9HY04F59+&(G<KNIVX
MVHW ^@IIBCAC,FQY)@NP.XR?I]*NCVHIVML',WN9EK93+ K2EQ,22PW\<FG:
MEI<6HZ9-ITX813J5=D;D9]ZOLH>-D!(!&,CK20*!"J[FPHQ\_6ERK<.=GE=G
M\)8M.U=+F2_F-K&^Y GRM@?WB/Z5Z(GVJV0)L,O/#+V7TYK1<!B.X%! *D"I
M5-)W1;JMK4JK$5W.AV[SG#$]:;=S201Y6&:3O^Y4$FD9Y=^XX"QMMD1OXAV8
M5'J.I)90.S&50HW!PFX$4T+6Z)8;F*[=D#?=.#&PJ1K>,OD@#(P:Y;2]3N+Z
M1;UE^8OA$VX#+G'R_P ZZMG#'&<-CD9IJTASBX,J6L0B>01D^43\JL<_E5HH
M6 897UI&A5L/DJP&,YJ/R66Z,YD=E*[2N?E'O0E8EN^I+DX/(R/6O,=5^)-_
MI6J36GV%2L4A5FER"PSVKT>ZF,$1=(9)6[)&,DUS[WMM<ZJ;?4M"<N.5N'A5
MEQ]>U9U7I9.QK12U;5S8TO4X]5TRWO(T9#+&'V-U%7?AC_JO%/\ V'I?_1,-
M4X6AR1:HO'# #;M'M5SX8?ZGQ3V_XGLO_HF&B7PHS>^AS'PY95^'^FEF"C][
MU_ZZO71"2'SED$O[Q>%*GUKF_AVB2> --#C('F_^C7KH[-+66/S;>-Q@D?.,
M8KJ@ERIF3))K=+D+Y@)P=PQP<T[]\9OX/+QTYSFE<,498G"R=CUJM=2W4014
M>(9X.>"Q]JI7$7N_7\Z> ".3U'%5[='B@5))#(X'+-U-3 D#GI2$Q65PN  #
MU)/I2$JZ%5;J.H/(J""\2Y9UC+%(C@G'&?8U);&.7=)L9"QY!7!.*+6 2T6&
M*$6\+EUA^0[CD@^YJQ\O?-0RRQP*&(;YFP,+GFG@T, 948C*_=/&:3RD$AEQ
M\[<$^M.'--C8O)* A CQDGOFD _:2>F3[563SDNW#RET?[JE0-GX]ZL$ #T[
MT<'GBG<!"@9U<DC;VSQ44<4ZW4C22JT9^XH'2IB1VR/K0.:5P%;@<*?SH (R
M6)^E*/?\*:2P90%R"?FYZ"@!492I(PU 09R0#]:AA>9C(LL(0*V$93G</7VJ
MQU7THL!EWD6J2W,?DR*D(.6!'6IGGF2Y2TR-\F&5L?= ZC]./K[5)<7<T1VQ
MPAVZ#)IK6C26TC;L74A5E?/"8_S^IIM-H8TW9\U(>?,,C9..,#/^%6T))Q5<
M6QB@5=[.ZL6R>Y.?\:=:M*RL9E*GM2L ->023M:AOF(P<'FIHT6)!&&)"\#)
MR:K1:=%"\DJ?ZQNC'M3_ -[;V@,C^9+W;&,TWY!IT+.<*2/2JD<<TMQOD=C&
M.BTRQ^TEYGEF#1/C:FWE?QJQ<7 MHS+*0L2]2!DTUV0K68]M_F*=P"#JI'6G
MKL/WP?;%5;KRFACD*2.-P*A!SS5KD1%<XS[<U(#)Y52%RL6]@/E4'K5>V^U/
M*SS*JQD?*G<4@T[8JGS7(#;N3S4[RF/;E6^8XR!3 AOC<M#LM@I8D9+= *2.
MV2U222*-%E?DHK';GVST%7XIS$K+L5L]R*K2Q12R(7.70Y49H3TL U3.;3)"
M"8CIV!J1XO.C43 ,1U]*9<&00L(L>8> 3T%2H,C&>@[TKAYB$;(PJ)T' ':E
M!?8%8].WI2DC''45&TJ"1(R?WC= .:!$IY/3''.*3^7TH(([U6N?.V*(45LL
M ^6QA?44P+2D+N/3C IHZC;@FD8DJ>-Q [U#%*-JAQLD(^[FD!C^.@5\#:Z#
MP?L4N1_P$UZ)I/\ R!K'_KWC_P#017G/CCGP+KA[_8I?_037HVD_\@:Q_P"O
M>/\ ]!%<];XC2&Q<KQSP#C_A"-,/^P__ *&U>QUXWX!Y\$:8 >=C_P#H;5,-
MRI;'2YYXI$W\[R.3Q@=*0NP54";AG)-/'O6I BN?-9&0A2/O>M9>EK)9Z]/&
M^?)9?D.W ^E:ZX)X.,5C:U))#=1W80[(R-S\D$Y]*F7<TIZWCW.N'2LO7[W[
M%IDC+]]AM7FK,5VKVJ2)\Q9<XSQ[\UAWLAU74K>*'YT5^23@$=S[TI/IW)IQ
M]Z[V0[3(I(;&UDMX47S!ON#GEN.,5JEB$!"@\_,"<8%."B)1$,?+Q\HXIKJ)
M$92.#P15(3=W< B"7SA]\KMSGM4@-0P[!'M5"HZ#-.>159%_B8[4 [FF(>12
M.R@,[?*H'-2+A'(F0Y(X [4T#MB@ 0@J",;>U(' DVXILZ$QL "<TRVC*H X
MZ<<GF@98) ."1["@9Q4#P?Z4MP96&U<;.Q]ZE).WJ3]!0!',\XF5(X0T94DR
M%ONGTQ3!]IDDVNJB/OGG-6(P?+ Y_'K3C@9)]*!IV%Q3<-N'/'I3)%\U%(=E
M(YR*D!Q0(SM219)427?L4;D"G!<_W?KT_.IH52V#E$P5*J?F]<?XT7%LS@$R
M >6,PECT?U/\OH33VB=TDY7YW5OE/IC/\J0[NUBR/H*0$;CBE!QWY%([,0Y
M!<CCZTQ"]B::/G7Y@/IG-0QO.%598\R;,L4^[GT%%N\K%C)$8P>@)YIV"PY[
MB.,X)R?[HZU#'!+-(LUSLW)GRP@.0#ZU9'E%R%*[UZXZBE) /7K25QE:ZMY)
MWA>.9HC"VXCLX]#4OVB$; 95W/PHSR33R-ZE>F:A6RMUF27R_G48!/:F'0L
M$49IBR([,%.=IP>*61BD3,B;F R%'?VH$(ZB1&0YP1@X--2-8HA&N0 ,#)S1
M$YDC5G0QL1DHW45"\JVTJQ+!*_F98LO(%'D,?$R2F0@?=;8WOBGHFP;#RG85
M%"L<,\J*V6=O,(],U,=V#MX/;-)>8WY&5:QJM[+!(JJ8CNB.!T/]:NK;8E,F
MXAF'.*RUOX9]<%IY/F2K]YAP%%;8Y.<T)E3NK#64,FUQG-)T 4<8'2GG.>::
M<C':F0-J&6:&+:MPR*'.U0W<U,PJ%XHI&7S$5RIRN1T-(:)&SP!TH^&/^J\4
M_P#8>E_]$PU')/#&2'D0$=B:D^&'^I\4_P#8=E_]$PU%38$<K\.MR^!-*8<J
M3*&!/0>:_2NIFME:1BDC#_:4X!KF?AQ@^ M-!/\ SU_]&O70R2S"YCBCFB'\
M3J?O$>U=$+\J(>X^VM4M0V"68\DDT^2/S'4-$I4'.6ID4'E$GS'(/]XYJ7GU
MQ3;UN!)@Y 5LBHKHS+;2&W"--CY%<\$^]$EQ'#&7E<(BC)8T^W*X4M(75CNW
M8[>U'F(CMYB^Z-UQ+'@2 +@9(SQ3(K4PW<EP;B4J_)C)^4?2K]Q.L[ A<8ZU
M#1<!(O,&\R,&RV5P.BTY(RAD.XMO(//\/L*?D#GC-1Q2I,'\MU.PX.#T- A9
MI4AC61@=N<' S2]LTR69(5!<@9.!4O0<"D!%<+&\#"8[4');.*D#(RJ8V#*1
MD$5'<0BYMY(6SMD4@U3TW2CII8B9YMP ^8] .G%-6L,TC!!)M,A;(.1CCFFH
MVVY8-&&BV_*0><^]+GCTI%=?.C0D!FZ GKCK2$*/3C\Z<I .<9'H:HKJ<,FH
MO9Q1RL4^])L^5?;-6LL"<@;.,'^=.S6X6 N=[(H/3(STJM:#47GWW7DQIM(\
MI,DYSP<_2I9Y)%C!A"EB>C' Q4ZG*Y[T7T&#$*I/4KSCO38W$J!\, PS@C%9
MVHZ=<W-U'+'-)&BG/R=ZTH]XB4/]X#DT:6"VA&I8W11V&TKD#%6"01A4"@5&
MSJ" <#/ J&YN)(/+"6\DN]]IV?P^YHW$+*+EI(A$ZJH<%SC/R]Q4QVDD=16?
M)<Z@]V(HK8+"/O.6Y_*K,-HL4KS[F\R0 -SQ3:L!-@*, 8J&YFDB:,);-,C-
MARI'R^^.]+*9.D8R>YIZ!MHW=:FXR0XZYSZ4$^W'K3?,'F;0PW=<#K3NB\T"
M$['TIDCE?WC%F"KPHI^1G'>D_P F@".-S/;K*JE=_0&HHK)%N?M#9,@! -6L
M<>E07<SV]N\B1F1Q@*@/+&@";^+IG'K23([0LR,JL>!CM0N2!ZTO?%"$0XEB
M@^==SJ,C'\5.C+/&LK1[';KGJ*==>?+#B)PL@&$XK-N(=4D\N/[2L:  N47D
MM_A5)#6IJ'=QSGFHI1-O3RMNW/SY/;VJ.6/?Y<[NX\D9VKT/X=ZD@G6XB65
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M^,^U-#(A"-)ECT!/)IB(+.Z\]2DD3I,@&_<, _2K)&00<T<<YZ4A/R_+^!-
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gmtxzzgtjwwl000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% @4# 2(  A$! Q$!_\0
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M3EMYMK#&YG#$%L>@49YQ5;5/ NKZYX%OO#.J>)DG$Z0QPW"V 4QK&ZMEAO\
MG8[0"<@>WKW5% '-^)?"K:WJ&GZG:74%O?V(D1#<VHN(I$?&Y63*GJH((8$$
M51O_  3=7CZ-/_:%B+C3Q*KH^FJUO)YF,LL6_P"1P!@-D\$YSDUV5% 'G@^&
M,D7@&U\'QZK:R6,0F222ZT\2N0\C.&3YQL=0V W/(S@=*NMX"FMM6N+O3-1M
M5CNUB^TQW^GBZ8LB!-R-N7:2JC.=PR,XKMJ* .(UKP!=:A-KZZ?KSZ?9ZY"$
MNX!:K(1($V!E8D8!  9<<@<%2<UO:[X:LO$7A6?P_?EC;S0K&SI@,I7!##.>
M00#6S10!R \+>(+O1-3TO6/%(O8KO3Y;*,I8+&5+KM\U_F.]@.P*CD^HPEKX
M*N=/NO#-S8ZLD<ND:>FFSF2UWBYA'EYP-P\MCY?7YL9[UV%% '#67P[-G\+X
M?!@U4N86+"Z-O\K_ +XR[7CW'<ASM*YY&:I_\*OD\S5KL:O!'?7\]C=(T-@$
MA@FMB2I$>_E3D<9SUY.:]%HH X[4O!EY=ZM!K%OJ5DNI&S2TNVNM.$T,VTDA
MU3>"C99OXB,'!SC-7?%/A)?$_@6X\-278MO/BC0W$<(P&1E;(3(&"5Z9[UTE
M% '&7O@S5=6TNWBU77K>YO[.Z6YL[A=-5(T(4J5>,N=ZD,<\@^F,58O/"%SJ
M/A2XTJYU"UAOI)TN(;RRL1"L,B,K(PCWG)!7NW.:ZNB@#C)O $3^$](TF.^
MO=+F%S'=R6ZNLLQW>8SQD\JY=\C.>>N1FB]\#W&IV.CQ76HV<<VG:S#JA:TT
M_P E)!&#B/;O.,Y^\2?I79T4 <K:^$)E\;+XDN[VVDEBBDAB6WLQ"[JY'$S[
MCYFW:,<#')J'7? O]M^(=3U;^T?)^W>'Y=$\KR-VS>Y;S<[AG&<;<#ZUV%%
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M2+W2UG-]<:?/))M"FRL/LH &>OSL6/XC'I6U10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 445D>*=7DT#PIJNK0QK)+9VLDR(_0L%)&?;- &O17):!J&K6_BV\T
M#5+_ /M #3X;^.=H%B92[R(R87C:-@QGGKDFL36/%6KVGCB335OQ BWMK%;Q
M>0K6TD4@7>)I<$I+P^U<KG*<-NS0!Z114%U>VMD@>[N8;=&. TL@0$^G-5?[
M?T;_ *"]A_X$I_C0!HT5#:W=M?6XGM)XIX2S*)(G#*2I*D9'H01^%34 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6^MHHK@BVN3/&T<AD5?F9$.[,3Y&W&-O)R0-B@ HHHH **** "BBB@ HHHH
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M"!1R2XQD\&F?$=]<)I<6GZ;:2WFHV\MY&DM]MB6!&09,L:."Y$L9PH*_>PY
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M7IOUD_\ 9:\_KZ+ ?[O'Y_F?!9W_ +]/Y?DC5\-?\C+IW_7=:ZWXE?ZC3O\
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MX_/\SX+._P#?I_+\D:OAG_D9=._Z[K76_$K_ %&G?[TG\EKDO#/_ ",VG?\
M7=:ZWXE?ZC3O]Z3^2UE6_P![I^G^9OA?^156]5^AY[6GX=_Y&33?^OA/YUF5
MI^'?^1DTW_KX3^==M7^'+T/)PW\:'JOS.I^)?^LTWZ2?^RUP==Y\2_\ 6:;]
M)/\ V6N#KGP/^[Q_KJ=N=?[]4^7Y(V?"?_(TZ?\ ]=/Z&O9*\;\)_P#(TZ?_
M -=/Z&O9*\_,_P"*O0][AS_=Y?XOT05S_B7_ (__  W_ -A4?^B)JH>*O^0I
M%_UQ'_H35AU\EB,Y]C5E3Y+V\_\ @'V=++_:04^;?R_X)Z717":'_P AFV_W
MC_(UW==V!QGUNFY\MK.V]SFQ.']A)1O<****[3F"BBB@ HHHH **** "N.\=
MS:M;3Z!<Z-81:C>17S,MC)/##YP\F0':TG(8 DY7)P#D8S78UY?X[MK.]U6+
M59]/\;R2:?=?9A%HZOB3,1/F( PPO[S:7&"2"O2@#=\"W$YN=6M;KP?8^&IT
M:.=XK:]AG:8OO^9Q& 5^[P6ZY..AKLZX3X=?V<[ZG+:Z)XHL;DB(37'B%'\R
M<#?M",S-D+SD#&-P]:[B::*V@DGGD2*&)2[R.<*J@9))[ "@!]%9>D>(M*UX
MS+IUWYKPX\Q&C:-@#G:VU@"5.#AAP<<&H;KQ9H5EK4.D7.H)%>S2"*-&1MID
M.,)OQMWG(PN<G/2@#:HHHH Y[P6<^'I"3G_B8W__ *5S5T-<]X+.?#TA)S_Q
M,;__ -*YJZ&@!DO^I?\ W37G%>CR_P"J?_=-><4T)A1113)/24^XOTKS3XC?
M\ARV_P"O8?\ H35Z6GW%^E>:?$;_ )#EM_U[#_T)J[,O_CH\G/O]R?JCCJ**
M*]\^%.^^&G_,4_[9?^SUW]<!\-/^8I_VR_\ 9Z[^OG<?_O$OE^2/OLE_W&'S
M_-A1117(>J%%%% !1110 4444 %%%% !1110 4444 %%%% !7DY;P5J^EM8W
MGBJ31F@N+RUN+2XU&&*1XGF)>)@?^69(&TCD*< \FO4+Z2YBL9Y+*W2XNE0F
M*%Y-BNV. 6P<#WQ7D</AGQ)JFE7$=Q\/_"\&I7,L_P#Q,[E8&>,F5MK&/R2&
MP, $_>P">IH ]C    Z"EI!G SU[XI: "BBB@ KG_$F?[6\+8&?^)L>W_3K<
M5T%<]XD_Y"WA;_L+'_TEN* ,/XE_ZO3?K)_[+7G]>@?$O_5Z;]9/_9:\_KZ+
M ?[O'Y_F?!9W_OT_E^2-7PS_ ,C-IW_7=:ZWXE?ZC3O]Z3^2UR7AG_D9=._Z
M[K76_$K_ %&G?[TG\EK*M_O=/T_S-\+_ ,BJMZK]#SVM/P[_ ,C)IO\ U\)_
M.LRM/P[_ ,C)IO\ U\)_.NVK_#EZ'DX;^-#U7YG4_$O_ %FF_23_ -EK@Z[S
MXE_ZS3?I)_[+7!USX'_=X_UU.W.O]^J?+\D;/A/_ )&G3_\ KI_0U[)7C?A/
M_D:=/_ZZ?T->R5Y^9_Q5Z'O<.?[O+_%^B.0\5?\ (4B_ZXC_ -":L.MSQ5_R
M%(O^N(_]":L.OS;,?]ZGZGZ+A/X$30T/_D-6W^\?Y&N[KA-#_P"0U;?[Q_D:
M[NO=R+^!+U_1'F9G_%7H%%%%>T><%%1RW$,&/.FCCW=-[ 9_.H_M]G_S]P?]
M_!0!8HJ.*X@G)$,T<F.NQ@<5)0 4444 %<!-XOM/"GC76HO%%[<VEO>-"VFS
M2AVMC&(\,JD957WAR<X)RO)XQW](RJXPRAAZ$4 <9X*UM_$>N:_JMC)>2>'Y
M3;K9/<!U5Y K>:T2L 53[@],ACW-:WC;3[K5O ^N:?91^9=7%E+'$F0-S%3@
M9/KTK>Z# HH \^TS4)7\2ZAXG32-76Q73;2P$)LG2:27S7+;8V )""1<MC'W
ML'@U'X@O3K7CVQTW4=&U==*TBYBNH9H]/ED2ZNB"$.]5*K&@8Y)/)/8*<^BT
M4 9^IPZS*8O[*O["U SYGVJR>?=TQC;*F._K^%9_V/QA_P!!W0__  33?_)5
M=!10!S?@43#POBXD2287]]YCHA16;[7+DA26('MDX]:Z2N?\%Y_X1^3)R?[1
MO^__ $]S5T% #)?]2_\ NFO.*]'E_P!2_P#NFO.*:$PHHHIDGI*?<7Z5YI\1
MO^0Y;?\ 7L/_ $)J]+3[B_2O-/B-_P ARV_Z]A_Z$U=F7_QT>3GW^Y/U1QU%
M%%>^?"G??#3_ )BG_;+_ -GKOZX#X:?\Q3_ME_[/7?U\[C_]XE\OR1]]DO\
MN,/G^;"BBBN0]4**** "BBB@ HHHH **** "BBB@ HHHH **** .<\;SV=KX
M;^T7MC]M$=W;&& S&(&8S((R6'( 8@G@\#H>E<CXR^''@/2='U/Q)=>&1=R1
MDW-PO]H3QEP6RY'S8SR2!P"<#C->BZMI5EK>E7.F:A )K2YC,<L9[@^_8]P>
MQKDD^&%E)-;KJ/B'Q#J=C;R>8EA>WN^$D,&7<-H+@$<!B: .X!! (Z&O./&-
M]J$NH^*/(U.[L_[#T1+^T6VE**TQ$Q)<?QC]VHVGCD\9KTBL35_"6B:[>)=Z
MC9F694$3%9G02H#N"2*K 2+GG:P(Y/')H DNIH[KPN+F^O9=.B:W6:XGCD$9
MC7 9OF(^4=03P?3%8_PZ35AX>N)M3NKJX@GO)9=.^V$F9;0D>4')Y)(&[GGY
MN:T]3\'Z%K-MJ5OJ%D9H=2>-[M?/D42&, )T8;<;1PN,XYJWI&B66AP20V(N
M-DC;V\^ZEG.<8X,C,0/8<4 4&\76JNR_V7KAP<9&E3X/_CM9.IZ]!J6O>%X4
ML=3A(U0MNN;&2)?^/:X'5EQGGI7;5SWB3_D+>%O^PL?_ $EN* ,/XE_ZO3?K
M)_[+7G]>@?$O_5Z;]9/_ &6O/Z^BP'^[Q^?YGP6=_P"_3^7Y(U?#/_(S:=_U
MW6NM^)7^HT[_ 'I/Y+7)>&?^1FT[_KNM=;\2O]1IW^])_):RK?[W3]/\S?"_
M\BJMZK]#SVM/P[_R,FF_]?"?SK,K3\._\C)IO_7PG\Z[:O\ #EZ'DX;^-#U7
MYG4_$O\ UFF_23_V6N#KO/B7_K--^DG_ ++7!USX'_=X_P!=3MSK_?JGR_)&
MSX3_ .1IT_\ ZZ?T->R5XWX3_P"1IT__ *Z?T->R5Y^9_P 5>A[W#G^[R_Q?
MHCD/%7_(4B_ZXC_T)JPZW/%7_(4B_P"N(_\ 0FK#K\VS'_>I^I^BX3^!$T-#
M_P"0S;?[Q_D:Z+6K?1[]HX=3FD5HCN58[F6'KZ[&&?QKG=#_ .0U;?[Q_D:G
M\2_\AAO]Q:[\%BI8;!2J15_>_0YL105;$*+[?J49]#T$>)K!(Y[W^S39W)GQ
MJ5SCS0\/EY._.=IE_7T%='HVGZ%8WI;3IIFG=2I$EY-*".IX=B.U<G6KX=_Y
M#47^ZW\C6V'SFK4JQ@XK5I=3.KE].$')-Z(WM4C\/WTJQZK;V%S)#D*+F%9"
MF>N,@X[5S3:-X5/BZ.3^R-)^P"P93_HB;/,WKCC;UVYY]*DU[_D-W/U7_P!!
M%9M*OG-:G5E!16C:ZA3RZG."DV]4=GI-KX>M;ESI%G86\SK\YMH%C9AGN0!D
M5L5QWAC_ )"Q_P"N1_F*[&O6P&*EB:/M)*VIPXJBJ-3E04445VG,%%%% !11
M10 4444 %%%% '/>"_\ D7I,?]!&_P#_ $KFKH:Y[P7_ ,B])[:C?C_R;FKH
M: &2_P"J?_=-><5Z/+_J7_W37G%-"84444R3TE/N+]*\T^(W_(<MO^O8?^A-
M7I:?<7Z5YI\1O^0Y;?\ 7L/_ $)J[,O_ (Z/)S[_ ')^J..HHHKWSX4[[X:?
M\Q3_ +9?^SUW]<!\-/\ F*?]LO\ V>N_KYW'_P"\2^7Y(^^R7_<8?/\ -A11
M17(>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M/>)/^0MX6_["Q_\ 26XKH:Y[Q)_R%O"W_86/_I+<4 8?Q+_U>F_63_V6O/Z]
M ^)?^KTWZR?^RUY_7T6 _P!WC\_S/@L[_P!^G\OR1J^&?^1ET[_KNM=;\2O]
M1IW^])_):Y+PS_R,VG?]=UKK?B5_J-._WI/Y+65;_>Z?I_F;X7_D55O5?H>>
MUI^'?^1DTW_KX3^=9E:?AW_D9--_Z^$_G7;5_AR]#R<-_&AZK\SJ?B7_ *S3
M?I)_[+7!UWGQ+_UFF_23_P!EK@ZY\#_N\?ZZG;G7^_5/E^2-GPG_ ,C3I_\
MUT_H:]DKQOPG_P C3I__ %T_H:]DKS\S_BKT/>X<_P!WE_B_1'(>*O\ D*1?
M]<1_Z$U8=;GBK_D*1?\ 7$?^A-6'7YMF/^]3]3]%PG\")H:'_P AJV_WC_(U
M/XE_Y##?[BU!H?\ R&K;_>/\C4_B7_D,-_N+6L?^1>_\7Z$/_>U_A_4R*U?#
MN/[:A^C?R-95:OAW_D-0_1OY&N?!?[S3]5^9KB/X,O1C->_Y#=S]5_\ 016;
M6EKW_(;N?JO_ *"*S:G%_P"\3]7^8Z'\*/HC:\,?\A8_]<C_ #%=C7'>&/\
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M@ HHHH **** "BBB@ HHHH **** "O&V\4:X'8?VE/P?6O9*\Y/PWNRQ(OX
M"?[AKOP,Z,.;VOD>'G5'%5>3ZM?2][.W8PHO%&MF9 =2GP6 /(KV&1MD;/C.
MT$XKSR/X<WB2*QOX."#PAKT1U#HR'HPP<48Z=&;C[(,EHXJDI_6;ZVM=W[G%
MZ?\ $)-1\.P:S#II,,_V2%%6<'-U.5'E9V_=7>N7^HQD5NZ-K%Q?7=[I^H6D
M-IJ%F$>2*&X,R%'SL8,54\[6&"HY7\:SK;P#I%II::?!)=)$L=LH974-YEOM
M\J;A<>8-J@G&"% (.*U]*T=-+,\KW=S>W=P09KJYV>8X'W1A%50!DX  ZD]2
M37 >X:5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 52.CZ8R!&TVS*"X^UA3 N!/G/F]/OYYW=<U=HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gmtxzzgtjwwl000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A M # 2(  A$! Q$!_\0
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M35;: ']PQ8=V&&&T\=^V><+;^-?MGBK3=-L]-N9["_TX7T=VH48!*X)!8':
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M6VH:A_95U?6@OIH+5;,1@B*+",[EW4<N'P <XQQUI;OXA:;!8I>6UC?WUO\
M8DOYG@6-?)A?(4MYCKR2K<#.,'..,EF+F1UU%<[=^,K"RL]<N)[:[ T4(;E
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MM;C[=Y_V?2(-,V^5MW>4S'?U.,[NG;'4U>N]#^U>*-,UK[1M^PP3Q>3LSO\
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M.W;UX&.N*ZVBBY7*F<1;?#T0>)(=7:]MI'AOWO%D-D/M+AU<&-YMV64;QMX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH Q&\7Z K%3J4>0<'Y6_PI/\ A,-
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MRQF-P<ML&#GW_P *GZM)+W395T]SSFR>;3[N":&8HRMC<.37KVD73ZAI,,C
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M4YZBGR:!;7ES%=:BSW4R(HV,Q$08#E@G;/XUK44 %%%% '%>(21XO7 !_P!
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M 0UV[/(X&!D8R3ZGI5*3B9N-RX.$)N!N4C&=O/\ ^NH+JZ6TLV>*(SE0'BC
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MUIRL$8E<;<<#')-/#B5&8D,P&T^A]J%V*<MN4D<9)(_&I5NA;OU(4+'6=+W
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MZ1_PF2#&=U@H'_?QJS-0MWFM%ED4RR*^ @'3C[PSSVK2UX9\9)C&?L"XR/\
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MNR+L5I/,8/QGG XZ\?3WK4%L_:%1]2*D,=\PQ]J@4^H@/]6I$MKO'[R_)/\
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M>HHAYE3M;3L>CZ;_ ,@JS_ZX)_Z"*M55TW_D%6?_ %P3_P!!%6JZ#A"BBB@
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M:]N[RZE;2[BZV/#+91VTXQ^YCC(2,9(R7Z,#C/ [U-=)=P6]Q%8M_I#J&B+
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M8_[2G@@@"AFVMN8G^Z/>O9Y=JW"Q[ $;G<.G/^%4O[0T^:_FL(;U&O(#S"I
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MG#CL#3Q<5&?39G)Z7X6NKV4'4%-K:]61F DD]L#[H]3U_G7?((XT5$VJJC
MZ >E.'6EJ*^(G6=Y&V#P5+"0Y::WW?5F#X,_Y%&P^C_^AM6]6#X,_P"11L/H
M_P#Z&U;U8'6%%,DECA4-+(D:D@ LP R>@K-35Y+G46M+2PN&C1F26YD79&A&
M>F>6Y]* .2L(]Z3E<[A<2@_3>:>[ 2;2N .-RCI4&EF2*&3S)-SM-(K!1A<[
MCT]LU?VN':17B)]!G\ZB^IO'8ACF,0*!\J<@G.?T/2EDEBG5 R'(]6QGWI61
M,?O%& .W:F^3NVF-E)7ID8./3WHO%E$D%RD)D5LE2203]/6B2Z\P<,RLN&!
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MS;E[;CG'T%;OV:II+<UE)21H1J$/F A]P*@XP1[U*UNTW\+L#@\# ..U-4G
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MJN[)8Y)S[<D\]*8C35@RAE.01D&FR1I(NUQD=?H?6L>SU,-J$]M$J[D>021
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M]X @D  ]J/,D^9%+%AR>V:H3ZM!;H3\J1\8:0YS]*GAOENE7:  1\K!L@_\
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M/.?M$7'_ (]63BVS>,XI")&V>058'KWI#NQCJ=V./_K4XV&NG_F#./I/'_\
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M)%LU31B<,!=J%;OC!KNZF3N8RW.?\&J3X5LSN8<R=,?\]&K>"G^\QK#\&?\
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M33\R79Z%])G69O+/VV\'R,X^6.(9Z$\X]P,D_P K<-AF5+B[<3SJ<KQA(_\
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M.0$:1@#C[I [5'/X>\5Z^ZM+I(TEO^$9N-,5I+M'*W#%, [,X4[3AAGC.0.
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MPE:Q1AB'S,2>>6;H/PKHE<*GREC\V" >U06&GMI^DQ6)E+M$ "Q]ATX'2KK
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M'_023_OAO\*W** ,(^,- ((_M%/^^&_PI?\ A,- _P"@BG_?#?X5N44 8?\
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M;GFIH->TJXMFN([^#R58*SLVT GH#G% &C1445S!.@>&:.1"<!D<$$^G%2T
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M<#/. .36E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gmtxzzgtjwwl000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ BD# 2(  A$! Q$!_\0
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MVE0V[:?#!>M;A5=-SS94C<0W&3P*Q['79SXZGU+5K.>\A7Q'_8]I.NINAMN
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MB5J6HF#S[6QASI%[=RE68J9K>7R_E8G_ %9P3Z^_% '>R:%I4W]H>;I]N_\
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M<*H& !^%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=DDDG;QS4^B>&-%\.";^R=/BM3-CS&4DLP'09))P.PZ#M6M10 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Q]S\1M(@L]?NEBN'BT5XHY
M6*A!*[MM 0L1QGC)P/3CFNAT;4AK&DV]^L2QK,"RJLR2C&<?>0E3^!K-F\-W
M/]H:W?6>IB"XU(6^PO;"183%GJI/S!L^Q'8YYJO9> M&71H;'5K:#5'CFFN/
M,FA  DE<N^U?X5R>!["@#J:*Y?X>QI#X-@AC4+''=7B(HZ*HN90 /8#%=10
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MSQJVX*XR ?7]:YSQ#X;T6WT9Y(=-MT<30X*K@X,J CCVXKK*Y3X@>(=*\/\
MAY9-4O([<37$2QA@6+XD5C@ $G !)H T_P#A%=!QC^R;7!_Z9BM9$6*-8T4*
MB@*H'8"H[.[M[^SAO+29)K>=!)%(ARKJ1D$5-0 4444 %%%% !1110 4444
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M?*6VI"^#-A>3*"<G&!@G@ >U</J<5HGQ%UA[J+3HV>^B*&Z\-S7SN/*C&5G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZF
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M@S$1 ^7'P!A<\]LD\?IR =S1110 4444 %%%% !1110 4444 %%%% !1110
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MK%$G)3Y4!D8\[5 SUKT'Q3;)/H%Q)+<RV\5LIN)&B@CF9E0$D!75@?RS7&^
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MZY+_ "%<]\2/^2:^(_\ L'R_^@FNAL?^0?;?]<E_D* )Z*** "BBB@ HHHH
M**** "BBB@"O?7MOINGW-_=R>5;6T32RN03M11DGCV%8GAKQWX;\77$\&AZC
M]JD@0/(/*=-H)P/O 5JZUIJ:SH=_I<DC1)>6\D#2*,E0RE<CWYKC_A]\+;'X
M?7M[<VNHW%VUU&L;"5%4+@YXQ0!WU%%% !1110 4444 %%%% !1110 4444
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MZ;@<58M+*UT^V6VLK:&V@3[L4,811] .* )Z*** .9\ _P#(IQ\8_P!,O?\
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M<>E %VBH?M5O_P _$7_?8H^U6_\ S\1?]]B@":BH?M5O_P _$7_?8H^U6_\
MS\1?]]B@":BH?M5O_P _$7_?8H^U6_\ S\1?]]B@":BH?M5O_P _$7_?8H^U
M6_\ S\1?]]B@":BH?M5O_P _$7_?8H-U;XP+B+/^^* )JR/#W_'M??\ 80N?
M_1AKQ3Q1X7^(MW\3Y-0LKB>32S<P,)HKM8H=H5-Q\HRY &&R._/K6K\3_"WC
M.]ATV/PY?M=XN+F:<6<JVI4R,K#.9?FYSCTP?6@#VVBN3\ PZEI?@S3K77KN
M,WT<0#H[@NAYR&;<=Q]ZZ;[5;_\ /Q%_WV* )J*A^U6__/Q%_P!]BC[5;_\
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AQO:6MS)<"64,6\XM( 4X) 0<<UW-% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gmtxzzgtjwwl000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F M # 2(  A$! Q$!_\0
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M5@MQ:6$\\189 =8V89'?D5P7AOQYJT7@749M7F%YK4%I;7-J2BQ_:/M4:F$
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MC[UG]9K7M?\  U]A2Y;V'_V_J&W/_"0^(,\9&+'_ .1JM6VHZE<*S'Q%X@1
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M+>VLML9 ,E ZE<X[XS7)K\-+?^TO"=V^H,PT*TCMIHQ#@7OE*/*9OF^7:^7
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MG S@'/%9%S"EO:'[0_E(N%+$<>E5);B"PANKB)P[(G"#]*?/)"Y(M:'2?VM
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MT9(SY>&D.1QU/:NV^)6FW>I)X3%K9RW*V_B2SGG$<9?9$-X9F _A&1DUW%%
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M[_67_P D4 =!17/_ /"0ZI_T)FN?]_K+_P"2*/[?U=ON>#]64_\ 36XM /\
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MD'H1T%:49:*%I&&58<KGO44<$AU3S/D,9&6^7YAZ5;M;26!IS<77F>:?EP
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M2HM[V]Z'".%;KANN1DC%<OJ'B:[CD>*UVQ@G*LXS^%8;:M/.?-=II9$^\=V
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M,@&ND8_L.<;LG)B=<?I5Q='NY8_-N].G:0\!1&2/RJ?^S=1_Z WBK_P?K_\
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MLQ<@AX6)]C5R"Y$BM&W#?P9_E6L97T9G*/81PDF >&)XYJO)$R'D&KS0Y^Z
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MA '3YE(.>>>F.0#JZ*** "BBB@ HHHH @OB1I]R0<$1-@CZ&L[PD /!FA #
M&GV^ /\ KFM:%_\ \@ZY_P"N3?R-9_A/_D3=#_[!\'_HM: -BL+Q5_R#HO\
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MP_\ 0FKTRO,_B-_R'+;_ *]A_P"A-7;E_P#'1X^??[D_5''4445[Y\*%%%%
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M+2K_ ,),OW?#7AT?35I/_D6BBCE78.9CL^)\Y_X1OP]G_L+2_P#R+1N\3_\
M0M^'O_!M+_\ (M%%'*@NPSXG_P"A;\/?^#:7_P"1:-WBC_H6_#W_ (-I?_D6
MBBCE078F?$__ $+7AW_P;2?_ "+1GQ./^9:\._\ @VD_^1:**.5=@NRMJ%CX
MFU2S6Q?1]#LX7G@DDEBU.1V"I*KG"_9U!/RD=1UKKZ**8@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gmtxzzgtjwwl000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, GD# 2(  A$! Q$!_\0
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M1A2Z>W41I$J6\@B<<9B9ARN0#DU)I=Q?ZAJGA5M M=(TIT@U6--MLSVDJ++
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MJSXB_P"$6/Q,NU\2QV,C'1;;[*MPBM*6$UQGRA][=T^[STH ])I&944L[!5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****  C(P>E%%% !1110 4=:** "DP,=!
M2T4 %&.<]Z** "BBB@ HHHH 3 .,CITI<?K110!DKX<TU=0:]$<QD,_VG8;B
M0QB7&-X3.T''MUYZUK444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %(S*BEF("@9)/:EJO)''>*H+DQJ_S*.C$=C^- #&\R:[VI
M<ND?E!AL"G/)[D&G_9Y?^?V?_OE/_B:!_P A%O\ KD/YFK% %?[/+_S^S_\
M?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y
M3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L
M_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#O
ME/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\
M?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y
M3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L
M_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#O
ME/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\
M?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y
M3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L
M_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#O
ME/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\
M?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y
M3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#OE/\ XFK%% %?[/+_ ,_L
M_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#O
ME/\ XFK%% %?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFK%% %?[/+_S^S_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR.(HVD;)"C)P,F@
M9U0J&."QVCW-1PVZPM(^2TDC99CU]A]!1;-,\6^=0K,<A1_".P/O4U !1110
M!7'_ "$6_P"N0_F:L57'_(1;_KD/YFK% !1110 4444 %%%% !1110 4444
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M444 %5[W_CW'_72/_P!#%6*KWO\ Q[C_ *Z1_P#H8H L4444 %%%% !1110
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M%)3_ ($O5?Y5F7'B*Q/B&&]03/:0Q/$\Z1DH&)'>B*J-M^0JDJ,8I;:K??\
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MW$<%G$&:.QFEVW4J]57(_GS^59.I66CV6H:=%IMUY2W#B.X6*X.&CR.2<_\
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M6US_ *!D_P"0J_;4_P"9?>9?5,1_(_N9D45K_P#"+:Y_T#)_R%'_  BVN?\
M0,G_ "%'MJ?\R^\/JF(_D?W,R**U_P#A%M<_Z!D_Y"C_ (1;7/\ H&3_ )"C
MVU/^9?>'U3$?R/[F9%%:_P#PBVN?] R?\A1_PBVN?] R?\A1[:G_ #+[P^J8
MC^1_<RGIEF=0U2UM.<32JK$=0,\G\LUNCPFL=P7FG:2UD8"V%L59YMVX@9.
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MS,BBM?\ X1;7/^@9/^0H_P"$6US_ *!D_P"0H]M3_F7WA]4Q'\C^YF14MO\
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MZ#K3UL?%*+M6UFVXD&#&I!$F-^?7.!2C&-K.#^[T_P""))6U13\+?\C-8_\
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M% !1110 4444 4KS2K._N(I[B-VDB5D4K*Z JV-RD*0&!VC@YZ5*+&V5=HB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_LB_\]9_^_K?XT?9%_YZS_\ ?UO\:L44 5_LB_\ /6?_ +^M_C1]D7_GK/\
M]_6_QJQ10!7^R+_SUG_[^M_C1]D7_GK/_P!_6_QJQ10!7^R+_P ]9_\ OZW^
M-'V1?^>L_P#W];_&K%% %?[(O_/6?_OZW^-'V1?^>L__ '];_&K%% %?[(O_
M #UG_P"_K?XT?9%_YZS_ /?UO\:L44 5_LB_\]9_^_K?XT?9%_YZS_\ ?UO\
M:L44 5_LB_\ /6?_ +^M_C1]D7_GK/\ ]_6_QJQ10!7^R+_SUG_[^M_C1]CC
5)&YYF (.&D)&0<BK%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gmtxzzgtjwwl000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z I8# 2(  A$! Q$!_\0
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MHN ><(V6/3C@]BP*:.MHKS;1O%]Q<:A>R6*&>35]1MTLTN9"$A1K*.8D]3P
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M9)4C('J1S18.='H5%<99>,;_ %>33X--M+/S;];BXC,TS;8X8F"?. N?,+,
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MA/LGMU/9_P#B<?\ 3C_X_1_Q./\ IQ_\?KSG5!=6OA)[<ZPUO?R6XB6?<?\
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M?_ U_P#XU1YVL?\ /C8_^!K_ /QJI]S>II=S?WC^= %?SM8_Y\;'_P #7_\
MC5'G:Q_SXV/_ (&O_P#&JGW-ZFD:38N2QP/>@"'SM8_Y\;'_ ,#7_P#C5'G:
MQ_SXV/\ X&O_ /&JYG6_&:0W(L--D26YZRL3Q$OJ:XI?&EI-H>LS2^(KQ'@&
MWSXBS;"3@%5[\U2@V;>Q?+>3L>M^=K'_ #XV/_@:_P#\:H\[6/\ GQL?_ U_
M_C5>6BW\4VNE6M[9:Q=ZK%(H.-S(_3/(/K4USJGB-K;]XT]H<?>DN ,'\ZKV
M?F4L/=;GIGG:Q_SXV/\ X&O_ /&J/.UC_GQL?_ U_P#XU7E=];:WJ>EZ<+#Q
M<ZW%G&5O)8YFVR9)(/N0.*A26YM[7]]XKU6Y;&<PN1^II^S7<2P\V>M>=K'_
M #XV/_@:_P#\:H\[6/\ GQL?_ U__C5>:Z7K$-\6MK74]2EO8XV,*7$[J9&]
M\<$5QB>(/&%]JSL]SJD+++L>!78*/_K4XT7*^NPG1:=FSWWSM8_Y\;'_ ,#7
M_P#C5'G:Q_SXV/\ X&O_ /&J\N33/%5XL:#6;^#<^2QF.<>U6KW6/%UIJ,>G
MV6GO=6,(4-<F\Q*P[L0:EP[,;H-.S9Z/YVL?\^-C_P"!K_\ QJCSM8_Y\;'_
M ,#7_P#C5>8?V%XDFU>ZENO%]\;'>#'' Y4_CZ8SVKT#P\Y\Z6(74LZQQJ#Y
MC%B#]:F44MG<3HR47)FO8W(O=/MKL)L$\2R;<YQN ./UJQ6?H/\ R+VF?]>D
M7_H K0J3$I7EW<0W-O;VUO%+)*';][*8P N.X5O7TIGG:Q_SXV/_ (&O_P#&
MJ+G_ )#EA_URF_\ 9*Y;7M4O](%_+-K+Q1O)L@"1!V0GHJKCDTTKE1BY;'4^
M=K'_ #XV/_@:_P#\:H\[6/\ GQL?_ U__C5>9:/\0=5M+5H-;CNX9O."QRS1
M<R!NF,#VKN6U*Z95"3LK[<G@8IRBUN6J39J>=K'_ #XV/_@:_P#\:H\[6/\
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M^:6&(%8\]![TXP<M$)TFE=L]#\[6/^?&Q_\  U__ (U1YVL?\^-C_P"!K_\
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M^@U7T^(QVWS=6.:L3_\ (3TOZ2?^@TD9224G8TZ***9)FZ7_ ,>MU_U]3?\
MH9KE-9\+75_K6J7*V&FSQWL421SW#'S("JD9  ]3D<UUFE_\>MU_U]3?^AFI
MZ (+*![6PM[>29IGBC5&D;JY QDU,U+3&YXI#0W#$\'ZU+2*,"EH!L*6DHH$
M%%%% !12U#/<1V\9>1@H% TF]$/8D#-<UXDU*>W18H'&]OH0!WJM?^*(IV=;
M19) G!8< 5Y9XH\: WAALG"Y;:\F<Y]A6E.FYL[*=-4USS-:_P!)QI-['!J4
M$.I7AW/(<8_W0>H%<]IGAC4_#L]C;RP136]Y+MGE7]XCCJ%^E)IUPMRC(\:
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MLK(#@C(S]177>#C)_;,"ECN#[LCD$$$']*4XJQ,_>@[GHTG_ "&;;_KWF_\
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MK@]P/7&:]&IR4X\_-9=3%\_;8N?;]>T>UNKSQ$;1H<M$J0<N^[C!].#T%1^
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MIO$6E7\5U:>1<03&)Q*/O@=".YK1JU[;'/%K3FWU,JT\!I!XAU3SHX)M)O\
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MJ>A'K5/7+IDT:XN+?+2K&SICMQ6)\/K"YL+:^N+V3+Z@4G"=U)'.:TLG#F[
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M&*%LD \"NV\76UCJ M;87"6^I.=UJS\;\=0#W-<FOAW6$N7AN42. Y:1BW
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M,I>W>8]GRKQ4%G#I%I9Q6O\ PE*2I&,9>YCR?J<UJ6FHZ):;MFKV1!];A/\
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M+_A)=$_M0Z9_:=M]L#F,Q;QG>!N*^FX#G;UQ3;+Q5H.HS>59:M:W#^29P(Y
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M0 4444 %%%% !1110 4444 %%%% !2,P52S'  R2>U+39(UEB>-QE74J?H:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gmtxzzgtjwwl000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Q I(# 2(  A$! Q$!_\0
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M^7\*NBTMENS=K;Q"Y:,1&8(-Y0$D+NZX!)..G)J:B@"I8:5IVEH4T^PM;1"
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M<+MFN%@422#T9L9/XU>HH HZ=HNE:/YW]F:;9V7G-NE^S0+'O/J< 9J]110
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MCVNOV?AO2;Y2UM=:TD;A20>8)^01Z'FN^J&>TMKIH6N+>*5H)!+$9$#>6X!
M9<]#@D9'J: /(-,\1:G8:GXDO[X)-K6A>'OLURAX\R2&25UE/'W71T?CU([5
MOZ)J?C&XMM08%S'-IIGL[G5);7Y;D] !;L<Q$$'YAD8ZG/'?"QLUNY;L6D N
M9D$<DPC&]U'12W4@9/'O5*V\,:!91W<=KHFG0I>*5N5CM443*<\. /F')X/J
M: /-=5U/4=0\,Z>C:YJUG?V?B"TMKPW*6WF1,[(?O1KY;* VX>N<-D<5?U;7
M=6TV'QI)87<*75I?Z9#!<&VC.1(MN&+X WYWMU/ /!&!CO1X<T-=(;2%T?3Q
MIK')M!;)Y1.<Y*8QG(!SZU,VCZ6R3(VFV92=D:53 N)"F-A;CDKM7&>FT8Z4
M ><ZGXEU_0+CQ-ITVKF[-O)IS6URUO&LD2W,NR10,!#@ E2PX[YKKO!AU>2R
MO9=5O;FZ0W3+:&Y$ D$(  +>2H&2=QYR<8Z9P+.O>%['7;:1&"VT\DL$KSQ1
M(6D,+[T5\CYU!['U-+X>\-P>'VU"6.9I)K^<3S$(L: A%0!448 PH]23WH V
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ..\/IXDUKPWI>JR>(UB>]LXKEHTL$(0N@8@9/09JXNF^(C+(G_"
M3_<QS]@CYS^-2^!/^2>>&O\ L%6O_HI:T[21Y7D>2,QNP4E"<D<4P,K^RO$7
M_0S_ /DA'_C47V36]@?_ (2Z+RV8(K?8HL,Q., YZYXKI*\]O;"2[U"_\/01
M#S;*:;5K0LY95=@&B+KD''G23$#H/*SP0*0&U.FJ6LOE7'C2VADP&V26L*G!
MZ'!/L?RJ2"SUNZC\RW\71S)G&Z.RB89^H-8.M7$.L?#+Q;KD;&2&^L[AK<NF
M-L:1;!CCD%E9@>^[(XQ7?.KK"PMUC#X^4,/ES[XH Q/[*\1?]#/_ .2$?^-1
M_8];\CS_ /A+H_)_YZ?8HMOYYJ3PG_:O]G7']J?>^W7FS?NW[?M,NW[W\.W;
MM_V<=JSQ&4U9_#B*2@NSJ2AB2#"3YF,_]=^,=-O'2@"W<V>MV=K-=7/BQ(H(
M4:221[&,*B@9))ST %$UIK5O")I_%T<4;,JAY+*)02Q"J,D]22 !W) KF=1U
M&\U#X?:S+-?6\AD\/W;W,'G[I5D\K_GF4!CVG<I7/' ZC-:VM7=]I-L4@OYG
MS)IG,@4D>9=K&^..-RG&.W;% &A<V>MV=K-=7/BQ(H(4:221[&,*B@9))ST
M%2#3/$+ $>*,@C(_T"/_ !KG]=U*&^\#^+%EU(MJ$=CJ$<MEN ,:JKA<IC(&
MW:0W\08'D$5H+J5\^L7%L+VVMY(;F!(8IY_+WQ%(R<)L._=EP&!ZC'!4T :!
MTOQ%D#_A)^O_ $X1_P"-+_97B+_H9_\ R0C_ ,:WC]Y:6@# _LKQ%_T,_P#Y
M(1_XT?V5XB_Z&?\ \D(_\:WZ* ,#^RO$7_0S_P#DA'_C1_97B+_H9_\ R0C_
M ,:WZ* ,#^RO$7_0S_\ DA'_ (T?V5XB_P"AG_\ )"/_ !K?HH P/[*\1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_P"!/^2>>&?^P5:_
M^BEK8C_X^I_^ _RK'\"?\D\\,_\ 8*M?_12UJVL0ADEB#,P4* 6.3TIH"S2#
M[S?A3J:/O-2 6BEHH 2BEHH 2BEHH 2BEHH :?O+^-+2'[R_6G4 )12T4 )1
M2T4 )12T4 )2'[I^E.I&^Z?I0 @Z#Z4M Z#Z4M "44M% "44M% "44M% "4@
MZM]?Z4ZFCJWU_I0 M%+10 E%+10 E%+10 E%+10!D>$_^1-T/_L'P?\ HM:*
M/"?_ ")NA_\ 8/@_]%K10!L4444 %%%% !1110 5%<-,MM*UNBR3!"8T8X#-
MC@$]N:EJ"\AEN+*>"&=K>62-E291DQDCA@/44 <KX-U[7-1U?5]+UH6,LEB(
MBT]D&$:2."6A.2<E>.??FO/Y_BUXBA\/Z_+Y5F;^VO=EF/+.TP@R;B1GD@1F
MO1_!?A"Z\(6LEH^N3:A;'E(Y($3:Q)+,67EB<\DDUA2_!_3I>6U*?=Y%Y#GR
MQSYY8Y^J[SB@#2?XC6-E!#]JM;N;R;6WGU&YMXP8K3S5!7?DY]^ <"GR_$?3
M8M5:Q6PU"0+??V?YZQKY9G*[E4'=D[ATX^M07OPVBNC-#%J]Q!97MO;V^HVZ
MQ*?M*P@*I#'E"0,'%6&^'UJ;@RB^E4?VW'K 4(,!D7:(_ICO0!S=A\4=5O(_
M#]TVAW COVO1+;1("[B(94H2V,#G.<<@UOCXGZ/+=Z=;VEK?7+WMM'<@1HN8
MT=MHR"P+$$'(7.,4FD_#I=,FTTMJTL\6G-=_9D,*KA9QRI.><'/-4+KX36]U
MIFEZ<^KR&VL84B^:V1G^5RVZ-^L;'."1GB@"_P#$/Q1>^'#HD=I?V6GQWUTT
M,UW>1ETB4(6!QD=QCKWJEH/Q'FGTB+[992:CJ$UU/#:C38L"ZBBQF90Y&%Y]
M>3TS74ZSX:M]:U'1;N:4@:7.TRQE0PDRA3!S]<U!KWA=M4O;#4=/U!],U"R5
MXXIHXED4QN,,I4\=@1Z$4 9?_"S]%EO=/M;.WO+M[R%9_P!TB@QJS%.59@20
M0<A02,59\->,9=:UC7[2\L6L8--N_L\4TI 63@<$Y^]WQZ$5DZA\)K*]L+#3
MTU*5+2UC"$/ CR%M^]I$DX,;L2<D?E6Q!X$L!J.K27S1W]AJ%REW]CN( PBF
M50NX-WX% &1IOQ&98FCOK&XN[R;4+RWM8K*,'<D'/.2.<=ZD3XEZ;YTFH-/(
M-,_LJ.^6+[/^\W/(4 W;NN>,8_&K=A\/+6PU"TNX[^4_9KF[N%38 #YXP5^B
M]JYFS^&CW%_J&C74=PFDPZ5#8P7K[-TTBRF7>%!/ ) (/7% '3+\2--EM4\B
MPOYM1:Z:U_LZ-4:8.J[V_BVXVX.<]ZS=3^(US%J>H6D.EW5O;P:(VI+<S09:
M-L$_,A8<#&,=2?;FKD?P[,%M:2VVK_9]6M;EYX[V*RC5?G7:4\L<%<>ISGO2
MWWP\:]>1FUVZ9KC27TN[>:-9'G5LD/GC!!;/Z4 2+\1=.A:*.:WO)8HQ;I>7
MT<($,$DJJ5#?-D?>&<9QD9J6T^(>F7FNQZ8MG?)YE]/IZW+QKY1GBR67.<\@
M'!Q523X:PM(\*:O<)IMPUO)>V8B7$\D2J =W50=BY ZX[59MOA_;6UY;7*W\
MI,&L3ZJ%V#!:4$%/H,]: .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#F/ ,LQ^'OAOS+=EQIEL%*L&ROE+@_CZ4[4/$<NFS;TT+5;SSH
M1*1;0AO+(P K9(P3D_E4O@3_ ))YX9_[!5K_ .BEK9C_ ./J?_@/\JUIRBI7
ME&Z["9SJ^,+IF;_BD]>  RNZ!,MZ_P 7%5SXXNO/V+X0U_E]I9H% ' ]_<_E
M784@^\U;*O0ZTOQ8K/N<JGC2XD,87PIKQ+YY\E,  XZ[J63QE<(,KX2\1/P"
M +=,YQG'WZZJBCVU#_GU^+"S[G+'QG,&91X4\1$A=W_'JN#[9WU+'XKN&0,W
MA?74)&2IACSG&<??KI**3K4>E/\ %A9]SEAXRF,LJ'PIXB C0,";5/FSV'SU
M&OC>X9U7_A$O$(5@PW&V4@,.QPQQQ_A76T4_;4/^?7XL+/N<H?&=T+?S?^$2
MU\G:&V^0G/\ X]2#QI<^<$/A+Q"%(SN^SKQQG^]7644>WH?\^OQ86?<Y$^-;
MHAC_ ,(AXAW(N=OV=>3Z [JD7QI,]LDR^$_$1W=5^RJ"/7(+UU)^\OUI:/;4
M/^?7XL+/N<M-XRGA4G_A%/$,A$A0B.V4G''S?>Z<_I27WC*ZM(0\?A+7YF9B
MH18$SQCGACP<_P ZZJBA5J":O2_%A9]SF(_&,LDKQ_\ ",:\I4J.;91U_P"!
M4V'QE<2;<^%-?4LL;'_1TX#?5ATQSWKJ:*7MJ'_/O\6%GW.43QI<-!'(WA;7
M 78J1Y .W Z]<_3CFD?QK<(Z@^%M;VF/>281R?0<_CS@^V>*ZRBG[:A_SZ_%
MA9]SCQXWOC'&Q\'ZZ&=L%/*7<ON><59B\7S2Q,S>&->0C@K]G0G.,_WZZ>D;
M[I^E#KT'M2_%A9]SE(/&=Y)&F_PCKRL8@Y A7 /IDL.:E3Q?<.RK_P (KKRY
M#'+0(,8./[]=..@HH=:CTI+[V%GW.7_X3"?*;?"VO$,^QOW"@KP#G&[IR?RH
ME\8SQM@>%?$#8/S$6R8 ]?O\_2NHHI>VH_\ /O\ %A9]SEQXPN><^$]?'RY!
M\A#D\\??SV].]-'C.9C"%\*Z^?,&?^/=!MZ=<MTY/Y5U5%'MJ'_/K\6%GW.9
MG\82PP"3_A%_$#9 ^46R9&3_ +]12^-9XWBC_P"$3\0-)(I(46Z<8QGG?CO^
ME=710JU!;T_Q86?<Y.;QG=QA0GA/779URH\E1W/4YXZ4#QK."0?"?B)B0I^2
MU4C)[<L,?C764@ZM]?Z4_;4/^?7XL+/N<JWC.Y7KX2\08W 9$">N#_'VJ5?%
M\[+(1X5\090D8^SQ\XQ_M^]=-12]M1_Y]?BPL^YRG_"9W/ER2'PEX@"H 1_H
MZY/X;J9%XXGDN6A_X137AA=P86ZX_'YN#7744_;T/^?7XL+/N<C;^,KQY6$O
MAG6"I 8"*%6,8/ #989.0>G]#4DGC&YBCNI&\+:V%A#%?W*Y? !&/FZ')_*N
MJHH=>@W?V7XL+/N<L/&4K!,>%]>9F!.%MT(&#CKOI9O&%S%)L7PIKS_NR^5@
M3&>,#[WO^E=112]M0O\ P_Q86?<R/"?_ ")NA_\ 8/@_]%K11X3_ .1-T/\
M[!\'_HM:*Y2C8HHHH ***S=9U=-&M[:9X6E$]U%; *0,&1@H/T&: -*BBB@
MHHHH **** "BBN>NO''AVR.HB?440Z>ZQW/!^1FZ"@#H:*YZX\<>';5K]9=1
MC4V,2RS\'Y5;I_GWK<MKB*[MHKF!P\,JAT8=P>0: ):*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GO
MHS\._#0R1G2;7D=OW2UK6J-%)*C2-(RA06;J>*Y[2-'\5:-HMCI=OJ6C20V5
MO';QO)92[F5%"@G$N,X%61:^+A([_;]$RV,_Z'+V_P"VM,#HLTT?>:L'R/%_
M_/\ :'_X!R__ !VC[/XOR3]NT/G_ *<Y?_CM(#H,T9KG_(\7_P#/]H?_ (!R
M_P#QVCR/%_\ S_:'_P" <O\ \=H Z#-&:Y_R/%__ #_:'_X!R_\ QVCR/%__
M #_:'_X!R_\ QV@#H,T9KG_(\7_\_P!H?_@'+_\ ':/(\7_\_P!H?_@'+_\
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M9/+4HA*J<$_,>@Z'W]J *'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
M\&,/_P 55^]D$,L&Z>6,3/Y2[,8!VLV3GZ5ERZN#:Q26DE[<RW.\VL42H6G5
M<9==Q"A?0L5'(]1E7?8EM]B7_A._!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_
M (,8?_BJLZ?.+])<3W<4L+^7+#)M#Q-@'!QD'@@Y!(YZU-&HFEF2+4'=H7\N
M158$QMM# -Z'#*<>A'K2N^PN:78H?\)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\
MZ&O0_P#P8P__ !5/_M*U$>IR/>W"C321<J2,IA ^?Q4@CZT:GJ$6EZ+?ZE+<
MW#?8K5[J2!67S-BKN(QZX&/2B[[!S2[#/^$[\'_]#7H?_@QA_P#BJ/\ A._!
M_P#T->A_^#&'_P"*J2_N/(TFXO([BXG\I0WE1.FXG(^7)P,_4@4FLWT>C:3>
MZA-=S,MI;2730JR[V5%+$#WX-.[[!S2[#/\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJT%4!8_,O9%:3[@+*"?;IS4OV=O^?F?_OH?X4KOL'-
M+L97_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5IO;28&VZG'/<
MC_"FO!(@+&\E"^^/\*+OL/FEV,[_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJM0VTF[BZFQCID?X4-:NT97[7< G^)6&1^E%WV!-]C+_X3OP?
M_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJT39S H4OKCCJ'(((_(<T[[-
M+CF[FS^'^%-M]AMM;(S/^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
MXJM/[-+WNYOT_P *7[-)CBZGZ#'(_P *5WV%S2[&7_PG?@__ *&O0_\ P8P_
M_%4?\)WX/_Z&O0__  8P_P#Q5:+6MP5.R]D#=B0#Z?\ UZ>;:3C%U..><D?X
M47?87-+L9?\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %5J_
M9V_Y^9_^^A_A3# X=5^US9;) X[?A1=]@YI=C-_X3OP?_P!#7H?_ (,8?_BJ
M/^$[\'_]#7H?_@QA_P#BJTS;2\8NYAZYQ_A2?9IB3MNYASWP:+OL'-+L9O\
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M:W49&<&I:Y3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4N,A77ID=Q6!\*OAD_P^@OY;J^2ZO+PJK>4I"(JYP.>2<DT >C4444 %%%%
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6^''_).?#_ /V#X/\
MT6M=0RAE*L 5(P01UKB?"TGB#0/"^F:3/X7NI9;.VCA=X[NWVL54 D9<''%:
M_P#;FM_]"E??^!=M_P#'*;W U6A7%Q%&JH&3' P.<U+$GEPQIUV*%S]!6"-8
MUSS&;_A$KWD ?\?=OVS_ --*=_;6M_\ 0I7W_@7;_P#QRB_0#?HK _MK6_\
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M2OO_  +M_P#XY0!OTG\0^E8/]M:W_P!"E??^!=O_ /'*3^V=;SG_ (1*^_\
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M^$IUW_OJ#_XU0!T=%<Y_PC=W_P!#3KG_ 'U!_P#&J!X<NCT\5:X>WWH/_C5
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MLX+5G2^0*QC0+N&1G!QFM7^U_$7_ $*__E0C_P *; UQ"L5PI5G.X-G<Q/\
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M]J^(O^A8_P#)^/\ PH_M7Q%_T+'_ )/Q_P"% &_FC-8']J^(O^A8_P#)^/\
MPH_M7Q%_T+'_ )/Q_P"% &_FD)Z?6L'^U?$7_0L?^3\?^%!U3Q%Q_P 4Q_Y/
MQ_X4 ;^:,U@?VKXB_P"A8_\ )^/_  H_M7Q%_P!"Q_Y/Q_X4 ;^:,U@?VKXB
M_P"A8_\ )^/_  H_M7Q%_P!"Q_Y/Q_X4 ;^:1C\I^E8/]J^(O^A8_P#)^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gmtxzzgtjwwl000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &H <,# 2(  A$! Q$!_\0
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M %%%% %:;4;&WG6">\MXIGQMC>558YZ8!.:LUY3KTOAF+XHZY_PDXL3;OHD
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M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 TQHS!BBEAT)'(I656
MQN4'!R,CI2T4 (44[LJ/FZ\=:38F<[%R. <4ZB@!C1QN0716QTR,T[8N[=M&
M[UQS2T4 -\M-I78N&.2,=:-B;MVU=WKBG44 -\M,,-BX;J,=:"BE-A4%>F,<
M4ZB@!@BC"E1&H4]1MX-.*@KM(!'IBEHH :44YRHYZ\=:7:N[=M&XC&<<TM%
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M=^48;SS]Y\@Y!^48Q30I'I5%%%(H**** "BBB@ HHHH **** "BBB@ HHHH
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M_MG_ .S5P==Y\.ON:A_VS_\ 9JZ\%_'C\_R-:/QH[BBBBO?.T**** "BBB@
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MQ\?@.>/2]/LO^$CU)C:79N3*7;=+DYV-\W3KTYY^N0#LZ*** "BBB@ HHHH
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MW/4P>'C7;4NAV7]N:;_S\C_OAO\ "C^W--_Y^1_WPW^%<+17D?VYB/Y5^/\
MF=_]F4N[_KY'=?VYIO\ S\C_ +X;_"C^W--_Y^1_WPW^%<+11_;F(_E7X_YA
M_9E+N_Z^1W7]N:;_ ,_(_P"^&_PJQ;:A:WC%;>7>5&2-I'\Z\]KH?"G_ !\S
M_P"Y_45TX3-JU:O&G)*S]?\ ,QQ& ITZ;FF]#JJ***^A/*"BBB@ KR'Q9K7A
MB^\6W:'Q!JFDWEDT2S-:VS2+,Z;\8&PX9=S#=T.[OBO7J\\\:6/B*75;B\TZ
MZU2&U@2#,6EB/S)5)<.<'EF7Y, D#&::)GL=AX<6%/#.F+;VTUK"+6,)#/\
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M:/QH[BBBBO?.T^1[O_C\F_WS_.H:FN_^/R;_ 'S_ #J&O6/EF%%%% @HHHH
M]3^"/_(9U3_KW7_T*O:Z\4^"/_(9U3_KW7_T*O:Z\_$?Q&>]@/X"^85YY?\
M_(0N/^NK?SKT.O/+_P#Y"%Q_UU;^=?-9]\$/5GT&5_%(KT445\T>P%%%% !7
M0^%/^/F?_<_J*YZNA\*?\?,_^Y_45WY9_O</ZZ'-C?X$CJJ***^U/G HHHH
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MLYU"W$0?,!X7#')%-"DSN]<_Y &H_P#7M)_Z":\2/4U[;KG_ " -1_Z]I/\
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M&,5Z77'>)O\ DH?@C_KK>?\ H@T(4CH=<_Y &H_]>TG_ *":\2/4U[;KG_(
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M*/\ A5_B/_H:K/\ \%?_ -LKA_LZMW7]?(Q]C,Y^BN@_X5?XC_Z&JS_\%?\
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M?_0VZ=_X*?\ [97+5DIRNCU,+3E2IJ,EJ=A7GE__ ,A"X_ZZM_.M/^Q_'?\
MT-NG?^"G_P"V5ER^!_%TLKR-XKL-SL6/_$J]?^VE>/FF"J8J,53:T[GJX+$Q
MHR;DGJ045)_P@?BS_H:[#_P5?_;*/^$#\6?]#78?^"K_ .V5XW]B8GNOO?\
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M<'&WYMN"YY^7IP?FJ.3QW,\P-CHDES:--;PK,;E4+-/&KI\I'3YP"<\=L]*
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M[B%SG.>V.:R+OQYJ<GAZYN[;2$MKE].-_9^;<!PR!E5MP X(W @<Y]J -A?
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M7WG'R\A-N"><BI]"\1W5YX;U6XN+F*74+*-FD\M%,2MY>\;&5B'7T.<^H!H
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M?3VJ155$5$4*JC  & !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+C(V>O.>U '4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gmtxzzgtjwwl000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &T BD# 2(  A$! Q$!_\0
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M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=M)K6EPVMM=2:A:I;W3*MO*TH"REN@4]\^U>-M;E[_XM6]O'G;:H$1!T"HW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHSF@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH Y:PF@G\<77V5I85@B>.99&?_2)25.0&XVH!@$=2Q X%6/&&JZQH>B3:GI5
MK97"6L;S7*W,K(=BKGY< Y/!ZUT-<_XZ_P"1 \1?]@VX_P#1;4UN)[&OI]V+
M_3;6\"%!<0I*%)SMW ''ZU9K-\._\BSI/_7G#_Z *TJ0T%%%% !1110 4444
M %%%>3>$M'7Q]-K>N:QJFII?V^J36UK';7CQ"R2,C:%4'&?7(.: /6:*\<G^
M)WB>?Q#??V5I$]W86.H&R-O%ILLIE56"NYG4[4;DG;CTSUK5_P"$U\1Q7_B^
M_E-@VC>'995\D1-YT^(\JN[.% .,G!SD^E 'ICNL:,[L%11EF8X 'J:2&:*X
MA2:"1)8G&Y'1@RL/4$=:\>TKQMXHURPU"WU73)FL+S1[B?[2-,EMDMW\LD('
M<D2*0>#QVIO@?Q#XDT/3_ MG>'39M'UB'[-#'"C":$JF58L3AL]Q@8H ]FHK
MQVS\>^+W^'B^*[J;2PDUU';0Q1P-D?O]C.Q+8Y&>!TP#6UXI\;ZOI&J>++>U
M-OLTK28KRWWQY/F,Q!W<\C':@#TBBO)T\4?$"778M'\[04FOM*&J12B&0K;J
M#@IC=\Y)(&>.Y]J[?P+X@F\4^"M+UJYB2*>ZB)D6/.W<&*G&>QQF@#H:***
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M2(HMVWS?M&=I(ZD8QUKV.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%,ED$,,DI5V"*6VHNYCCL!W- "QR)*@>-U=3T93D&G5X_X*T]M5\10ZM'#
MKVF/<%YY([6T^Q62!7X5U;(E9NYZ]>E>P4 %%%% '&?$C_D&Z%_V'K'_ -&"
MNSKC/B1_R#="_P"P]8_^C!79T^@EN%%%%(84444 %%%% !17,^-I[N*QTN"S
MO9[-KO4X+:2:#;O",3G&X$#\J3_A$;K_ *&[Q%_W^A_^-4 =/17,?\(C=?\
M0W>(O^_T/_QJC_A$;K_H;O$7_?Z'_P"-4 =/17,?\(C=?]#=XB_[_0__ !JC
M_A$;K_H;O$7_ '^A_P#C5 '3T5S'_"(W7_0W>(O^_P!#_P#&J/\ A$;K_H;O
M$7_?Z'_XU0!T3VT$DRS/!&TJ_=<H"PZ]#^)_.I:YC_A$;K_H;O$7_?Z'_P"-
M4?\ "(W7_0W>(O\ O]#_ /&J .GHKF/^$1NO^AN\1?\ ?Z'_ .-4?\(C=?\
M0W>(O^_T/_QJ@#IZ*YC_ (1&Z_Z&[Q%_W^A_^-4?\(C=?]#=XB_[_0__ !J@
M#IZ*YC_A$;K_ *&[Q%_W^A_^-4?\(C=?]#=XB_[_ $/_ ,:H Z>BN/TF*^TO
MQY)I4FLZAJ%J^F?:0MXR,5?S=N055>U=A0 4444 (ZAT9&^ZPP<'%>:6%E=6
MWQ$6*TTN\OK"*4JUVTMS MIA< ?.Y2?T^4=Z]+=%D1D895A@CVKRS0[.Y_X2
M6*XFTC1[-8-4>T6X&I32,55#MC5/NE\8Y)['C- 'JE%%% !7/^.O^1 \1?\
M8-N/_1;5T%<_XZ_Y$#Q%_P!@VX_]%M36XGL7O#O_ "+.D_\ 7G#_ .@"M*LW
MP[_R+.D_]></_H K2I M@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !45U;17EK);3!C%(NU@K%3CZC
MD?A4M5K^W6[T^XMVA6821D>6SE0_'0D<CZT <!X-AO5\7W3?V9=36063;JLK
MW,"DEON>3*Y#?[R@#BO2*\R\#0W3:O8ZA=:;I%E)=17!9X+^69YV5P#L4_*
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M'E#@'^M:-4[/2K#3[BYN+2UCAFNFWSNHYD;).3ZGDT 7**** "BBB@ HHHH
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MT^]D,=I?6UPX&XK%,KD#UP#5NO*;+Q=#ILK2V'AW2K61EVEX(@A(],@=.*]
M\.:M+K6CI>RQ)&[.R[4)QP:SJX6K2CS36AOALSPV)GR4G=^AK4445SG>8WB3
M7)M"LK:6WLA>7%S=1VL41F\H%G)P2V#@<>E4?[7\7_\ 0IV?_@W'_P :JUXF
MTRZU-=(%JJM]FU."YEW-C"*3N(]3[5NT <Q_:_B__H4[/_P;C_XU1_:_B_\
MZ%.S_P#!N/\ XU73T4 <Q_:_B_\ Z%.S_P#!N/\ XU1_:_B__H4[/_P;C_XU
M73T4 <Q_:_B__H4[/_P;C_XU1_:_B_\ Z%.S_P#!N/\ XU73T4 <Q_:_B_\
MZ%.S_P#!N/\ XU1_:_B__H4[/_P;C_XU73T4 <Q_:_B__H4[/_P;C_XU6CX<
MUB37='%[-:?9)1--!)")?,"M'(T9PV!D97/2M:L7PMIUSI>D2V]VJK(U[=3
M*V?EDG=U_P#'6% &U1110 4444 %%%% !1110 CN(T9VX51D\5YGI]V;GXBB
M:TUI[&UEE+&R1+F7[8"N06\Q0D7K\M>FUX[INKO:_$<:+<ZGKUW&-5<QF6ZA
MCC+E6X\L#>R+@\ A?NG R* /8J*** "N?\=?\B!XB_[!MQ_Z+:N@KG_'7_(@
M>(O^P;<?^BVIK<3V,C6/^28Z?_U[6_\ Z"*\WDD2*-I)&5$0;F9C@ >IKTC6
M/^28Z?\ ]>UO_P"@BO.>HP>:]W+OX+]3XKB#_>U_A7YLY^\UG2VUC2G74K0H
MAFWL)EPN4P,\UM6UY;7B%[6XBG13@M&X8 ^G%2>7'_SS3_OD4H 7[J@?08KL
MC&2;;>YY-2=.44HIZ>?FWV\SN?AO_P ?UY_UR'\Q7HM>=?#?_C^O/^N0_F*]
M%KPLP_COY'VF1?[E'U?YA65XGOY]*\*:OJ-J5%Q:V4TT6\9&Y4)&1W&16K5+
M6=-36=$O]+DD:-+RWD@9T RH92N1GOS7$>P8,.E>+I8(Y/\ A+;<;U#8_LE>
MX_ZZ4_\ L;Q=_P!#=;_^"E?_ (Y72Q1B*%(P<A%"Y/M3Z .7_L;Q=_T-UO\
M^"E?_CE']C>+O^ANM_\ P4K_ /'*ZBB@#E_[&\7?]#=;_P#@I7_XY1_8WB[_
M *&ZW_\ !2O_ ,<KJ** .7_L;Q=_T-UO_P""E?\ XY1_8WB[_H;K?_P4K_\
M'*ZBB@#E_P"QO%W_ $-UO_X*5_\ CE']C>+O^ANM_P#P4K_\<KJ** .+NG\3
M:'JFBF[UZWOK:]OUM9(AIXB."CMD,'/.4':NTK.U72(]5ETV225XS8W:W:A0
M/G(5EP?;YS^5:- !1110 4444 %%%% !1110 4444 %0W5S%9VLES.Q6*)=S
M$*6('T')J:F2H9(9(UD:-F4@.N,KGN,\9H \Y\%R2MXON@FLM';$28TA!<3(
M#G[_ )LP&T_[*\<UZ37D'P\UHW'BNWTR>_UR[:WBN%A>]NHMC@%26:)1OY!
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M45]"?!!7J_@,8\+1?]='_G7E%>L>!?\ D6(O^NC5P9E_!^9[O#W^]O\ PO\
M-%CQASX6O?HG_H8KRBO6/%__ "*]Y_P#_P!#%>3U\/F/\5>G^9]5B/B"BBBN
M P.M^'__ "&Y_P#KW;_T):]'KSCX?_\ (;G_ .O=O_0EKT>O<P'\$[:'P'R?
MK7_(=U#_ *^)/_0C5&KVM?\ (=U#_KXD_P#0C5&OHUL?.RW85M>$?^1QT7_K
M]A_]#%8M;7A'_D<=%_Z_8?\ T,4I;,=/XUZGU)7E?C__ )&0_P#7):]4KROQ
M_P#\C(?^N2UEEO\ &^1U<0_[HO5?J<M1117NGQ(#J*]NT3_D Z?_ ->T?_H(
MKQ$=17MVB?\ (!T__KVC_P#017EYI\$3Z7AO^+4]$5/$_P#R"T_ZZC^1KCJ[
M'Q/_ ,@M/^NH_D:XZOSC.?\ >ODC],R[^#\PHHHKR3N.L\*_\>DW^\*WZP/"
MO_'I-_O"M^OM<L_W2']=3YS&?QY!1117><P5C'PU9_:Y+A9KE-TDDR(L@VQ2
MNNUI%X^]@GKD DG%;-% &;'HL0U**^FN;FXE@#"$2L-L>[ 8C !)('<FLWQ]
M!#-X"UYI88Y&CT^X9"Z [3Y9Y&>AKI*Y_P =?\B!XB_[!MQ_Z+:FMQ/8R-8_
MY)CI_P#U[6__ *"*\YKT;6/^28Z?_P!>UO\ ^@BO.:]W+?X/S/B>(/\ >U_A
M7ZA1117>>&=Q\-_^/Z\_ZY#^8KO[S_CRG_ZYM_*N ^&__']>?]<A_,5W]W_Q
MY3_]<V_E7SV8_P :7]=#[O(O]QC\_P SQ-_OM]:S+O1+2]:4SR7A67(=%NY%
M0@]1M!QCVK2?[[?6DKXN,G'5&R;6Q1M=)M[.998IKQBHP%ENI'7\B<5JV?\
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MNO\ KC_[,*](KS?X<?\ (4NO^N/_ +,*](KY_,/X[^1]UD/^Y1]7^9YY?_\
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MB!XB_P"P;<?^BVIK<3V,C6/^28Z?_P!>UO\ ^@BO.:]&UC_DF.G_ /7M;_\
MH(KSFO=RW^#\SXGB#_>U_A7ZA1117>>&=Q\-_P#C^O/^N0_F*[^[_P"/*?\
MZYM_*N ^&_\ Q_7G_7(?S%=_=_\ 'E/_ -<V_E7SV8_QI?UT/N\B_P!QC\_S
M/$G^^WUI*5_OM]:2OBC4*GL_^/V'_?%05/9_\?L/^^*:W&CVVO#OC9_R,MA_
MUYC_ -#:O<:\.^-G_(RV'_7F/_0VKZ_#_&:X_P#@,\RHHHKO/""OHOX5?\D]
MT_\ WY?_ $8U?.E?1?PJ_P"2>Z?_ +\O_HQJY\3\!WY=_%?I_D:/CC_D5;G_
M 'D_]"%>25ZWXX_Y%6Y_WD_]"%>25WY;_!?K_D>+Q#_O:_PK\V%%%%>@>"=K
M\./^0I=?]<?_ &85Z17F_P ./^0I=?\ 7'_V85Z17S^8?QW\C[K(?]RCZO\
M,\\O_P#D(7/_ %U;^9JO5B__ .0A<_\ 75OYFJ]?F57XWZGZ'#X4%6+'_C_M
M_P#KHO\ .J]6+'_C_M_^NB_SI4_C7J$_A9Z'1117Z"?*A1110 4444 %%%%
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MC_D5;G_>3_T(5Y)7?EO\%^O^1XO$/^]K_"OS84445Z!X)VOPX_Y"EU_UQ_\
M9A7I%>;_  X_Y"EU_P!<?_9A7I%?/YA_'?R/NLA_W*/J_P SSR__ .0A<_\
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M_P#H8K%K:\(_\CCHO_7[#_Z&*4MF.G\:]3ZDKROQ_P#\C(?^N2UZI7E?C_\
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M5(*T78SJX/#U9<U2";\SR[_A4VK_ /0X#_P6)_\ %T?\*FU?_H<!_P""Q/\
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MC3?-""3\E8XFZ\"ZK>6[6]QXWUAXGQN7RX><'/\ <K-_X5,W_0V:M_WQ%_\
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MJC#()"I^:1#D!Q\V."3C-=+;V\-K;QV\$:QPQJ%1%&  *DHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (;6TM[*(Q6L"0QEV<HBX&YCDG'N234U%%
M!1110 4444 %%%% !1110 4444 %%%% !534M-M-7L);*]A$L$@Y!Z@CD$'L
M0>01T-6Z* *MAI]OIUL(8$4' WN$56D;&-S;0 2?6K5%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% #)H8KB%X9XDEB<;71U#*P]"#UI
MX&!@=*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"D-)LQJKZDL6VX
MDC$<A!^60 _*6'0L.@/7!Q5VBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gmtxzzgtjwwl000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& M # 2(  A$! Q$!_\0
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M:BB[#E04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW7=';GK&FQ5QS@D\L2!D\"H/^%>Z=*)'OM0U.]NGABA^U33*)%$4GF1E=J@
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MB,W7S $++N$?!VKNY"5VE !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_#7_']XC_["K?\ HF&N@H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!S'(G!1QU_ UT/PG_P"1)/\ V$+S_P!'O4U.C'%E7XS_ /(@?]O]M_Z,%>-
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M.V\#^(+@:[K\ABTVX?9+J+LC8C8X8=P>XKT.L#QT"?A[XE &2=*NL ?]<FH
MK?\ "$Q?]##XC_\ !F]'_"$Q?]##XC_\&;UU%% '+_\ "$Q?]##XC_\ !F]'
M_"$Q?]##XC_\&;UU%% '+_\ "$Q?]##XC_\ !F]'_"$Q?]##XC_\&;UU%% '
MGGA_PA'->:\IUW7T\K4BF4U%P6_=1'+>IYZ^PK;_ .$)B_Z&'Q'_ .#-ZN>'
MH98;SQ 98G02:F70LI&Y?)B&1ZC(//M6Y0!R_P#PA,7_ $,/B/\ \&;T?\(3
M%_T,/B/_ ,&;UU%% '+_ /"$Q?\ 0P^(_P#P9O1_PA,7_0P^(_\ P9O7444
M<O\ \(3%_P!##XC_ /!F]'_"$Q?]##XC_P#!F]=110!R_P#PA,7_ $,/B/\
M\&;T?\(3%_T,/B/_ ,&;UU%% '+_ /"$Q?\ 0P^(_P#P9O1_PA,7_0P^(_\
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M"&2!B>&3NOU!/ZT7NBJ^FO8DL[64PNK,K]X;3NV<_E2WC/K&FP:E:,/+W+(
M1D[".1[$$_I1;4O1C+J5]/LP;QUDE@?,CH.HZ9Q],5O?"?\ Y$D_]A"\_P#1
M[UCQ7:7,]S,\ E1E52G_ #TRO3-;'PG_ .1)/_80O/\ T>]3/9($5?C0<?#\
MG_I^MO\ T8*\$GD>ZT]HS,[R1.9%4J,'/6O>OC1_R3\_]?UM_P"C!7BMCI%S
M.CW2N(5B0["QQN;M633>B-J;2U.>8)+MXPW\JFM[3+ E6;+9&!UK;DT>"!XO
M/NHV+)NF<>OM5UK.\U%[:/2;?_1]P624<MCN?:G[.[Y4R^=)7+>D:38KHMU<
M7JXBB_>F/.-S>E<_<W;:[< Q_N<<1QGH!6MXSD$5[!I\ :*U2,$Y/WV[YKGX
M'%N#.P!/2(>I]:52=UR]@@OM=Q\]N;4[+J<%QQLCY/YTY=1$%E,8[=(9<;4<
M-S_]>JCMN)9V!9CR2:LP:/+=N[2?(L W,>N[Z 5$(M[%MI;C_"^AR^)=<CM
M3Y8_>3N>RCK^)KTC6M5\LBUTX1+!9@('?[D?^T?4X' I-'B@\-^#Y+N*U7[5
M<KD ?>8=A7%2V]Q"MO?S"VU&::3;]B5B8U<G@$#[V,\?B:[J5-P27<Y924Y-
M]$='H>GWWB#6FUF.\41@-%!(J_ZE#]YN>KGMV'X5U>M7 T+0EL]/ $K 1IN;
MD9ZL3W/>J/A[5;:Q^SZ*K^=>D8>54 3?W  [#H/I702Z'93W:74\32RH,99C
MC\JW:TY4<\I>]>1XI?6=[*%=+1I9%?8P_'M75>'OAS-/,]WJSQ1V[8,4$0.<
M^^:[K3O#6G:7,\D"RON)*K-(7"9Z[<]*I^+O%<7ABU@/DO/<7#^7&BG[OJ3Z
M5SQP\(*\M3:6(E-V@4O$EU::38C1K B"[GA,JHIV>8%XPS=LUR-C%&NH WTL
M<U[9QL[S,P2"#/5$]3ZL:K6^J:A<ZI<7MZEO-=WA(@8=(X5'+,3_  #(_&N:
MUGQ8MQK"QQ6=K/IL#@F)X_EG8=6;N<G]*<ZL4DUU+A3:5F>C^%-,LHK.XUF>
MX,ELS%WO+C@SX_N@]$]*AU0Z5KFM)>R2K<^1L\N%S^[A1AD$+C[Q[9^M9MW/
M)K]@]WF>5EB4VUDJGR8PPQA5'WL8X[<U/I6F7^E6<D\D?G:I=MA(=P98L_QR
M,.-WTZ  5K"TTK,SDN5W>YJ:S=QZ18R_9K0R7#C<%4XSCJ6/91W_ "J5+^>R
MTJ*2YCVS2HOG1+T0GG&?7%9<]A=3:E:I<N9+.VC,D\V?]9)S@$>F2"!5^ZL6
MU;[':!V\I9$FNFQC]V#DC\3P*T22V)>VIMZ59I8PJT< %U=?-'".B^CN>YQ^
M7:MFWMK;2-/9(PB1IEW8+C<QY)/N32V<#;Y+J8;99>B?W%'05Q?Q-UJ>SLHK
M&VF"><"9<'G'I64Y*$>8B*=2?*<#XN\1RZOJ\ID<^2IP@4=!6;II>+4(WC;!
M*D\J",8YR#5/R"[L[9 [@UT7A;0KC5[FY2-=P2/:2#@(K<9]O:O/2<I:;GH:
M16NQF1^;?W/E6D!P3DA?NH/7V%9.IK!<W#RP1N@0!%8G/F8XR![GFNW&EMY5
M[9V[&)K62.)(0<-(3PS$]^:PM7NM0CGDM[N6-3$NW$:KD+ZY ZG\ZZ*E%4XW
M>Y,9<S(=/\(ZA?WL-C;11R. DDY+#:@;^]^':O8M7M$LQX:A2-45-<L54#^Z
M)DP/:L;X6:>!H<E]N!CEF.S@C) QSZUT?B;_ (^/#G_8=LO_ $<E7&%J39S5
M)WJ6/6Z***YB@HHKA+;7]<O[**ZCO+>'?K,VG%/LV["+-(@;.[KA10!W=%<]
MK^L7>D7?AZ",QN+V^^SW#,G)40R/D<\'*#]:R#X[^V>%K[4OL-Y8+_8YU."4
M-$[F,J>@.0&& 0&!!R/<  [BBN8B\96[ZO+IZVEQ(EO/]FGG 'ROY(EW$?W,
M$+GKN/3'-4Y/&6HSVGAF]LM)5;;6KJ-%\^4;C$\$DH(VGY6^0=<CMWR #LZ*
MY/\ X2LP:U>:<D5Q=W3ZI]BMXF*(B$6JSGYL9V[<GG)W''3&*\7Q$@N&D-OI
M5U)';QQR73[T'D[IY(&&"?F*O$_3@@<'H" =I14$,TLD]Q&]M)$D3A4D9E(E
M!4$E<'( )(YQR#VP:GH **HZSJ0T;1;W4VMY;A+2%IFBA +LJC)QGOC-8NN^
M-[/15N/+M+B^:"&VE*6P&6\^7RXE&2!DD,?H/>@#J**R-)\1V6MW<D-D6>-;
M.WO%FXVNDQDVX]QY9S]15>U\7Z5-8F[N9?LB&]FL8Q,>9)(F92% ZYV,0.M
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M* "BBB@#A/B[_P B&W_7]:?^CDK(MM/&IZ3K.F;5B:Z.]'(R,E1@_@16Q\7
M#X$8'H;^T_\ 1Z5!;0+I<UDJS>:D@,>\GJ<Y%4K68F^QXC:2W=E-=:7."%*N
M4:/D*Z]?PZUOZ)%'96:.\R3&Y DC7;SN!RW/XBI=;CA\,^/=0AD7]S?@75MD
M?QG[RCZ\_I51?LLRF:*X548[XU!VE#T.T=O3\*R5HG;?G7DS3N/W^D:HCI$Z
MI"7/&,#/&/RKD['4DFLI7;8)XVRCE@&"KR![Y.*EUJ:78M_9WB!#&UO(#QD]
M>?\ &N<TVUBB629D,C%&,:*W(..H^G<4>V=T^Q2A:Z.HNM(M[G3K%;(!WPOG
M2@]0-V"?H:9*&EU6QE$3I)<1;F<'<%7;T_#^=4;6\B%E''YI6;A@@^7@C'';
MU_&M.W5X0LOSO!-&8IF7G9_MX[8-2VY:L=K&Y=PJZ,+2.*:)(P'C+?,-HP/E
M[^_TJ]IFJ?9)MER#'O *J#\I/&,>AXQBLFS<P21WC'?(%"OQP1MQYBGN" ,@
MTCO;3630O*5AGD8)E<F$_>"^W?!]*T:M[T61:_NM'I ,&MVGG6<B-.%QN/4^
MS>]4K*SGM$O%N L<S.K1P[N @X.#W_\ K5S7A*]EM/$:QW)7%WB,^6V"KJ.&
M]\\?G7<W5IJ-Q&!((&DBF)C*C[Z<8SZ'KGZ5O"=T<<X\CL9V]'B"-MC;/;T]
MJ=:ZM_9EU;VUTI6VG.Q)1R$D[ ^@/8UGB*.>&:S<[9TD8J^[E6SR/UJO#!J1
MB^SR(S/"=WEN>=I!^Z?\]JN2N@274ZW4#LN+.7G9OPQ7KTXJM]GM(;=[.39$
MLI*1#.-RL<X_4U6TG6=MP+"]B,3,<02%MP8'D GL?\*FUFTM]3@>U<D2(!(C
M X8$=&'H:@BUG9E-;2XL;BV\F,S!-IEP<8QP/ZFMOX3_ /(DG_L(7G_H]ZQ;
M>2^BU"*$K*V^-"6;[K,.O/TK:^$__(DG_L(7G_H]ZB994^-/_)/C_P!?UM_Z
M,%>%Z=J#_8;M969XQC;WVBO=/C3_ ,D^;/\ S_6W_HP5X-IEI')%*B3D?:EV
M0LJ%@7SQN]!46E+1&E-I:L;=S).XP1Y8Z>U=I\,K&^^UW5ZP(M5.%&?O?2LS
M2_ RV[>9XFU2TL8U&[R8Y@SR >W:MVV^)&A:9"]O9:=.MI",(S$ R'Z5I3BH
MN\F*K)RC:"N2Z]X/O]=DC:&VB4&4L[3/RH]!6'/X.U"_N7C-G):_9QM0@95L
M>E=AX?\ '*ZS=O!>V7]G@1^8C2R?>%;KZ_I,=W;6C:A";BY/[F-3DM[\=![F
MNATX35F8*K4@]CRK4_"%QIME$_V::YN7?(VKD)^%=YX3T>'P_ID27RI]JNU,
MDDC]$_V3Z<?R-=*EU'*Y6VD2=\X/EL&"_4CI]*Y3Q)KL*6DBVL;WC+,8Y3$F
M2[#JJ?B0":E4U!\R#VDJONLYO7?%-EX@O8[>SG$5D2X>:13@1IUP.VX@\GL*
MV/L-T/!7VO2DCMY[HQ[)7&!!&3\TG/?'2L+0/"^EF4O=)LBB16N86D!SMY$9
M]>3SCZ5!XF\3W,D4\LMSLBD^6&W7[HQTI2K<L;LU5.[Y8[(N>(M?TWPA;QPZ
M+=B6\D&)KAE!?&.Q[4_X87-[KFN7VJ3ZC<21P1A#"S':S'N?I7E$DB2"225S
M)(WS')Z5[=X$L1X1^'_VR[C"W5R3,48]2?NC\JSI3E.IS/H%:*C#E6[-+QCX
MNAT*![.U??JCH&51TB!Z%O\ "O*&DN;Z<R7UW)<,_)=V)'X5#-=&[O[R]G=I
M);B9I&=C]X_X>E:6@0M<7^\1G9$-Q';V_P :SJ3]J]#6E3]FC-U[5%L]-328
M5 N9!BXDVX*IG(C_ )$URZIND*D<?P@=SZ5NSZ)JNN:U.]K 09&)42?*=H[X
M]*[7PMX'T^PNXWU&$WMZ%W@[OW41[8'?\:7LY2=AN:CJ7[>RU"V\.Z?IT4QM
MIYD5;AX_O 8&8U/8\_SJU<^?I5B+&SC4SLNU3C*PH.I/J?;N3]:OS-=+)+"
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MDMK.5IH)D6\:SNI(R-N3D(PP3]X^7QG^/VJ&YU?4/L*WBLT<+Q33PO%;-,&
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MXB"L@7&S!R ?4Y)JI*VHGM<2[,D4$$F)6:*0F7R@#CW(ZX^G2KWPG_Y$D_\
M80O/_1[TPR!;N9596W#=D'D?_7Z_E3_A/_R))_["%Y_Z/>LIC14^-(S\/6'K
M?6W_ *,%>#@7%KH$2W'F12+*%QG!R.A_*O>_C(I?P&J#'S:A:CG_ *ZBO#_%
MVG7&GW5K;:@D8FADDRT394\X_I6;3MS&M-ZV.?D_>2&63+MV)ZFMJPT;YUN[
MW"P@;UCZDTS3M-CO;:8XA5P!LDDDV@?_ %ZW--\.WVFR++>989WD\Y?CCKT
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ML;>348;]H\W4,4D,;[C\J.4+#'3DQI^7N:L444 %%%% !1110 4444 %%%%
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M;4]#.G6T4RW(X,&U5#GKD8^]QQ5RJ)*T2E!MWD-UK6AN^QVK+]E8YRBX//\
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MRQ7:S:Y9$C'_ $V2LZGP,J&Z/8:***X#I"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .&^+?\ R(Q_Z_[3_P!'I2:J4MY8[B61UA=3
M"Z[CMYZ''K[T?%S/_""-CK]NM/\ T>E6FC%_I[12J 9(\$=<'UJXDO<YJ*&T
MCU*&X1UAN%G568G!88(VGMWKJ+RUCOK*>SF7,4\;1L/8C%<BR0.K6MY!YJ_<
M90,D,/ZUM^'[\36:6DTV^XB&-Q7;O7L1_*M)+0<D]SQ/3K_^Q9KO2+F2020,
M\&%'*_-_7L171VUFDD,^HPLEP@\HW2CH6&1OQ[J>?>L_XJ>'KFS\4F[M4 M=
M8 #L>BRJ.>>V1S7.^'[K6=&G6:!RBJ_ER-(N^.8>X[C'%<CDX:';&TU='6ZW
MIR1W-O<12R)II&X1KT\[KG/^UTY]*J:C_9LBF\MXPC2G'D(2NUAC)7NI]5Z'
M%;!.GV6FV]W%%(+*_F"O"7WK#(.P/IW'UK!O[94U1^"DP7SH'ZAP.JY[\#(/
M:G4LTG$=-=RG;7]A9ZA:S7%Q<@RA@<@AAG(RI],T_4[B:2-+.!Q]HWX!CQNV
M;1GCOWJB]K!JGE;Y?)V@R*<EVCR>,C^Z:OZG#%:06L^I>7)<';]DN(S]WT#$
M?H361J6/"=W%IWB/S4,4DL)D5-W*LQ'4^_48K0:S>.]N'FLUA4AI5DA<J68]
M5Z\>PK)TK2(M;G=T$:W5P#GRQRV.3P#U[Y_&NCTN9VG;3-0/G-LS$[#&[V;U
MQZUI%='U(=D^9&1%H"26LD\;W2S0MYP65@ X'//IW'X5#87PTXPW,FY_)NAM
M\M<&-Q_#]"*Z*TMGBU=3/*5MRA*JS=!GH?=3D>X(K&DT.=)KO?F)Y7*R CY2
M?X&'Y"M94;.]R5-/0]F@N([VU29,&.5 V/8BN4U" BY^SX.]66)9#SQVJUX*
MU2.ZTYK)R?M5L<2 CKGICVJYKEO&TD32+\C,,-CHP-;09PM<DFBSIL[2*L,N
M!+&FTC'45)\)_P#D23_V$+S_ -'O60)VM]425&4I(I>3'7KS^7\C6O\ "?\
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MN3G@G&3[^U=G:V]KHNE%21'#"ADE<G\236/X>MI&O#<"$BW6/B5S]YL\!1Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*8=F<;2,,Q/4UZ16-?>&=(U&^DGN(YB\H!GACNY8XI\ +^]B5@DF5 4[U.5
M4Y  H V:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=GV*"<[MZX'7:"3Z2_\ "1W):U@^PR13S+,[;X92 (W"@A0N[#;@02!@>O%
M'145P\'B"Y/CKR3#+%+?:58M';W!94A8R7)?/'WMJ], MM'0 D=!:ZI=W,MW
M!Y$*7<3,$MI69"4#8#[L88%<'*@@$XZT ;%%%% !7/\ _-0_^X5_[5KH*Y__
M )J'_P!PK_VK0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <_J/_ "/.@_\ 7I>?SAKH*Y_4?^1YT'_KTO/YPUT%
M !1110 4444 9^O?\B]J?_7I+_Z :-!_Y%[3/^O2+_T 4:]_R+VI_P#7I+_Z
M :-!_P"1>TS_ *](O_0!0!H4444 <-\6_P#D1C_U_P!I_P"CTK/O[FXM_P![
M>A)$#[O)7!"#' SW)K0^+?/@8C_I_M/_ $>E9DFH6D\[PM"Y!D;:C1XWD'!P
M:T@'4IOXJ@N'5EMT)R%4@G#'/W>*LP:C::M<LMO$8[B),M"5_P!8O<J3P<5%
M!X3T\RR;"]KYC[S%O#9/K]:CCT*32KN]GM]2D\H?O%0C.P@?KQ51\RWR/X2Y
M#'"8X_*DE>V/)C#E0#[>GTJTMW?1%C&(WA4#"2-COS@COBHM,CM;J-)YX!%=
M,02 W#>C+Z@U?DM%B=KA0V5!Z,<8^E#9#?0MQ2QW4"R(=T;C(S7"_$/2GFT^
M:1VQ!D2@CC!'8^QK=\.:D9+<QRJ!&92$8'.#GH?3-6?$5L]QI<P8KY*@.Y_B
M4 Y)'OBDUT'"\)GDWAPZB8;VS#Q6]O$3@7'\+$#&X==O>N8U[2DT[5(;"WG2
M><RF7<JX4 \]_P"5:_BBWOM,U9H(+-WAN26=8W.90,,S'N!G%9MG$GG^="WG
MS>85*2G.WC=G/H.@-<DM-#M6NIU^B6\-](MZ^%NRK%HPV6 /"[O3/7%8'BS7
MV<SZ1IJ>9'.RBYE"\SR+TVCLHY'OS5M;F>WTN^NM/D-PLI0"0J<C/W\=SCIG
MWH5([W4KY8X5@O;A<P.O(V+C*D>_/(IK5**0VNHVUU.WNI$B$#6L-LN9&3_E
MJ<XX_P ?>I(YQ/=74[[E8C<4;@1Y.?\ #\Z;<0+9Z#B(+/(\FV5]F"@SG&.V
M*B:ZMY995AF61)WXSZ$<_CCI]:N$TM!N+)+B[DL]-^WLI68-Y*,1T4< _K73
M10IY-I [%I5 S(.IQUKE4O8YDGMIE807)S%O^;8ZG.#[5K0:@EY%!+<G[+/;
MR[0 3D,>![$&MJ52+E=F<XRV/6;*\2\L4FASAA@<<C''-)\)_P#D23_V$+S_
M -'O5/P_;R0VDCR,-LK[D53P!5SX3_\ (DG_ +"%Y_Z/>E,XK6;*GQJ_Y)ZW
M_7];?^C!7SIX6\,2ZKK91P3:0,&G)X..P_&OHOXT_P#)/6_Z_K;_ -&"O%O!
M]^Z+?D2[4C5"2YP, TH).23+UY6T:M[!):M)JLR06VFZ>S"VA&=TC#@$]@":
M\^&KW+WLM[-*99)&W2@]_IZ5Z[<VL&M^&A$0?W\9< =1^'M7GJ^$UBN8K>YN
M8XU9OG+G:Q [ >]%=24E$JE)--FAH-@GB*;[?<W(@T^U7,LDW R.P]:M:EK,
M'B#7_L4,GFK&<63=$5@O&%]<]S^%5O$LUBWAR'2;!H8YX9!(;>$$Y7'0MW/.
M<>U4;!#H%G%?6Z*=3G=5@:5<^4I^\^WVZ#-/FDFH/9!9.\NIU/BS55\.:=I^
M@:9-MN(R)+IU/W>/N^Y).37&V]]>/=[H[B1G8C+$\FJUW,]U=W$]PSF1W)9F
MZDU>T+2-3U>]\O34550%I9W.U(Q_>)J)2=61<8JG$[.TMI;1[J\O1]JFN0J"
M!1N38 ,<=%]Q5W5]5@N]#FL[8&&_78B)"VS82<#)[ 5-IMO'%I)MC??;(CD/
M/'QO_'OS5SPQX;C:Z.IWD2.J-F!#DC</XSZD=!75!3C-6V.:4HV;>Y(G@:RU
M&UA.JHK2_*[O&,.[ =2>PJ.\N8X[_P"R:8BF*!UC8)T [_4UH>)_$\&BR0VC
M2*LUP"-Q_AST_'-<U>7%Y:RK_9MI%*&0.S22;58^F1S6K;YK(RC>2O+Y$K:I
M/=>(%@M8(YH]S"YD_P">8! '3OUK2N699I'3*PX,2#N?\#Q7'V4O]@:_>VT
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M^S;,<8W;LT 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Y_4?^1YT'_KTO/YPUT%49]-2?6;+4C(P>UBEC5 .&\S9
MDGZ;/UJ]0 4444 %%%% &?KW_(O:G_UZ2_\ H!HT'_D7M,_Z](O_ $ 59O;8
M7MA<6K,56>)HRPZC<,9_6BRMA96%O:JQ98(EC#'J=HQG]* )Z*** .&^+?\
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M*9#B3&-VX>O3C&>:T3H]@?L7[C'V)R]N [ (2".F>1ST.0, ]0,+-IL,LS7
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ME%M"T@B09:0@<*H[DG 'N:Q++QE&-/MSJEJ\.I/>R:>]I:YG(G56? ([%%#
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M6D4GEX!"&/>6"!R2K'(W;>^W- '2T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gmtxzzgtjwwl000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '7 ?<# 2(  A$! Q$!_\0
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M9KS3X8^&MC"L8<@\D@C//2MNBASN"II'%26KP)XCLETR;S[CS9+>2.#*E2@
M 8=\YXJQ?6IL;'1X[?3%&!^\E2U\UH6V 9V>IZ9/2NMHHYP]F<+IFG32KHUM
M<V$Q6UO+CSA-#\H!#%3Z8Y'3C-.DTV2"VN/]%NX4BU5Y8&@@#A%*\-L/WEZ]
M*[BBG[1WN+V2L<9:V-S<?V(]QIJJ$NYB^VWV#85;#,O\.3SCUJFNES_VC-:W
M:7_F/?\ GH\-JC*1NRK>:>0 .",^U=_11[1W!TDU8PM T\07>JW,UJ$FDO9"
MDC)AF3C&#Z=:W:**ANYI%6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "J&J_ZB#_KYB_\ 0Q5^J&J_ZB#_ *^8O_0Q36XI;%^BBBD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M/Y_VRT\O
M=Y6YO-QTQM.,_CBK-5I[AXKRUA505F9@Q/;"D_TJS3$@HHHI#"BBB@ HHHH
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M_P!1!_U\Q?\ H8IIML322+]%%%24%%%% !1110 4444 %%%% !1110 4444
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MVIH44R*19HDD0Y5U##Z&GT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M68AHB2H]<C%356GMVEN[68, L+,2/7*D?UJS2!!1110,**** "BBB@ HHHH
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MZQBC4.9]OR-:BLC^SM2_Z";'\*/L&IC_ )?L_P# B/Z4:AS/L:]%9/V+4O\
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M%Q_I#?,%&1CT_"MG2([C4O!LUL;J;SLRQ1S;SO&UB%YZ]A72!%&,*!MZ<=*
M HP  /:B4[A&G8X,:GJ-]HNH:K#),C06\=J "?E<$>:^/49Z^U,%S<0:=J#6
MFIQR6F81)]FN'F:%2V'8,PXR.W:N_"J!@  'T%-2*.-2J1JJGJ N :?.NQ/L
MGW.'U6'3)O#E\;&_N;JW@GB<YG9UCY&[#=QCD\G!]*DN9].:^$,^J31:6EIO
MM)$NF D?<=QWYRQ'&!FNT6*-(_+6-0G]T#BD\B$HJ&)-J\J-HP/I1SC]F<AI
M2W>J:E81ZC<72D:<DSQK(4WL)#@L![8S4_B."R3Q)I-S?3R0PLLJ-)Y[(H(
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M<,IP1M/!_*D_M6R_Y[?^.'_"L6Z_X_KC_KH:BKC>(FG8R<V;_P#:ME_SV_\
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MMO\ GI_XZ:HW?B72;%KP7-R\:V<+SS/Y$A0*@+-A@N&8 $E5)8>E3:7K5IK
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MX/G+"']Z")"I4&(CDAL$_*>^Q;^$$_LW3+.[U/4'BLK".S,4,WE!RFP^9YB
M2AB47HX''3DYW?,NO^?:/_O[_P#6H\RZ_P"?:/\ [^__ %J.9!<Y3Q'X0M9[
M'PW$FD+K$&D70WPW1265X3$Z$;I3@_,8V()'W..0!1!X=NI=?9KRSC=&N+AK
MN\DCB9;VUD$@CMB,EL)O3.X ?)QG<:ZOS+K_ )]H_P#O[_\ 6H\RZ_Y]H_\
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MVFH77VB>-ANWDR>8_P IRN!N.,'IG V/,NO^?:/_ +^__6H\RZ_Y]H_^_O\
M]:CF07+%%5_,NO\ GVC_ ._O_P!:CS+K_GVC_P"_O_UJ.9!<%_Y",O\ UR3^
M;58J@LES]OD/V=-WE+QYONWM4_F77_/M'_W]_P#K5,9*PDR#7+!]5T#4M.CE
M,4EW:RP+(IP4+*5!'TS5#34O3K$^J7&FW5N;N.&T,#21-Y0B,S>:<,1M8R!1
M@EONY YQK>9=?\^T?_?W_P"M1YEU_P ^T?\ W]_^M5<R'<XM/#FJ26&F0M#<
MQR:);16Z,TR?Z<4FMY2PPQP&%OCYMI^=N,<U%X@\-:_J^@ZY-8O';3:C'</_
M &;=PB5]SVR0JJNLH2-L(W.74>83SBNY\RZ_Y]H_^_O_ -:CS+K_ )]H_P#O
M[_\ 6HYD%Q;-)X[&!+EXWN%C42-&A12V.2%).![9/UJ>J_F77_/M'_W]_P#K
M4>9=?\^T?_?W_P"M1S(+A<_Z^S_Z['_T!Z*BD>=KFT$D*HOFGD/G^!O:BE%W
M;!%VBBBK&8^IZG_8GA[6M6\GSOL,4]SY6[;OV(6VYP<9QC.#5:'Q5%+>V<!M
M9 LUA<7DNS=(\30O&C1A%4ECF0].?EX!S5G4],_MOP]K6D^=Y/VZ*>V\W;NV
M;T*[L9&<9SC(JK-X32779=3COYH?,T^6S,<0P5:0QYE5NS8B3CVS4QV$MB*/
MQ[HLNOVFBQQZH;RYC,JJVF7">6H95!<,@*@EOO$;0!DD9&;4GC'08;.RNY+_
M !!?0+<V[^2_SQL\<8;&W(^::,8.#\WH#C!TCX=/H_C!?$EM?6$,[6XM9X+?
M3?*CE3>69N),^8?D^<D_=/!R KC\/9"FEPG5U^S:9#';VR"UY\M+BWF7<=_+
M8MPN<#[V<<8-#.DN_$>GV,D*W(O8UEB$HE-A/Y2*<_?DV;8SQR&(([XS69%X
MSC;0?#&JRV9C37'C4HKES#O@>48PN7.4VX &=WX5'XQ\%+XMBFBDN;9(Y;5H
M,7-F+CR6(;$D66 1\L,GDD  8ZU8LO"GV32/"UA]MW_V"Z-O\K'G[;>2'IGY
M?]9N[],=\T 6)O%>DPFS=KN,0744DJ,0^X['2,J%V\MOD5=I(;)  )SB"R\;
M:5?:U)I<<&J131P+<-)<Z;/#&%._J70;?]6W+8!Z DY I'P3-&L+07]JTD0O
MP!=V1EC875RDYRHD4G:%*]>20>,8+T\%/FX2YU1[J"^TYM/OEEB.Z1-TK+Y;
M!LICSF7G<=H7G()(!I'Q9HRQQ.UQ,IEG^SQHUK*'=]K. $V[B"J,0<8.."<B
MM"WU2SNV@6"4LT\;2QC8PRJD YR.,%@,'!Z^AK"3PC+)J]EJUYJ$<M];7$<C
MM%;E%DCCBGC1-I<X(^T,Q;)SCH!C%S1-$.F:KJ]SEA#<SYMXN,1J?G? ']Z5
MY&.>>1[4 -O/%5E:ZU8::@\QKBY>WEE.Y$AV0R2D[B-K8\O! /&[GT-C_A)=
M+^RS7'FS[8F"-&;67S23G&V/;O8'!P5!!P<9K%OO B:@PMI;X#2_M5W<FV$)
MWL;F*9) 9-WK.S# XZ<\$,LO OV! UI_8EI<P7"7%I+9:1Y'S*DB?O@LO[WY
M96'&S!)(Z\ &C:>+(+O49+7R3#_I\=E"9MZ/*6M5N<["F48*2-K8^Z<D'Y:L
M:?XLT35+=;BTO2\30"X1FA=-\9P,KN4;N2!@9() //%48O"<W]K1ZE<:C&\_
M]IIJ,@CMRBLPL_LQ4 N2 3\_4XZ<_>JD_P .K:XTC2-.O+M;B'3M+^P%7@&V
M4B2"17*DD8S;C*'((;&?4 ZNPU"VU.V\^U9RH.UEDB:-T/7#(P#*<$<$ \U:
MK'\.:+_8.G26OE:5%OE,F-,T_P"QQ\@#E-[Y;C[V>F!CBMB@ HHHH *KW_\
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M[## =^&4;3N/[M^#M&%//:FIXB9]02-;5'LYIY;6WE2<&26>(.7380 !^Z<
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MN0JP(/R+_A111R(+#_(G_P"?R3_OA?\ "CR)_P#G\D_[X7_"BBCE06#R)_\
MG\D_[X7_  H\B?\ Y_)/^^%_PHHHY4%@\B?_ )_)/^^%_P */(G_ .?R3_OA
M?\***.5!8/(G_P"?R3_OA?\ "CR)_P#G\D_[X7_"BBCE06#R)_\ G\D_[X7_
M  I@M)1*T@NY-S  _(O;/M[T44<B"P_R)_\ G\D_[X7_  H\B?\ Y_)/^^%_
MPHHHY4%@\B?_ )_)/^^%_P */(G_ .?R3_OA?\***.5!8/(G_P"?R3_OA?\
M"CR)_P#G\D_[X7_"BBCE06#R)_\ G\D_[X7_  ID=I+%&L:W<FU1@?(O^%%%
M'(@L/\B?_G\D_P"^%_PH\B?_ )_)/^^%_P ***.5!8/(G_Y_)/\ OA?\*/(G
M_P"?R3_OA?\ "BBCE06#R)_^?R3_ +X7_"CR)_\ G\D_[X7_  HHHY4%AD=I
M+&I"W<F"Q;[B]2<^E/\ (G_Y_)/^^%_PHHHY$%D'D3_\_DG_ 'PO^%'D3_\
M/Y)_WPO^%%%'*@L'D3_\_DG_ 'PO^%'D3_\ /Y)_WPO^%%%'*@L'D3_\_DG_
M 'PO^%'D3_\ /Y)_WPO^%%%'*@L,%I*)6D^UR;BH4_(O09]O>G^1/_S^2?\
M?"_X444<B"P>1/\ \_DG_?"_X4>1/_S^2?\ ?"_X444<J"P>1/\ \_DG_?"_
MX4>1/_S^2?\ ?"_X444<J"P>1/\ \_DG_?"_X4>1/_S^2?\ ?"_X444<J"P@
9MG,L;R7#N(VW!2H'.".P]Z***:26P['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gmtxzzgtjwwl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K M # 2(  A$! Q$!_\0
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MT'=1_P# EO\ &C_A*O$7_0=U'_P);_&IO^$3U#_GO9?]_O\ ZU'_  B>H?\
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MJ'_/>R_[_?\ UJ/^$3U#_GO9?]_O_K4>PJ_RO[@^NX;_ )^1^]$/_"5>(O\
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M:F_X1/4/^>]E_P!_O_K4?\(GJ'_/>R_[_?\ UJ/85?Y7]P?7<-_S\C]Z(?\
MA*O$7_0=U'_P);_&K$WBCQ +*T8:YJ 9M^3]H;G#<=Z;_P (GJ'_ #WLO^_W
M_P!:II?#%\UK;1B>RW1[]W[[U.1VH]A5_E?W!]=PW_/R/WHI_P#"5>(O^@[J
M/_@2W^-'_"5>(O\ H.ZC_P"!+?XU-_PB>H?\][+_ +_?_6H_X1/4/^>]E_W^
M_P#K4>PJ_P K^X/KN&_Y^1^]$/\ PE7B+_H.ZC_X$M_C6OI4_C#6+5[BUUZ[
MVK((L/=N"2<?A_$._P!*SO\ A$]0_P">]E_W^_\ K5/#H&M6Z(D-_;1JDGFJ
M%N" 'QC=TZT>PJ_RO[@^NX;_ )^1^]%_;XW\HR/K-[&H>)&,EVZA3(!C)/
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M #TM?^^S_A2_\*\UC_GK:?\ ?9_PK3ZW0_F1S_V7C/\ GVSDJ*ZW_A7FK_\
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M_P!__P#ZU'MZ?</J5?\ E_(R**U_["'_ $%=-_[_ /\ ]:C^PA_T%=-_[_\
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M;_W_ /\ ZU']A#_H*Z;_ -__ /ZU'MZ?</J5?^7\C(HK7_L(?]!73?\ O_\
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MG_A M6_YZVO_ 'V?\*/^$"U;_GK:_P#?9_PH^MT/YD']EXS_ )]LY:M?PO\
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M_"C_ (0N_P#^>\'_ (]_A47]M^(O6?\ [\?_ %J/[;\1>L__ 'X_^M1_M?\
M-'^OD'_"7_S[G_7S)?\ A"[_ /Y[P?\ CW^%'_"%W_\ SW@_\>_PJ+^V_$7K
M/_WX_P#K4?VWXB]9_P#OQ_\ 6H_VO^:/]?(/^$O_ )]S_KYDO_"%W_\ SW@_
M\>_PI?\ A"K_  #Y\'/^]_A4/]M^(O6?_OQ_]:C^W/$>!S/[?N/_ *U'^U_S
M1_KY!_PE_P#/N?\ 7S)?^$+O_P#GO!_X]_A1_P (7?\ _/>#_P >_P *B_MO
MQ%ZS_P#?C_ZU']M^(O6?_OQ_]:C_ &O^:/\ 7R#_ (2_^?<_Z^9+_P (7?\
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MA7[A_8."[/[SDK3P?=Q7<4DMRJHK DQ9W?AQ71:O82:C82VJ,$+NIW.FX8#
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MY>PYZ]JU+.[M]0M([NTG$L$HRCKT(K)/A/1 @5K0[-V0K3O@-@ $<]0  /3
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MT(H86/[LJH.&W[6V@.>%.!Z]JR4U_P 26]M&EQIC?:"TA;S(&/! 9/\ 5Y
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MX_YES_A"+C_G\C_[]FC_ (0BX_Y_(_\ OV:I_:_$_P#T^_\ ?K_ZU'VOQ/\
M]/O_ 'Z_^M1_M/\ S\C_ %\@MEW_ #XG^/\ F7/^$(N/^?R/_OV:/^$(N/\
MG\C_ ._9JG]K\3_]/O\ WZ_^M1]K\3_]/O\ WZ_^M1_M/_/R/]?(+9=_SXG^
M/^9<_P"$(N/^?R/_ +]FC_A"+C_G\C_[]FJ?VOQ/_P!/O_?K_P"M1]K\3_\
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M8WH/S%&QO0?F*;10 [8WH/S%.*-L7IW[BHZ<?N)^- !L;T'YBC8WH/S%-HH
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M /K5I->^&-[9%KG)S^Z_^QI/MOA?^[:_]^O_ +&O3M1_Y\O\3YQO%7_WN/\
MY*9W_"<3?\^,?_??_P!:C_A.)O\ GQC_ .^__K5H_;?"_P#=M?\ OU_]C1]M
M\+_W;7_OU_\ 8T[4?^?+_$+XK_H+C_Y*9W_"<3?\^,?_ 'W_ /6H_P"$XF_Y
M\8_^^_\ ZU:/VWPO_=M?^_7_ -C1]M\+_P!VU_[]?_8T6H_\^7^(7Q7_ $%Q
M_P#)3._X3B;_ )\8_P#OO_ZU'_"<3?\ /C'_ -]__6K1^V^%_P"[:_\ ?K_[
M&C[;X7_NVO\ WZ_^QHM1_P"?+_$+XK_H+C_Y*9W_  G$W_/C'_WW_P#6H_X3
MB;_GQC_[[_\ K5H_;?"_]VU_[]?_ &-'VWPO_=M?^_7_ -C1:C_SY?XA?%?]
M!<?_ "4SO^$XF_Y\8_\ OO\ ^M6KHGB,ZM-+"]OY3JFX%?F&/?CBH_MOA?\
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M)Z-^= !O;V_(4;V]OR%'R>C?G1\GHWYT &]O;\A1O;V_(4?)Z-^='R>C?G0
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M;OXD.T,2VVFF"5@6D,K!RHV,PV+QNZ#/89]ZUSXIN203;09'0\\4?\)3<_\
M/M!^M>>LXPG\S^YG7]0K]OQ*LWCY3!/Y&G;9X=VY99 ?NN%P /O'!SA2< CG
MFFGXCVJQF1M+GV!'8%9 VXJJL%X[X;YLX"X.3FKG_"47(_Y=8./K1_PE%S_S
MZP=_7O1_;&$[_@P^H5^WXC]%\6MK/B!=.&GBV46IFDWRJSAOW> -O&W#\-GG
M'L:ZK:/05R0\4W*_=M8!QCC-+_PE=W_S[P_F:/[8PG=_<P_L^OV_$ZS:/04;
M1Z"N3_X2N[_Y]X?S-'_"5W?_ #[P_F:/[8PG=_<P^H5^WXFYK-ZVG:>9XUB!
MWHA>7.R,,0-S8[#\/J.M<_%XFO[F;9;QVYC-N769[=@I<*Q_O?[/W?3G)Q4A
M\571!!MH2#USFD'BFY P+:  = ,T?VQA/YG]S#ZA7[?B=+8-+-I]O+<>69GC
M#-Y:E5R1G@$G^=6-H]!7)_\ "5W7_/O#^9H_X2N[_P"?>'\S1_;.$[_@Q?V?
M7[?B=9M'H*-H]!7)_P#"5W?_ #[P_F:/^$KN_P#GWA_,T?VQA.[^YC^H5^WX
MG6;1Z"C:/05R?_"5W?\ S[P_F:/^$KN_^?>'\S1_;&$[O[F'U"OV_$MZAXC^
MP75S#Y$<LD$A_<J<.T7D[]WTW_+GI^-59O%KI<QVZV*)(/,$P:4$J5$GW1P6
M&8_O<=13?^$IN=V[[-!G&,\T?\)3<YS]F@SZ\T?VQA.[^YA]0K]OQ)3XN0WT
M]DEK$LT88@R3@!@!G@ <DGHN<X!)Q5<^.88]F^P)!^\5E!*]1@K][<2.%]""
M2*=_PD]Q_P ^EOUSWZ^M'_"47&<_9;?.<YYZT?VQA._X,/[/K]OQ':=XQ.IW
M]C;)IP@\^3:_F3JS ;78%0O4?+@GL3BNLVCT%<B/$]POW;6W&/3-._X2N[_Y
M]X?S-']LX3N_N8?4*_;\3K-H]!1M'H*Y/_A*[O\ Y]X?S-'_  E=W_S[P_F:
M/[8PG=_<P^H5^WXG6;1Z"C:/05R?_"5W?_/O#^9H_P"$KN_^?>'\S1_;&$[O
M[F'U"OV_$ZS:/04;1Z"N3_X2N[_Y]X?S-'_"5W?_ #[P_F:/[8PG=_<P^H5^
MWXG6;1Z"C:/05R?_  E=W_S[P_F:/^$KN_\ GWA_,T?VQA.[^YA]0K]OQ.1D
M\8ZJLC@&# 8C[G_UZ;_PF6J^L'_?'_UZWS?0DY_L^VY_V1_A2?;8?^@?;?\
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M5^WXG245S?\ PDEQ_P ^\7YFC_A)+C_GWB_,T?VQA.[^YA]0K]OQ.DHKF_\
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M2FG4X3N^5_F7 ./N?*!@<].*?;:SHMWX>AU2'3(GE:1(YK59D+PEI/+))!Y
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M[?F* &6\%O;11P0)Y<48"HBC 4>@K:K)"-N'3KZBM:@ HHHH **** "BBB@
MHHHH *<G^L7ZTVG)_K%^M %NFG[RTZFL,LM '-^(;#5;C4UEL+J]AA^PS!C
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M;V]?TH ;13M[>OZ4;V]?TH 0?>'UK8[UDAVW#GOZ5K4 %%%% !1110 4444
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M ,K_ '/UHRO]S]:-H_OK^M&T?WU_6@ RO]S]:,K_ '/UHVC^^OZT;1_?7]:
M#*_W/UIQ*[%^3U[TW:/[Z_K3BHV+\X[T -RO]S]:,K_<_6C:/[Z_K1M']]?U
MH ,K_<_6C*_W/UHVC^^OZT;1_?7]: #*_P!S]:,K_<_6C:/[Z_K1M']]?UH
M,K_<_6C*_P!S]:-H_OK^M&T?WU_6@ RO]S]:,K_<_6C:/[Z_K1M']]?UH  5
MR/D[^M*Q7>WR=_6D"C(^=>OO2LHWM\Z]: $RO]S]:,K_ '/UHVC^^OZT;1_?
M7]: #*_W/UHRO]S]:-H_OK^M&T?WU_6@ RO]S]:,K_<_6C:/[Z_K1M']]?UH
M ,K_ '/UHRO]S]:-H_OK^M&T?WU_6@ RO]S]:,K_ '/UHVC^^OZT;1_?7]:
M%!7</D[^M:U9(4;A\Z]?>M:@ HHHH **** "BBB@ HHHH *<G^L7ZTVG)_K%
M^M %NFG[RTZFG[RT <UKWAZ]U/4_/M;F&**1(%D+$[T,4ID!7'!SG'.,=>>E
M8=QX+\1W*P)/KJ3K$"4\Z61MK%&4G!X;);.3T XZUMZ_K&J:?JGV>SMVD61(
M&A @+!SYI$HW#@83!Y_6L*[\8>(Y8H8XM&EM9"&:1DB=V8;&8!,I@8.T'/<\
M"D@9=F\+>(+B">"?6$EB?=Y8>9SLS(&!(QAS@8Q@ 8&,Y)II\,^*_+;9XBVR
M%'7)F=@"54!AQP2P)[A=Q !X-+-XMUJ2"=(=(:*9-^T^4[ARL@&$XP?E.23C
MKQT--/C76%C+GP[(PV2%0BODLJJ=I!48QD@GD97CK3 T-$\/:K8^(%O[_4C=
M1):F%!).SN,[..@7@H?FP"<\]*ZK(]17*:'X@U?4_$"VMUIZ6MLMJ9'*AF#/
M\F"'( VG<V!UX.>E=7@>E'0 R/449'J*,#THP/2@#F-5\/7E]JD\\,EIY<Z%
M3)*N9$!C*;5R#@9^;@CJ<@U8TKPY'I]W;3NMM)) DR"01 -\[ C&!A<#(P..
M>*=?ZKJEMJ9B@T^*6U5E!<E]Y^[G "X_B/?L:KG6=5 8?8#L$9P^UMY?:S#C
M;C'RX^I% ;G2Y'J*,CU%<EK/BR]T[5%L8=-C:4PM*$DE^9AD@$8SQQDCKC/I
M31XGUH6#W+:+&21A KL0""@+,=OW?G)&/[IH Z_(]11D>HJ"QFDN;"WGFB6.
M22-69%;<%)'0'O4^!Z4 &1ZBC(]11@>E&!Z4 <[J&BZA<W=R;>ZBACDD,\<H
M9A(C^5Y6.!C'?.<^W>J\_AW4Y;J,G4 \$7F>5YD\A*@B0*"#PQPZ_,3GY:L:
MAK-_:7ES!!;--)%(72/RFP\7DYSN Q_K./7VJK/K^L"[BMA8*C*)/-*QNV_:
M).4.,!<HO7GYA1T'J/.B:PU_.TE\LEI(&"QM=2 J2, X  (']S&.<DGBH&\/
M>( 4\K5PFSC=]HD*GKABF,<# "@A>,G/2IF\2:@U_/:+9HFW<$E,;L"0O"Y
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M.V_[X/\ C1_PEFH?\\[;_O@_XU@Y'J*,CU%'UJM_,P]I/N;W_"6:A_SSMO\
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M #[0?]^E_P */LUO_P ^T'_?I?\ "I\IZ-^=&4]&_.CDCV"R(/LUO_S[0?\
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M'L%D0?9K?_GV@_[]+_A1]FM_^?:#_OTO^%3Y3T;\Z,IZ-^=')'L%D0?9K?\
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M(;;_ //[)_WR*!X-M^<WTG S]T5B_8M=_P">5[_WT?\ &MSP[!JL33_;/,6
MK]V4DL3[5I3C2G)1=)K[RHJ+=N49_P (=;?\_P!)^0H_X0ZV_P"?Z3\A7045
MU_4Z'\IK[*'8Y_\ X0ZV_P"?Z3\A1_PAUM_S_2?D*Z"BCZG0_E#V4.QS_P#P
MAUM_S_2?D*U=-TJ'3+<Q1/N+'+.QY)JW15PP]*F^:*U'&G&+ND.V_P"TOYT;
M?]I?SIM%;%CMO^TOYT;?]I?SIM% #MO^TOYTXK\B_,O?O4=./W$_&@ V_P"T
MOYT;?]I?SIM% #MO^TOYT;?]I?SIM% #MO\ M+^=&W_:7\Z;10 [;_M+^=&W
M_:7\Z;10 [;_ +2_G1M_VE_.FT4 ."\CYEZ^M*R_.WS+U]::.H^M#??;ZT +
MM_VE_.C;_M+^=-HH =M_VE_.C;_M+^=-HH =M_VE_.C;_M+^=-HH =M_VE_.
MC;_M+^=-HH =M_VE_.C;_M+^=-HH >%^8?,O7UK6K''WA]:V.] &/XM./!>N
M<\?8)O\ T UR>MZM<VGPOT33-.6275-6M(;2VCB(W[3&#(PSZ+GGW%=]=PM<
M6<T"L$:1"H8KD#(ZX[U1&ESB2T<72YMU*_ZH9QMQ@>E']?UZ[$N33LE_7_ W
M.#TB[D\->--/8Z!?:-I&HV\>G2?:BFWST'[IOE)Y(RISUJ>S\-VZ_$^?1S,Y
MT>SC&LP:>1^[2X=BO_?((+ >IKN'TZXE!6:[65<Y57C! /.#SW&1^5(-.N1>
MFY^V#)B$9_=C<2,\YZX]JA2;OI_78+O33_@''ZC+I^F^)]7N=)\:VFC7\K*U
M]9WL2O&[A0 PW8/3'W2:R;C5=4\3MX%NXY(=-OY;R[2.=(=\;!4(\Q4;'RL!
MQGUKN]1\/RZBJF2Z@:16RKS6JR%1@\#-+%HNH"XA>?5O-CB5@B>2H*$KC*MU
MXJD-'+&WU33OB?H#ZWK45\OV&\976V6 1* -V<$Y_P#K5STQU3Q3::WK,'AO
M4[BXU"5)-*O8C&%@CA/[HC+ \G)/'.:]&GT#4IWRVM%L1LBE[=2R@XSSW]\^
MM/\ [&U81E8]>:(!2(UCMU55SVQ[=L4QD_AK7(_$?AVSU1!M>5,31]XY1PZG
MZ$&MA/\ 6+]:H:992V$,L<DR2[Y3("L87&<=<=3GO5]/]8OUH MTUOO+3J0C
M.,'&* .9U[Q+-I&I&T2WB<LD#Q*V=TNZ4K(%]=J@'VSSQ6#=_$>5H8DMM-,$
MK M(9&#E1L9AL'&[H,]AGWKT/:2021D=.*-I]1^5 '$S>/LP3^1IVV>'=E99
M,_=<+@ ?>.#DA3QD<TT_$>!8VD;29MH1V!60-N*JK!>!P<-\V<!<$9)KM]GN
M/RHV>X_*@#E]%\6R:SX@73O[/%L@M3-)OE5W#?N\ ;>-N'.#GG';!KJMH]!2
M!2.A ^@HPW][]* %VCT%&T>@I,-_>_2C#?WOTH YV;Q+-%>30G3"(D+A9O-!
MR5\S'RX[F,]^XIP\2.9G0Z>X <*A4AC(-X1N.,')XY-=!@_WOTHP?[WZ4 <I
M<>-1"]V%TJ1Q;S) ,S*I+$,3NSPN-OJ<D@4+XT8W%I"VCS!KE@4_?( $+%<D
MG W9!^4$\#K710Z=:6\\\\-O#'+<$&9UC +D>OK5@IG&2#CIQ0 [:/04;1Z"
MDPW][]*,-_>_2@!=H]!1M'H*3#?WOTHPW][]* .?U#Q&;"ZN8/(CED@D/[D'
M#M%Y._=]-_RYZ?C5:;Q;*ES';K8QI(/,$P:7)!42?<& 6&8_O<=174[3G.1G
MIG%&TYSD9^E SF#XN4WT]DEK$LT88@R3@!@!G@ <DG^'.< DXJNWCF./9OT\
MD'[Q64%EZC!3&=Q(X7T()(KKO+^G7/W>]&SG/&<YSB@1RNF^,7U._LK9-.6#
MSY-K[YU=L;7(*A>H^4 GC!.,5UFT>@IH3'3 ^BTN&_O?I0 NT>@HVCT%)AO[
MWZ48;^]^E "[1Z"C:/04F&_O?I1AO[WZ4 +M'H*-H]!28;^]^E&&_O?I0 NT
M>@HVCT%)AO[WZ48;^]^E 'F#^,+T2./(AX8CJWK]:;_PF-]_SPA_-O\ &NZ/
MA?2223:19)S]P4?\(OI/_/I%_P!\"N#V&)_G,.2I_,<+_P )C??\\(?S;_&C
M_A,;[_GA#^;?XUW7_"+Z3_SZ1?\ ? H_X1?2?^?2+_O@4>PQ/\X<E3^8X7_A
M,;[_ )X0_FW^-'_"8WW_ #PA_-O\:[K_ (1?2?\ GTB_[X%'_"+Z3_SZ1?\
M? H]AB?YPY*G\QPO_"8WW_/"'\V_QH_X3&^_YX0_FW^-=U_PB^D_\^D7_? H
M_P"$7TG_ )](O^^!1[#$_P X<E3^8X7_ (3&^_YX0_FW^-'_  F-]_SPA_-O
M\:[K_A%])_Y](O\ O@4?\(OI/_/I%_WP*/88G^<.2I_,<+_PF-]_SPA_-O\
M&M;0]?EU.2:&6(JZKN#)DKCW]*Z3_A%])_Y](O\ O@5/!H=E;*RP1B)6ZA !
MFKITJ\9)RG=%1C-/5F;O;^\?SHWM_>/YUK?V5!_>?\Z/[*@_O/\ G78:F3O;
M^\?SHWM_>/YUK?V5!_>?\Z/[*@_O/^= &3O;^\?SHWM_>/YUK?V5!_>?\Z/[
M*@_O/^= &3O;^\?SHWM_>/YUK?V5!_>?\Z/[*@_O/^= &3O;^\?SHWM_>/YU
MK?V5!_>?\Z/[*@_O/^= &3O;^\?SI2[;%^8]^]:O]E0?WG_.C^RX< ;GX]Z
M,G>W]X_G1O;^\?SK6_LJ#^\_YT?V5!_>?\Z ,G>W]X_G1O;^\?SK6_LJ#^\_
MYT?V5!_>?\Z ,G>W]X_G1O;^\?SK6_LJ#^\_YT?V5!_>?\Z ,G>W]X_G1O;^
M\?SK6_LJ#^\_YT?V5!_>?\Z ,G>W]X_G1O;^\?SK6_LJ#^\_YT?V5!_>?\Z
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M<?WC0!!14_V<?WC1]G']XT 04Y/]8OUJ7[./[QI1  P.X\&@"6BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gmtxzzgtjwwl000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #@ KH# 2(  A$! Q$!_\0
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MI&"/ZT?V/9^7Y>QO+W[MN[C.W;_*K]%+F8<J,[^R(4W/&[^?M90[G/48Y^@
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MLNZ)MR#=P#C'2GRZ=#-?1WC%_.BX0AN@[C\:GGD,,+R!"^T9VCO3;:?[1")
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M9%*1D8-5K(E4> ]8FVCZ=1^E+9@6:***H HHHH **** "BBB@ HHHH ****
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M@_A;]XGX]?U_G5JJMY^[,=P/^6;?-_NG@T2[@6J***H HHHH **** "BBB@
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M8C(!/8X[5I5C0: L#Q*+ES CI*8RH^9U  .?3@<5LTW;H3&_4****104444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MINQDXJY#K\LEX4DM!'#'#(\I\P%E9#@@ =142^(Y_M,3/9@6SQ([$2J2FYL
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ML0@@J#D8/%,@MX;6(101)'&#G:HP*EHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gmtxzzgtjwwl000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U ;X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0>O:O:**.GW?@/K?^M3Q_P#X0#6;3PKX+M8K3S;VVUA=0U/$BC86)+G.><9
MXSTK?T70]7TKXC>)FN-*-SH^N&-Q>+,FV,*A!5D)W$G..!7H-%._]?=_D*W]
M??\ YGB'POT&\3XA:C;7$PGTWPOYUI8L.<&5]V,^H7(]J]OJG8:5I^E"86%E
M!;">0RR^2@7>YZL<=3[U<I=$A]6PHHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,;Q/::K>Z.8=(U$Z?*9%,LZ1>9)Y0Y81@\;ST!-
M>;67B[79_!-C;_VE.M[>^(/[+6XEC7[3;P%C_K%Q@2[1Z=P:]*\1Z#_PD&G1
MVZ:A=Z?/#,L\-S:OAD=>F0>&')R#Q6 /AM9MH4]G-J=Y)J,U^NI-J9"B47*X
MVN%QM  &,8Q0!6\+^*9M,LO$MOX@OI[N/0]0^SK=^07D>)@I3<(QEF!;!(%7
M4^*GA%[FWMS?74<EQ*L,7FZ?.@9V. ,L@%:WA?PS%X:L[I!=S7EU>7+75U=3
M !I9&P,X   P ,"N2^,A_P!!\*#_ *F*U_DU 'I5%%% !1110 4444 %%%%
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MV$#J#'' 4SO1>G+9&X?W0*N>$[BX'AFX,"M=QP7-Q'8[I>985<A/G/;' )[
M4 =/29&<9&3VKFO".KZSJHU#^U+#R%AO)XHW\Q3PKD!< <X'\7>F^,(3:-IG
MB*+A]*N-TQ];:3Y)?R&'_P" 4 =/D9QGGTHR,XSSZ5YG_:M]_:@U6S2<MKUX
M\,,MNB.ZVL"'9L#D+EVW-SV/0U#'J&LWVMRWXO!:75KHESN=8XW,ACN&"Y&6
M5<[?F .0<@8H ]2!!) (R.OM1D9QGGTKSVS\1:E?ZJMK'-!9MJ$]NIG2%2R
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M?&3_ (\?"G_8Q6O_ +-0!Z71110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKU6O*OV??^2;-_U^R_\ LM>JU^*5/B/104445 PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***YOQCXBN=!M=/AT^"*;4=2O$L[83$B-6;)+-CG  )P* .DKS3XR?\
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M9"GFV]I''(GNK!<@UC>$?@YX7\+17'G6T>KS3$?O+^%'V*.@4$8'N>]>A44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gmtxzzgtjwwl000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 9H# 2(  A$! Q$!_\0
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M^+X;KQ+=:<P80JR1P'R7W,_\6[T&>A.*ZBDXM;A&2EL%%%%(H**** "BBB@
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M8&99+5HR>6 /(8UWU%+G=[C=--6N>=7FEZVFFZUI$6DO*EQ=&X2X$BA2I8'
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M;ZC'E+AKF<RQ;EE<XQ\N>@]#1S*VX<KOL.\&M(=3U(64]S/HB[1;R7#$Y?\
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M6[FM4><8^;)&<=,CH<>]6H+:&V\SR8PGFR&1\?Q,>IJ6BB["R"BBBD,****
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M7<%P66.12Z_?3/S+[$=J46T*W!N%B42L-I<#!(]_6N?U'2KN"".*S0,G5[@
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M[TM8MAH]W9VL*+J#QNH^9%0,F?3![?E6UVIQ=UJC5-]0HHHIC"BBB@ HHHH
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MUCQ'+OYFZC!'I[U82.2UMF6,R7##E1(XS],_XU)!-YT0<QR1G."L@P14RC<
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M** "BBB@ HHHH *A@G$SSJ%QY4FP\]?E!S^M35#!.LSSJJ[3%)L/N=H.?UH
MFHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"&YNH+.!I[F58HUZLQQ5<ZQIRV:79O(O(<[5?/4^F.N?:J>HKJMM#)+&
M5OB7'E1"W4&+G[_+?-@?2J%O:36D]GJ"65Y,$:;STD""4N^T^8 #C'&, \ U
M:BK$.33T.FAFCN(4EA=9(W&593D$55/_ "'$_P"O9O\ T(54TO39DT?R)WEM
MG>9YML+@&,,Q8+GVS3!INW653[=>MFW)R9>?O#VI65PN[(VZ*H_V;_T_7G_?
MW_ZU']F_]/UY_P!_?_K4M"KLO451_LW_ *?KS_O[_P#6H_LW_I^O/^_O_P!:
MC0+LO451_LW_ *?KS_O[_P#6H_LW_I^O/^_O_P!:C0+LO451_LW_ *?KS_O[
M_P#6H_LW_I^O/^_O_P!:C0+LO451_LW_ *?KS_O[_P#6H_LW_I^O/^_O_P!:
MC0+LO451_LW_ *?KS_O[_P#6JO96CSP,[WUYD2R+_K!T#$#MZ"BPKLUJ*H_V
M;_T_7G_?W_ZU']F_]/UY_P!_?_K4:#NR]15'^S?^GZ\_[^__ %J/[-_Z?KS_
M +^__6HT"[+U%4?[-_Z?KS_O[_\ 6H_LW_I^O/\ O[_]:C0+LO451_LW_I^O
M/^_O_P!:C^S?^GZ\_P"_O_UJ- NR]15'^S?^GZ\_[^__ %J/[-_Z?KS_ +^_
M_6HT"[+U1Q,&:4"(IM?!)&-W Y'KZ?A57^S?^GZ\_P"_O_UJK6EH\SW0>^O,
M1S%%_>=L ^GO19"NS7HJC_9O_3]>?]_?_K4?V;_T_7G_ ']_^M1H.[+U%4?[
M-_Z?KS_O[_\ 6H_LW_I^O/\ O[_]:C0+LO451_LW_I^O/^_O_P!:C^S?^GZ\
M_P"_O_UJ- NR]15'^S?^GZ\_[^__ %J/[-_Z?KS_ +^__6HT"[+U%4?[-_Z?
MKS_O[_\ 6H_LW_I^O/\ O[_]:C0+LO451_LW_I^O/^_O_P!:FV >.]O(&GEE
M5-A7S&R1D<T6"YH4444AA1110 4444 %%%% !1110 4444 %%%% !5>ZNK6R
M3[1=2Q0K]W>Y _"K';BL#46U2UCB+1QWDK2826&TR;<8.6P6.2>@Z4TKBD[(
MW(I8YXEEB=7C<95E.01]:?5#1H([;2+>&))D50>)UP^<DDD=LG)J_0]P3N@H
MHHI#"BBB@ HHHH **** "H$GMA<-:QRQ><HWM$I&X GJ1]31=)<O#BUFCBDS
M]Z2,N,?3(K.BLYT\1Q7#QJV;)DEF1-JL^]?<]A32);:-BBBBD4%%%% !1110
M 4444 %%%% !56TO;&Z>5;2X@D93F01L"<^IQ]*748)+K3+JWA;9++"R(V>A
M((%8VFPS3:EI\HL);-+.U:&7S% W$[<*N.H&"<]*I*Z)DVFCHJ***DH****
M"BBB@ HHHH **** "H(;BVFFF6"6)Y$($H1@2I[ U/6586K0:YJDHA\N&41%
M& P&(!S30FS5HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC &G5)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gmtxzzgtjwwl000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmtxzzgtjwwl000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )X ?0# 2(  A$! Q$!_\0
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MLAF>/).2<'*\G@+]:WOA9;W+^%YM;O0XN];NY+]U=MVQ6.$ /IM (^M1^,_
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M,<B!E)[@C(K!U+P+X<U?4WU"^T_SII"IE4S.(Y2H !>,':Q  ZCL/2NA "@
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MXDU4Z-'?7ES+'%:QSS;HW@,4*R'R]ZJ3E#PQ4MM W <TNC^&M;M;+P_!<VR
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M"3@X.6W<=^@ZXZU=OX'NM-NK="H>6%T4D\ D$466@7EJ9,FNW'V> Q)#YO\
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M3^-#Y?F>IT54_LZ'^_<?]_W_ ,:/[.A_OW'_ '_?_&N&\NQZ&I;HJI_9T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@D
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M>.R7_EH=TGL@Z_F<#\Z4G9 .T]#Y#3N,27#>8P/;/0?@,5;HHH2LK %%%%,
MHHHH IWW[EH;L?\ +)L/_N-P?RX/X5<IKHLD;(XRK#!'J*K6#L(VMY#F6 ["
M3_$/X3^(_7-3M+U$6Z***H84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !113#+&)1$9$$A&0F[DCZ4
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M6@S@J>Y7_"K$%U#<@^6^6'WD(PR_4'D4E+H]P)J***H HHHH **** "BBB@
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M<M93JL,20I.PBDBA\I95P/FV_7(]\5LT44-W8)65@HHHI#"D8!E*GH1@TM%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(\'?\C/:?1__ $$UTTE:$T<E9WJ0;/5****Y#N"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HIC1J94DYW*"!R<<^WX4^@ HK%TB:[;6]5@NI_-,(@P%
M&%7*DG HUDRQS1?9;F;[=,ZK!%O^10#\Q*CJ,9SG/;&*OEUL1S^[<VJ*ANY9
M(+626*'SF09V;L$COCWQ4&GZ@NHB26%/]&!"QR;OOGOQV Z?G4V=KE75[%VB
MN=N;V]M-=O/,FWQQ:=)<)&HPH(?C/J< <_6FZ7--->0V;W$Y6YTZ.Z=C(20Y
M;#8/\((/;&.V#S5<CM<CVBO8Z2BN;D2^&FZ5&+.Y>.&.W9EC*@EPR9# D'@
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M% !7.'6[W:=0 A^P"[^S>3M._&_9OW9Z[NV.E='69_8-G]L\_,VSS?/\C?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*HZ1_P @\?\ 763_ -#:KU4=(_Y!X_ZZR?\ H;4^@NI>HHHI#"BBB@ HHHH
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M7?M?P2^;$(IX)6AE0-D!AW!]""#^-59=!1I9+B*YDBN3<FXCD !V$J%(QW!
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M_OW%_P#$4?:=1_Z"EQ_W[B_^(H^M1[/\/\P]HCJ:*Y;[3J/_ $%+C_OW%_\
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M?X?YA[1'3>4@F,NT>85"EN^!GC]33ZY;[3J/_04N/^_<7_Q%'VG4?^@I<?\
M?N+_ .(H^M1[/\/\P]HCJ:*Y;[3J/_04N/\ OW%_\11]IU'_ *"EQ_W[B_\
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M_P#GPM_^^!1_8>E_\^%O_P!\"M"BCV<.R#E78S_[#TO_ )\+?_O@4?V'I?\
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M[.D_Z"5[^:?_ !-5S/L.[[%ZFR(LL;1MG:P*G#$'!]QR*I_V=)_T$KW\T_\
MB:/[.D_Z"5[^:?\ Q-',^P7?8CAT*PM]/FLHEN%CGYED^U2^<YP!DR[O,S@
M9W9XJ:WTNTM88(;=)(XX)#*H69QN8@@ESGY\[B3NSS@]0#3?[.D_Z"5[^:?_
M !-']G2?]!*]_-/_ (FCF?8+OL%AI%GILDTMNDIEF^_)-.\KD9)"[G)(49.%
M' SP*O51_LZ3_H)7OYI_\31_9TG_ $$KW\T_^)HYGV"[[%ZBJ/\ 9TG_ $$K
MW\T_^)H_LZ3_ *"5[^:?_$T<S[!=]B]15'^SI/\ H)7OYI_\31_9TG_02O?S
M3_XFCF?8+OL7J*H_V=)_T$KW\T_^)H_LZ3_H)7OYI_\ $T<S[!=]B]15'^SI
M/^@E>_FG_P 31_9TG_02O?S3_P")HYGV"[[%ZFR(LL;1MG:P*G#$'!]QR*I_
MV=)_T$KW\T_^)H_LZ3_H)7OYI_\ $T<S[!=]B.'0K"WT^:RB6X6.?F63[5+Y
MSG &3+N\S. !G=GBIK?2[2UA@AMTDCC@D,JA9G&YB""7.?GSN).[/.#U --_
MLZ3_ *"5[^:?_$T?V=)_T$KW\T_^)HYGV"[[#-/T+3M+G::T@9'*[%W2NXC7
MCY4#$A%X'RK@<=*T:H_V=)_T$KW\T_\ B:/[.D_Z"5[^:?\ Q-',^P7?8O45
M1_LZ3_H)7OYI_P#$T?V=)_T$KW\T_P#B:.9]@N^Q>HJC_9TG_02O?S3_ .)H
M_LZ3_H)7OYI_\31S/L%WV#2O]3<?]?4W_H9HIFC(8[6=3(\F+F7YGQG[Q]**
M*?PH([$=E=P6'AH7MU(([>W@:65ST55R2?R%9=_XBUBTTB._DTF&V6:XM(XQ
M)/YC!99XHV$B@ *X$C8VLXRO)['4L[2#4/#(LKF,26]Q T4J'HRMD$?D:H7/
MAW4;[35L+S6(Y(8I[:6(K:;6(AFCD^<[SN8^61D;0-V<'%%/X$$=D3#Q=I2%
M4GG/FO)=)&D$,LI802".0X"9R"1GC'4@D#-61X@L/M4R?:83#%9Q7AD5F)*2
M,X4_=P0=AQ@DGT'&<_3_  E]AU.&\^W;_+.HG9Y6,_:YUFZY_AVX]\YXZ54M
M? <<%C%;27YD\K3-/LD80[</:2-(DN-W=BIV_P"SU.:L9J'Q9I:"-I4U*&.1
M2_F3Z7<QH@!(R[-& G0_>(XP>A%9D_BN[@\0R6+10?9TUE; L$8OY1L#<D\'
MEM_'3IQC/-1>(? ]UXITZ6#5=0T^:>6V:#S#II9(6.[;)$C2G8_S8)R2<#&V
MM!O"F[7CJ?VWKJJZEY?E>EG]FV9S_P "SCVQWH W(;ZVN)5CAE#LT*SC:#C8
MWW3GIS@X^AK*/C#0P9@+J5FA>5&5+65B6B8K(J@+\Q4@Y"Y..>G-2>'M*?38
M;DRJ5+S,D*G'[N!21&G'8#)'^]4.G^&OL#JWVOS-MS>S_P"KQ_Q\2F3'7^'.
M,]_:@"]-KNFP&TW7!9;H*8GCC9TPWW2S*"%!Z L0">!39=>L(-4_L^;[5'-N
M51(]G,L+,V-H$Q7RR3D# ;KQUKGX?A_;6XT.0#3+JZTVRMK%IK_3O/+)#G#1
M_./*<DL<Y;MP<"K&M>"DUC6H=1DN+?=%=VUU&TMH))8C$Z,4CD+#8C!.0!U8
MGGI0!;3QGHMQH]QJ5I=AX8K)KY6EBEC5X@N2P)3) XSM#$9QC/%65\3:4=0>
MP-R1=1RI!(!$^Q)'1752^W:,AUQD\YQUR*PV\ [M M=+_M/_ (]_#]QHGF>1
M][S5B'FXW<8\K[N><]1CF]-X2\UKX_;L?:M4L]1_U7W?($ V=>=WD=>V[H<<
M@%N3Q5I2:DVGAKR2X5)'(AL)Y%(C^_AU0J2#Q@'.XA>I JEX6\4KK6EZ?=7<
MJ1S:G ]Y:VXM9(RD*; P8L3N(+K\PVA@P*@CFJFB:;K5CXLNY);&+[%+/,PG
M9LE(W9G^0^:>2VS<OE1CU9RN6LV?A&33].T&"VU%1<Z38-8><]OD2QL(PQV[
MAM;,2D')QSP: +>E>(5U?7I(+5HY-.;2[2_MY0C*SB9IASGMMC4@8!Y.?:OK
M/BZ"V@==-W3W$5Y;V\CM;2F ;[F."0"7 0NN]OE#9!'(X-2>'/"W]@26[_;/
M/\G2+/3,>5MSY'F?/U/WO,Z=L=3FJU[X0NM0N[F6;5(8HY+F&98;:T*(?+N(
MY@9 9#ODQ'LWC;]XDJ>  #:_MS3_ +;+:>;)YL2DL?)?8<9)57QM9@ <J"2/
M2GG6+ /(OGDF.%)V(1B-CDA2#C!)VG@<]..1G.M?#0M]2BE-PC6=M=S7UM (
MB'2>7S/,9GW88?OI,#:,9ZG PVU\,?9Q;*;L,D$V=HBP#$"GEQ_>."OE1Y/?
M#<#=P /'B[2D*I/.?->2Z2-((992P@D$<AP$SD$C/&.I!(&:EU#Q5I&FQP//
M/-(LZH\?V6UEN,ASA"?+5L!CP,]3TJGI_A+[#J<-Y]NW^6=1.SRL9^USK-US
M_#MQ[YSQTK"F\-:UI$VB0:;;1:A%8:=;6GF2_*DDD.[:SKYJ[!G:0=LQ!/"C
M;E@#H?%OB;_A&+2PFV61^V78MO,OKS[+#%^[D?<TFQL?ZO &.K"J]SXLGLK7
MS;BTLF:WMA>W_D7Q=(;<LP5T8QCS"0C'!"C@\G'._J$=_+:E=.N;:WN"1\]S
M;M,F.XVJZ']:YW_A!XD@^S0W8%O<0&VOUEAWM<1F1Y"%.X;/FE?LP ;&.AH
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M]^6_^*HHHY%W"P;=5_Y[67_?EO\ XJC;JO\ SVLO^_+?_%444<B[A8-NJ_\
M/:R_[\M_\51MU7_GM9?]^6_^*HHHY%W"P;=5_P">UE_WY;_XJC;JO_/:R_[\
MM_\ %444<B[A8-NJ_P#/:R_[\M_\51MU7_GM9?\ ?EO_ (JBBCD7<+!MU7_G
MM9?]^6_^*HVZK_SVLO\ ORW_ ,5111R+N%@VZK_SVLO^_+?_ !5&W5?^>UE_
MWY;_ .*HHHY%W"P;=5_Y[67_ 'Y;_P"*HVZK_P ]K+_ORW_Q5%%'(NX6#;JO
M_/:R_P"_+?\ Q5&W5?\ GM9?]^6_^*HHHY%W"P;=5_Y[67_?EO\ XJC;JO\
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MO_BJ-NJ_\]K+_ORW_P 5111R+N%@VZK_ ,]K+_ORW_Q5&W5?^>UE_P!^6_\
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G+?\ Q5%%'(NX6':=;3VT$BW#QM(\KR9C! ^8Y[T44525E9#2L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>34
<FILENAME>tsha-20210331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-11T01:24:34.7875237+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 1f73c44147c0412f9cfba93145d27295 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:tsha="http://tayshagtx.com/20210331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="tsha-20210331.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_tshaProduct">
    <xbrli:measure>tsha:Product</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_tshaPromissoryNote">
    <xbrli:measure>tsha:PromissoryNote</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001806310_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20210511">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-05-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200916_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-16</xbrli:startDate>
      <xbrli:endDate>2020-09-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200928_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-28</xbrli:startDate>
      <xbrli:endDate>2020-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-28</xbrli:startDate>
      <xbrli:endDate>2020-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200928_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-28</xbrli:startDate>
      <xbrli:endDate>2020-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200928_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-28</xbrli:startDate>
      <xbrli:endDate>2020-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200928_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-28</xbrli:startDate>
      <xbrli:endDate>2020-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200301_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200701_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_tshaLaboratoryEquipmentMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsha:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:UTSouthwesternAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:UTSouthwesternAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:UTSouthwesternAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:QueensAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:QueensAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:QueensAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:QueensAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_srtRangeAxis_srtMaximumMember_20200221">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:QueensAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20200801_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaCLN1AgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20201001_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaCLN1AgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaCLN1AgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_srtRangeAxis_srtMaximumMember_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaCLN1AgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaCLN1AgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:AbeonaRettAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20201029">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:AbeonaRettAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:AbeonaTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:AbeonaRettAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapTypeOfArrangementAxis_tshaAcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_20210301_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-03-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapTypeOfArrangementAxis_tshaAcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20200728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200929_20200929">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-29</xbrli:startDate>
      <xbrli:endDate>2020-09-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAPurchaseAgreementMember_20200304_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesAPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-04</xbrli:startDate>
      <xbrli:endDate>2020-03-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAPurchaseAgreementMember_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesAPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAPurchaseAgreementInitialClosingMember_20200304_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesAPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-04</xbrli:startDate>
      <xbrli:endDate>2020-03-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAAchievementOfSpecificClinicalMilestoneOneMember_20200305_20200305">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesAAchievementOfSpecificClinicalMilestoneOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-05</xbrli:startDate>
      <xbrli:endDate>2020-03-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAAchievementOfSpecificClinicalMilestoneTwoMember_20200305_20200305">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesAAchievementOfSpecificClinicalMilestoneTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-05</xbrli:startDate>
      <xbrli:endDate>2020-03-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember_20200304_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-04</xbrli:startDate>
      <xbrli:endDate>2020-03-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-29</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200701_20200702">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaPBMTGTHoldingsLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:PBMTGTHoldingsLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-29</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaNolanCapitalLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:NolanCapitalLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-29</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200728_20200728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesBPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-28</xbrli:startDate>
      <xbrli:endDate>2020-07-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200728_20200728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesBPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-28</xbrli:startDate>
      <xbrli:endDate>2020-07-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200728">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesBPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200701_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:SeriesBPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-04</xbrli:startDate>
      <xbrli:endDate>2020-03-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200629_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-29</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapMeasurementInputTypeAxis_tshaMeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tsha:MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_20200304">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-16</xbrli:startDate>
      <xbrli:endDate>2020-09-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-16</xbrli:startDate>
      <xbrli:endDate>2020-09-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20210101_20210101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsha:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtTitleOfIndividualAxis_tshaCertainEmployeesAndConsultantsMember_us-gaapAwardTypeAxis_tshaCancelledOptionsMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsha:CancelledOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tsha:CertainEmployeesAndConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200902_20200902">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-02</xbrli:startDate>
      <xbrli:endDate>2020-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200902_20200902">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-02</xbrli:startDate>
      <xbrli:endDate>2020-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200902_20200902">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-02</xbrli:startDate>
      <xbrli:endDate>2020-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheThreeMember_20200902_20200902">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-02</xbrli:startDate>
      <xbrli:endDate>2020-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_tshaShareBasedCompensationAwardTrancheFourMember_20200902_20200902">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">tsha:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-02</xbrli:startDate>
      <xbrli:endDate>2020-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsha:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tsha:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200701_20200701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tshaSeriesAConvertiblePreferredStockMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tsha:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_20200101_20200131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tsha:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapLongtermDebtTypeAxis_tshaSecuredPromissoryNotesMember_20200131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tsha:SecuredPromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tsha:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapLongtermDebtTypeAxis_tshaSecuredPromissoryNotesMember_20200301_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tsha:SecuredPromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tsha:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapRelatedPartyTransactionAxis_tshaServicesAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_tshaPBMCapitalGroupLLCMember_20200301_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tsha:PBMCapitalGroupLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tsha:ServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapRelatedPartyTransactionAxis_tshaServicesAgreementMember_20200301_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">tsha:ServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_tshaPBMTGTHoldingsLLCMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tsha:PBMTGTHoldingsLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20201217">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:DurhamLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20201217_20201217">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:DurhamLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-17</xbrli:startDate>
      <xbrli:endDate>2020-12-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20210101_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:DurhamLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:DallasLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:PegasusParkLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111_20210111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsha:DallasLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsha:PegasusParkLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-11</xbrli:startDate>
      <xbrli:endDate>2021-01-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001806310_us-gaapLeaseContractualTermAxis_tshaDallasLeaseMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tsha:DallasLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001806310_20210101_20210331">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001806310_20210101_20210331">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001806310_20210101_20210331">2021-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001806310_20210101_20210331">2021</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001806310_20210101_20210331">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001806310_20210101_20210331">TSHA</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001806310_20210101_20210331">Taysha Gene Therapies, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001806310_20210101_20210331">0001806310</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001806310_20210101_20210331">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="F_000009" contextRef="C_0001806310_20210101_20210331">No</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="F_000010" contextRef="C_0001806310_20210101_20210331">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000011" contextRef="C_0001806310_20210101_20210331">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000012" contextRef="C_0001806310_20210101_20210331">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000013" contextRef="C_0001806310_20210101_20210331">false</dei:EntityExTransitionPeriod>
  <dei:EntityShellCompany id="F_000014" contextRef="C_0001806310_20210101_20210331">false</dei:EntityShellCompany>
  <dei:EntityFileNumber id="F_000015" contextRef="C_0001806310_20210101_20210331">001-39536</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000016" contextRef="C_0001806310_20210101_20210331">84-3199512</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000017" contextRef="C_0001806310_20210101_20210331">3000 Pegasus Park Drive</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000018" contextRef="C_0001806310_20210101_20210331">Ste 1430</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000019" contextRef="C_0001806310_20210101_20210331">Dallas</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000020" contextRef="C_0001806310_20210101_20210331">TX</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000021" contextRef="C_0001806310_20210101_20210331">75247</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000022" contextRef="C_0001806310_20210101_20210331">214</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000023" contextRef="C_0001806310_20210101_20210331">612-0000</dei:LocalPhoneNumber>
  <dei:EntityCommonStockSharesOutstanding id="F_000024" contextRef="C_0001806310_20210511" decimals="INF" unitRef="U_xbrlishares">37917473</dei:EntityCommonStockSharesOutstanding>
  <dei:Security12bTitle id="F_000025" contextRef="C_0001806310_20210101_20210331">Common stock, par value $0.00001 per share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000026" contextRef="C_0001806310_20210101_20210331">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityIncorporationStateCountryCode id="F_000027" contextRef="C_0001806310_20210101_20210331">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent id="F_000028" contextRef="C_0001806310_20210101_20210331">Yes</dei:EntityInteractiveDataCurrent>
  <dei:DocumentQuarterlyReport id="F_000029" contextRef="C_0001806310_20210101_20210331">true</dei:DocumentQuarterlyReport>
  <dei:DocumentTransitionReport id="F_000030" contextRef="C_0001806310_20210101_20210331">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000031" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">228684000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000032" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">251253000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000033" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">10817000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000034" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">6626000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:DeferredOfferingCosts id="F_000035" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">128000</us-gaap:DeferredOfferingCosts>
  <us-gaap:AssetsCurrent id="F_000036" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">239629000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000037" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">257879000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredCostsLeasingNetNoncurrent id="F_000038" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">703000</us-gaap:DeferredCostsLeasingNetNoncurrent>
  <us-gaap:DeferredCostsLeasingNetNoncurrent id="F_000039" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">715000</us-gaap:DeferredCostsLeasingNetNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000040" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">2497000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000041" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">287000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets id="F_000042" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">242829000</us-gaap:Assets>
  <us-gaap:Assets id="F_000043" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">258881000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000044" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">4083000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000045" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">1994000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000046" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">14875000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000047" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">5135000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LiabilitiesCurrent id="F_000048" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">18958000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000049" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">7129000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000050" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">999000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000051" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">450000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000052" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">19957000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000053" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">7579000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000054" xsi:nil="true" contextRef="C_0001806310_20210331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000055" xsi:nil="true" contextRef="C_0001806310_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000056" xsi:nil="true" contextRef="C_0001806310_20210331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000057" xsi:nil="true" contextRef="C_0001806310_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000058" xsi:nil="true" contextRef="C_0001806310_20210331" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000059" xsi:nil="true" contextRef="C_0001806310_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdditionalPaidInCapital id="F_000060" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">316022000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000061" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">312428000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000062" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">-93150000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000063" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">-61126000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000064" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">222872000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000065" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">251302000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000066" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">242829000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000067" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">258881000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000068" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000069" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000070" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000071" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000072" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000073" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000074" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000075" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000076" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000077" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000078" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000079" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000080" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_xbrlishares">37761435</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000081" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_xbrlishares">37761435</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000082" contextRef="C_0001806310_20210331" decimals="INF" unitRef="U_xbrlishares">37761435</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000083" contextRef="C_0001806310_20201231" decimals="INF" unitRef="U_xbrlishares">37761435</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000084" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">23854000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000085" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">5514000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000086" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">8236000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000087" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">70000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000088" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">32090000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000089" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">5584000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000090" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-32090000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000091" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-5584000</us-gaap:OperatingIncomeLoss>
  <tsha:ChangeInFairValueOfPreferredStockTrancheLiability id="F_000092" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">180000</tsha:ChangeInFairValueOfPreferredStockTrancheLiability>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="F_000093" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">66000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestExpense id="F_000094" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000095" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">66000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000096" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">153000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000097" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-32024000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000098" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-5431000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000099" contextRef="C_0001806310_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.87</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000100" contextRef="C_0001806310_20200101_20200331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000101" contextRef="C_0001806310_20210101_20210331" decimals="0" unitRef="U_xbrlishares">36992377</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000102" contextRef="C_0001806310_20200101_20200331" decimals="0" unitRef="U_xbrlishares">10894999</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:CommonStockSharesOutstanding id="F_000103" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">37761435</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000104" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">312428000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000105" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-61126000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000106" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3594000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000107" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3594000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000108" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-32024000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000109" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" unitRef="U_xbrlishares">37761435</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000110" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" unitRef="U_iso4217USD">316022000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000111" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" unitRef="U_iso4217USD">-93150000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesOutstanding id="F_000112" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">10894999</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000113" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">980000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000114" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-1115000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000115" contextRef="C_0001806310_20191231" decimals="-3" unitRef="U_iso4217USD">-135000</us-gaap:StockholdersEquity>
  <tsha:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000116" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200101_20200331" decimals="INF" unitRef="U_xbrlishares">6000000</tsha:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000117" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">16520000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss id="F_000118" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-5431000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000119" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200331" decimals="INF" unitRef="U_xbrlishares">6000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000120" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200331" decimals="-3" unitRef="U_iso4217USD">16520000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockSharesOutstanding id="F_000121" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" unitRef="U_xbrlishares">10894999</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000122" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" unitRef="U_iso4217USD">980000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000123" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" unitRef="U_iso4217USD">-6546000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000124" contextRef="C_0001806310_20200331" decimals="-3" unitRef="U_iso4217USD">-5566000</us-gaap:StockholdersEquity>
  <tsha:TemporaryEquityStockOfferingCosts id="F_000125" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">430000</tsha:TemporaryEquityStockOfferingCosts>
  <tsha:TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability id="F_000126" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">1050000</tsha:TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability>
  <us-gaap:ProfitLoss id="F_000127" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-32024000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000128" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-5431000</us-gaap:ProfitLoss>
  <us-gaap:Depreciation id="F_000129" contextRef="C_0001806310_20210101_20210331" decimals="0" unitRef="U_iso4217USD">32000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000130" contextRef="C_0001806310_20200101_20200331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:Depreciation>
  <us-gaap:ResearchAndDevelopmentInProcess id="F_000131" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">5500000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess id="F_000132" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">3000000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ShareBasedCompensation id="F_000133" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3594000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000134" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000135" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">4184000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000136" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000137" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">1872000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000138" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInAccountsPayable>
  <tsha:IncreaseDecreaseInAccruedExpenseAndOtherLiabilities id="F_000139" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3183000</tsha:IncreaseDecreaseInAccruedExpenseAndOtherLiabilities>
  <tsha:IncreaseDecreaseInAccruedExpenseAndOtherLiabilities id="F_000140" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">907000</tsha:IncreaseDecreaseInAccruedExpenseAndOtherLiabilities>
  <us-gaap:IncreaseDecreaseInDueToRelatedParties id="F_000141" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-8000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <us-gaap:IncreaseDecreaseInDueToRelatedParties id="F_000142" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000143" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-22035000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000144" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-1699000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000145" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">534000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000146" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000147" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-534000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000148" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000149" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">18000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromRelatedPartyDebt id="F_000150" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">1673000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:RepaymentsOfRelatedPartyDebt id="F_000151" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">1646000</us-gaap:RepaymentsOfRelatedPartyDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000152" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">18027000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000153" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-22569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000154" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">16328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000155" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">251253000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000156" contextRef="C_0001806310_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000157" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">228684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000158" contextRef="C_0001806310_20200331" decimals="-3" unitRef="U_iso4217USD">16328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <tsha:ResearchAndDevelopmentLicenseNotYetPaid id="F_000159" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">5500000</tsha:ResearchAndDevelopmentLicenseNotYetPaid>
  <tsha:ResearchAndDevelopmentLicenseNotYetPaid id="F_000160" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">3000000</tsha:ResearchAndDevelopmentLicenseNotYetPaid>
  <tsha:PropertyAndEquipmentInAccountsPayableAndAccruedExpenses id="F_000161" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">1101000</tsha:PropertyAndEquipmentInAccountsPayableAndAccruedExpenses>
  <tsha:PropertyAndEquipmentInAccountsPayableAndAccruedExpenses id="F_000162" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</tsha:PropertyAndEquipmentInAccountsPayableAndAccruedExpenses>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 id="F_000163" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">607000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 id="F_000164" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000165" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">128000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000166" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <tsha:AllocationOfPreferredStockTrancheLiability id="F_000167" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">1050000</tsha:AllocationOfPreferredStockTrancheLiability>
  <us-gaap:StockIssued1 id="F_000168" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">430000</us-gaap:StockIssued1>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000169" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"&gt;&lt;/a&gt;&lt;a name="NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"&gt;&lt;/a&gt;Note 1&amp;#8212;Organization and Description of Business Operations &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Taysha Gene Therapies, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Taysha&amp;#8221;) was originally formed under the laws of the State of Texas on September 20, 2019 (&amp;#8220;Inception&amp;#8221;). Taysha converted to a Delaware corporation on February 13, 2020, which had no impact to the Company&amp;#8217;s par value or issued and authorized capital structure. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Taysha is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Split &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 16, 2020, the Company effected a 1.0895-for-one stock split of its authorized, issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&amp;#8217;s convertible preferred stock as discussed in Note 5. Accordingly, all share and per share amounts for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the convertible preferred stock conversion ratios. On September 16, 2020, the Company also increased the number of shares of common stock authorized for issuance under the 2020 Equity Incentive Plan (the &amp;#8220;Existing Plan&amp;#8221;) to 3,845,294. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Initial Public Offering &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 23, 2020, the Company&amp;#8217;s registration statement on Form S-1 (File No. 333-248559) related to the initial public offering (&amp;#8220;IPO&amp;#8221;) of its common stock became effective and on September 28, 2020, the IPO closed. Pursuant to the IPO, the Company issued and sold 9,050,000 shares of common stock at a public offering price of $20.00 per share, which included 1,180,434 shares of common stock issued upon the exercise in full of the underwriters&amp;#8217; option to purchase additional shares. The Company received net proceeds of $165.9 million after &lt;font style="color:#000000;"&gt;deducting underwriting discounts and commissions and other offering costs of $2.5&amp;#160;million. The shares began trading on the Nasdaq Global Select Market on September 24, 2020.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 28, 2020, in connection with the closing of the IPO, 10,000,000 shares of Series A and 5,647,048 shares of Series B convertible preferred stock automatically converted into an aggregate of 17,047,378 shares of common stock with a conversion ratio of 1.0895 shares of common stock for each share of Series A and Series B convertible preferred stock. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the IPO, including the underwriters&amp;#8217; exercise in full of their option to purchase additional shares, and the conversions of the Series A and B convertible preferred stock, the Company&amp;#8217;s total number of outstanding shares increased by 26,097,378 immediately following the closing of the IPO.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the effectiveness of the Company&amp;#8217;s registration statement related to the IPO, the Company&amp;#8217;s 2020 Stock Incentive Plan (the &amp;#8220;New Plan&amp;#8221;) and 2020 Employee Stock Purchase Plan became effective. At that time, all shares reserved for issuance under the Existing Plan ceased to be available for issuance under such plan and became available for issuance under the New Plan.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Capital Resources &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2021, the Company had an accumulated deficit of $93.2 million. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the closing of the Company&amp;#8217;s IPO, between March and July 2020, the Company closed on the sale of an aggregate of 10,000,000 shares of Series A convertible preferred stock for gross proceeds of $30.0 million. Between July and August 2020, the Company closed on the sale of an aggregate of 5,647,048 shares of Series B convertible preferred stock for gross proceeds of $96.0 million. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future capital requirements will depend on many factors, including the timing and extent of spending on research and development and the market acceptance of the Company&amp;#8217;s products. The Company will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable to the Company.&lt;font style="color:#000000;"&gt; As of March 31, 2021, the Company had cash of&lt;/font&gt; $228.7 &lt;font style="color:#000000;"&gt;million which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the novel coronavirus (&amp;#8220;COVID-19&amp;#8221;) emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a global pandemic, resulting in federal, state and local governments and private entities implementing various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders, and advisories and quarantining people who may have been exposed to the virus. The Company has been actively monitoring COVID-19 and its impact globally. Management believes the financial results for the three months ended March 31, 2021 were not significantly impacted by COVID-19. In addition, management believes the remote working arrangements and travel restrictions imposed by various governmental jurisdictions have had limited impact on the Company&amp;#8217;s ability to maintain internal operations during the three months ended March 31, 2021. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&amp;#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000170" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 2&amp;#8212;Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") as determined by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X and are consistent in all material respects with those included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission ("SEC") on March 3, 2021 (the &amp;#8220;2020 Annual Report&amp;#8221;). In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The consolidated balance sheet as of December 31, 2020 is derived from audited financial statements, however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes in the Company&amp;#8217;s 2020 Annual Report.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying interim condensed consolidated financial statements include the accounts of Taysha and its inactive wholly owned U.S. subsidiaries that were incorporated during 2020. All intercompany transactions and balances have been eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company&amp;#8217;s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company&amp;#8217;s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company&amp;#8217;s critical and significant accounting estimates, including assessment of impairment of long-lived assets.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no changes in the Company&amp;#8217;s significant accounting policies as disclosed in Note 2 to the audited consolidated financial statements included in the 2020 Annual Report.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as amended, with guidance regarding the accounting for and disclosure of leases. This update requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheets. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will become effective for the Company for annual reporting periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The new standard requires the use of one of the following two approaches, either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company has not yet concluded which approach will be utilized to adopt the new standard and is currently evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="F_000171" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 3&amp;#8212;Balance Sheet Components &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,462&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid bonus&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;409&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical trial&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;944&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;331&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment consisted of the following (in thousands):&lt;font style="margin-left:36pt;"&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,889&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense was $32,000 for the three months ended March 31, 2021. There was no depreciation expense for the three months ended March 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued license fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,766&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and consulting fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000172" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 4&amp;#8212;Research, Collaboration and License Agreements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;UT Southwestern Agreement &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 19, 2019, the Company entered into a research, collaboration and license agreement (&amp;#8220;UT Southwestern Agreement&amp;#8221;) with the Board of Regents of the University of Texas System on behalf of The University of Texas Southwestern Medical Center (&amp;#8220;UT Southwestern&amp;#8221;). Under the UT Southwestern Agreement, UT Southwestern is primarily responsible for preclinical development activities with respect to licensed products for use in certain specified indications (up to investigational new drug application-enabling studies), and the Company is responsible for all subsequent clinical development and commercialization activities with respect to the licensed products. UT Southwestern will conduct such preclinical activities for a two-year period under mutually agreed upon sponsored research agreements that were entered into beginning in April 2020. During the initial research phase, the Company has the right to expand the scope of specified indications under the UT Southwestern Agreement. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the UT Southwestern Agreement, the Company obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern and a non-exclusive, worldwide, royalty-free license under certain know-how of UT Southwestern, in each case to make, have made, use, sell, offer for sale and import licensed products for use in certain specified indications. Additionally, the Company obtained a non-exclusive, worldwide, royalty-free license under certain patents and know-how of UT Southwestern for use in all human uses, with a right of first refusal to obtain an exclusive license under certain of such patent rights and an option to negotiate an exclusive license under other of such patent rights. The Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 2, 2020, the Company amended the UT Southwestern Agreement to include the addition of another licensed product and certain indications, and a right of first refusal to the Company over certain patient dosing patents. No additional consideration was transferred in connection with this amendment. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The UT Southwestern Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last valid claim of a licensed patent in such country for such licensed product. After the initial research term, the Company may terminate the agreement, on an indication-by-indication and licensed product-by-licensed product basis, at any time upon specified written notice to UT Southwestern. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2019, as partial consideration for the license rights granted under the UT Southwestern Agreement, the Company issued 2,179,000 shares of its common stock, or 20% of its then outstanding fully-diluted common stock, to UT Southwestern. As additional consideration, UT Southwestern was entitled to receive additional shares if their holdings fell below 10% on a fully-diluted basis before or as a result of the completion of a qualified financing. In March 2020, following the initial closing of the Series A convertible preferred stock agreement, which met the definition of such qualified financing, the anti-dilution feature expired and no additional shares were issued. The Company does not have any future milestone or royalty obligations to UT Southwestern under the UT Southwestern Agreement other than costs related to maintenance of patents. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Queen&amp;#8217;s Agreement &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In late December 2019, the Company entered into a research grant agreement (&amp;#8220;RGA&amp;#8221;) with Queen&amp;#8217;s University at Kingston (&amp;#8220;Queen&amp;#8217;s&amp;#8221;), for certain research and development activities related to the generation of AAV9 vector. The Company committed to fund $3.8 million under the RGA with Queen&amp;#8217;s. The Company issued Queen&amp;#8217;s a promise-to-pay note whereby any amounts paid directly by Queen&amp;#8217;s for the manufacture of the vector for use in the funded research activities, to the extent such amounts had not already been funded by the Company to Queen&amp;#8217;s, would become a loan obligation for the Company (the &amp;#8220;Note&amp;#8221;), subject to an interest rate of 6%. Any amounts outstanding under the Note were required to be repaid, along with any accrued interest, by or before June 30, 2020. In the event of default, any amount outstanding was deemed immediately payable by RA Session II, the Company&amp;#8217;s President and Chief Executive Officer, as a personal guarantor (see Note 8). For the period from Inception through December 31, 2019, the Company did not incur any expenses associated with the Queen&amp;#8217;s RGA, and no amounts were due or outstanding under the Note as of December 31, 2019. &lt;font style="color:#000000;"&gt;For the year ended December 31, 2020, the Company paid all expenses associated with the Queen&amp;#8217;s RGA, thus no amounts were due or outstanding under the Note as of December 31, 2020, and the promise-to-pay has therefore expired.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 21, 2020, the Company entered into a license agreement with Queen&amp;#8217;s (the &amp;#8220;Queen&amp;#8217;s Agreement&amp;#8221;) to obtain the exclusive perpetual, royalty-bearing license, with the right to sublicense through multiple tiers, under certain patent rights and know-how of Queen&amp;#8217;s, including certain improvements to such patent rights and know-how, to develop products in any field which use one or more valid claims of the patents licensed under the Queen&amp;#8217;s Agreement (the &amp;#8220;Licensed Patents&amp;#8221;), or the technology, information and intellectual property related to the patents licensed under the Queen&amp;#8217;s Agreement (together with the Licensed Patents, the &amp;#8220;Licensed Products&amp;#8221;), and to make, have made, use, sell, offer for sale, import and export Licensed Products and otherwise exploit such patents and know-how for use in certain specified indications. In exchange for the rights granted to the Company, the Company made a cash payment of $3.0 million in April 2020 which is recorded in research and development expenses in the condensed consolidated statements of operations for the three months ended March 31, 2020. The Company is obligated to make aggregate cash payments of up to $10.0 million upon the completion of a combination of regulatory milestones and up to $10.0 million upon the completion of a combination of commercial milestones. In further consideration of the rights granted, beginning with the Company&amp;#8217;s first commercial sale of the Licensed Products, the Company will also pay an annual earned royalty in the low single digits on net sales of Licensed Products, subject to certain customary reductions, and a percentage of non-royalty sublicensing revenue ranging in the low double digits. Royalties are payable, on a Licensed Products-by-Licensed Products and a country-by-country basis, until expiration of the last valid claim of a Licensed Patent covering such Licensed Products in such country and the expiration of any regulatory exclusivity for such Licensed Products in such country. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Abeona CLN1 Agreements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company entered into license and inventory purchase agreements with Abeona Therapeutics Inc. (&amp;#8220;Abeona&amp;#8221;) for worldwide exclusive rights to certain intellectual property rights and know-how relating to the research, development and manufacture of ABO-202, an AAV-based gene therapy for CLN1 disease (also known as infantile Batten disease). Under the terms of the agreements, the Company made initial cash payments to Abeona of $3.0 million for the license fee and $4.0 million for purchase of clinical materials and reimbursement for previously incurred development costs in October 2020. In exchange for the license rights, the Company recorded an aggregate of $7.0 million within research and development expenses in the consolidated statements of operations for the year ended December 31, 2020 since the acquired license or acquired inventory do not have an alternative future use. The Company is obligated to make up to $26.0 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed CLN1 product. The Company will also pay an annual earned royalty in the high single digits on net sales of any licensed CLN1 products. The license agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. The Company may terminate the license agreement for convenience upon specified prior written notice to Abeona.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No additional milestone payments were made in connection with this agreement during the three months ended March 31, 2021.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Abeona Rett Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 29, 2020, the Company entered into a license agreement (the &amp;#8220;Abeona Rett Agreement&amp;#8221;) with Abeona pursuant to which the Company obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to certain obligations of Abeona, the Company is required to use commercially reasonable efforts to develop at least one licensed product and commercialize at least one licensed product in the United States.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Abeona Rett Agreement, the Company paid Abeona a one-time upfront license fee of $3.0 million which is recorded in research and development expenses in the consolidated statements of operations for the year ended December 31, 2020 since the acquired license does not have an alternative future use. The Company is obligated to pay Abeona up to $26.5 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed Rett product and high single-digit royalties on net sales of licensed Rett products. Royalties are payable on a licensed product-by-licensed product and country-by-country basis until the latest of the expiration or revocation or complete rejection of the last licensed patent covering such licensed product in the country where the licensed product is sold, the loss of market exclusivity in such country where the product is sold, or, if no licensed product exists in such country and no market exclusivity exists in such country, ten years from first commercial sale of such licensed product in such country.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Abeona Rett Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. The Company may terminate the agreement for convenience upon specified prior written notice to Abeona.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No additional milestone payments were made in connection with the Abeona Rett Agreement during the three months ended March 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Acquisition of Worldwide Rights for TSHA-120 for the treatment of GAN &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, the Company acquired the exclusive worldwide rights to a clinical-stage AAV9 gene therapy program, now known as TSHA-120, for the treatment of Giant Axonal Neuropathy (&amp;#8220;GAN&amp;#8221;). TSHA-120 is an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health in close collaboration with a leading patient advocacy group focused on finding treatments and cures for GAN. TSHA-120 has received rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration for the treatment of GAN. The worldwide rights was acquired through a license agreement, effective March 29, 2021, between Hannah&amp;#8217;s Hope Fund for Giant Axonal Neuropathy, Inc. (&amp;#8220;HHF&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the agreement, in exchange for granting the Company the exclusive worldwide rights to TSHA-120, HHF will receive an upfront payment of $5.5 million and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3 million, as well as a low, single-digit royalty on net sales upon commercialization of the product. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In exchange for the license rights, the Company recorded an aggregate of $5.5 million within research and development expenses in the condensed consolidated statements of operations since the acquired license does not have an alternative future use. This license fee was not paid as of March 31, 2021 and has been recorded in accrued expenses and other current liabilities.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000173" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 5&amp;#8212;Stockholders&amp;#8217; Equity (Deficit), Convertible Preferred Stock and Tranche Liability &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized Shares&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company amended its certificate of incorporation on March 4, 2020, July 2, 2020 and again on July 28, 2020 such that the total number of shares of common stock authorized to be issued was increased to 32,685,000, and the total number of shares of preferred stock authorized to be issued was increased to 15,647,052, of which 10,000,000 preferred shares were designated Series A convertible preferred stock and 5,647,052 were designated Series B convertible preferred stock. On September 28, 2020, the Company amended its certificate of incorporation such that the total number of shares of common stock authorized to be issued was increased to 200,000,000, and the total number of shares of new preferred stock authorized to be issued was 10,000,000. As of March 31, 2021 and December 31, 2020, no shares of preferred stock were issued or outstanding.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;IPO&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 28, 2020, the Company issued an aggregate of 7,869,566 shares of common stock in the IPO, and on September 29, 2020, the Company issued an aggregate of 1,180,434 shares of common stock upon the underwriters&amp;#8217; exercise in full of their option to purchase additional shares, each at the public offering price of $20.00 per share less underwriting discounts and commissions. In connection with the IPO, the Company received gross proceeds of $181.0 million, which was offset by issuance costs, including underwriters&amp;#8217; discounts and commissions, of approximately $15.1 million.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A and B convertible preferred stock&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 4, 2020, the Company entered into a purchase agreement (the &amp;#8220;Series A Purchase Agreement&amp;#8221;) providing for a private placement of up to 10,000,000 shares of Series A convertible preferred stock at an original issuance price of $3.00 per share, subject to separate closings, including: (1) 6,000,000 shares at the initial closing on March 4, 2020, and (2) 2,000,000 shares at each of two subsequent closings triggered by the achievement of specific clinical milestones. The Series A Purchase Agreement obligated the Company to issue and sell and the Series A investors to purchase up to a total of 4,000,000 additional shares of Series A convertible preferred stock (the &amp;#8220;Milestone Shares&amp;#8221;) at the same price per share upon the achievement of certain defined clinical milestones (the &amp;#8220;tranche liability&amp;#8221;). The determination as to whether the milestone events had been met was subject to certification by the Board of Directors. Each Series A investor had the right, but not the obligation, to purchase all or any portion of the Milestone Shares at any time in its sole option and in its sole and absolute discretion, whether or not the Company had achieved the applicable clinical milestone.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 30, 2020, several affiliated Series A investors elected to exercise in full their options to purchase 200,000 shares, representing all of their remaining pro-rata portion of the Milestone Shares, prior to the Company&amp;#8217;s achievement of the clinical milestones for gross proceeds of $0.6 million. The remainder of the Series A investors exercised in full their options to purchase 3,800,000 shares, representing all of their remaining pro-rata portion of the Milestone Shares, prior to the Company&amp;#8217;s achievement of the clinical milestones, for gross proceeds of $11.4 million between July 1, 2020 and July 2, 2020. As part of this issuance, the Company issued and sold 3,266,667 shares to PBM TGT Holdings, LLC and 400,000 shares to Nolan Capital, LLC, which stockholders are controlled by certain members of the Company&amp;#8217;s board of directors.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 2, 2020, the Company entered into a purchase agreement (the &amp;#8220;Series B Purchase Agreement&amp;#8221;), as later amended on July 28, 2020, providing for a private placement of up to 5,647,052 shares of Series B convertible preferred stock. The Company sold 5,647,048 shares of Series B convertible preferred stock at a price of $17.00 per share in multiple closings in July and August 2020 for gross proceeds of $96.0 million. The majority of investors that participated in the Series B Purchase Agreement were new investors.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As described above, in connection with the closing of the IPO, all shares of Series A and Series B convertible preferred stock were automatically converted into an aggregate of 17,047,378 shares of common stock with a conversion ratio, which was adjusted for the stock split, of 1.0895 shares of common stock for each share of Series A and Series B convertible preferred stock then outstanding.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock tranche liability&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company concluded that the tranche liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable from the initial closing of the Series A convertible preferred stock. The estimated fair value of the tranche liability was determined using a Monte Carlo simulation at the initial issuance date. As of March 4, 2020, the simulations occurred based on the implied aggregate equity value of the Company derived from the Series A convertible preferred stock offering price of $3.00 per share, along with, in part, the following subjective assumptions: risk-free rate of 0.59%, an expected volatility of 80%, the expected term to a liquidity event of 1 year, and a 60% probability of achieving the clinical milestones and timing thereof. Subsequently, the estimated fair value of the tranche liability was determined using a backsolve approach at June 30, 2020, immediately prior to the issuance of the Milestone Shares, which was calculated based on the aggregate equity value of the Company derived from the Series B convertible preferred stock offering price of $17.00 per share. The subsequent remeasurement also considered, in part, a risk-free rate of 0.17%, an expected volatility of 80%, and the expected term to a liquidity event of 0.5 years.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the analysis, the Company recorded a preferred stock tranche liability of $1.1 million at the issue date to account for the obligation to issue the Milestone Shares at a predetermined fixed price at a future settlement date. The Company remeasured the tranche liability at March 31, 2020, resulting in a gain of $0.2 million that was recorded in other income, net in the condensed consolidated statements of operations. The tranche liability was again later remeasured to fair value and reclassified to convertible preferred stock when the remaining Milestone Shares were sold to the investors.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000174" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 6&amp;#8212;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 1, 2020, the Company&amp;#8217;s board of directors approved the Existing Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, RSAs, RSUs and other stock-based awards to employees, directors, officers and consultants. On July 1, 2020, 3,529,412 shares of common stock were authorized for issuance under the Existing Plan. On September 16, 2020, the Company increased the number of shares of common stock authorized for issuance under the Existing Plan to 3,845,294. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 16, 2020, the Company&amp;#8217;s stockholders approved the New Plan, which became effective upon the execution of the underwriting agreement in connection with the IPO. The number of shares available for future issuance under the New Plan is the sum of (1) 3,390,168 new shares of common stock,&amp;nbsp;&amp;nbsp;(2) 209,841 remaining shares of common stock reserved under the Existing Plan that became available for issuance upon the effectiveness of the New Plan and (3) the number of shares of common stock subject to outstanding awards under the Existing Plan when the New Plan became effective that thereafter expire or are forfeited, canceled, withheld to satisfy tax withholding or to purchase or exercise an award, repurchased by the Company or are otherwise terminated. At December 31, 2020, there were 2,941,509 shares available for future grant under the New Plan. The number of shares of common stock reserved for issuance under the New Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2021 continuing through January 1, 2030, by 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&amp;#8217;s board of directors.&amp;nbsp;&amp;nbsp;On January 1, 2021 the board of directors increased the number of common stock reserved for issuance under the New Plan by 1,434,934 shares.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furthermore, on September 16, 2020, the Company&amp;#8217;s stockholders approved the Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;), which became effective upon the execution of the underwriting agreement in connection with the IPO. The maximum number of shares of common stock that may be issued under the ESPP will not exceed 362,000 shares of common stock, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the IPO Date and ending on (and including) January 1, 2030, in an amount equal to the lesser of (i) one percent (1.0%) of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year, and (ii) 724,000 shares of common stock. No shares have been added to the ESPP as of January 1, 2021 and no issuances have been made under the ESPP as of March 31, 2021.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Options &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 1, 2020, options to purchase 2,896,782 shares of common stock under the Existing Plan were awarded to certain employees and consultants of the Company with an exercise price per share of $0.80, which were expected to vest over a four-year period, all of which were subsequently cancelled (the &amp;#8220;Cancelled Options&amp;#8221;). The grant date fair value of the Cancelled Options was $13.8 million at the original grant date. In exchange, the Company awarded 2,518,932 RSUs on September 2, 2020, which are expected to vest over a four-year term. The Company accounted for the changes in award terms as a modification in accordance with ASC 718 Compensation &amp;#8211; Stock Compensation. The modification was accounted for as an exchange of the original award for a new award with total compensation cost equal to the grant-date fair value of the original award plus any incremental value measured on the modification date. The Company determined that there was no incremental value as the fair value of the original award immediately before the modification was greater than the fair value of the new award immediately after the modification. Accordingly, the Company continues to recognize the remaining compensation cost of the Cancelled Options over the vesting period of the RSUs.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended March 31, 2021, 1,621,900 shares of common stock under the New Plan were awarded with a weighted-average grant date fair value per share of $18.75. The stock options vest over four years and have a ten-year contractual term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The following weighted-average assumptions were used to estimate the fair value of stock options that were granted during the three months ended March&amp;#160;31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity, during the three months ended March&amp;#160;31, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674,842&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,621,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options cancelled or forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,286,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;213&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,286,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;213&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value in the above table is calculated as the difference between the fair value of the Company&amp;#8217;s common stock as of March&amp;#160;31, 2021 and the exercise price of the stock options. As of March&amp;#160;31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $37.0&amp;#160;million, which the Company expects to recognize over a weighted-average period of approximately 3.7 years.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 2, 2020, the Company issued 331,121 RSUs to an employee under the Existing Plan; 25% of the shares of common stock underlying the RSUs vest at each anniversary over a four-year period. The RSUs are subject to a service-based vesting condition. The RSUs were also subject to a liquidity-based performance vesting condition that was met upon the closing of the IPO. The Company at any time may accelerate the vesting of the RSUs. Such shares are not accounted for as outstanding until they vest.&lt;font style="color:#000000;"&gt; As of March 31, 2021, the total unrecognized compensation related to unvested RSUs granted, including the remaining compensation cost associated with the RSUs granted on September 2, 2020 in exchange for the Cancelled Options, was $15.4 million which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 1.7 years.&lt;/font&gt; The Company&amp;#8217;s RSU activity for the three months ended March&amp;#160;31, 2021 was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,850,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted units granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,850,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Stock Awards&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RA Session II, the Company&amp;#8217;s President and Chief Executive Officer, was awarded 769,058 RSAs under the Existing Plan on July 1, 2020, which are expected to vest over a three-year term, subject to continuous employment. As of March 31, 2021, the total unrecognized compensation related to unvested RSAs granted was $3.0 million which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 2.0 years. The fair value of these RSAs at the grant date of July 1, 2020 was $5.28 per share. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s RSA activity for the three months ended March&amp;#160;31, 2021 was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;769,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;769,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the total stock-based compensation expense for the stock options, RSAs and RSUs recorded in the condensed consolidated statements of operations for the three months ended March&amp;#160;31, 2021 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended March&amp;#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,579&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,594&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000175" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 7&amp;#8212;Net Loss Per Common Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Since the Company had a net loss in all periods presented, basic and diluted net loss per common share are the same. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table represents the calculation of basic and diluted net loss per common share (in thousands, except share and per share data):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,431&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock outstanding used to compute net loss per&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; common share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,992,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,894,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following common stock equivalents outstanding as of March 31, 2021 and 2020 were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti&amp;#8209;dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,850,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested RSAs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;769,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,286,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,905,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000176" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 8&amp;#8212;Related Party Transactions &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RA Session II, President and Chief Executive Officer and a member of the Company&amp;#8217;s board of directors, was a guarantor under the Guaranty and Security Agreement between himself, Queen&amp;#8217;s and the Company, and in the event of the Company&amp;#8217;s failure to fund its obligations under the RGA with Queen&amp;#8217;s, had personally guaranteed payments due by the Company to Queen&amp;#8217;s. In addition, the Company entered into two secured promissory notes with Mr. Session in January 2020 for an aggregate of $1.67 million, with 10% interest. The Company secured the notes with a first priority security interest in certain assets of the Company. During March 2020, the Company repaid $1.65&amp;#160;million of the notes, and the remaining balance was repaid in July 2020.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the Company entered into a services agreement with PBM Capital Group, LLC (&amp;#8220;PBM&amp;#8221;), an affiliate of PBM TGT Holdings, LLC whereby PBM provides accounting and other administrative and management services related to payroll administration, human resources, bookkeeping, preparation of financial statements and tax returns, accounts payable and receivable, and other similar functions for a fee of $2,500 per month. Paul B. Manning, a member of the Company&amp;#8217;s board of directors and a holder of more than 5% of the Company&amp;#8217;s capital stock, is the Chief Executive Officer of PBM Capital Group, LLC and has sole voting and investment power with respect to the shares held by PBM TGT Holdings, LLC. In September 2020, PBM TGT Holdings, LLC distributed all of the shares of Series A convertible preferred stock it previously held to its beneficial owners, including Mr. Manning and entities controlled by Mr. Manning, for no additional consideration in accordance with the terms of its operating agreement. As of March 31, 2021, and December 31, 2020, the Company had recorded an immaterial amount due to PBM in the consolidated balance sheets.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000177" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 9&amp;#8212;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. There is no provision for income taxes because the Company has incurred operating losses and capitalized certain items for income tax purposes since its inception and maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the period differs from the amount that would result from applying the federal statutory tax rate to net loss before taxes primarily because of the change in valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, there were no material changes to either the nature or the amounts of the uncertain tax positions previously determined for the year ended December 31, 2020.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000178" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 10&amp;#8212;Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Litigation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Commitments &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. The Company&amp;#8217;s maximum exposure under these arrangements is unknown at March 31, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Durham Lease&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 17, 2020, the Company entered into a lease agreement (the &amp;#8220;Durham Lease&amp;#8221;) with Patriot Park Partners II, LLC, a Delaware limited liability company (the &amp;#8220;Durham Landlord&amp;#8221;), pursuant to which the Company agreed to lease approximately 187,500 square feet of a manufacturing facility located at 5 National Way, Durham, North Carolina (the &amp;#8220;Facility&amp;#8221;). The Durham Lease commenced on April 1, 2021 and is expected to have a term of approximately fifteen years and six months. The Company has two options to extend the term of the Durham Lease, each for a period of an additional five years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company was not required to provide a security deposit in connection with its entry into the Durham Lease. The Company will be responsible for constructing interior improvements within the Facility. The Durham Landlord has the right to terminate the Durham Lease upon specified events of default, including the Company&amp;#8217;s failure to pay rent in a timely manner and upon the occurrence of certain events of insolvency with respect to the Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may terminate the Durham Lease if construction of the base building shell of the Facility is not complete by May 16, 2021. The Company incurred initial direct costs to enter into the Durham Lease of approximately $0.8 million. The costs have been recorded on the consolidated balance sheets as a deferred lease asset and will be amortized into earnings over the term of the Durham Lease.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dallas Lease&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 11, 2021, the Company entered into a lease agreement (the &amp;#8220;Dallas Lease&amp;#8221;) with Pegasus Park, LLC, a Delaware limited liability company (the &amp;#8220;Dallas Landlord&amp;#8221;), pursuant to which the Company will lease approximately 15,000 square feet of office space at 3000 Pegasus Park Drive, Dallas, Texas 75247 (the &amp;#8220;Office Space&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Lease commences on the date on which certain improvements to the Office Space have been made and the Office Space is tendered to the Company for possession, which the Company and the Dallas Landlord presently anticipate to be delivered on or about May 15, 2021, and will have a term of approximately ten years. The Company has an option to extend the term of the Lease for one additional period of five years. The Company&amp;#8217;s obligation for the payment of base rent for the Office Space will initially be approximately $32,500 per month and will increase annually, up to an estimated monthly base rent of $50,000 during the term of the Lease. The Company is obligated to pay operating costs and utilities applicable to the Office Space. The Company was required to provide a security deposit of $32,500 in connection with its entry into the Lease. &lt;font style="color:#000000;"&gt;Total future minimum lease payments under the Dallas Lease over the initial 10 year term are approximately $4.9 million. &lt;/font&gt;The Company will be responsible for costs of constructing interior improvements within the Office Space that exceed a construction allowance provided by the Dallas Landlord not to exceed $40.00 per rentable square foot.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a right of first refusal with respect to certain additional adjacent office space before the Dallas Landlord accepts any offer for such space.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Landlord has the right to terminate the Lease, or the Company&amp;#8217;s right to possess the Office Space without terminating the Lease, upon specified events of default, including the Company&amp;#8217;s failure to pay rent in a timely manner and upon the occurrence of certain events of insolvency with respect to the Company. The Company may terminate the Lease if the Office Space is not delivered will all improvements to be made by the Landlord pursuant to the Lease substantially completed by May 31, 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, the Company recognized approximately $0.6 million of lease construction incentive based on the construction allowance provided. The construction incentive has been recorded on the consolidated balance sheets as a deferred lease incentive obligation and will be amortized into earnings as a deduction of rent expense over the term of the Dallas Lease.&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000179" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") as determined by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X and are consistent in all material respects with those included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission ("SEC") on March 3, 2021 (the &amp;#8220;2020 Annual Report&amp;#8221;). In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The consolidated balance sheet as of December 31, 2020 is derived from audited financial statements, however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes in the Company&amp;#8217;s 2020 Annual Report.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000180" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying interim condensed consolidated financial statements include the accounts of Taysha and its inactive wholly owned U.S. subsidiaries that were incorporated during 2020. All intercompany transactions and balances have been eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000181" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company&amp;#8217;s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company&amp;#8217;s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company&amp;#8217;s critical and significant accounting estimates, including assessment of impairment of long-lived assets.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000182" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as amended, with guidance regarding the accounting for and disclosure of leases. This update requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheets. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will become effective for the Company for annual reporting periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The new standard requires the use of one of the following two approaches, either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company has not yet concluded which approach will be utilized to adopt the new standard and is currently evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock id="F_000183" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,462&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid bonus&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;409&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical trial&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;944&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;331&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000184" contextRef="C_0001806310_20210101_20210331">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,889&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;296&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <tsha:ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock id="F_000185" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued license fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,766&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and consulting fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</tsha:ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000186" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">The following weighted-average assumptions were used to estimate the fair value of stock options that were granted during the three months ended March&amp;#160;31, 2021:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock id="F_000187" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity, during the three months ended March&amp;#160;31, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674,842&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,953&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,621,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options cancelled or forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,286,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;213&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,286,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;213&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,552&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock id="F_000188" contextRef="C_0001806310_20210101_20210331">The Company&amp;#8217;s RSU activity for the three months ended March&amp;#160;31, 2021 was as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,850,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted units granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,850,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock id="F_000189" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s RSA activity for the three months ended March&amp;#160;31, 2021 was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;769,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;769,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000190" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the total stock-based compensation expense for the stock options, RSAs and RSUs recorded in the condensed consolidated statements of operations for the three months ended March&amp;#160;31, 2021 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended March&amp;#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,579&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,594&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000191" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table represents the calculation of basic and diluted net loss per common share (in thousands, except share and per share data):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended March&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,431&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock outstanding used to compute net loss per&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; common share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,992,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,894,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000192" contextRef="C_0001806310_20210101_20210331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following common stock equivalents outstanding as of March 31, 2021 and 2020 were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti&amp;#8209;dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.16%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,850,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested RSAs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;769,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,286,142&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,905,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000193" contextRef="C_0001806310_20210101_20210331">2020-02-13</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000194" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200916_20200916" decimals="4" unitRef="U_xbrlipure">1.0895</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000195" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200916" decimals="INF" unitRef="U_xbrlishares">3845294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000196" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">9050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000197" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20210331" decimals="INF" unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000198" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200928_20200928" decimals="INF" unitRef="U_xbrlishares">1180434</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000199" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928" decimals="-5" unitRef="U_iso4217USD">165900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsForUnderwritingExpense id="F_000200" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928" decimals="-5" unitRef="U_iso4217USD">2500000</us-gaap:PaymentsForUnderwritingExpense>
  <tsha:TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock id="F_000201" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200928_20200928" decimals="INF" unitRef="U_xbrlishares">10000000</tsha:TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock>
  <tsha:TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock id="F_000202" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200928_20200928" decimals="INF" unitRef="U_xbrlishares">5647048</tsha:TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000203" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200928_20200928" decimals="INF" unitRef="U_xbrlishares">17047378</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000204" contextRef="C_0001806310_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200928_20200928" decimals="4" unitRef="U_xbrlipure">1.0895</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <tsha:CommonStockIncreaseInOutstandingShares id="F_000205" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928" decimals="INF" unitRef="U_xbrlishares">26097378</tsha:CommonStockIncreaseInOutstandingShares>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000206" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200301_20200731" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000207" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200701_20200831" decimals="INF" unitRef="U_xbrlishares">5647048</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000208" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200301_20200731" decimals="-5" unitRef="U_iso4217USD">30000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000209" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200701_20200831" decimals="-5" unitRef="U_iso4217USD">96000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:Cash id="F_000210" contextRef="C_0001806310_20210331" decimals="-5" unitRef="U_iso4217USD">228700000</us-gaap:Cash>
  <tsha:PrepaidResearchAndDevelopmentContracts id="F_000211" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">6281000</tsha:PrepaidResearchAndDevelopmentContracts>
  <tsha:PrepaidResearchAndDevelopmentContracts id="F_000212" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">2462000</tsha:PrepaidResearchAndDevelopmentContracts>
  <us-gaap:PrepaidInsurance id="F_000213" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">1654000</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance id="F_000214" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">2480000</us-gaap:PrepaidInsurance>
  <tsha:PrepaidBonus id="F_000215" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">1115000</tsha:PrepaidBonus>
  <tsha:PrepaidBonus id="F_000216" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">409000</tsha:PrepaidBonus>
  <tsha:PrepaidClinicalTrial id="F_000217" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">928000</tsha:PrepaidClinicalTrial>
  <tsha:PrepaidClinicalTrial id="F_000218" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">944000</tsha:PrepaidClinicalTrial>
  <us-gaap:OtherAssetsCurrent id="F_000219" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">839000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000220" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">331000</us-gaap:OtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000221" contextRef="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210331" decimals="-3" unitRef="U_iso4217USD">242000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000222" contextRef="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">95000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000223" contextRef="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_tshaLaboratoryEquipmentMember_20210331" decimals="-3" unitRef="U_iso4217USD">407000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000224" contextRef="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210331" decimals="-3" unitRef="U_iso4217USD">1889000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000225" contextRef="C_0001806310_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" unitRef="U_iso4217USD">201000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000226" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">2538000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000227" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">296000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000228" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">41000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000229" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <tsha:AccruedResearchAndDevelopmentCurrent id="F_000230" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">5672000</tsha:AccruedResearchAndDevelopmentCurrent>
  <tsha:AccruedResearchAndDevelopmentCurrent id="F_000231" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">2106000</tsha:AccruedResearchAndDevelopmentCurrent>
  <tsha:AccruedLicenseFeesCurrent id="F_000232" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">5500000</tsha:AccruedLicenseFeesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000233" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">1427000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000234" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">1766000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000235" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">1119000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000236" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">999000</us-gaap:AccruedProfessionalFeesCurrent>
  <tsha:AccruedConstructionInProgressCurrent id="F_000237" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">1029000</tsha:AccruedConstructionInProgressCurrent>
  <tsha:AccruedConstructionInProgressCurrent id="F_000238" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">173000</tsha:AccruedConstructionInProgressCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000239" contextRef="C_0001806310_20210331" decimals="-3" unitRef="U_iso4217USD">128000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000240" contextRef="C_0001806310_20201231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <tsha:PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements id="F_000241" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20200401_20200430">P2Y</tsha:PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements>
  <tsha:MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize id="F_000242" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20200401_20200430" decimals="INF" unitRef="U_tshaProduct">1</tsha:MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize>
  <us-gaap:CommonStockSharesIssued id="F_000243" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20191130" decimals="INF" unitRef="U_xbrlishares">2179000</us-gaap:CommonStockSharesIssued>
  <tsha:PercentageOfFullyDilutedCommonStockSharesOutstanding id="F_000244" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20191130" decimals="2" unitRef="U_xbrlipure">0.20</tsha:PercentageOfFullyDilutedCommonStockSharesOutstanding>
  <tsha:PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis id="F_000245" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20191130" decimals="2" unitRef="U_xbrlipure">0.10</tsha:PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis>
  <us-gaap:CommonStockSharesIssued id="F_000246" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaUTSouthwesternAgreementMember_20200331" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:CommonStockSharesIssued>
  <tsha:ResearchGrantOfCommittedFundAmount id="F_000247" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_20191201_20191231" decimals="-5" unitRef="U_iso4217USD">3800000</tsha:ResearchGrantOfCommittedFundAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000248" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <tsha:ResearchGrantOutstandingFundAmount id="F_000249" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</tsha:ResearchGrantOutstandingFundAmount>
  <tsha:PaymentsToAcquireLicenseRight id="F_000250" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331" decimals="-5" unitRef="U_iso4217USD">3000000</tsha:PaymentsToAcquireLicenseRight>
  <tsha:LicenseAgreementRegulatoryMilestonesPayment id="F_000251" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_srtRangeAxis_srtMaximumMember_20200221" decimals="INF" unitRef="U_iso4217USD">10000000</tsha:LicenseAgreementRegulatoryMilestonesPayment>
  <tsha:LicenseAgreementCommercialMilestonesPayment id="F_000252" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaQueensAgreementMember_srtRangeAxis_srtMaximumMember_20200221" decimals="INF" unitRef="U_iso4217USD">10000000</tsha:LicenseAgreementCommercialMilestonesPayment>
  <tsha:PaymentOfLicenseFee id="F_000253" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20200801_20200831" decimals="-5" unitRef="U_iso4217USD">3000000</tsha:PaymentOfLicenseFee>
  <tsha:PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts id="F_000254" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20201001_20201031" decimals="-5" unitRef="U_iso4217USD">4000000</tsha:PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000255" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">7000000</us-gaap:ResearchAndDevelopmentExpense>
  <tsha:LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment id="F_000256" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_srtRangeAxis_srtMaximumMember_20200831" decimals="INF" unitRef="U_iso4217USD">26000000</tsha:LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment>
  <tsha:LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment id="F_000257" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_srtRangeAxis_srtMaximumMember_20200831" decimals="INF" unitRef="U_iso4217USD">30000000</tsha:LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment>
  <tsha:AdditionalMilestonePayments id="F_000258" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaCLN1AgreementsMember_20210101_20210331" decimals="INF" unitRef="U_iso4217USD">0</tsha:AdditionalMilestonePayments>
  <tsha:PaymentOfOneTimeUpfrontLicenseFee id="F_000259" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">3000000</tsha:PaymentOfOneTimeUpfrontLicenseFee>
  <tsha:RegulatoryRelatedMilestonesObligationPayable id="F_000260" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20201029" decimals="INF" unitRef="U_iso4217USD">26500000</tsha:RegulatoryRelatedMilestonesObligationPayable>
  <tsha:SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable id="F_000261" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20201029" decimals="INF" unitRef="U_iso4217USD">30000000</tsha:SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable>
  <tsha:AdditionalMilestonePayments id="F_000262" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaAbeonaTherapeuticsIncMember_us-gaapTypeOfArrangementAxis_tshaAbeonaRettAgreementMember_20210101_20210331" decimals="INF" unitRef="U_iso4217USD">0</tsha:AdditionalMilestonePayments>
  <tsha:UpfrontPayment id="F_000263" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaAcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_20210301_20210331" decimals="-5" unitRef="U_iso4217USD">5500000</tsha:UpfrontPayment>
  <tsha:ClinicalRegulatoryAndCommercialMilestonesToBeReceived id="F_000264" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaAcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_20210331" decimals="-5" unitRef="U_iso4217USD">19300000</tsha:ClinicalRegulatoryAndCommercialMilestonesToBeReceived>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000265" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaAcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_20210301_20210331" decimals="-5" unitRef="U_iso4217USD">5500000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CommonStockSharesAuthorized id="F_000266" contextRef="C_0001806310_20200728" decimals="INF" unitRef="U_xbrlishares">32685000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000267" contextRef="C_0001806310_20200928" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000268" contextRef="C_0001806310_20200728" decimals="INF" unitRef="U_xbrlishares">15647052</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000269" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200728" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000270" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200728" decimals="INF" unitRef="U_xbrlishares">5647052</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000271" contextRef="C_0001806310_20200928" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000272" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928" decimals="INF" unitRef="U_xbrlishares">7869566</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000273" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200929_20200929" decimals="INF" unitRef="U_xbrlishares">1180434</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000274" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928" decimals="INF" unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:SharesIssuedPricePerShare>
  <tsha:ProceedsFromIssuanceOfCommonStockGross id="F_000275" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928" decimals="-5" unitRef="U_iso4217USD">181000000</tsha:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000276" contextRef="C_0001806310_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200928_20200928" decimals="-5" unitRef="U_iso4217USD">15100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000277" contextRef="C_0001806310_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAPurchaseAgreementMember_20200304_20200304" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000278" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAPurchaseAgreementMember_20200304" decimals="INF" unitRef="U_iso4217USD_xbrlishares">3.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000279" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAPurchaseAgreementInitialClosingMember_20200304_20200304" decimals="INF" unitRef="U_xbrlishares">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000280" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAAchievementOfSpecificClinicalMilestoneOneMember_20200305_20200305" decimals="INF" unitRef="U_xbrlishares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000281" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAAchievementOfSpecificClinicalMilestoneTwoMember_20200305_20200305" decimals="INF" unitRef="U_xbrlishares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000282" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember_20200304_20200304" decimals="INF" unitRef="U_xbrlishares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000283" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630" decimals="INF" unitRef="U_xbrlishares">200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ProceedsFromCollaborators id="F_000284" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000285" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200701_20200702" decimals="INF" unitRef="U_xbrlishares">3800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ProceedsFromCollaborators id="F_000286" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200701_20200702" decimals="-5" unitRef="U_iso4217USD">11400000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000287" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPBMTGTHoldingsLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630" decimals="INF" unitRef="U_xbrlishares">3266667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000288" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaNolanCapitalLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200629_20200630" decimals="INF" unitRef="U_xbrlishares">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000289" contextRef="C_0001806310_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200728_20200728" decimals="INF" unitRef="U_xbrlishares">5647052</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000290" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200728_20200728" decimals="INF" unitRef="U_xbrlishares">5647048</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000291" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200728" decimals="INF" unitRef="U_iso4217USD_xbrlishares">17.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000292" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_tshaSeriesBPurchaseAgreementMember_20200701_20200831" decimals="-5" unitRef="U_iso4217USD">96000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <tsha:ConvertiblePreferredStockTrancheLiabilityOfferingPrice id="F_000293" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304" decimals="INF" unitRef="U_iso4217USD_xbrlishares">3.00</tsha:ConvertiblePreferredStockTrancheLiabilityOfferingPrice>
  <tsha:ConvertiblePreferredStockTrancheLiabilityOfferingPrice id="F_000294" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200630" decimals="INF" unitRef="U_iso4217USD_xbrlishares">17.00</tsha:ConvertiblePreferredStockTrancheLiabilityOfferingPrice>
  <tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput id="F_000295" contextRef="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304" decimals="4" unitRef="U_xbrlipure">0.0059</tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput>
  <tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput id="F_000296" contextRef="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200630" decimals="4" unitRef="U_xbrlipure">0.0017</tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput>
  <tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput id="F_000297" contextRef="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304" decimals="2" unitRef="U_xbrlipure">0.80</tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput>
  <tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput id="F_000298" contextRef="C_0001806310_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200630" decimals="2" unitRef="U_xbrlipure">0.80</tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput>
  <tsha:ConvertiblePreferredStockTrancheLiabilityLiquidityTerm id="F_000299" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304_20200304">P1Y</tsha:ConvertiblePreferredStockTrancheLiabilityLiquidityTerm>
  <tsha:ConvertiblePreferredStockTrancheLiabilityLiquidityTerm id="F_000300" contextRef="C_0001806310_us-gaapStatementClassOfStockAxis_tshaSeriesBConvertiblePreferredStockMember_20200629_20200630">P6M</tsha:ConvertiblePreferredStockTrancheLiabilityLiquidityTerm>
  <tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput id="F_000301" contextRef="C_0001806310_us-gaapMeasurementInputTypeAxis_tshaMeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember_us-gaapStatementClassOfStockAxis_tshaSeriesAConvertiblePreferredStockMember_20200304" decimals="2" unitRef="U_xbrlipure">0.60</tsha:ConvertiblePreferredStockTrancheLiabilityMeasurementInput>
  <tsha:PreferredStockTrancheLiability id="F_000302" contextRef="C_0001806310_20200304" decimals="-5" unitRef="U_iso4217USD">1100000</tsha:PreferredStockTrancheLiability>
  <tsha:ChangeInFairValueOfPreferredStockTrancheLiability id="F_000303" contextRef="C_0001806310_20210101_20210331" decimals="-5" unitRef="U_iso4217USD">200000</tsha:ChangeInFairValueOfPreferredStockTrancheLiability>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000304" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200701" decimals="INF" unitRef="U_xbrlishares">3529412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000305" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200916" decimals="INF" unitRef="U_xbrlishares">3845294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000306" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916" decimals="INF" unitRef="U_xbrlishares">3390168</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000307" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200916" decimals="INF" unitRef="U_xbrlishares">209841</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000308" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916_20200916">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <tsha:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate id="F_000309" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916_20200916">2021-01-01</tsha:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate id="F_000310" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916_20200916">2030-01-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <tsha:PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance id="F_000311" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20200916_20200916" decimals="INF" unitRef="U_xbrlipure">0.05</tsha:PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward id="F_000312" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331">At December 31, 2020, there were 2,941,509 shares available for future grant under the New Plan. The number of shares of common stock reserved for issuance under the New Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2021 continuing through January 1, 2030, by 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors.  On January 1, 2021 the board of directors increased the number of common stock reserved for issuance under the New Plan by 1,434,934 shares.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000313" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101" decimals="INF" unitRef="U_xbrlishares">1434934</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000314" contextRef="C_0001806310_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916" decimals="INF" unitRef="U_xbrlishares">362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000315" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916_20200916">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate id="F_000316" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916_20200916">2030-01-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <tsha:PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance id="F_000317" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916_20200916" decimals="INF" unitRef="U_xbrlipure">0.010</tsha:PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000318" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20200916" decimals="INF" unitRef="U_xbrlishares">724000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000319" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20210101_20210101" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000320" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward id="F_000321" contextRef="C_0001806310_us-gaapAwardTypeAxis_tshaEmployeeStockPurchasePlanMember_20210101_20210331">The number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the IPO Date and ending on (and including) January 1, 2030, in an amount equal to the lesser of (i) one percent (1.0%) of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year, and (ii) 724,000 shares of common stock.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000322" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaCertainEmployeesAndConsultantsMember_us-gaapAwardTypeAxis_tshaCancelledOptionsMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701" decimals="INF" unitRef="U_xbrlishares">2896782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000323" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaCertainEmployeesAndConsultantsMember_us-gaapAwardTypeAxis_tshaCancelledOptionsMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000324" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaCertainEmployeesAndConsultantsMember_us-gaapAwardTypeAxis_tshaCancelledOptionsMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <tsha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue id="F_000325" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaCertainEmployeesAndConsultantsMember_us-gaapAwardTypeAxis_tshaCancelledOptionsMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701" decimals="-5" unitRef="U_iso4217USD">13800000</tsha:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
  <tsha:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod id="F_000326" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200902_20200902" decimals="INF" unitRef="U_xbrlishares">2518932</tsha:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000327" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200902_20200902">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost id="F_000328" contextRef="C_0001806310_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20210101_20210331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000329" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">1621900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000330" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">18.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000331" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000332" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyStockIncentivePlanMember_20210101_20210331">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000333" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="4" unitRef="U_xbrlipure">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000334" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000335" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2" unitRef="U_xbrlipure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000336" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" unitRef="U_xbrlishares">674842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000337" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">1621900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000338" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">10600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000339" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="INF" unitRef="U_xbrlishares">2286142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000340" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="INF" unitRef="U_xbrlishares">2286142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000341" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="INF" unitRef="U_xbrlishares">27552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000342" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">20.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000343" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">28.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000344" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">26.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000345" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">26.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000346" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">26.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000347" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">20.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000348" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000349" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000350" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000351" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000352" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-3" unitRef="U_iso4217USD">3953000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000353" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-3" unitRef="U_iso4217USD">213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="F_000354" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-3" unitRef="U_iso4217USD">213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000355" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000356" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-5" unitRef="U_iso4217USD">37000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000357" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P3Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000358" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200902_20200902" decimals="INF" unitRef="U_xbrlishares">331121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000359" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200902_20200902" decimals="2" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000360" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200902_20200902" decimals="2" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000361" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheThreeMember_20200902_20200902" decimals="2" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000362" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_tshaShareBasedCompensationAwardTrancheFourMember_20200902_20200902" decimals="2" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_000363" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331" decimals="-5" unitRef="U_iso4217USD">15400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000364" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000365" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" unitRef="U_xbrlishares">2850053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000366" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331" decimals="INF" unitRef="U_xbrlishares">2850053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000367" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000368" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000369" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701" decimals="INF" unitRef="U_xbrlishares">769058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="F_000370" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_tshaTwoThousandTwentyEquityIncentivePlanMember_20200701_20200701">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_000371" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210331" decimals="-5" unitRef="U_iso4217USD">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000372" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20210331">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000373" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200701_20200701" decimals="INF" unitRef="U_iso4217USD_xbrlishares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000374" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">769058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000375" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210331" decimals="INF" unitRef="U_xbrlishares">769058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000376" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000377" contextRef="C_0001806310_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210331" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000378" contextRef="C_0001806310_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">1579000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000379" contextRef="C_0001806310_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">2015000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000380" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">3594000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000381" contextRef="C_0001806310_20210101_20210331" decimals="-3" unitRef="U_iso4217USD">-32024000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000382" contextRef="C_0001806310_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-5431000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000383" contextRef="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">2850053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000384" contextRef="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">769058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000385" contextRef="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">2286142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000386" contextRef="C_0001806310_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tshaSeriesAConvertiblePreferredStockMember_20200101_20200331" decimals="INF" unitRef="U_xbrlishares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000387" contextRef="C_0001806310_20210101_20210331" decimals="INF" unitRef="U_xbrlishares">5905253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000388" contextRef="C_0001806310_20200101_20200331" decimals="INF" unitRef="U_xbrlishares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <tsha:NumberOfSecuredPromissoryNotes id="F_000389" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_20200101_20200131" decimals="INF" unitRef="U_tshaPromissoryNote">2</tsha:NumberOfSecuredPromissoryNotes>
  <us-gaap:DebtInstrumentFaceAmount id="F_000390" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapLongtermDebtTypeAxis_tshaSecuredPromissoryNotesMember_20200131" decimals="-4" unitRef="U_iso4217USD">1670000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000391" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapLongtermDebtTypeAxis_tshaSecuredPromissoryNotesMember_20200131" decimals="INF" unitRef="U_xbrlipure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:RepaymentsOfDebt id="F_000392" contextRef="C_0001806310_srtTitleOfIndividualAxis_tshaPresidentAndChiefExecutiveOfficerMember_us-gaapLongtermDebtTypeAxis_tshaSecuredPromissoryNotesMember_20200301_20200331" decimals="-4" unitRef="U_iso4217USD">1650000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000393" contextRef="C_0001806310_us-gaapRelatedPartyTransactionAxis_tshaServicesAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_tshaPBMCapitalGroupLLCMember_20200301_20200331" decimals="0" unitRef="U_iso4217USD">2500</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <tsha:OwnershipPercentageInExcessOfCapitalStock id="F_000394" contextRef="C_0001806310_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapRelatedPartyTransactionAxis_tshaServicesAgreementMember_20200301_20200331" decimals="2" unitRef="U_xbrlipure">0.05</tsha:OwnershipPercentageInExcessOfCapitalStock>
  <tsha:AdditionalConsiderationToRelatedPartyUnderOperatingAgreement id="F_000395" contextRef="C_0001806310_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_tshaPBMTGTHoldingsLLCMember_20200930" decimals="INF" unitRef="U_iso4217USD">0</tsha:AdditionalConsiderationToRelatedPartyUnderOperatingAgreement>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000396" contextRef="C_0001806310_20210101_20210331" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits id="F_000397" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20201217" decimals="0" unitRef="U_utrsqft">187500</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits>
  <us-gaap:OperationsCommencedDate1 id="F_000398" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20201217_20201217">2021-04-01</us-gaap:OperationsCommencedDate1>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000399" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20201217">P15Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LesseeOperatingLeaseRenewalTerm id="F_000400" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20201217">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
  <tsha:OperatingLeasesInitialDirectCosts id="F_000401" contextRef="C_0001806310_us-gaapTypeOfArrangementAxis_tshaDurhamLeaseMember_20210101_20210331" decimals="-5" unitRef="U_iso4217USD">800000</tsha:OperatingLeasesInitialDirectCosts>
  <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits id="F_000402" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111" decimals="0" unitRef="U_utrsqft">15000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits>
  <us-gaap:OperationsCommencedDate1 id="F_000403" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111_20210111">2021-05-15</us-gaap:OperationsCommencedDate1>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000404" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="F_000405" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111_20210111">Company has an option to extend the term of the Lease for one additional period of five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend id="F_000406" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111_20210111">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
  <us-gaap:LesseeOperatingLeaseRenewalTerm id="F_000407" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
  <tsha:ObligationForPaymentOfInitialBaseRentForOfficeSpace id="F_000408" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111" decimals="-3" unitRef="U_iso4217USD">32500000</tsha:ObligationForPaymentOfInitialBaseRentForOfficeSpace>
  <tsha:MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease id="F_000409" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111_20210111" decimals="INF" unitRef="U_iso4217USD">50000000</tsha:MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease>
  <us-gaap:SecurityDeposit id="F_000410" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111" decimals="-3" unitRef="U_iso4217USD">32500000</us-gaap:SecurityDeposit>
  <tsha:MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot id="F_000411" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111_20210111" decimals="2" unitRef="U_utrsqft">40.00</tsha:MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000412" contextRef="C_0001806310_srtCounterpartyNameAxis_tshaPegasusParkLLCMember_us-gaapTypeOfArrangementAxis_tshaDallasLeaseMember_20210111" decimals="-5" unitRef="U_iso4217USD">4900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LeaseIncentiveReceivable id="F_000413" contextRef="C_0001806310_us-gaapLeaseContractualTermAxis_tshaDallasLeaseMember_20210331" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:LeaseIncentiveReceivable>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>tsha-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-11T01:24:34.7875237+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 1f73c44147c0412f9cfba93145d27295 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:tsha="http://tayshagtx.com/20210331" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tayshagtx.com/20210331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://tayshagtx.com/20210331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tsha-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tsha-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tsha-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tsha-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="Role_StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Parenthetical) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperations" id="Role_DisclosureOrganizationAndDescriptionOfBusinessOperations">
        <link:definition>100070 - Disclosure - Organization and Description of Business Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100090 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements" id="Role_DisclosureResearchCollaborationAndLicenseAgreements">
        <link:definition>100100 - Disclosure - Research, Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability" id="Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability">
        <link:definition>100110 - Disclosure - Stockholders&apos; Equity (Deficit), Convertible Preferred Stock and Tranche Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100120 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100130 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100140 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100180 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100190 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100200 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails">
        <link:definition>100210 - Disclosure - Organization and Description of Business Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100220 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail">
        <link:definition>100230 - Disclosure - Balance Sheet Components - Schedule of Property Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100240 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100250 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Research, Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Stockholders&apos; Equity (Deficit), Convertible Preferred Stock and Tranche Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails">
        <link:definition>100290 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Options and Cancelled Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>100300 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails">
        <link:definition>100310 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails">
        <link:definition>100320 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails" id="Role_DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails">
        <link:definition>100330 - Disclosure - Stock-Based Compensation - Schedule of Total Stock-Based Compensation Expense for Stock Options, RSAs and RSUs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCalculationOfBasicAndDilutedNetLossPerCommonShareDetails" id="Role_DisclosureNetLossPerCommonShareScheduleOfCalculationOfBasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>100340 - Disclosure - Net Loss Per Common Share - Schedule of Calculation of Basic and Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100350 - Disclosure - Net Loss Per Common Share - Schedule of Common Stock Equivalents Outstanding Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" name="ChangeInFairValueOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_TemporaryEquityStockOfferingCosts" name="TemporaryEquityStockOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" name="TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" name="IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_ResearchAndDevelopmentLicenseNotYetPaid" name="ResearchAndDevelopmentLicenseNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" name="PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_AllocationOfPreferredStockTrancheLiability" name="AllocationOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" name="ResearchCollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" name="ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" name="OrganizationAndDescriptionOfBusinessOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" name="OrganizationAndDescriptionOfBusinessOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" name="TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_CommonStockIncreaseInOutstandingShares" name="CommonStockIncreaseInOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_PrepaidResearchAndDevelopmentContracts" name="PrepaidResearchAndDevelopmentContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_PrepaidBonus" name="PrepaidBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_PrepaidClinicalTrial" name="PrepaidClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_AccruedLicenseFeesCurrent" name="AccruedLicenseFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_AccruedConstructionInProgressCurrent" name="AccruedConstructionInProgressCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" name="PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" name="MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_UTSouthwesternAgreementMember" name="UTSouthwesternAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_QueensAgreementMember" name="QueensAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_AbeonaCLN1AgreementsMember" name="AbeonaCLN1AgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_AbeonaRettAgreementMember" name="AbeonaRettAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_AbeonaTherapeuticsIncMember" name="AbeonaTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" name="AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" name="PercentageOfFullyDilutedCommonStockSharesOutstanding" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" name="PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="tsha_ResearchGrantOfCommittedFundAmount" name="ResearchGrantOfCommittedFundAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_ResearchGrantOutstandingFundAmount" name="ResearchGrantOutstandingFundAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_LicenseAgreementRegulatoryMilestonesPayment" name="LicenseAgreementRegulatoryMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_LicenseAgreementCommercialMilestonesPayment" name="LicenseAgreementCommercialMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_PaymentsToAcquireLicenseRight" name="PaymentsToAcquireLicenseRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_PaymentOfLicenseFee" name="PaymentOfLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" name="PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" name="LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" name="LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_AdditionalMilestonePayments" name="AdditionalMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_RegulatoryRelatedMilestonesObligationPayable" name="RegulatoryRelatedMilestonesObligationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" name="SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_PaymentOfOneTimeUpfrontLicenseFee" name="PaymentOfOneTimeUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" name="ClinicalRegulatoryAndCommercialMilestonesToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_SeriesAPurchaseAgreementMember" name="SeriesAPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_SeriesAPurchaseAgreementInitialClosingMember" name="SeriesAPurchaseAgreementInitialClosingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" name="SeriesAAchievementOfSpecificClinicalMilestoneOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" name="SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" name="SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" name="PBMTGTHoldingsLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_NolanCapitalLimitedLiabilityCompanyMember" name="NolanCapitalLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_SeriesBPurchaseAgreementMember" name="SeriesBPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" name="MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" name="ConvertiblePreferredStockTrancheLiabilityOfferingPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" name="ConvertiblePreferredStockTrancheLiabilityMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" name="ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_PreferredStockTrancheLiability" name="PreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_CancelledOptionsMember" name="CancelledOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_CertainEmployeesAndConsultantsMember" name="CertainEmployeesAndConsultantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_PresidentAndChiefExecutiveOfficerMember" name="PresidentAndChiefExecutiveOfficerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" name="PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_NumberOfSecuredPromissoryNotes" name="NumberOfSecuredPromissoryNotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_SecuredPromissoryNotesMember" name="SecuredPromissoryNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_PBMCapitalGroupLLCMember" name="PBMCapitalGroupLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_PBMTGTHoldingsLLCMember" name="PBMTGTHoldingsLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_ServicesAgreementMember" name="ServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_OwnershipPercentageInExcessOfCapitalStock" name="OwnershipPercentageInExcessOfCapitalStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" name="AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_DurhamLeaseMember" name="DurhamLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_DallasLeaseMember" name="DallasLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_PegasusParkLLCMember" name="PegasusParkLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="tsha_OperatingLeasesInitialDirectCosts" name="OperatingLeasesInitialDirectCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" name="ObligationForPaymentOfInitialBaseRentForOfficeSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" name="MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" name="MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>36
<FILENAME>tsha-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-11T01:24:34.7875237+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 1f73c44147c0412f9cfba93145d27295 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="tsha-20210331.xsd#TemplateLink" roleURI="http://tayshagtx.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsLeasingNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNetNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCostsLeasingNetNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" xlink:type="locator" xlink:label="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10160.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidClinicalTrial" xlink:type="locator" xlink:label="tsha_PrepaidClinicalTrial" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidBonus" xlink:type="locator" xlink:label="tsha_PrepaidBonus" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidResearchAndDevelopmentContracts" xlink:type="locator" xlink:label="tsha_PrepaidResearchAndDevelopmentContracts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="tsha_PrepaidResearchAndDevelopmentContracts" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="tsha_PrepaidBonus" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="tsha_PrepaidClinicalTrial" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedConstructionInProgressCurrent" xlink:type="locator" xlink:label="tsha_AccruedConstructionInProgressCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedLicenseFeesCurrent" xlink:type="locator" xlink:label="tsha_AccruedLicenseFeesCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="tsha_AccruedResearchAndDevelopmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="tsha_AccruedResearchAndDevelopmentCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="tsha_AccruedLicenseFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="tsha_AccruedConstructionInProgressCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>37
<FILENAME>tsha-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-11T01:24:34.7885232+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 1f73c44147c0412f9cfba93145d27295 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="tsha-20210331.xsd#TemplateLink" roleURI="http://tayshagtx.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockOfferingCosts" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockOfferingCosts" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsha_TemporaryEquityStockOfferingCosts" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CommonStockIncreaseInOutstandingShares" xlink:type="locator" xlink:label="tsha_CommonStockIncreaseInOutstandingShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:type="locator" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:type="locator" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsha_TwoThousandTwentyEquityIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesBConvertiblePreferredStockMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="tsha_CommonStockIncreaseInOutstandingShares" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_Cash" order="11290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="tsha_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsha_LaboratoryEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" xlink:type="locator" xlink:label="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_UpfrontPayment" xlink:type="locator" xlink:label="tsha_UpfrontPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" xlink:type="locator" xlink:label="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_RegulatoryRelatedMilestonesObligationPayable" xlink:type="locator" xlink:label="tsha_RegulatoryRelatedMilestonesObligationPayable" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentOfOneTimeUpfrontLicenseFee" xlink:type="locator" xlink:label="tsha_PaymentOfOneTimeUpfrontLicenseFee" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AdditionalMilestonePayments" xlink:type="locator" xlink:label="tsha_AdditionalMilestonePayments" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" xlink:type="locator" xlink:label="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentOfLicenseFee" xlink:type="locator" xlink:label="tsha_PaymentOfLicenseFee" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAgreementCommercialMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAgreementCommercialMilestonesPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAgreementRegulatoryMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAgreementRegulatoryMilestonesPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentsToAcquireLicenseRight" xlink:type="locator" xlink:label="tsha_PaymentsToAcquireLicenseRight" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchGrantOutstandingFundAmount" xlink:type="locator" xlink:label="tsha_ResearchGrantOutstandingFundAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchGrantOfCommittedFundAmount" xlink:type="locator" xlink:label="tsha_ResearchGrantOfCommittedFundAmount" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" xlink:type="locator" xlink:label="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" xlink:type="locator" xlink:label="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" xlink:type="locator" xlink:label="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" xlink:type="locator" xlink:label="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" xlink:type="locator" xlink:label="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaTherapeuticsIncMember" xlink:type="locator" xlink:label="tsha_AbeonaTherapeuticsIncMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaRettAgreementMember" xlink:type="locator" xlink:label="tsha_AbeonaRettAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaCLN1AgreementsMember" xlink:type="locator" xlink:label="tsha_AbeonaCLN1AgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_QueensAgreementMember" xlink:type="locator" xlink:label="tsha_QueensAgreementMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_UTSouthwesternAgreementMember" xlink:type="locator" xlink:label="tsha_UTSouthwesternAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_UTSouthwesternAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_QueensAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_AbeonaCLN1AgreementsMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_AbeonaRettAgreementMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_AbeonaTherapeuticsIncMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_ResearchGrantOfCommittedFundAmount" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_ResearchGrantOutstandingFundAmount" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PaymentsToAcquireLicenseRight" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAgreementRegulatoryMilestonesPayment" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAgreementCommercialMilestonesPayment" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PaymentOfLicenseFee" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_AdditionalMilestonePayments" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PaymentOfOneTimeUpfrontLicenseFee" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_RegulatoryRelatedMilestonesObligationPayable" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_UpfrontPayment" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" order="12090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_PreferredStockTrancheLiability" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="tsha_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" xlink:type="locator" xlink:label="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBPurchaseAgreementMember" xlink:type="locator" xlink:label="tsha_SeriesBPurchaseAgreementMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_NolanCapitalLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="tsha_NolanCapitalLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" xlink:type="locator" xlink:label="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" xlink:type="locator" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" xlink:type="locator" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAPurchaseAgreementInitialClosingMember" xlink:type="locator" xlink:label="tsha_SeriesAPurchaseAgreementInitialClosingMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAPurchaseAgreementMember" xlink:type="locator" xlink:label="tsha_SeriesAPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesBConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAPurchaseAgreementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAPurchaseAgreementInitialClosingMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_NolanCapitalLimitedLiabilityCompanyMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesBPurchaseAgreementMember" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ProceedsFromIssuanceOfCommonStockGross" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_PreferredStockTrancheLiability" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" order="12690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationAwardTrancheFourMember" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationAwardTrancheFourMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CertainEmployeesAndConsultantsMember" xlink:type="locator" xlink:label="tsha_CertainEmployeesAndConsultantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CancelledOptionsMember" xlink:type="locator" xlink:label="tsha_CancelledOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="tsha_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsha_TwoThousandTwentyEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsha_TwoThousandTwentyStockIncentivePlanMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsha_EmployeeStockPurchasePlanMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsha_CancelledOptionsMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tsha_CertainEmployeesAndConsultantsMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="tsha_ShareBasedCompensationAwardTrancheFourMember" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tsha_PresidentAndChiefExecutiveOfficerMember" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="13450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="13800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" xlink:type="locator" xlink:label="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OwnershipPercentageInExcessOfCapitalStock" xlink:type="locator" xlink:label="tsha_OwnershipPercentageInExcessOfCapitalStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_NumberOfSecuredPromissoryNotes" xlink:type="locator" xlink:label="tsha_NumberOfSecuredPromissoryNotes" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ServicesAgreementMember" xlink:type="locator" xlink:label="tsha_ServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMTGTHoldingsLLCMember" xlink:type="locator" xlink:label="tsha_PBMTGTHoldingsLLCMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMCapitalGroupLLCMember" xlink:type="locator" xlink:label="tsha_PBMCapitalGroupLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SecuredPromissoryNotesMember" xlink:type="locator" xlink:label="tsha_SecuredPromissoryNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tsha_SecuredPromissoryNotesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tsha_PresidentAndChiefExecutiveOfficerMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tsha_PBMCapitalGroupLLCMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tsha_PBMTGTHoldingsLLCMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tsha_ServicesAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tsha_NumberOfSecuredPromissoryNotes" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tsha_OwnershipPercentageInExcessOfCapitalStock" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivable" xlink:type="locator" xlink:label="us-gaap_LeaseIncentiveReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" xlink:type="locator" xlink:label="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" xlink:type="locator" xlink:label="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" xlink:type="locator" xlink:label="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OperatingLeasesInitialDirectCosts" xlink:type="locator" xlink:label="tsha_OperatingLeasesInitialDirectCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:type="locator" xlink:label="us-gaap_OperationsCommencedDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PegasusParkLLCMember" xlink:type="locator" xlink:label="tsha_PegasusParkLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_DallasLeaseMember" xlink:type="locator" xlink:label="tsha_DallasLeaseMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_DurhamLeaseMember" xlink:type="locator" xlink:label="tsha_DurhamLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_DurhamLeaseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_DallasLeaseMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_PegasusParkLLCMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tsha_DallasLeaseMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_OperatingLeasesInitialDirectCosts" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseIncentiveReceivable" order="11400.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>38
<FILENAME>tsha-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-11T01:24:34.7885232+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 1f73c44147c0412f9cfba93145d27295 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsLeasingNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNetNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsLeasingNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred lease asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsLeasingNetNoncurrent" xlink:to="us-gaap_DeferredCostsLeasingNetNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsLeasingNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Leasing Net Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies - Note 10</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2021 and December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.00001 par value per share; 200,000,000 shares authorized and 37,761,435 issued and outstanding as of March 31, 2021 and December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:label xml:lang="en-US" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value preferred stock tranche liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Preferred Stock Tranche Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesAConvertiblePreferredStockMember" xlink:to="tsha_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock balance</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockOfferingCosts" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_TemporaryEquityStockOfferingCosts" xlink:to="tsha_TemporaryEquityStockOfferingCosts_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance of preferred stock tranche liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" xlink:to="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Of Preferred Stock Tranche Liability</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" xlink:type="locator" xlink:label="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued expense and other liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" xlink:to="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchAndDevelopmentLicenseNotYetPaid" xlink:type="locator" xlink:label="tsha_ResearchAndDevelopmentLicenseNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchAndDevelopmentLicenseNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development license not yet paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ResearchAndDevelopmentLicenseNotYetPaid" xlink:to="tsha_ResearchAndDevelopmentLicenseNotYetPaid_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:to="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AllocationOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_AllocationOfPreferredStockTrancheLiability" />
    <link:label xml:lang="en-US" xlink:label="tsha_AllocationOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allocation of preferred stock tranche liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AllocationOfPreferredStockTrancheLiability" xlink:to="tsha_AllocationOfPreferredStockTrancheLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock tranche liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development license expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Expense And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due To Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of Series A convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from note payable to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of note payable to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash at the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchAndDevelopmentLicenseNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of research and development license not yet paid</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchAndDevelopmentLicenseNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development License Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of property, plant and equipment funded by landlord</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Fixed Assets Acquired1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs not yet paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AllocationOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AllocationOfPreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocation Of Preferred Stock Tranche Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A issuance costs not yet paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchCollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research, collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="tsha_ResearchCollaborationAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchCollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research, Collaboration and License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity (Deficit), Convertible Preferred Stock and Tranche Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" xlink:type="locator" xlink:label="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expense and other current labilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" xlink:to="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Accrued Expense And Other Current Labilities</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expense And Other Current Labilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Estimate Fair Value of Stock Options and Cancelled Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Stock Units Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Stock Awards Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Stock-Based Compensation Expense for Stock Options, RSAs and RSUs (Detail)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Basic and Diluted Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Equivalents Outstanding Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:type="locator" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" />
    <link:label xml:lang="en-US" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:type="locator" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" />
    <link:label xml:lang="en-US" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="tsha_OrganizationAndDescriptionOfBusinessOperationsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business Operations [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="tsha_TwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters&#8217; Option to Purchase Additional Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesBConvertiblePreferredStockMember" xlink:to="tsha_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business Operations [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business Operations [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Issuance of shares of common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issue price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and other offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Underwriting Expense</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion shares of convertible preferred stock to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" xlink:to="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock to common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Shares Of Convertible Preferred Stock To Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CommonStockIncreaseInOutstandingShares" xlink:type="locator" xlink:label="tsha_CommonStockIncreaseInOutstandingShares" />
    <link:label xml:lang="en-US" xlink:label="tsha_CommonStockIncreaseInOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock increase in outstanding shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_CommonStockIncreaseInOutstandingShares" xlink:to="tsha_CommonStockIncreaseInOutstandingShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_CommonStockIncreaseInOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Increase in outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_CommonStockIncreaseInOutstandingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Increase In Outstanding Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from sale of convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidResearchAndDevelopmentContracts" xlink:type="locator" xlink:label="tsha_PrepaidResearchAndDevelopmentContracts" />
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidResearchAndDevelopmentContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PrepaidResearchAndDevelopmentContracts" xlink:to="tsha_PrepaidResearchAndDevelopmentContracts_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidBonus" xlink:type="locator" xlink:label="tsha_PrepaidBonus" />
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid bonus.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PrepaidBonus" xlink:to="tsha_PrepaidBonus_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidClinicalTrial" xlink:type="locator" xlink:label="tsha_PrepaidClinicalTrial" />
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidClinicalTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PrepaidClinicalTrial" xlink:to="tsha_PrepaidClinicalTrial_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidResearchAndDevelopmentContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidResearchAndDevelopmentContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Contracts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidClinicalTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical trial</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PrepaidClinicalTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Trial</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="tsha_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_LaboratoryEquipmentMember" xlink:to="tsha_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="tsha_AccruedResearchAndDevelopmentCurrent" />
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AccruedResearchAndDevelopmentCurrent" xlink:to="tsha_AccruedResearchAndDevelopmentCurrent_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedLicenseFeesCurrent" xlink:type="locator" xlink:label="tsha_AccruedLicenseFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedLicenseFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued license fees current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AccruedLicenseFeesCurrent" xlink:to="tsha_AccruedLicenseFeesCurrent_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedConstructionInProgressCurrent" xlink:type="locator" xlink:label="tsha_AccruedConstructionInProgressCurrent" />
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedConstructionInProgressCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued construction in progress current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AccruedConstructionInProgressCurrent" xlink:to="tsha_AccruedConstructionInProgressCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedLicenseFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued license fees</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedLicenseFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued License Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedConstructionInProgressCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued construction in progress</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AccruedConstructionInProgressCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Construction In Progress Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" xlink:type="locator" xlink:label="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" />
    <link:label xml:lang="en-US" xlink:label="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical activities period under sponsored research agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" xlink:to="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" xlink:type="locator" xlink:label="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" />
    <link:label xml:lang="en-US" xlink:label="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum licensed product to develop obtain regulatory approval for and commercialize.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" xlink:to="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_UTSouthwesternAgreementMember" xlink:type="locator" xlink:label="tsha_UTSouthwesternAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_UTSouthwesternAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UT southwestern agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_UTSouthwesternAgreementMember" xlink:to="tsha_UTSouthwesternAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_UTSouthwesternAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UT Southwestern Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_UTSouthwesternAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U T Southwestern Agreement [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_QueensAgreementMember" xlink:type="locator" xlink:label="tsha_QueensAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_QueensAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Queen&apos;s agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_QueensAgreementMember" xlink:to="tsha_QueensAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_QueensAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Queen&apos;s Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_QueensAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Queens Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaCLN1AgreementsMember" xlink:type="locator" xlink:label="tsha_AbeonaCLN1AgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaCLN1AgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Abeona CLN1 agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AbeonaCLN1AgreementsMember" xlink:to="tsha_AbeonaCLN1AgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaCLN1AgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Abeona CLN1 Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaCLN1AgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abeona C L N1 Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaRettAgreementMember" xlink:type="locator" xlink:label="tsha_AbeonaRettAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaRettAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Abeona Rett agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AbeonaRettAgreementMember" xlink:to="tsha_AbeonaRettAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaRettAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abeona Rett Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaRettAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abeona Rett Agreement [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaTherapeuticsIncMember" xlink:type="locator" xlink:label="tsha_AbeonaTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Abeona Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AbeonaTherapeuticsIncMember" xlink:to="tsha_AbeonaTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abeona</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AbeonaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abeona Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" xlink:type="locator" xlink:label="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition of worldwide rights for TSHA 120 for treatment of giant axonal neuropathy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" xlink:to="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TSHA-120</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Of Worldwide Rights For T S H A120 For Treatment Of Giant Axonal Neuropathy [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical activities period under sponsored research agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical Activities Period Under Sponsored Research Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum licensed product to develop obtain regulatory approval for and commercialize</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Licensed Product To Develop Obtain Regulatory Approval For And Commercialize</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" xlink:type="locator" xlink:label="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fully diluted common stock shares outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" xlink:to="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" xlink:type="locator" xlink:label="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" />
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock shares entitled to receive additional shares on fully diluted basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" xlink:to="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fully diluted common stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fully Diluted Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of entitled to receive additional shares on fully diluted basis</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock Shares Entitled To Receive Additional Shares On Fully Diluted Basis</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchGrantOfCommittedFundAmount" xlink:type="locator" xlink:label="tsha_ResearchGrantOfCommittedFundAmount" />
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchGrantOfCommittedFundAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research grant of committed fund amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ResearchGrantOfCommittedFundAmount" xlink:to="tsha_ResearchGrantOfCommittedFundAmount_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchGrantOutstandingFundAmount" xlink:type="locator" xlink:label="tsha_ResearchGrantOutstandingFundAmount" />
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchGrantOutstandingFundAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research grant outstanding fund amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ResearchGrantOutstandingFundAmount" xlink:to="tsha_ResearchGrantOutstandingFundAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchGrantOfCommittedFundAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research grant of committed fund amount</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchGrantOfCommittedFundAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Grant Of Committed Fund Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchGrantOutstandingFundAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research grant outstanding fund amount</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ResearchGrantOutstandingFundAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Grant Outstanding Fund Amount</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAgreementRegulatoryMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAgreementRegulatoryMilestonesPayment" />
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAgreementRegulatoryMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement regulatory milestones payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_LicenseAgreementRegulatoryMilestonesPayment" xlink:to="tsha_LicenseAgreementRegulatoryMilestonesPayment_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAgreementCommercialMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAgreementCommercialMilestonesPayment" />
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAgreementCommercialMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement commercial milestones payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_LicenseAgreementCommercialMilestonesPayment" xlink:to="tsha_LicenseAgreementCommercialMilestonesPayment_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentsToAcquireLicenseRight" xlink:type="locator" xlink:label="tsha_PaymentsToAcquireLicenseRight" />
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentsToAcquireLicenseRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire license right.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PaymentsToAcquireLicenseRight" xlink:to="tsha_PaymentsToAcquireLicenseRight_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentsToAcquireLicenseRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment to acquire license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentsToAcquireLicenseRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire License Right</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAgreementRegulatoryMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement regulatory milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAgreementRegulatoryMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Regulatory Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAgreementCommercialMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement commercial milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAgreementCommercialMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Commercial Milestones Payment</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentOfLicenseFee" xlink:type="locator" xlink:label="tsha_PaymentOfLicenseFee" />
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentOfLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PaymentOfLicenseFee" xlink:to="tsha_PaymentOfLicenseFee_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" xlink:type="locator" xlink:label="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" />
    <link:label xml:lang="en-US" xlink:label="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of clinical materials and reimbursement incurred development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" xlink:to="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" />
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and inventory purchase agreement regulatory related milestones payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" xlink:to="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" />
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and inventory purchase agreement sales related milestones payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" xlink:to="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AdditionalMilestonePayments" xlink:type="locator" xlink:label="tsha_AdditionalMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="tsha_AdditionalMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AdditionalMilestonePayments" xlink:to="tsha_AdditionalMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentOfLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentOfLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of License Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of clinical materials and reimbursement incurred development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Clinical Materials And Reimbursement Incurred Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and inventory purchase agreement regulatory related milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Inventory Purchase Agreement Regulatory Related Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and inventory purchase agreement sales related milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Inventory Purchase Agreement Sales Related Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AdditionalMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AdditionalMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payments</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_RegulatoryRelatedMilestonesObligationPayable" xlink:type="locator" xlink:label="tsha_RegulatoryRelatedMilestonesObligationPayable" />
    <link:label xml:lang="en-US" xlink:label="tsha_RegulatoryRelatedMilestonesObligationPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory related milestones obligation payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_RegulatoryRelatedMilestonesObligationPayable" xlink:to="tsha_RegulatoryRelatedMilestonesObligationPayable_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" xlink:type="locator" xlink:label="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" />
    <link:label xml:lang="en-US" xlink:label="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale-related milestones per licensed product and royalties on net sales of licensed products payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" xlink:to="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentOfOneTimeUpfrontLicenseFee" xlink:type="locator" xlink:label="tsha_PaymentOfOneTimeUpfrontLicenseFee" />
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentOfOneTimeUpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of one-time upfront license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PaymentOfOneTimeUpfrontLicenseFee" xlink:to="tsha_PaymentOfOneTimeUpfrontLicenseFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentOfOneTimeUpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of one-time upfront license fee</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PaymentOfOneTimeUpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of One Time Upfront License Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_RegulatoryRelatedMilestonesObligationPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory related milestones obligation payable</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_RegulatoryRelatedMilestonesObligationPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Related Milestones Obligation Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale-related milestones per licensed product and royalties on net sales of licensed products payable</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Related Milestones Per Licensed Product And Royalties On Net Sales Of Licensed Products Payable</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_UpfrontPayment" xlink:type="locator" xlink:label="tsha_UpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="tsha_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_UpfrontPayment" xlink:to="tsha_UpfrontPayment_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" xlink:type="locator" xlink:label="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical, regulatory and commercial milestones to be received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" xlink:to="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical, regulatory and commercial milestones to be received</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Regulatory And Commercial Milestones To Be Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriters&#8217; Option to Purchase Additional Shares</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAPurchaseAgreementMember" xlink:type="locator" xlink:label="tsha_SeriesAPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesAPurchaseAgreementMember" xlink:to="tsha_SeriesAPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAPurchaseAgreementInitialClosingMember" xlink:type="locator" xlink:label="tsha_SeriesAPurchaseAgreementInitialClosingMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAPurchaseAgreementInitialClosingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A purchase agreement initial closing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesAPurchaseAgreementInitialClosingMember" xlink:to="tsha_SeriesAPurchaseAgreementInitialClosingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAPurchaseAgreementInitialClosingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Closing</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAPurchaseAgreementInitialClosingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Purchase Agreement Initial Closing [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" xlink:type="locator" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A achievement of specific clinical milestone one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" xlink:to="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specific Clinical Milestone One</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Achievement Of Specific Clinical Milestone One [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" xlink:type="locator" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A achievement of specific clinical milestone two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" xlink:to="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specific Clinical Milestone Two</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Achievement Of Specific Clinical Milestone Two [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" xlink:type="locator" xlink:label="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A upon achievement of certain defined clinical milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" xlink:to="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upon Achievement of Certain Defined Clinical Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Upon Achievement Of Certain Defined Clinical Milestones [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">PBM TGT holdings, limited liability company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" xlink:to="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PBM TGT Holdings, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P B M T G T Holdings Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_NolanCapitalLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="tsha_NolanCapitalLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_NolanCapitalLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nolan capital, limited liability company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_NolanCapitalLimitedLiabilityCompanyMember" xlink:to="tsha_NolanCapitalLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_NolanCapitalLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nolan Capital, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_NolanCapitalLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nolan Capital Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBPurchaseAgreementMember" xlink:type="locator" xlink:label="tsha_SeriesBPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesBPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SeriesBPurchaseAgreementMember" xlink:to="tsha_SeriesBPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesBPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SeriesBPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk Free Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" xlink:type="locator" xlink:label="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input probability of achieving clinical milestones and timing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" xlink:to="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Achieving Clinical Milestones and Timing</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Probability Of Achieving Clinical Milestones And Timing [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="tsha_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="tsha_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock, gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ProceedsFromIssuanceOfCommonStockGross" xlink:to="tsha_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during period</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs, including underwriters&#8217; discounts and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Clinical milestones for gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" />
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock tranche liability offering price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock tranche liability measurement input.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" />
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock tranche liability liquidity term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock tranche liability, offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Tranche Liability Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock tranche liability, measurement input</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Tranche Liability Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock tranche liability, term</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Tranche Liability Liquidity Term</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_PreferredStockTrancheLiability" />
    <link:label xml:lang="en-US" xlink:label="tsha_PreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Stock Tranche Liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PreferredStockTrancheLiability" xlink:to="tsha_PreferredStockTrancheLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PreferredStockTrancheLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_TwoThousandTwentyStockIncentivePlanMember" xlink:to="tsha_TwoThousandTwentyStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="tsha_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_EmployeeStockPurchasePlanMember" xlink:to="tsha_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CancelledOptionsMember" xlink:type="locator" xlink:label="tsha_CancelledOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_CancelledOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cancelled options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_CancelledOptionsMember" xlink:to="tsha_CancelledOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_CancelledOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled Options</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_CancelledOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cancelled Options [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CertainEmployeesAndConsultantsMember" xlink:type="locator" xlink:label="tsha_CertainEmployeesAndConsultantsMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_CertainEmployeesAndConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Certain employees and consultants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_CertainEmployeesAndConsultantsMember" xlink:to="tsha_CertainEmployeesAndConsultantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_CertainEmployeesAndConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain Employees and Consultants</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_CertainEmployeesAndConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certain Employees And Consultants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Three [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationAwardTrancheFourMember" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationAwardTrancheFourMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation award tranche four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationAwardTrancheFourMember" xlink:to="tsha_ShareBasedCompensationAwardTrancheFourMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Four</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationAwardTrancheFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Four [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">President and chief executive officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PresidentAndChiefExecutiveOfficerMember" xlink:to="tsha_PresidentAndChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RA Session II</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">President And Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of automatic increase every year in common stock shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" xlink:to="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of automatic increase every year in common stock shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Automatic Increase Every Year In Common Stock Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, terms of award issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment award, options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issued under ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grants in period grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options replacement units grants in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment award, options granted, exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, options grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares awarded</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Replacement Units Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, plan modification, incremental cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, options, weighted-average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding. Stock Options, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options cancelled or forfeited, Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding. Stock Options, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2021, Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at March 31, 2021, Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Weighted Average Exercise Price, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options cancelled or forfeited, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2021, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at March 31, 2021, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement By share based payment award options granted weighted average remaining contractual term1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2021, Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Options exercisable at March 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grants in period intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options cancelled or forfeited in period intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Aggregate Intrinsic Value, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options cancelled or forfeited, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Or Forfeited In Period Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Aggregate Intrinsic Value, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at March 31, 2021, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at March 31, 2021, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, options, compensation cost not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, compensation cost not yet recognized, weighted-average period of recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment award, RSU/RSA granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, vesting rights percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, unvested RSU/RSA granted, compensation cost not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested, Number of Shares, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted units/stock granted, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested, Number of Shares, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested, Weighted Average Grant Date Fair Value per Share, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted units/stock granted, Weighted Average Grant Date Fair Value per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Grant Date Fair Value per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested, Weighted Average Grant Date Fair Value per Share, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award requisite service vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment award, RSU/RSA granted, weighted average grant date fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested RSUs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested RSAs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_NumberOfSecuredPromissoryNotes" xlink:type="locator" xlink:label="tsha_NumberOfSecuredPromissoryNotes" />
    <link:label xml:lang="en-US" xlink:label="tsha_NumberOfSecuredPromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of secured promissory notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_NumberOfSecuredPromissoryNotes" xlink:to="tsha_NumberOfSecuredPromissoryNotes_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SecuredPromissoryNotesMember" xlink:type="locator" xlink:label="tsha_SecuredPromissoryNotesMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_SecuredPromissoryNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Secured promissory notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_SecuredPromissoryNotesMember" xlink:to="tsha_SecuredPromissoryNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_SecuredPromissoryNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Promissory Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_SecuredPromissoryNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secured Promissory Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMCapitalGroupLLCMember" xlink:type="locator" xlink:label="tsha_PBMCapitalGroupLLCMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_PBMCapitalGroupLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">PBM Capital Group, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PBMCapitalGroupLLCMember" xlink:to="tsha_PBMCapitalGroupLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PBMCapitalGroupLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PBM Capital Group, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PBMCapitalGroupLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P B M Capital Group L L C [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMTGTHoldingsLLCMember" xlink:type="locator" xlink:label="tsha_PBMTGTHoldingsLLCMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_PBMTGTHoldingsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">PBM TGT Holdings, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PBMTGTHoldingsLLCMember" xlink:to="tsha_PBMTGTHoldingsLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PBMTGTHoldingsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PBM TGT Holdings, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PBMTGTHoldingsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P B M T G T Holdings L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ServicesAgreementMember" xlink:type="locator" xlink:label="tsha_ServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_ServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ServicesAgreementMember" xlink:to="tsha_ServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_ServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Services Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Paul B. Manning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_NumberOfSecuredPromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of secured promissory notes</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_NumberOfSecuredPromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Secured Promissory Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount, related party transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Debt</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OwnershipPercentageInExcessOfCapitalStock" xlink:type="locator" xlink:label="tsha_OwnershipPercentageInExcessOfCapitalStock" />
    <link:label xml:lang="en-US" xlink:label="tsha_OwnershipPercentageInExcessOfCapitalStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership percentage in excess of capital stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_OwnershipPercentageInExcessOfCapitalStock" xlink:to="tsha_OwnershipPercentageInExcessOfCapitalStock_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" xlink:type="locator" xlink:label="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" />
    <link:label xml:lang="en-US" xlink:label="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional consideration to related party under operating agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" xlink:to="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting and other administrative and management services fee per month</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_OwnershipPercentageInExcessOfCapitalStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage more than capital stock</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_OwnershipPercentageInExcessOfCapitalStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage In Excess Of Capital Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration payable under operating agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Consideration To Related Party Under Operating Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_DurhamLeaseMember" xlink:type="locator" xlink:label="tsha_DurhamLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_DurhamLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Durham lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_DurhamLeaseMember" xlink:to="tsha_DurhamLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_DurhamLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Durham Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_DurhamLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Durham Lease [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_DallasLeaseMember" xlink:type="locator" xlink:label="tsha_DallasLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_DallasLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dallas lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_DallasLeaseMember" xlink:to="tsha_DallasLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_DallasLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dallas Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_DallasLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dallas Lease [Member]</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PegasusParkLLCMember" xlink:type="locator" xlink:label="tsha_PegasusParkLLCMember" />
    <link:label xml:lang="en-US" xlink:label="tsha_PegasusParkLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pegasus Park, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_PegasusParkLLCMember" xlink:to="tsha_PegasusParkLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_PegasusParkLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pegasus Park L L C</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_PegasusParkLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pegasus Park L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating lease landlord square feet manufacturing facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Or Available For Operating Lease Number Of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:type="locator" xlink:label="us-gaap_OperationsCommencedDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operations Commenced Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease extend term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OperatingLeasesInitialDirectCosts" xlink:type="locator" xlink:label="tsha_OperatingLeasesInitialDirectCosts" />
    <link:label xml:lang="en-US" xlink:label="tsha_OperatingLeasesInitialDirectCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases initial direct costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_OperatingLeasesInitialDirectCosts" xlink:to="tsha_OperatingLeasesInitialDirectCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="tsha_OperatingLeasesInitialDirectCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases initial direct costs</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_OperatingLeasesInitialDirectCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Initial Direct Costs</link:label>
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" xlink:type="locator" xlink:label="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" />
    <link:label xml:lang="en-US" xlink:label="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation for payment of initial base rent for office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" xlink:to="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" xlink:type="locator" xlink:label="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" />
    <link:label xml:lang="en-US" xlink:label="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum estimated monthly base rent increase annually during term of lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" xlink:to="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease_lbl" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" xlink:type="locator" xlink:label="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" />
    <link:label xml:lang="en-US" xlink:label="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum construction allowance provided by landlord per rentable square foot.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" xlink:to="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, option to extend description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation for payment of initial base rent for office space</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Obligation For Payment Of Initial Base Rent For Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum estimated monthly base rent increase annually during term of lease</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Estimated Monthly Base Rent Increase Annually During Term Of Lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum construction allowance provided by landlord per rentable square foot</link:label>
    <link:label xml:lang="en-US" xlink:label="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Construction Allowance Provided By Landlord Per Rentable Square Foot</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivable" xlink:type="locator" xlink:label="us-gaap_LeaseIncentiveReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseIncentiveReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease construction incentive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentiveReceivable" xlink:to="us-gaap_LeaseIncentiveReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseIncentiveReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentive Receivable</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>39
<FILENAME>tsha-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-11T01:24:34.7885232+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 1f73c44147c0412f9cfba93145d27295 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tayshagtx.com/20210331/role/TemplateLink" xlink:href="tsha-20210331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tsha-20210331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsLeasingNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNetNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsLeasingNetNoncurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityStockOfferingCosts" xlink:type="locator" xlink:label="tsha_TemporaryEquityStockOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsha_TemporaryEquityStockOfferingCosts" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="tsha-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AllocationOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_AllocationOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchAndDevelopmentLicenseNotYetPaid" xlink:type="locator" xlink:label="tsha_ResearchAndDevelopmentLicenseNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" xlink:type="locator" xlink:label="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsha_ResearchAndDevelopmentLicenseNotYetPaid" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsha_AllocationOfPreferredStockTrancheLiability" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperations" xlink:href="tsha-20210331.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="tsha-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements" xlink:href="tsha-20210331.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability" xlink:href="tsha-20210331.xsd#Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShare" xlink:href="tsha-20210331.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="tsha-20210331.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="tsha-20210331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="tsha-20210331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tsha-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" xlink:type="locator" xlink:label="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="tsha-20210331.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CommonStockIncreaseInOutstandingShares" xlink:type="locator" xlink:label="tsha_CommonStockIncreaseInOutstandingShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:type="locator" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember_li0l2" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:type="locator" xlink:label="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsha_TwoThousandTwentyEquityIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesBConvertiblePreferredStockMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember_li0l2" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsTable" xlink:to="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="tsha_CommonStockIncreaseInOutstandingShares" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems" xlink:to="us-gaap_Cash" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidClinicalTrial" xlink:type="locator" xlink:label="tsha_PrepaidClinicalTrial" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidBonus" xlink:type="locator" xlink:label="tsha_PrepaidBonus" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PrepaidResearchAndDevelopmentContracts" xlink:type="locator" xlink:label="tsha_PrepaidResearchAndDevelopmentContracts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_PrepaidResearchAndDevelopmentContracts" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_PrepaidBonus" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_PrepaidClinicalTrial" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="tsha_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsha_LaboratoryEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedConstructionInProgressCurrent" xlink:type="locator" xlink:label="tsha_AccruedConstructionInProgressCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedLicenseFeesCurrent" xlink:type="locator" xlink:label="tsha_AccruedLicenseFeesCurrent" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="tsha_AccruedResearchAndDevelopmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_AccruedResearchAndDevelopmentCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_AccruedLicenseFeesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="tsha_AccruedConstructionInProgressCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" xlink:type="locator" xlink:label="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_UpfrontPayment" xlink:type="locator" xlink:label="tsha_UpfrontPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" xlink:type="locator" xlink:label="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_RegulatoryRelatedMilestonesObligationPayable" xlink:type="locator" xlink:label="tsha_RegulatoryRelatedMilestonesObligationPayable" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentOfOneTimeUpfrontLicenseFee" xlink:type="locator" xlink:label="tsha_PaymentOfOneTimeUpfrontLicenseFee" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AdditionalMilestonePayments" xlink:type="locator" xlink:label="tsha_AdditionalMilestonePayments" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" xlink:type="locator" xlink:label="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentOfLicenseFee" xlink:type="locator" xlink:label="tsha_PaymentOfLicenseFee" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAgreementCommercialMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAgreementCommercialMilestonesPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_LicenseAgreementRegulatoryMilestonesPayment" xlink:type="locator" xlink:label="tsha_LicenseAgreementRegulatoryMilestonesPayment" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PaymentsToAcquireLicenseRight" xlink:type="locator" xlink:label="tsha_PaymentsToAcquireLicenseRight" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchGrantOutstandingFundAmount" xlink:type="locator" xlink:label="tsha_ResearchGrantOutstandingFundAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchGrantOfCommittedFundAmount" xlink:type="locator" xlink:label="tsha_ResearchGrantOfCommittedFundAmount" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" xlink:type="locator" xlink:label="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" xlink:type="locator" xlink:label="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" xlink:type="locator" xlink:label="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" xlink:type="locator" xlink:label="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" xlink:type="locator" xlink:label="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaTherapeuticsIncMember" xlink:type="locator" xlink:label="tsha_AbeonaTherapeuticsIncMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaRettAgreementMember" xlink:type="locator" xlink:label="tsha_AbeonaRettAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AbeonaCLN1AgreementsMember" xlink:type="locator" xlink:label="tsha_AbeonaCLN1AgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_QueensAgreementMember" xlink:type="locator" xlink:label="tsha_QueensAgreementMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_UTSouthwesternAgreementMember" xlink:type="locator" xlink:label="tsha_UTSouthwesternAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsha_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_UTSouthwesternAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_QueensAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_AbeonaCLN1AgreementsMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_AbeonaRettAgreementMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_AbeonaTherapeuticsIncMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_ResearchGrantOfCommittedFundAmount" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_ResearchGrantOutstandingFundAmount" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PaymentsToAcquireLicenseRight" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAgreementRegulatoryMilestonesPayment" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAgreementCommercialMilestonesPayment" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PaymentOfLicenseFee" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_AdditionalMilestonePayments" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_PaymentOfOneTimeUpfrontLicenseFee" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_RegulatoryRelatedMilestonesObligationPayable" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_UpfrontPayment" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ChangeInFairValueOfPreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PreferredStockTrancheLiability" xlink:type="locator" xlink:label="tsha_PreferredStockTrancheLiability" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" xlink:type="locator" xlink:label="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="tsha_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" xlink:type="locator" xlink:label="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBPurchaseAgreementMember" xlink:type="locator" xlink:label="tsha_SeriesBPurchaseAgreementMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_NolanCapitalLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="tsha_NolanCapitalLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" xlink:type="locator" xlink:label="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" xlink:type="locator" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" xlink:type="locator" xlink:label="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAPurchaseAgreementInitialClosingMember" xlink:type="locator" xlink:label="tsha_SeriesAPurchaseAgreementInitialClosingMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAPurchaseAgreementMember" xlink:type="locator" xlink:label="tsha_SeriesAPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsha_SeriesBConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAPurchaseAgreementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAPurchaseAgreementInitialClosingMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_NolanCapitalLimitedLiabilityCompanyMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_SeriesBPurchaseAgreementMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ProceedsFromIssuanceOfCommonStockGross" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_PreferredStockTrancheLiability" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsha_ChangeInFairValueOfPreferredStockTrancheLiability" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationAwardTrancheFourMember" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationAwardTrancheFourMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CertainEmployeesAndConsultantsMember" xlink:type="locator" xlink:label="tsha_CertainEmployeesAndConsultantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_CancelledOptionsMember" xlink:type="locator" xlink:label="tsha_CancelledOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="tsha_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="tsha_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsha_TwoThousandTwentyEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsha_TwoThousandTwentyStockIncentivePlanMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsha_EmployeeStockPurchasePlanMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsha_CancelledOptionsMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tsha_CertainEmployeesAndConsultantsMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="tsha_ShareBasedCompensationAwardTrancheFourMember" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tsha_PresidentAndChiefExecutiveOfficerMember" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="13440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="13790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="locator" xlink:label="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriodIntrinsicValue" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCalculationOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureNetLossPerCommonShareScheduleOfCalculationOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCalculationOfBasicAndDilutedNetLossPerCommonShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="tsha_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tsha_SeriesAConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="tsha-20210331.xsd#tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" xlink:type="locator" xlink:label="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OwnershipPercentageInExcessOfCapitalStock" xlink:type="locator" xlink:label="tsha_OwnershipPercentageInExcessOfCapitalStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_NumberOfSecuredPromissoryNotes" xlink:type="locator" xlink:label="tsha_NumberOfSecuredPromissoryNotes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ServicesAgreementMember" xlink:type="locator" xlink:label="tsha_ServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMTGTHoldingsLLCMember" xlink:type="locator" xlink:label="tsha_PBMTGTHoldingsLLCMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PBMCapitalGroupLLCMember" xlink:type="locator" xlink:label="tsha_PBMCapitalGroupLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="tsha_PresidentAndChiefExecutiveOfficerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_SecuredPromissoryNotesMember" xlink:type="locator" xlink:label="tsha_SecuredPromissoryNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tsha_SecuredPromissoryNotesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tsha_PresidentAndChiefExecutiveOfficerMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tsha_PBMCapitalGroupLLCMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tsha_PBMTGTHoldingsLLCMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="tsha_ServicesAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tsha_NumberOfSecuredPromissoryNotes" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tsha_OwnershipPercentageInExcessOfCapitalStock" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tsha-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivable" xlink:type="locator" xlink:label="us-gaap_LeaseIncentiveReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" xlink:type="locator" xlink:label="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" xlink:type="locator" xlink:label="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" xlink:type="locator" xlink:label="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_OperatingLeasesInitialDirectCosts" xlink:type="locator" xlink:label="tsha_OperatingLeasesInitialDirectCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:type="locator" xlink:label="us-gaap_OperationsCommencedDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_PegasusParkLLCMember" xlink:type="locator" xlink:label="tsha_PegasusParkLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_DallasLeaseMember" xlink:type="locator" xlink:label="tsha_DallasLeaseMember" />
    <link:loc xlink:href="tsha-20210331.xsd#tsha_DurhamLeaseMember" xlink:type="locator" xlink:label="tsha_DurhamLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_DurhamLeaseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsha_DallasLeaseMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsha_PegasusParkLLCMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tsha_DallasLeaseMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_OperatingLeasesInitialDirectCosts" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseIncentiveReceivable" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940007864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TSHA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Taysha Gene Therapies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-3199512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 Pegasus Park Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Ste 1430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">612-0000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,917,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631942696264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 228,684<span></span>
</td>
<td class="nump">$ 251,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,817<span></span>
</td>
<td class="nump">6,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">239,629<span></span>
</td>
<td class="nump">257,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsLeasingNetNoncurrent', window );">Deferred lease asset</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">242,829<span></span>
</td>
<td class="nump">258,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,083<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">14,875<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,958<span></span>
</td>
<td class="nump">7,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,957<span></span>
</td>
<td class="nump">7,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies - Note 10</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2021 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value per share; 200,000,000 shares authorized and 37,761,435 issued and outstanding as of March 31, 2021 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">316,022<span></span>
</td>
<td class="nump">312,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(93,150)<span></span>
</td>
<td class="num">(61,126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">222,872<span></span>
</td>
<td class="nump">251,302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 242,829<span></span>
</td>
<td class="nump">$ 258,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsLeasingNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents costs incurred by the lessor that are (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction. The costs represented by this element are those costs not expected to be recognized in (amortized to) earnings within one year from the date of the statement of financial position or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121585684&amp;loc=d3e40246-112709<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsLeasingNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631939991880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">37,761,435<span></span>
</td>
<td class="nump">37,761,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">37,761,435<span></span>
</td>
<td class="nump">37,761,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940419960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 23,854<span></span>
</td>
<td class="nump">$ 5,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">32,090<span></span>
</td>
<td class="nump">5,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(32,090)<span></span>
</td>
<td class="num">(5,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ChangeInFairValueOfPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,024)<span></span>
</td>
<td class="num">$ (5,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">36,992,377<span></span>
</td>
<td class="nump">10,894,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ChangeInFairValueOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ChangeInFairValueOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631942491096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
<td class="num">$ (1,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,894,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,431)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="num">(5,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="num">(6,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,894,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 251,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,428<span></span>
</td>
<td class="num">(61,126)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,024)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 222,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,022<span></span>
</td>
<td class="num">$ (93,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631947525880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (Unaudited)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability', window );">Issuance of preferred stock tranche liability</a></td>
<td class="nump">$ 1,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_TemporaryEquityStockOfferingCosts', window );">Issuance of convertible preferred stock, offering costs</a></td>
<td class="nump">$ 430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issuance of preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_TemporaryEquityStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_TemporaryEquityStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940030024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (32,024,000)<span></span>
</td>
<td class="num">$ (5,431,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ChangeInFairValueOfPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development license expense</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,594,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,184,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,872,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">3,183,000<span></span>
</td>
<td class="nump">907,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related party</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,035,000)<span></span>
</td>
<td class="num">(1,699,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(534,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(534,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuances of Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of note payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,646,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,027,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(22,569,000)<span></span>
</td>
<td class="nump">16,328,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at the beginning of the period</a></td>
<td class="nump">251,253,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at the end of the period</a></td>
<td class="nump">228,684,000<span></span>
</td>
<td class="nump">16,328,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ResearchAndDevelopmentLicenseNotYetPaid', window );">Purchase of research and development license not yet paid</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses', window );">Property, plant and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">1,101,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Acquisition of property, plant and equipment funded by landlord</a></td>
<td class="nump">607,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Deferred offering costs not yet paid</a></td>
<td class="nump">$ 128,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AllocationOfPreferredStockTrancheLiability', window );">Allocation of preferred stock tranche liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Series A issuance costs not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_AllocationOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocation of preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_AllocationOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ChangeInFairValueOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ChangeInFairValueOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued expense and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_IncreaseDecreaseInAccruedExpenseAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PropertyAndEquipmentInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ResearchAndDevelopmentLicenseNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development license not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ResearchAndDevelopmentLicenseNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631944098968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business Operations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"></a><a name="NOTE_1ORGANIZATION_DESCRIPTION_BUSINESS_"></a>Note 1&#8212;Organization and Description of Business Operations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taysha Gene Therapies, Inc. (the &#8220;Company&#8221; or &#8220;Taysha&#8221;) was originally formed under the laws of the State of Texas on September 20, 2019 (&#8220;Inception&#8221;). Taysha converted to a Delaware corporation on February 13, 2020, which had no impact to the Company&#8217;s par value or issued and authorized capital structure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taysha is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Split </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2020, the Company effected a 1.0895-for-one stock split of its authorized, issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s convertible preferred stock as discussed in Note 5. Accordingly, all share and per share amounts for the periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the convertible preferred stock conversion ratios. On September 16, 2020, the Company also increased the number of shares of common stock authorized for issuance under the 2020 Equity Incentive Plan (the &#8220;Existing Plan&#8221;) to 3,845,294. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 23, 2020, the Company&#8217;s registration statement on Form S-1 (File No. 333-248559) related to the initial public offering (&#8220;IPO&#8221;) of its common stock became effective and on September 28, 2020, the IPO closed. Pursuant to the IPO, the Company issued and sold 9,050,000 shares of common stock at a public offering price of $20.00 per share, which included 1,180,434 shares of common stock issued upon the exercise in full of the underwriters&#8217; option to purchase additional shares. The Company received net proceeds of $165.9 million after <font style="color:#000000;">deducting underwriting discounts and commissions and other offering costs of $2.5&#160;million. The shares began trading on the Nasdaq Global Select Market on September 24, 2020.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2020, in connection with the closing of the IPO, 10,000,000 shares of Series A and 5,647,048 shares of Series B convertible preferred stock automatically converted into an aggregate of 17,047,378 shares of common stock with a conversion ratio of 1.0895 shares of common stock for each share of Series A and Series B convertible preferred stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the IPO, including the underwriters&#8217; exercise in full of their option to purchase additional shares, and the conversions of the Series A and B convertible preferred stock, the Company&#8217;s total number of outstanding shares increased by 26,097,378 immediately following the closing of the IPO.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the effectiveness of the Company&#8217;s registration statement related to the IPO, the Company&#8217;s 2020 Stock Incentive Plan (the &#8220;New Plan&#8221;) and 2020 Employee Stock Purchase Plan became effective. At that time, all shares reserved for issuance under the Existing Plan ceased to be available for issuance under such plan and became available for issuance under the New Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of March 31, 2021, the Company had an accumulated deficit of $93.2 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of the Company&#8217;s IPO, between March and July 2020, the Company closed on the sale of an aggregate of 10,000,000 shares of Series A convertible preferred stock for gross proceeds of $30.0 million. Between July and August 2020, the Company closed on the sale of an aggregate of 5,647,048 shares of Series B convertible preferred stock for gross proceeds of $96.0 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future capital requirements will depend on many factors, including the timing and extent of spending on research and development and the market acceptance of the Company&#8217;s products. The Company will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable to the Company.<font style="color:#000000;"> As of March 31, 2021, the Company had cash of</font> $228.7 <font style="color:#000000;">million which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the novel coronavirus (&#8220;COVID-19&#8221;) emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a global pandemic, resulting in federal, state and local governments and private entities implementing various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders, and advisories and quarantining people who may have been exposed to the virus. The Company has been actively monitoring COVID-19 and its impact globally. Management believes the financial results for the three months ended March 31, 2021 were not significantly impacted by COVID-19. In addition, management believes the remote working arrangements and travel restrictions imposed by various governmental jurisdictions have had limited impact on the Company&#8217;s ability to maintain internal operations during the three months ended March 31, 2021. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632030275928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2&#8212;Summary of Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X and are consistent in all material respects with those included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission ("SEC") on March 3, 2021 (the &#8220;2020 Annual Report&#8221;). In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The consolidated balance sheet as of December 31, 2020 is derived from audited financial statements, however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes in the Company&#8217;s 2020 Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated financial statements include the accounts of Taysha and its inactive wholly owned U.S. subsidiaries that were incorporated during 2020. All intercompany transactions and balances have been eliminated in consolidation. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company&#8217;s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company&#8217;s critical and significant accounting estimates, including assessment of impairment of long-lived assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in the Company&#8217;s significant accounting policies as disclosed in Note 2 to the audited consolidated financial statements included in the 2020 Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as amended, with guidance regarding the accounting for and disclosure of leases. This update requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheets. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will become effective for the Company for annual reporting periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The new standard requires the use of one of the following two approaches, either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company has not yet concluded which approach will be utilized to adopt the new standard and is currently evaluating the impact of this standard on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631943904840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3&#8212;Balance Sheet Components </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,462</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid bonus</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical trial</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">944</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">331</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,817</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,626</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment consisted of the following (in thousands):<font style="margin-left:36pt;"></font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,889</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $32,000 for the three months ended March 31, 2021. There was no depreciation expense for the three months ended March 31, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,672</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,106</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued license fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,766</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,119</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631944207400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research, Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research, Collaboration and License Agreements</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4&#8212;Research, Collaboration and License Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">UT Southwestern Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 19, 2019, the Company entered into a research, collaboration and license agreement (&#8220;UT Southwestern Agreement&#8221;) with the Board of Regents of the University of Texas System on behalf of The University of Texas Southwestern Medical Center (&#8220;UT Southwestern&#8221;). Under the UT Southwestern Agreement, UT Southwestern is primarily responsible for preclinical development activities with respect to licensed products for use in certain specified indications (up to investigational new drug application-enabling studies), and the Company is responsible for all subsequent clinical development and commercialization activities with respect to the licensed products. UT Southwestern will conduct such preclinical activities for a two-year period under mutually agreed upon sponsored research agreements that were entered into beginning in April 2020. During the initial research phase, the Company has the right to expand the scope of specified indications under the UT Southwestern Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the UT Southwestern Agreement, the Company obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern and a non-exclusive, worldwide, royalty-free license under certain know-how of UT Southwestern, in each case to make, have made, use, sell, offer for sale and import licensed products for use in certain specified indications. Additionally, the Company obtained a non-exclusive, worldwide, royalty-free license under certain patents and know-how of UT Southwestern for use in all human uses, with a right of first refusal to obtain an exclusive license under certain of such patent rights and an option to negotiate an exclusive license under other of such patent rights. The Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2020, the Company amended the UT Southwestern Agreement to include the addition of another licensed product and certain indications, and a right of first refusal to the Company over certain patient dosing patents. No additional consideration was transferred in connection with this amendment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UT Southwestern Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last valid claim of a licensed patent in such country for such licensed product. After the initial research term, the Company may terminate the agreement, on an indication-by-indication and licensed product-by-licensed product basis, at any time upon specified written notice to UT Southwestern. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, as partial consideration for the license rights granted under the UT Southwestern Agreement, the Company issued 2,179,000 shares of its common stock, or 20% of its then outstanding fully-diluted common stock, to UT Southwestern. As additional consideration, UT Southwestern was entitled to receive additional shares if their holdings fell below 10% on a fully-diluted basis before or as a result of the completion of a qualified financing. In March 2020, following the initial closing of the Series A convertible preferred stock agreement, which met the definition of such qualified financing, the anti-dilution feature expired and no additional shares were issued. The Company does not have any future milestone or royalty obligations to UT Southwestern under the UT Southwestern Agreement other than costs related to maintenance of patents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Queen&#8217;s Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2019, the Company entered into a research grant agreement (&#8220;RGA&#8221;) with Queen&#8217;s University at Kingston (&#8220;Queen&#8217;s&#8221;), for certain research and development activities related to the generation of AAV9 vector. The Company committed to fund $3.8 million under the RGA with Queen&#8217;s. The Company issued Queen&#8217;s a promise-to-pay note whereby any amounts paid directly by Queen&#8217;s for the manufacture of the vector for use in the funded research activities, to the extent such amounts had not already been funded by the Company to Queen&#8217;s, would become a loan obligation for the Company (the &#8220;Note&#8221;), subject to an interest rate of 6%. Any amounts outstanding under the Note were required to be repaid, along with any accrued interest, by or before June 30, 2020. In the event of default, any amount outstanding was deemed immediately payable by RA Session II, the Company&#8217;s President and Chief Executive Officer, as a personal guarantor (see Note 8). For the period from Inception through December 31, 2019, the Company did not incur any expenses associated with the Queen&#8217;s RGA, and no amounts were due or outstanding under the Note as of December 31, 2019. <font style="color:#000000;">For the year ended December 31, 2020, the Company paid all expenses associated with the Queen&#8217;s RGA, thus no amounts were due or outstanding under the Note as of December 31, 2020, and the promise-to-pay has therefore expired.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 21, 2020, the Company entered into a license agreement with Queen&#8217;s (the &#8220;Queen&#8217;s Agreement&#8221;) to obtain the exclusive perpetual, royalty-bearing license, with the right to sublicense through multiple tiers, under certain patent rights and know-how of Queen&#8217;s, including certain improvements to such patent rights and know-how, to develop products in any field which use one or more valid claims of the patents licensed under the Queen&#8217;s Agreement (the &#8220;Licensed Patents&#8221;), or the technology, information and intellectual property related to the patents licensed under the Queen&#8217;s Agreement (together with the Licensed Patents, the &#8220;Licensed Products&#8221;), and to make, have made, use, sell, offer for sale, import and export Licensed Products and otherwise exploit such patents and know-how for use in certain specified indications. In exchange for the rights granted to the Company, the Company made a cash payment of $3.0 million in April 2020 which is recorded in research and development expenses in the condensed consolidated statements of operations for the three months ended March 31, 2020. The Company is obligated to make aggregate cash payments of up to $10.0 million upon the completion of a combination of regulatory milestones and up to $10.0 million upon the completion of a combination of commercial milestones. In further consideration of the rights granted, beginning with the Company&#8217;s first commercial sale of the Licensed Products, the Company will also pay an annual earned royalty in the low single digits on net sales of Licensed Products, subject to certain customary reductions, and a percentage of non-royalty sublicensing revenue ranging in the low double digits. Royalties are payable, on a Licensed Products-by-Licensed Products and a country-by-country basis, until expiration of the last valid claim of a Licensed Patent covering such Licensed Products in such country and the expiration of any regulatory exclusivity for such Licensed Products in such country. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abeona CLN1 Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into license and inventory purchase agreements with Abeona Therapeutics Inc. (&#8220;Abeona&#8221;) for worldwide exclusive rights to certain intellectual property rights and know-how relating to the research, development and manufacture of ABO-202, an AAV-based gene therapy for CLN1 disease (also known as infantile Batten disease). Under the terms of the agreements, the Company made initial cash payments to Abeona of $3.0 million for the license fee and $4.0 million for purchase of clinical materials and reimbursement for previously incurred development costs in October 2020. In exchange for the license rights, the Company recorded an aggregate of $7.0 million within research and development expenses in the consolidated statements of operations for the year ended December 31, 2020 since the acquired license or acquired inventory do not have an alternative future use. The Company is obligated to make up to $26.0 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed CLN1 product. The Company will also pay an annual earned royalty in the high single digits on net sales of any licensed CLN1 products. The license agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. The Company may terminate the license agreement for convenience upon specified prior written notice to Abeona.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No additional milestone payments were made in connection with this agreement during the three months ended March 31, 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abeona Rett Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 29, 2020, the Company entered into a license agreement (the &#8220;Abeona Rett Agreement&#8221;) with Abeona pursuant to which the Company obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain obligations of Abeona, the Company is required to use commercially reasonable efforts to develop at least one licensed product and commercialize at least one licensed product in the United States.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Abeona Rett Agreement, the Company paid Abeona a one-time upfront license fee of $3.0 million which is recorded in research and development expenses in the consolidated statements of operations for the year ended December 31, 2020 since the acquired license does not have an alternative future use. The Company is obligated to pay Abeona up to $26.5 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed Rett product and high single-digit royalties on net sales of licensed Rett products. Royalties are payable on a licensed product-by-licensed product and country-by-country basis until the latest of the expiration or revocation or complete rejection of the last licensed patent covering such licensed product in the country where the licensed product is sold, the loss of market exclusivity in such country where the product is sold, or, if no licensed product exists in such country and no market exclusivity exists in such country, ten years from first commercial sale of such licensed product in such country.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Abeona Rett Agreement expires on a country-by-country and licensed product-by-licensed product basis upon the expiration of the last royalty term of a licensed product. Either party may terminate the agreement upon an uncured material breach of the agreement or insolvency of the other party. The Company may terminate the agreement for convenience upon specified prior written notice to Abeona.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No additional milestone payments were made in connection with the Abeona Rett Agreement during the three months ended March 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Acquisition of Worldwide Rights for TSHA-120 for the treatment of GAN </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the Company acquired the exclusive worldwide rights to a clinical-stage AAV9 gene therapy program, now known as TSHA-120, for the treatment of Giant Axonal Neuropathy (&#8220;GAN&#8221;). TSHA-120 is an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health in close collaboration with a leading patient advocacy group focused on finding treatments and cures for GAN. TSHA-120 has received rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration for the treatment of GAN. The worldwide rights was acquired through a license agreement, effective March 29, 2021, between Hannah&#8217;s Hope Fund for Giant Axonal Neuropathy, Inc. (&#8220;HHF&#8221;).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, in exchange for granting the Company the exclusive worldwide rights to TSHA-120, HHF will receive an upfront payment of $5.5 million and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3 million, as well as a low, single-digit royalty on net sales upon commercialization of the product. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the license rights, the Company recorded an aggregate of $5.5 million within research and development expenses in the condensed consolidated statements of operations since the acquired license does not have an alternative future use. This license fee was not paid as of March 31, 2021 and has been recorded in accrued expenses and other current liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research, collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631944050376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5&#8212;Stockholders&#8217; Equity (Deficit), Convertible Preferred Stock and Tranche Liability </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Authorized Shares</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company amended its certificate of incorporation on March 4, 2020, July 2, 2020 and again on July 28, 2020 such that the total number of shares of common stock authorized to be issued was increased to 32,685,000, and the total number of shares of preferred stock authorized to be issued was increased to 15,647,052, of which 10,000,000 preferred shares were designated Series A convertible preferred stock and 5,647,052 were designated Series B convertible preferred stock. On September 28, 2020, the Company amended its certificate of incorporation such that the total number of shares of common stock authorized to be issued was increased to 200,000,000, and the total number of shares of new preferred stock authorized to be issued was 10,000,000. As of March 31, 2021 and December 31, 2020, no shares of preferred stock were issued or outstanding.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IPO</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2020, the Company issued an aggregate of 7,869,566 shares of common stock in the IPO, and on September 29, 2020, the Company issued an aggregate of 1,180,434 shares of common stock upon the underwriters&#8217; exercise in full of their option to purchase additional shares, each at the public offering price of $20.00 per share less underwriting discounts and commissions. In connection with the IPO, the Company received gross proceeds of $181.0 million, which was offset by issuance costs, including underwriters&#8217; discounts and commissions, of approximately $15.1 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series A and B convertible preferred stock</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2020, the Company entered into a purchase agreement (the &#8220;Series A Purchase Agreement&#8221;) providing for a private placement of up to 10,000,000 shares of Series A convertible preferred stock at an original issuance price of $3.00 per share, subject to separate closings, including: (1) 6,000,000 shares at the initial closing on March 4, 2020, and (2) 2,000,000 shares at each of two subsequent closings triggered by the achievement of specific clinical milestones. The Series A Purchase Agreement obligated the Company to issue and sell and the Series A investors to purchase up to a total of 4,000,000 additional shares of Series A convertible preferred stock (the &#8220;Milestone Shares&#8221;) at the same price per share upon the achievement of certain defined clinical milestones (the &#8220;tranche liability&#8221;). The determination as to whether the milestone events had been met was subject to certification by the Board of Directors. Each Series A investor had the right, but not the obligation, to purchase all or any portion of the Milestone Shares at any time in its sole option and in its sole and absolute discretion, whether or not the Company had achieved the applicable clinical milestone.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2020, several affiliated Series A investors elected to exercise in full their options to purchase 200,000 shares, representing all of their remaining pro-rata portion of the Milestone Shares, prior to the Company&#8217;s achievement of the clinical milestones for gross proceeds of $0.6 million. The remainder of the Series A investors exercised in full their options to purchase 3,800,000 shares, representing all of their remaining pro-rata portion of the Milestone Shares, prior to the Company&#8217;s achievement of the clinical milestones, for gross proceeds of $11.4 million between July 1, 2020 and July 2, 2020. As part of this issuance, the Company issued and sold 3,266,667 shares to PBM TGT Holdings, LLC and 400,000 shares to Nolan Capital, LLC, which stockholders are controlled by certain members of the Company&#8217;s board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2020, the Company entered into a purchase agreement (the &#8220;Series B Purchase Agreement&#8221;), as later amended on July 28, 2020, providing for a private placement of up to 5,647,052 shares of Series B convertible preferred stock. The Company sold 5,647,048 shares of Series B convertible preferred stock at a price of $17.00 per share in multiple closings in July and August 2020 for gross proceeds of $96.0 million. The majority of investors that participated in the Series B Purchase Agreement were new investors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described above, in connection with the closing of the IPO, all shares of Series A and Series B convertible preferred stock were automatically converted into an aggregate of 17,047,378 shares of common stock with a conversion ratio, which was adjusted for the stock split, of 1.0895 shares of common stock for each share of Series A and Series B convertible preferred stock then outstanding.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock tranche liability</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that the tranche liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable from the initial closing of the Series A convertible preferred stock. The estimated fair value of the tranche liability was determined using a Monte Carlo simulation at the initial issuance date. As of March 4, 2020, the simulations occurred based on the implied aggregate equity value of the Company derived from the Series A convertible preferred stock offering price of $3.00 per share, along with, in part, the following subjective assumptions: risk-free rate of 0.59%, an expected volatility of 80%, the expected term to a liquidity event of 1 year, and a 60% probability of achieving the clinical milestones and timing thereof. Subsequently, the estimated fair value of the tranche liability was determined using a backsolve approach at June 30, 2020, immediately prior to the issuance of the Milestone Shares, which was calculated based on the aggregate equity value of the Company derived from the Series B convertible preferred stock offering price of $17.00 per share. The subsequent remeasurement also considered, in part, a risk-free rate of 0.17%, an expected volatility of 80%, and the expected term to a liquidity event of 0.5 years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the analysis, the Company recorded a preferred stock tranche liability of $1.1 million at the issue date to account for the obligation to issue the Milestone Shares at a predetermined fixed price at a future settlement date. The Company remeasured the tranche liability at March 31, 2020, resulting in a gain of $0.2 million that was recorded in other income, net in the condensed consolidated statements of operations. The tranche liability was again later remeasured to fair value and reclassified to convertible preferred stock when the remaining Milestone Shares were sold to the investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632048617544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6&#8212;Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2020, the Company&#8217;s board of directors approved the Existing Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, RSAs, RSUs and other stock-based awards to employees, directors, officers and consultants. On July 1, 2020, 3,529,412 shares of common stock were authorized for issuance under the Existing Plan. On September 16, 2020, the Company increased the number of shares of common stock authorized for issuance under the Existing Plan to 3,845,294. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2020, the Company&#8217;s stockholders approved the New Plan, which became effective upon the execution of the underwriting agreement in connection with the IPO. The number of shares available for future issuance under the New Plan is the sum of (1) 3,390,168 new shares of common stock,&nbsp;&nbsp;(2) 209,841 remaining shares of common stock reserved under the Existing Plan that became available for issuance upon the effectiveness of the New Plan and (3) the number of shares of common stock subject to outstanding awards under the Existing Plan when the New Plan became effective that thereafter expire or are forfeited, canceled, withheld to satisfy tax withholding or to purchase or exercise an award, repurchased by the Company or are otherwise terminated. At December 31, 2020, there were 2,941,509 shares available for future grant under the New Plan. The number of shares of common stock reserved for issuance under the New Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2021 continuing through January 1, 2030, by 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors.&nbsp;&nbsp;On January 1, 2021 the board of directors increased the number of common stock reserved for issuance under the New Plan by 1,434,934 shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, on September 16, 2020, the Company&#8217;s stockholders approved the Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective upon the execution of the underwriting agreement in connection with the IPO. The maximum number of shares of common stock that may be issued under the ESPP will not exceed 362,000 shares of common stock, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the IPO Date and ending on (and including) January 1, 2030, in an amount equal to the lesser of (i) one percent (1.0%) of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year, and (ii) 724,000 shares of common stock. No shares have been added to the ESPP as of January 1, 2021 and no issuances have been made under the ESPP as of March 31, 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2020, options to purchase 2,896,782 shares of common stock under the Existing Plan were awarded to certain employees and consultants of the Company with an exercise price per share of $0.80, which were expected to vest over a four-year period, all of which were subsequently cancelled (the &#8220;Cancelled Options&#8221;). The grant date fair value of the Cancelled Options was $13.8 million at the original grant date. In exchange, the Company awarded 2,518,932 RSUs on September 2, 2020, which are expected to vest over a four-year term. The Company accounted for the changes in award terms as a modification in accordance with ASC 718 Compensation &#8211; Stock Compensation. The modification was accounted for as an exchange of the original award for a new award with total compensation cost equal to the grant-date fair value of the original award plus any incremental value measured on the modification date. The Company determined that there was no incremental value as the fair value of the original award immediately before the modification was greater than the fair value of the new award immediately after the modification. Accordingly, the Company continues to recognize the remaining compensation cost of the Cancelled Options over the vesting period of the RSUs.&nbsp;&nbsp; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, 1,621,900 shares of common stock under the New Plan were awarded with a weighted-average grant date fair value per share of $18.75. The stock options vest over four years and have a ten-year contractual term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The following weighted-average assumptions were used to estimate the fair value of stock options that were granted during the three months ended March&#160;31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.64</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity, during the three months ended March&#160;31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,842</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,953</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.81</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled or forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,600</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.42</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value in the above table is calculated as the difference between the fair value of the Company&#8217;s common stock as of March&#160;31, 2021 and the exercise price of the stock options. As of March&#160;31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $37.0&#160;million, which the Company expects to recognize over a weighted-average period of approximately 3.7 years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 2, 2020, the Company issued 331,121 RSUs to an employee under the Existing Plan; 25% of the shares of common stock underlying the RSUs vest at each anniversary over a four-year period. The RSUs are subject to a service-based vesting condition. The RSUs were also subject to a liquidity-based performance vesting condition that was met upon the closing of the IPO. The Company at any time may accelerate the vesting of the RSUs. Such shares are not accounted for as outstanding until they vest.<font style="color:#000000;"> As of March 31, 2021, the total unrecognized compensation related to unvested RSUs granted, including the remaining compensation cost associated with the RSUs granted on September 2, 2020 in exchange for the Cancelled Options, was $15.4 million which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 1.7 years.</font> The Company&#8217;s RSU activity for the three months ended March&#160;31, 2021 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at January 1, 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted units granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Awards</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Session II, the Company&#8217;s President and Chief Executive Officer, was awarded 769,058 RSAs under the Existing Plan on July 1, 2020, which are expected to vest over a three-year term, subject to continuous employment. As of March 31, 2021, the total unrecognized compensation related to unvested RSAs granted was $3.0 million which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 2.0 years. The fair value of these RSAs at the grant date of July 1, 2020 was $5.28 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s RSA activity for the three months ended March&#160;31, 2021 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the total stock-based compensation expense for the stock options, RSAs and RSUs recorded in the condensed consolidated statements of operations for the three months ended March&#160;31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632019853784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7&#8212;Net Loss Per Common Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Since the Company had a net loss in all periods presented, basic and diluted net loss per common share are the same. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the calculation of basic and diluted net loss per common share (in thousands, except share and per share data):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding used to compute net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,992,377</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,894,999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following common stock equivalents outstanding as of March 31, 2021 and 2020 were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti&#8209;dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSAs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,905,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632029089688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8&#8212;Related Party Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Session II, President and Chief Executive Officer and a member of the Company&#8217;s board of directors, was a guarantor under the Guaranty and Security Agreement between himself, Queen&#8217;s and the Company, and in the event of the Company&#8217;s failure to fund its obligations under the RGA with Queen&#8217;s, had personally guaranteed payments due by the Company to Queen&#8217;s. In addition, the Company entered into two secured promissory notes with Mr. Session in January 2020 for an aggregate of $1.67 million, with 10% interest. The Company secured the notes with a first priority security interest in certain assets of the Company. During March 2020, the Company repaid $1.65&#160;million of the notes, and the remaining balance was repaid in July 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company entered into a services agreement with PBM Capital Group, LLC (&#8220;PBM&#8221;), an affiliate of PBM TGT Holdings, LLC whereby PBM provides accounting and other administrative and management services related to payroll administration, human resources, bookkeeping, preparation of financial statements and tax returns, accounts payable and receivable, and other similar functions for a fee of $2,500 per month. Paul B. Manning, a member of the Company&#8217;s board of directors and a holder of more than 5% of the Company&#8217;s capital stock, is the Chief Executive Officer of PBM Capital Group, LLC and has sole voting and investment power with respect to the shares held by PBM TGT Holdings, LLC. In September 2020, PBM TGT Holdings, LLC distributed all of the shares of Series A convertible preferred stock it previously held to its beneficial owners, including Mr. Manning and entities controlled by Mr. Manning, for no additional consideration in accordance with the terms of its operating agreement. As of March 31, 2021, and December 31, 2020, the Company had recorded an immaterial amount due to PBM in the consolidated balance sheets.&nbsp;&nbsp; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631944158664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9&#8212;Income Taxes </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. There is no provision for income taxes because the Company has incurred operating losses and capitalized certain items for income tax purposes since its inception and maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the period differs from the amount that would result from applying the federal statutory tax rate to net loss before taxes primarily because of the change in valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, there were no material changes to either the nature or the amounts of the uncertain tax positions previously determined for the year ended December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632020285528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10&#8212;Commitments and Contingencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commitments </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. The Company&#8217;s maximum exposure under these arrangements is unknown at March 31, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Durham Lease</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2020, the Company entered into a lease agreement (the &#8220;Durham Lease&#8221;) with Patriot Park Partners II, LLC, a Delaware limited liability company (the &#8220;Durham Landlord&#8221;), pursuant to which the Company agreed to lease approximately 187,500 square feet of a manufacturing facility located at 5 National Way, Durham, North Carolina (the &#8220;Facility&#8221;). The Durham Lease commenced on April 1, 2021 and is expected to have a term of approximately fifteen years and six months. The Company has two options to extend the term of the Durham Lease, each for a period of an additional five years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was not required to provide a security deposit in connection with its entry into the Durham Lease. The Company will be responsible for constructing interior improvements within the Facility. The Durham Landlord has the right to terminate the Durham Lease upon specified events of default, including the Company&#8217;s failure to pay rent in a timely manner and upon the occurrence of certain events of insolvency with respect to the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the Durham Lease if construction of the base building shell of the Facility is not complete by May 16, 2021. The Company incurred initial direct costs to enter into the Durham Lease of approximately $0.8 million. The costs have been recorded on the consolidated balance sheets as a deferred lease asset and will be amortized into earnings over the term of the Durham Lease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dallas Lease</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 11, 2021, the Company entered into a lease agreement (the &#8220;Dallas Lease&#8221;) with Pegasus Park, LLC, a Delaware limited liability company (the &#8220;Dallas Landlord&#8221;), pursuant to which the Company will lease approximately 15,000 square feet of office space at 3000 Pegasus Park Drive, Dallas, Texas 75247 (the &#8220;Office Space&#8221;).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease commences on the date on which certain improvements to the Office Space have been made and the Office Space is tendered to the Company for possession, which the Company and the Dallas Landlord presently anticipate to be delivered on or about May 15, 2021, and will have a term of approximately ten years. The Company has an option to extend the term of the Lease for one additional period of five years. The Company&#8217;s obligation for the payment of base rent for the Office Space will initially be approximately $32,500 per month and will increase annually, up to an estimated monthly base rent of $50,000 during the term of the Lease. The Company is obligated to pay operating costs and utilities applicable to the Office Space. The Company was required to provide a security deposit of $32,500 in connection with its entry into the Lease. <font style="color:#000000;">Total future minimum lease payments under the Dallas Lease over the initial 10 year term are approximately $4.9 million. </font>The Company will be responsible for costs of constructing interior improvements within the Office Space that exceed a construction allowance provided by the Dallas Landlord not to exceed $40.00 per rentable square foot.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a right of first refusal with respect to certain additional adjacent office space before the Dallas Landlord accepts any offer for such space.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Landlord has the right to terminate the Lease, or the Company&#8217;s right to possess the Office Space without terminating the Lease, upon specified events of default, including the Company&#8217;s failure to pay rent in a timely manner and upon the occurrence of certain events of insolvency with respect to the Company. The Company may terminate the Lease if the Office Space is not delivered will all improvements to be made by the Landlord pursuant to the Lease substantially completed by May 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the Company recognized approximately $0.6 million of lease construction incentive based on the construction allowance provided. The construction incentive has been recorded on the consolidated balance sheets as a deferred lease incentive obligation and will be amortized into earnings as a deduction of rent expense over the term of the Dallas Lease.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631947681976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") as determined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X and are consistent in all material respects with those included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission ("SEC") on March 3, 2021 (the &#8220;2020 Annual Report&#8221;). In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The consolidated balance sheet as of December 31, 2020 is derived from audited financial statements, however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes in the Company&#8217;s 2020 Annual Report.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated financial statements include the accounts of Taysha and its inactive wholly owned U.S. subsidiaries that were incorporated during 2020. All intercompany transactions and balances have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company&#8217;s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. In response to the ongoing and rapidly evolving COVID-19 pandemic, management considered the impact of the estimated economic implications on the Company&#8217;s critical and significant accounting estimates, including assessment of impairment of long-lived assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as amended, with guidance regarding the accounting for and disclosure of leases. This update requires lessees to recognize the liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheets. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will become effective for the Company for annual reporting periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The new standard requires the use of one of the following two approaches, either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption through a cumulative-effect adjustment. The Company has not yet concluded which approach will be utilized to adopt the new standard and is currently evaluating the impact of this standard on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632028962648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,462</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid bonus</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical trial</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">944</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">331</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,817</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,626</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,889</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,497</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock', window );">Schedule Of Accrued Expense And Other Current Labilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,672</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,106</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued license fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,766</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,119</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expense and other current labilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ScheduleOfAccruedExpenseAndOtherCurrentLabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940423704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text">The Company&#8217;s RSU activity for the three months ended March&#160;31, 2021 was as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at January 1, 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted units granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Awards Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s RSA activity for the three months ended March&#160;31, 2021 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Total Stock-Based Compensation Expense for Stock Options, RSAs and RSUs (Detail)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the total stock-based compensation expense for the stock options, RSAs and RSUs recorded in the condensed consolidated statements of operations for the three months ended March&#160;31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,594</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Stock Options and Cancelled Options</a></td>
<td class="text">The following weighted-average assumptions were used to estimate the fair value of stock options that were granted during the three months ended March&#160;31, 2021:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.64</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:87.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity, during the three months ended March&#160;31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,842</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,953</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.81</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled or forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,600</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.42</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,552</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632029090248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Calculation of Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the calculation of basic and diluted net loss per common share (in thousands, except share and per share data):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended March&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,431</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding used to compute net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,992,377</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,894,999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Outstanding Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following common stock equivalents outstanding as of March 31, 2021 and 2020 were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti&#8209;dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,850,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSAs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,142</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,905,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631936777640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business Operations - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 13,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (93,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,647,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,647,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters&#8217; Option to Purchase Additional Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock, shares</a></td>
<td class="nump">1,180,434<span></span>
</td>
<td class="nump">1,180,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,869,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discounts and commissions and other offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_CommonStockIncreaseInOutstandingShares', window );">Increase in outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,097,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,845,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0895<span></span>
</td>
<td class="nump">1.0895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,047,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems', window );"><strong>Organization and Description of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,845,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_CommonStockIncreaseInOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock increase in outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_CommonStockIncreaseInOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_OrganizationAndDescriptionOfBusinessOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion shares of convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_TemporaryEquityConversionSharesOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631941137688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PrepaidResearchAndDevelopmentContracts', window );">Prepaid research and development</a></td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="nump">$ 2,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PrepaidBonus', window );">Prepaid bonus</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PrepaidClinicalTrial', window );">Prepaid clinical trial</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 10,817<span></span>
</td>
<td class="nump">$ 6,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PrepaidBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid bonus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PrepaidBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PrepaidClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PrepaidClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PrepaidResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PrepaidResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940070824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property Plant and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsha_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsha_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsha_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631944166552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940407800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 5,672<span></span>
</td>
<td class="nump">$ 2,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AccruedLicenseFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting fees</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AccruedConstructionInProgressCurrent', window );">Accrued construction in progress</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 14,875<span></span>
</td>
<td class="nump">$ 5,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_AccruedLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_AccruedLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631935850280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research, Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>Product</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 21, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,761,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,854,000<span></span>
</td>
<td class="nump">$ 5,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember', window );">TSHA-120</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived', window );">Clinical, regulatory and commercial milestones to be received</a></td>
<td class="nump">$ 19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_UTSouthwesternAgreementMember', window );">UT Southwestern Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements', window );">Preclinical activities period under sponsored research agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize', window );">Minimum licensed product to develop obtain regulatory approval for and commercialize | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,179,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding', window );">Percentage of fully diluted common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis', window );">Percentage of entitled to receive additional shares on fully diluted basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_QueensAgreementMember', window );">Queen's Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ResearchGrantOfCommittedFundAmount', window );">Research grant of committed fund amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ResearchGrantOutstandingFundAmount', window );">Research grant outstanding fund amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_QueensAgreementMember', window );">Queen's Agreement | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PaymentsToAcquireLicenseRight', window );">Cash payment to acquire license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_QueensAgreementMember', window );">Queen's Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_LicenseAgreementRegulatoryMilestonesPayment', window );">License agreement regulatory milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_LicenseAgreementCommercialMilestonesPayment', window );">License agreement commercial milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_AbeonaCLN1AgreementsMember', window );">Abeona CLN1 Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PaymentOfLicenseFee', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts', window );">Purchase of clinical materials and reimbursement incurred development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AdditionalMilestonePayments', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_AbeonaCLN1AgreementsMember', window );">Abeona CLN1 Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment', window );">License and inventory purchase agreement regulatory related milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment', window );">License and inventory purchase agreement sales related milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_AbeonaTherapeuticsIncMember', window );">Abeona | Abeona Rett Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AdditionalMilestonePayments', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PaymentOfOneTimeUpfrontLicenseFee', window );">Payment of one-time upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsha_AbeonaTherapeuticsIncMember', window );">Abeona | Maximum | Abeona Rett Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_RegulatoryRelatedMilestonesObligationPayable', window );">Regulatory related milestones obligation payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable', window );">Sale-related milestones per licensed product and royalties on net sales of licensed products payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_AdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_AdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical, regulatory and commercial milestones to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ClinicalRegulatoryAndCommercialMilestonesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_LicenseAgreementCommercialMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement commercial milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_LicenseAgreementCommercialMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_LicenseAgreementRegulatoryMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement regulatory milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_LicenseAgreementRegulatoryMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and inventory purchase agreement regulatory related milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and inventory purchase agreement sales related milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum licensed product to develop obtain regulatory approval for and commercialize.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PaymentOfLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PaymentOfLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PaymentOfOneTimeUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of one-time upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PaymentOfOneTimeUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PaymentsToAcquireLicenseRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire license right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PaymentsToAcquireLicenseRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock shares entitled to receive additional shares on fully diluted basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PercentageOfCommonStockSharesEntitledToReceiveAdditionalSharesOnFullyDilutedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fully diluted common stock shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical activities period under sponsored research agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of clinical materials and reimbursement incurred development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_RegulatoryRelatedMilestonesObligationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory related milestones obligation payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_RegulatoryRelatedMilestonesObligationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ResearchGrantOfCommittedFundAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research grant of committed fund amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ResearchGrantOfCommittedFundAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ResearchGrantOutstandingFundAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research grant outstanding fund amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ResearchGrantOutstandingFundAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale-related milestones per licensed product and royalties on net sales of licensed products payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_AcquisitionOfWorldwideRightsForTSHA120ForTreatmentOfGiantAxonalNeuropathyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_UTSouthwesternAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_UTSouthwesternAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_QueensAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_QueensAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_AbeonaCLN1AgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_AbeonaCLN1AgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_AbeonaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_AbeonaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_AbeonaRettAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_AbeonaRettAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631932773752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 16, 2020</div></th>
<th class="th">
<div>Jul. 28, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 02, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,685,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,647,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuances of Series A convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PreferredStockTrancheLiability', window );">Preferred stock tranche liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ChangeInFairValueOfPreferredStockTrancheLiability', window );">Change in fair value of preferred stock tranche liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,047,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0895<span></span>
</td>
<td class="nump">1.0895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,869,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs, including underwriters&#8217; discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters&#8217; Option to Purchase Additional Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="nump">1,180,434<span></span>
</td>
<td class="nump">1,180,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Clinical milestones for gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuances of Series A convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice', window );">Convertible preferred stock tranche liability, offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm', window );">Convertible preferred stock tranche liability, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Risk Free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput', window );">Convertible preferred stock tranche liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput', window );">Convertible preferred stock tranche liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Probability of Achieving Clinical Milestones and Timing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput', window );">Convertible preferred stock tranche liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | PBM TGT Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Nolan Capital, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Private Placement | Series A Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Private Placement | Series A Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Private Placement | Initial Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Private Placement | Achievement of Specific Clinical Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Private Placement | Achievement of Specific Clinical Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Private Placement | Upon Achievement of Certain Defined Clinical Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,647,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuances of Series A convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice', window );">Convertible preferred stock tranche liability, offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm', window );">Convertible preferred stock tranche liability, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Risk Free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput', window );">Convertible preferred stock tranche liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput', window );">Convertible preferred stock tranche liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Private Placement | Series B Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,647,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuances of Series A convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Private Placement | Series B Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,647,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ChangeInFairValueOfPreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value preferred stock tranche liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ChangeInFairValueOfPreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock tranche liability liquidity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ConvertiblePreferredStockTrancheLiabilityLiquidityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock tranche liability measurement input.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ConvertiblePreferredStockTrancheLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock tranche liability offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ConvertiblePreferredStockTrancheLiabilityOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PreferredStockTrancheLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Tranche Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PreferredStockTrancheLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock, gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsha_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=tsha_MeasurementInputProbabilityOfAchievingClinicalMilestonesAndTimingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_PBMTGTHoldingsLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_NolanCapitalLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_NolanCapitalLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_SeriesAPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_SeriesAPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_SeriesAPurchaseAgreementInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_SeriesAPurchaseAgreementInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_SeriesAAchievementOfSpecificClinicalMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_SeriesAAchievementOfSpecificClinicalMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_SeriesAUponAchievementOfCertainDefinedClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsha_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_SeriesBPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_SeriesBPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631935688120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Sep. 16, 2020</div></th>
<th class="th"><div>Sep. 02, 2020</div></th>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tsha_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-based payment award, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance', window );">Percentage of automatic increase every year in common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based payment award, terms of award issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares of common stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the IPO Date and ending on (and including) January 1, 2030, in an amount equal to the lesser of (i) one percent (1.0%) of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year, and (ii) 724,000 shares of common stock.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based payment award, options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares of common stock issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tsha_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan (&#8220;ESPP&#8221;) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment award, compensation cost not yet recognized, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment award, unvested RSU/RSA granted, compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based payment award, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,621,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based payment award, options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based payment award, options, compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment award, compensation cost not yet recognized, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment award, compensation cost not yet recognized, weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment award, unvested RSU/RSA granted, compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based payment award, RSU/RSA granted, weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,845,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Share-based payment award, plan modification, incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Cancelled Options | Certain Employees and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based payment award, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based payment award, options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Share-based payment award, options grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod', window );">Number of shares awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,518,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based payment award, RSU/RSA granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, vesting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Units | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, vesting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Units | Share-based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, vesting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Units | Share-based Payment Arrangement, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, vesting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Awards | RA Session II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based payment award, RSU/RSA granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,845,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyStockIncentivePlanMember', window );">New Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,434,934<span></span>
</td>
<td class="nump">3,390,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate', window );">Share-based payment award, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-based payment award, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance', window );">Percentage of automatic increase every year in common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based payment award, terms of award issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">At December 31, 2020, there were 2,941,509 shares available for future grant under the New Plan. The number of shares of common stock reserved for issuance under the New Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2021 continuing through January 1, 2030, by 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors.  On January 1, 2021 the board of directors increased the number of common stock reserved for issuance under the New Plan by 1,434,934 shares.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyStockIncentivePlanMember', window );">New Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based payment award, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,621,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based payment award, options, weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of automatic increase every year in common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_PercentageOfAutomaticIncreaseEveryYearInCommonStockSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options replacement units grants in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReplacementUnitsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants in period grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsha_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsha_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tsha_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsha_CancelledOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsha_CancelledOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tsha_CertainEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tsha_CertainEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=tsha_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=tsha_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tsha_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tsha_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tsha_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tsha_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631947681144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Options and Cancelled Options (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631942463464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding. Stock Options, Beginning Balance</a></td>
<td class="nump">674,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, Stock Options</a></td>
<td class="nump">1,621,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled or forfeited, Stock Options</a></td>
<td class="num">(10,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding. Stock Options, Ending Balance</a></td>
<td class="nump">2,286,142<span></span>
</td>
<td class="nump">674,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at March 31, 2021, Stock Options</a></td>
<td class="nump">2,286,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable at March 31, 2021, Stock Options</a></td>
<td class="nump">27,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 20.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted Average Exercise Price</a></td>
<td class="nump">28.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled or forfeited, Weighted Average Exercise Price</a></td>
<td class="nump">26.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">26.42<span></span>
</td>
<td class="nump">$ 20.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at March 31, 2021, Weighted Average Exercise Price</a></td>
<td class="nump">26.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at March 31, 2021, Weighted Average Exercise Price</a></td>
<td class="nump">$ 20.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at March 31, 2021, Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options exercisable at March 31, 2021</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="nump">$ 3,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">$ 3,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at March 31, 2021, Aggregate Intrinsic Value</a></td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at March 31, 2021, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140632046276536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted units/stock granted, Weighted Average Grant Date Fair Value per Share</a></td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631940006648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Total Stock-Based Compensation Expense for Stock Options, RSAs and RSUs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631947553512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Calculation of Basic and Diluted Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (32,024)<span></span>
</td>
<td class="num">$ (5,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">36,992,377<span></span>
</td>
<td class="nump">10,894,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631942463288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Common Stock Equivalents Outstanding Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,905,253<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">2,850,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">769,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">2,286,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tsha_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tsha_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tsha_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631935605256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>PromissoryNote</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsha_PBMCapitalGroupLLCMember', window );">PBM Capital Group, LLC | Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Accounting and other administrative and management services fee per month</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsha_PBMTGTHoldingsLLCMember', window );">PBM TGT Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement', window );">Additional consideration payable under operating agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tsha_PresidentAndChiefExecutiveOfficerMember', window );">RA Session II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_NumberOfSecuredPromissoryNotes', window );">Number of secured promissory notes | PromissoryNote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Paul B. Manning | Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OwnershipPercentageInExcessOfCapitalStock', window );">Ownership percentage more than capital stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tsha_SecuredPromissoryNotesMember', window );">Secured Promissory Notes | RA Session II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount, related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional consideration to related party under operating agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_AdditionalConsiderationToRelatedPartyUnderOperatingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_NumberOfSecuredPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of secured promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_NumberOfSecuredPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_OwnershipPercentageInExcessOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage in excess of capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_OwnershipPercentageInExcessOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsha_PBMCapitalGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsha_PBMCapitalGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=tsha_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=tsha_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsha_PBMTGTHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsha_PBMTGTHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tsha_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tsha_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tsha_SecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tsha_SecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631944196360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631936560632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 17, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tsha_DallasLeaseMember', window );">Dallas Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentiveReceivable', window );">Lease construction incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsha_DurhamLeaseMember', window );">Durham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits', window );">Number of operating lease landlord square feet manufacturing facility | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extend term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_OperatingLeasesInitialDirectCosts', window );">Operating leases initial direct costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsha_DallasLeaseMember', window );">Dallas Lease | Pegasus Park L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits', window );">Number of operating lease landlord square feet manufacturing facility | ft&#178;</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Operating lease commencement date</a></td>
<td class="text">May 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease extend term of contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease, option to extend description</a></td>
<td class="text">Company has an option to extend the term of the Lease for one additional period of five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace', window );">Obligation for payment of initial base rent for office space</a></td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease', window );">Maximum estimated monthly base rent increase annually during term of lease</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot', window );">Maximum construction allowance provided by landlord per rentable square foot | ft&#178;</a></td>
<td class="nump">40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum lease payments</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum construction allowance provided by landlord per rentable square foot.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_MaximumConstructionAllowanceProvidedByLandlordPerRentableSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum estimated monthly base rent increase annually during term of lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_MaximumEstimatedMonthlyBaseRentIncreaseAnnuallyDuringTermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligation for payment of initial base rent for office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_ObligationForPaymentOfInitialBaseRentForOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsha_OperatingLeasesInitialDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases initial direct costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsha_OperatingLeasesInitialDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents a receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e40019-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e40010-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units (items of property) under operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tsha_DallasLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tsha_DallasLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_DurhamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_DurhamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsha_DallasLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsha_DallasLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsha_PegasusParkLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsha_PegasusParkLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140631935653064">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units R S U [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
<td class="nump">2,850,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
<td class="nump">2,850,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
<td class="nump">$ 6.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
<td class="nump">$ 6.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
<td class="nump">769,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
<td class="nump">769,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M1F ;JM@D+4Z,3/-]QI4T1L;YX5;P0"C[ -Q?2VD.)_8'JJWJR7]02P,$%
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MF*,S]\*%'PP2)A%T835#4'>0RJADGX#@.3PTO[L[L!:USH3D_T($LRRE>'W
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M@.=; 56PO3 ?/;J/7.O_ %!+ P04    "  ;@JM2+AY&D-$"  !Q"0  &
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M@S0&^/]6"'T:F 7:5G_U/U!+ P04    "  ;@JM2FQWZ!O,#   ^#P  &
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MJJZ!^-AU2*-"2[MZ-%U,/#)I5&F'W2C F/34*3ZU(GQ5+^K9P7N<(VW1XW&
MO69C6EYC>2[\U'GP<.LIO@Y&YCLXANTUA<.!HJ;M=PIV6]EP_=!KYJ+=F<ZL
MSH6>VA(>[DM#NVT)/4NK"V'WFNF_:'<N[M2C\'"3ZMES<:=8OUW3A$S&K9IN
MV[DX< AI.M6V&X4N]OL6ZJF]X>'^=F'W[7:NW=+Z:OH*RX-PNW:2,"=+$/'"
M,X42M@&H<S<&#GDXK!TF6NR*P\6ST'!4*89;.. R:0S@^48(?9R8\TIU9)[_
M U!+ P04    "  ;@JM2/#VF1FD"  !X!0  &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;(U444_;0 S^*U:$-) FDJ8MFU :B0+3>$"JZ-B>KXG3G+C<
ME3NGA7\_WR7-.@;57A+[;'_^_"6^;&?LDZL1"5X:I=TLJHDVEW'LBAH;X<[-
M!C5'*F,;0>S:=>PV%D49BAH5ITER$3="ZBC/PMG"YIEI24F-"PNN;1IA7^>H
MS&X6C:+]P8-<U^0/XCS;B#4ND1XW"\M>/*"4LD'MI-%@L9I%5Z/+^=3GAX2?
M$G?NP 8_R<J8)^_<E;,H\81084$>0?!KB]>HE =B&L\]9C2T](6']A[]6YB=
M9UD)A]=&_9(EU;/H:P0E5J)5]&!VW[&?)Q LC'+A";L^-XF@:!V9IB]F!HW4
MW5N\]#H<%*2C#PK2OB -O+M&@>6-()%GUNS ^FQ&\T88-50S.:G]1UF2Y:CD
M.LJOC2Y98BR!+6>4+ 6QLR1^L?;DP%0^M$5+<J40%JP:6AMR3/$$0O=6;52)
MUGV"V^=6TBN<WF E"TEG<+H0EJ%J)%D(Q?ZC%FTIN<\9G(#4\*,VK6,@E\7$
M,WEF<='SGW?\TP_XC^'>,+2#6YZC_+L^9BT&0=*](//T*."]L.<P'GV&-$F3
MQ^4-G)Z<'8$=#SJ/ ^SD ]@[YUJA"_1R;@8)79"0+$=J!"7%2BK6[CT9.OB+
M .\W;9N/DFF2Q=MW2$T&4I.CI)9H)3JX.O:!C\P^'=I,_WOVXJ#3&QT^<YQ]
MJ=><Y>C=GV'ZCPJ3\5L1XH-M:-"NP\X[QFPU=8LQG [7RE6W37_2NSN)?X:U
MU X45ER:G'_A_K;;\\XALPF[M3+$FQK,FJ]&M#Z!XY4QM'=\@^&RS7\#4$L#
M!!0    ( !N"JU(95LE.!08  #,8   8    >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&ULE5E-;]LX$/TKA+&'%FAJD;+\$20&$F<7NX<N@AC=/=,2;7,KB2I)
M.?6_WR$E2TI$4<ZED>0A^>9Q9MZ0O7L5\H<Z,J;1KRS-U?WDJ'5Q.YVJ^,@R
MJKZ*@N7PRU[(C&IXE8>I*B2CB1V4I5,2!/-I1GD^6=_9;\]R?2=*G?*</4ND
MRBRC\OS(4O%Z/\&3RX<7?CAJ\V&ZOBOH@6V9_EX\2WB;-K,D/&.YXB)'DNWO
M)P_X=A.&9H"U^(>S5]5Y1L:5G1 _S,M?R?TD,(A8RF)MIJ#PY\0V+$W-3(#C
M9SWII%G3#.P^7V;_PSH/SNRH8AN1_LL3?;R?+"<H87M:IOI%O/[):H<B,U\L
M4F7_1:^5[6(^07&IM,CJP8 @XWGUE_ZJB>@,@'G< T@]@+P?,!L8$-8#+'/3
M"IEUZXEJNKZ3XA5)8PVSF0?+C1T-WO#<;.-62_B5PSB]WH@\@4UA"8(G)5*>
M4 TO6PU_8+>T0F*/-E0=T1^PXPI]^I[3,N%@\QG=H._;)_3IM\]W4PU0S(33
MN%[VL5J6#"P;HF\BUT>%?H?ED[?CI^!"XP>Y^/%(O!-^H_(K"O$71 *"'7@V
MUP\//'#"AM;0SA<.T6H8VUO&]E)D"-).4LWS0Q6W7'.F/,O,FF5F=IG9P#)_
M0YZG0BG7!E0CYW:D2>;3^B8$[V9!  Z>NM0X+*-9B+N&;]!%#;K(2\)#\A\$
M<!5%6D#2QR*/><I07L,V7\US;-@J31#RW$G5K8>K>8-F[N7JB4&=BSFUU8/]
M*DS4NWBK9HDZ; !M/<[Z5@-D+1IX"R^\S9'F!V8(V%,NT8FF)3.Y!Z#W3$K@
M!FI!_ -I27.HY2CE=,=3KL\N'Q8]=#?&AYX7#CN\# 8W?MGXLO3Z\L(4HS(^
M(IHG4%-/(!:%"0, '1O:??0O>Y"BR 6];Q<&P3#T50-]Y86^-23?&&%(4"PR
M ]-&C OJJ@\A6CGRJV\W !(';=4._/7%1HMZER]*,4@U0_HE.D9R!W=D GMY
M>9:LH#RY[%RUBM!')NMEG1J ^_$UPTL'10[+(8Y("YEX(3_$L2A-[2GHF>Y2
M9[354W37Q<N%(]\=AD, 6XW X1A 63(GIYW]<\(.^Z&'EZ$#=M]P%2P&LP2W
MPH/]RO,$U<G6]-3V"P65[DI43_,F!)8.G'VS:!AE*T X&M7'47%QPHX<%90$
M8>2 [C#%\]5J&'ZK6'C^H2Z"YR>FKN\B<*L]V"\^SR54:ZAYE> 8DO3Y"RI2
M"C7;!"7[67);P9U<.50D"EU)WC<<HJA5&NR7FMX.CW-4H^X+R #JON$0ZE9D
M\.I#&[OG.:CZU1M+6IT@P4C9%C%CR25^E"IA'6:;^BV3L IZ )D#RJ3F4"+?
M=QO.1CIPE$R?]))69,B8R'31YD*S2^V^IM9L2%]$\'P1#@-KI83XI>0%Q.]L
M.Q@@[N.X^MH!%6(V'P;62@CQ2T@3_I"U)PY'*;0[7Q%--:Z^.,!.DF%Y(*T\
MD/&#R:>$Q9)!5?D,25D]F02U<$U1L0^FLD"O:\X(KBPE#OD@))JO^GGJ,,7S
MD"R'O6EEA/AEQ*8KU0BD&>W8@>>Y(1="P7R 8LE%X@3?5P8281(Y=-IA.H2Z
M50_B/_!T43/368SB[1]J"%G.7?V:PW2$[%:+R,);&[=E4:3V[H&F*.$JAI-B
M*5F5>;D-FDZ-![]<X>YK>DDK+L0O+EU9E&-G&B@+Z QA;]ID)[O7GFP<AMZC
M#6EEA_@/-\\^:3>Y2=^US-:"OFM3G<[USS@8!]CAW-6'H; 5N= O<@\Q^*"X
M/=B/-3!H7^9UF80?DU1(YV:%?9&;O^V;*W<<=D/NM"H8^E7PZ2+!8@\/)JYC
MH6!/Q@*LGK9[CX.)H]<.KSYKA:U AB-GK305,6UWX.-W%IO0<10+HN&P#SMW
M<7Z1;#J=2_]S':&;>MHNH;/0 6C:N7[-F#S86VF%;"I5-YC-U^;F^\'>][[[
M_HAO-]7]=3M-=9W^C4J0'852MH<I@Z\+H$E6-]35BQ:%O>3=":U%9A^/C"9,
M&@/X?2^@:ZE?S +-_Q.L_P=02P,$%     @ &X*K4O+Q3\'("@  X1L  !@
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M2P7/>^BLC77[W(S\;.8^]>!CZ^QH9:S!A+HV?'%29.)I&+@(M1@0 MXYO0Y
M L90%['7B+"NI0I);A9>ZK+/]W&<@"ZXCU%&V9!#8"/E"85H,A,>-F"3<G&
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M!2Y*E,XQA'&:7VJ4J!#PDM.1?A7'#D0X:+P0;FMB?3411@H)S:GHKK>-@_$
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M1]NY($4[>638GS&#'DP]8;6Q'JDG*0%?5$/'J,2!GZJ: H.MWH$S%V$]JY*
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M?(KK^JA!%4OX:RSE2*0WYQ T D*,0UXN,R.N_V<K)3=&YP^_-SU:,!6M37Z
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MK20PD"9@?&F,K6YH@_ICHG?_!E!+ P04    "  ;@JM23UB4QM\#   D"0
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MBP'>-PZM=5J(@_D[9_L/4$L#!!0    ( !N"JU),46V/%P@  'D6   9
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MMOY2NPW<C KE5JQW]3:PK4I'.=6@4F$:9!6R7+A5;7[G9/.:8%8IM#HJ%%+
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M@?S8\@XR9LH1 T1WJ"-Q]VLSO6KP?G^\:=2)SD$L<2RI)NN)H3#_6,<^D3%
M"N) DO ,V+ UJ@!6.-YNG4?'%UH1^R%LD22\-7):$-^ &&/XM<OJ$DDDH.BF
MFHF$#*?B $ ]E7B;1F9B-70/!?-KG<]384YQ3XT2I7.,HYSF[S5*5 B,R^G(
M9A7'#D0XB(>)X#2-QQ5-UA02(O3HKK>U@_% 1.0XCH-L?RE7Z$.TL&M'14C@
M@V$["TA++#GUP@,FB56LNYTQHR#%<#I584E@RB>V,[EE07=WZ]2!8&$CRA:Y
ME#']2PU41ZXB\M#L<V=XOL5BVUG6S"V7,M&VK'0.M]2S+9[IY>VOO]U].!G^
M54!IKDJ==3>!CZ=HY%ZEN1RF9>U8UOB2"R3$6)RE#46Z GBJR%T.933W4E&2
M/9NHLG'7:</4353)]J,LO&\&0[)%N^97 2=/"I[=8O4<&C0N6G:Z.,@M#Q@1
M34"T[M!QD+QY577P&*-3A+)=M/5_$DT)_:2FP"",R:/!\$VL$KJ.86"-9R>/
MXA?;X]63P:@K_H'.I=O?%XS^F7A[-@+8$3"6?#OI1K*;UR!R @2GYC*VT\8T
M0C^I<5^34\'""9G0VW7%%-1R)B8FKQ3?V:A+D=L_XI"SV<?-Z(A--"='@9N)
M3@6.IV8MWH4%,828H[D#PQ&0?C@"._'WC51M6Z/^-V8"QNUK6QEF\$P0").2
MMTH\J=7V\-Y %BB)[.*(;<Q025<;U]2;(!VT"O<G37+-M25U10JRB3"P3;Z$
M''-M#-?^C%QN[RS#\W07Y$DQ#:#-*0H6>'@&1R"5KJ7?ES2*3&_4DAB:;_3K
M2/%5,<Y9UJP'#HRD=LE16%I"6F<EV O94IJ!]FAX#!G!6;YNPWF4.P*LL"LQ
M][<>KR]QS2"Q<W!87U7JDN_^STV$UU67-S/2VO,&MJ0#S_G XP!/B<_JE?XN
M<?S1Z+4#^Z0F <1>N65RQFMGZSG5[=K.DV3G^AH< ]^4PT+&B^1*,?BFCQ*1
M5YL0MZA?![34'ZF32"M;LI5#K@_?3 8,_'$*2>V^B>C8UYZ#^70!^>Y-9B?,
M]C>^BI;*S?G;+PD#L,0/I.W;]O/R.'Y576^/WZ8_2X= 4[/.<'30N\!MSL7O
MO?%'L!5_8YW:$&S)CPN0OW*T >MTW6Y^D(+VH_OU_P!02P,$%     @ &X*K
M4CVTG_K7 P  F D  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK5;;
M;N,V$'WG5Q!N422 $4G4Q5)J&W N10MTL4:R;1^*/M#2V":6$K4DM4[^OD/*
M4EPT<;- 7W0A9\[,G)DC<7Y0^K/9 UCZ5,O&+"9[:]OK(##E'FINKE0+#>YL
ME:ZYQ5>]"TRK@5?>J98!"\,LJ+EH)LNY7UOKY5QU5HH&UIJ:KJZY?KX!J0Z+
M2309%A[$;F_=0K"<MWP'CV!_:]<:WX(1I1(U-$:HAFK8+B:KZ/HF<_;>X'<!
M!W/R3%TE&Z4^NY=?JL4D= F!A-(Z!(ZWKW +4CH@3./+$7,RAG2.I\\#^D^^
M=JQEPPW<*OF'J.Q^,<DGM((M[Z1]4(>?X5A/ZO!*)8V_TD-OF\XFM.R,5?71
M&3.H1=/?^=.1AQ.'/'S#@1T=F,^[#^2SO..6+^=:':AVUHCF'GRIWAN3$XUK
MRJ/5N"O0SRYON.1-"?313\"MJEO50&,-O?C$-Q+,Y3RP&,89!^41\J:'9&]
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M=7\.Z%^L:OV_=Z,L_LG]XQZ/3J"= >YOE;+#BPLP'L:6?P-02P,$%     @
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M&PD  !8W   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;,6;67/;.!*
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MX$;G&@%8QQ_"]0*\CK[Z_?D>Q.D6N_K"W!'4=O34OB[3!P8]GH\K[I'J@B\
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MPGL!UA=<7DYUOA+\](:HG3U!2>\]:^=S3WI SOX"A:?7#K-_OB1FGKYF8,K
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MCL[Q;S>N*P1DBW\%;)W5KI$8RF.2?!4WM_[IR! 6L9!Y7*B@\.^97;(P%)K
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MRF0 O5\(H=\;R03Y/=3D)U!+ P04    "  ;@JM2AF(":#D"  "[!   &0
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M*FM ^PLIS79B ]1_!@9_ %!+ P04    "  ;@JM29PL1/\("  #O!@  &0
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MY?-B!I<75W !(6B[JX$)>!;,Z&M<Q/'W7)8:B?4P-*C/9AFFE9:)UQ*?T)+
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M^[N$F#C0T4#=A"'::G0C&9:U>P/ ^ "WO],:3X87&%Z5XC=02P,$%     @
M&X*K4EI&< *>!   31$  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
MO5A=;]LV%'WN?@7A#4,+9)$I?Z9S#-0VBF5(MJ!!MX=A#[1T91.A1)6DXAC8
MC]\E)4M.(M-.L2X!8DGF/3SW4/=<,I.-5/=Z#6#(8RHR?=E9&Y._#P(=K2%E
M^ESFD.$WB50I,WBK5H'.%;#8!:4B"+O=89 RGG6F$_?L5DTGLC""9W"KB"[2
ME*GM#(3<7'9H9_?@$U^MC7T03"<Y6\$=F,_YK<*[H$:)>0J9YC(C"I++S@?Z
M?A'V;8 ;\0>'C=Z[)C:5I93W]N8JONQT+2,0$!D+P?#C >8@A$5"'E\JT$X]
MIPW<O]ZA?W3)8S)+IF$NQ9\\-NO+SKA#8DA8(<PGN?D%JH0&%B^20KN_9%.-
M[79(5&@CTRH8&:0\*S_98R7$*0%A%1 ^"Z#C P&]*J#W+""D!P+Z58"3.BA3
M<3HLF&'3B9(;HNQH1+,73DP7C>GSS*[[G5'X+<<X,YW+-.4&%])HPK*8S&5F
M>+:"+.*@R4_D0QQSNT!,D*NL?,WL<KU=@&%<Z'>3P" +BQ5$U8RS<L;PP(R_
MLNR<4'I&PFY(/]\MR-L?WB7FQ^_I:/QS"]K<C[: "-%&#JWK@5GX86Z8.B>]
MIZ2>H@0H;*UN6*L;.MC^(79,"*;)->";Z8'KU7 ]!]<[ '<MM7ZV0G]=XQAR
M92#5?WMFZ-<S]+V$'5,2R4P;5925R;,(WPXLSC952[2A0[,6\S ==NW/)'AH
M83&H60S\LA5JS=*CL@UKN.$WDFU4SS#R$OZM2)>@B$P(&K)B=B(BG)0"BTI(
M%:.A%4P!2:R7IRPK$G2\0MF!>,4%-UOR#_'50<E@L"<U'8\&AZ0>U\S'7N:_
M/^,;H1^@1F =@<3,M*WZW _Y(<=:HF??O7ECB\FC[D7-\>)5' VHU&J-KZE1
M*&,;13\B'9 M,*7)D*0(LM8>EK3;6&GW53SAT0!:ZBETCR!7='TL]PR?OH:E
MQ@)'AT=_C[G"9HPTM=&M#DI?%/O84^RT,4EZNDMB$=S"BNE"DUNF[LDU_LY]
M>3?>2;^5>=+&/:G?/O\''YA5%)X8P>#P*C2>2_VF^S5.,#N"><.VA Y.L +:
M>#D=_M=F,#L"2;O'RZOI!-3?"K[>!&9'D$\P@<;UJ=^C7:V=X5OJ6KR1.YHQ
MZ$AQ][25H1\5-Y,YR[9DS>QF\B6Z63?K9:_+BL==)9%8AZS9:J*&7,9V6((;
MCS+O<U_B32NA?N<_D'AKLGXDW"#Y-B=ATS;"(VUC*?BJW%9;*7*V=26'R>^<
MV1YL\)"%#YU62<(C(#IG46M-5M/M^W0O''B<.FQZ1^CO'3?LD:=%2D ;CB<!
MB,OV*;9[%'&_J-RZLBPKT-FW)"[];;?RXN6VKB).7SA;2?L@\;U]N+_%W$&$
M)-!;8\BEYJWE5T&\0K>F]X2]DW1[LK%&;>2&H<.27,D''J.:RVW3*+ &G*!L
M*:#N&E*:(^VA8K(O8O\0_Z:OA?Z^]K' '@7V_.G2*)VM>E';]@JS\.7!H'_1
M)F6P=W2U_VC @]B*9QJG2#"R>S["1%1Y=B]OC,S=:78I#9Z-W>4:6 S*#L#O
MK42[&WM KO^#,OT74$L#!!0    ( !N"JU*L7?BQ @,  /\0   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;-V876^;,!2&_XK%_0(A(1]5@I2P=JNT
MME&RM!?3-#GA)%@%3&V3-/]^MB&4;8$UNYAH;X)M_!X_AQ<.,:,]98\\ !#H
M.0IC/C8"(9(+T^3K "+,6S2!6)[94!9A(;ML:_*$ ?:U* I-V[)Z9H1);+@C
M/39C[HBF(B0QS!CB:11A=IA"2/=CHVT<!^9D&P@U8+JC!&]A 6*9S)CLF444
MGT00<T)CQ& S-B;M"Z^M!7K&/8$]+[612F5%Z:/J7/MCPU)$$,):J!!8'G;@
M01BJ2)+C*0]J%&LJ8;E]C'ZEDY?)K# 'CX8/Q!?!V!@8R(<-3D,QI_O/D"?D
MJ'AK&G+]B_;Y7,M ZY0+&N5B21"1.#OBY_Q"O$9@YP+[-T&[4R'HY(*.3C0C
MTVE]Q *[(T;WB*G9,IIJZ&NCU3(;$BL;%X+)LT3JA/L%KR <F4*&4@/F.I=-
MZV67(4@OQ0FAEPGM"N$]#E/X569*Y(+;+KAM':=;$6<.7#"R%N"CA:#K1[2,
MB>!HCA9HB;[=0+0"]KUFG4ZQ3J=VG46 &:"IO%%\Y-%(/CT<Z_MOPAB.M_HJ
MH.D!E>?-\$$/3_:8^>CR*27B@*YC"9RJ<8[N1  ,?0UPC.X2%8VC6QKO9$I2
M?9LJ]E.6U).F_,,6X^2')M$@9=X2[O3P,B5'U:09:(E38RK*'+)@K$3T,D1'
M(ZH*LG/M@6-93F=D[DZXT"U<Z+X9%^I)&^%"]SP7G,(%IV$N/.@J+!N3'3#Y
M5D&?Y$("R4H'Z H3ADZ4D\RE^DS^HTO'%/(,= **7^%7T7L9_:!D8*_5Z9]V
MKU>XUWLW[M5GTG3W>F>XUR_<ZY_WOGO%.VY0Q!XT[,ZHKJ[UI(VHKH,_JFN_
M-[2<P6F#AX4)PS=C0CUI(TP8GF5"VWKY.VPUS(9_KY)_2:7I93+'+]=)IV57
M.5C:T+3?CX/UJ33>P?9K'#1+NU/U:> &LRV1%S"$C919K;Y\BEFVV\XZ@B9Z
MY[FB0FY_=3, [ -3$^3Y#:7BV%%[X.*;A_L34$L#!!0    ( !N"JU)F.I?'
M'P,  !@2   -    >&PO<W1Y;&5S+GAM;-U846O;,!#^*T8=HX51)W'CQFL2
MV *%P38*[</>BA++B4"6/%GIDO[ZZ2S'=E)=Z?JP-7-(+=VG^^[3W;DR&9=F
M*]CMBC$3;'(ARPE9&5-\#,-RL6(Y+<]5P:1%,J5S:NQ4+\.RT(RF)3CE(AST
M>G&84R[)="S7^75NRF"AUM),R$5C"MSM2SHA_?B"!(YNIE(V(?>G[W^NE;EZ
M%[C[R8>3D][]V=6A_;0"SDCH)1V^@/2\!Q=*[6 L0/RR ,^Q8]27^]2M&$O6
MD5:YAW6.I^-,R3;5$7$&RT]S%CQ0,2$S*OA<<_#*:,[%UID'8%@HH71@;(UM
MP#Y8RD<']]T,RE_SY%PJ7<5V$=S?>;W\ -C-0" 7HA$X(,XP'1?4&*;EM9U4
MBROC$RBHQW?;PBI<:KKM#X:D=:AN-LA<Z93I)DR?[$S3L6 9R-%\N8*[444(
MH#$JMX.4TZ62M-*P\Z@'EG;!A+B%9^-'ML>]R3J5ZT'=9#.T@NJAHW$3X.^R
M.>XN[>MX@X(_*/-Y;;<CJSGT&KO1+..;:K[)&@$8>Q]GIT4AMI\$7\J<N<V_
M..!T3'=^P4II_FBC0:LLK(%I$CPP;?BB:_FE:7''-F;73IL,USPX0LU_-\]+
M)IFFHBO:]OY;SO*K%4>7_TIR]5_E4+!78WW@O761PV,0&1^#R"/HR2AYDQK#
M^FCLG+][IV]C#> M9T*^PUN3:(,&\S47ALMZMN)IRN230]C2&SJWK[U[_'9]
MRC*Z%N:N 2>D'7]C*5_G2;/J!A)1KVK'7V%[_;AYQ;*QN$S9AJ6S>JJ7\VH8
MV(&-6E_@<(A<5Y<?P7P<YD< P^)@"C ?YX7%^9_V,T+WXS!,V\B+C%"?$>KC
MO'S(K/I@<?P^B;W\.TV2*(IC+*.SF5?!#,M;',/7SX9I P\L#D3ZLUSCU<8[
MY/D^P&KZ7(=@.\4[$=LIGFM _'D#CR3Q5QN+ QY8%;#>@?C^.-!3?I\H@JIB
MVK G&$>2!$.@%_T]&L=(=F+X^.N#/251E"1^!#"_@BC"$'@:<013 !HP)(JJ
M<_#@/ IWYU38_A8T_0U02P,$%     @ &X*K4I>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
M1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2
M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;
MZ/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  ;@JM2\OJ?H:8#  #(
M&@  #P   'AL+W=O<FMB;V]K+GAM;,696T_;,!2 _XJ5ES$)UL8I5U$DH&RK
MA !1QNOD.FYCX4MGN]Q^_4Z2=3BJ>K07KT]M',?Y<IR<SR<Y?;'N:6KM$WG5
MROAA5H6P..GU/*^$9OZ+70@#>V;6:19@T\U[?N$$*WTE1-"J1_O]@YYFTF1G
MIZNQ[EPOWK!!\""M@<:ZX5&*%_^QO]XDS]++J50RO VSYK\2&='22"W?13G,
M^AGQE7WY;IU\MR8P->'.*C7,\G;'HW!!\K7F20WYP*:^:0EL>L\ 9)@=]&'
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MGV3]T'KYUQ^LVS6I5=D<_%GW5V#V!5!+ 0(4 Q0    ( !N"JU('04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ &X*K4EP5KX[O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ &X*K4IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  ;
M@JM2G9%C%6L%  "V%@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ &X*K4J[PSTOZ!   \!(  !@
M         ("!KPT  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( !N"JU(N'D:0T0(  '$)   8              " @=\2  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  ;@JM2A!M#F,L#  #V"P
M&               @('F%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ &X*K4IL=^@;S P  /@\  !@              ("!YQD  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !N"JU(\/:9&:0(
M '@%   8              " @1 >  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    "  ;@JM2&5;)3@4&   S&   &               @(&O
M(   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ &X*K4O+Q
M3\'("@  X1L  !@              ("!ZB8  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( !N"JU+4+99XX @  -H6   8
M  " @>@Q  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  ;
M@JM2]?^M/\0#   R"0  &0              @('^.@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !N"JU*B&5?*;A   -0W   9
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M970Q-2YX;6Q02P$"% ,4    "  ;@JM2E>Q@%_L#  #S"   &0
M    @('A;P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M !N"JU),46V/%P@  'D6   9              " @1-T  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ &X*K4IU:0WGS"   @!<  !D
M             ("!87P  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    "  ;@JM2/;2?^M<#  "8"0  &0              @(&+A0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !N"JU*%AY'D(@4
M '0.   9              " @9F)  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ &X*K4I>PA7+- P  ! D  !D              ("!
M\HX  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  ;@JM2
MP2\:F;4%  "E&@  &0              @('VD@  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( !N"JU*7E1"FU@(  . '   9
M      " @>*8  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ &X*K4LR;73#U @  0 H  !D              ("![YL  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  ;@JM2QX&Q6S\"   D!0
M&0              @($;GP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( !N"JU+1H6DV!P,  (\(   9              " @9&A  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ &X*K4LDYL(<L
M!P  ;R,  !D              ("!SZ0  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    "  ;@JM2]M+I]1L)   6-P  &0
M@($RK   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !N"
MJU+N(#C@O D  - W   9              " @82U  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ &X*K4JMA"FR, @  *08  !D
M         ("!=[\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    "  ;@JM28[9>CVX$  "3$@  &0              @($ZP@  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !N"JU*&8@)H.0(  +L$
M   9              " @=_&  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ &X*K4A=X'+7, @  & @  !D              ("!3\D
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  ;@JM29PL1
M/\("  #O!@  &0              @(%2S   >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( !N"JU+#*=9K4P,  +8,   9
M  " @4O/  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M&X*K4F'R'D+F P  YPP  !D              ("!U=(  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    "  ;@JM2L<00A!$"  !A!   &0
M            @('RU@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( !N"JU):1G "G@0  $T1   9              " @3K9  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ &X*K4JQ=^+$" P
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M2P$"% ,4    "  ;@JM20+O#+8<!  "\%P  &@              @ %.Z0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  ;@JM2_WEJ
MDI\!   =&   $P              @ $-ZP  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     +P O , ,  #=[      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>308</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Description of Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperations</Role>
      <ShortName>Organization and Description of Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Research, Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements</Role>
      <ShortName>Research, Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability</Role>
      <ShortName>Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tayshagtx.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Organization and Description of Business Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessOperationsAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Balance Sheet Components - Schedule of Property Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Research, Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research, Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiabilityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity (Deficit), Convertible Preferred Stock and Tranche Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockAndTrancheLiability</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Options and Cancelled Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsAndCancelledOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Options and Cancelled Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-Based Compensation - Schedule of Total Stock-Based Compensation Expense for Stock Options, RSAs and RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseForStockOptionsRsasAndRsusDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Total Stock-Based Compensation Expense for Stock Options, RSAs and RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss Per Common Share - Schedule of Calculation of Basic and Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCalculationOfBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Calculation of Basic and Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Net Loss Per Common Share - Schedule of Common Stock Equivalents Outstanding Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsOutstandingExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Common Stock Equivalents Outstanding Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tsha-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - tsha-20210331.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - tsha-20210331.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tsha-20210331.xml</File>
    <File>tsha-20210331.xsd</File>
    <File>tsha-20210331_cal.xml</File>
    <File>tsha-20210331_def.xml</File>
    <File>tsha-20210331_lab.xml</File>
    <File>tsha-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001564590-21-026559-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-026559-xbrl.zip
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MM1_+\Z)DZ[@FZ-2$JC0 ?@EBI$( _!PY^)Z=V.D+AA*^2V$A6>6&3E\ZE F
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M63&86VCGX0%(;ACB 48XH9C-,UNU@!7V^T&LRR:D64Z6\*:,"0V(CA^Q<-E
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M5PWG1"X -<<R..?(?H;+)2\_(WOTB<9T!66[A<MD6!WM\O9]TB%_>?N=K4#
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MIJ8!2/[.E)K[K1%DZOYC,=7 ,A=^)QY\"XH 9%\B!\!Y1"R3@[Q)V'_&0-D
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M4X:L"A;R)C6^1A&?EDU/L>7N?,< 5EC +570N!>6.O%0%1\F1"'=(/4#V_$
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MU 6= W.(UR>O$;<CM4WC-@;F"*;BJ#T_POO\F%D!()'9,>DD!_C!<?$!<_9
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M?X;Q;1(]*SOYS>*"T\>G!JTE>H%ZW3:'Z.;",+TYQ$H8S4:W/U062JU\M6T
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M[ &^.!/>5.+*F<UU>Q&3K__& WFFNX9H7.&RL>^X7DU[UCVX]S'0883PBQ8
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MTLT92/Z/7'";,RYS\7^37L5,1TFK><'#OT/O#P<.<F#+ ,1CA?B'"WDG7?Y
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M,D'ZL*5[N> MU'% V]X(+&2!E$Y&C<$'\0)<K3#XI:\9S8U/@WN8X;3FP'O
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M(=PC3WSC@Y#I2O',EX^4#*8LCGKX,&,9Z> \$V6,;/;C)>5<7R:L;TH5R)<
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M:[( C$[FAL?&3!C>.'93EAMQ (KMP+UX@15G(#O;9<(8?4)<G"+M;REAI-A
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M!,:2U1 ^I,@5 &%?#7")X)"\5Q_*:/N81#X7^<KT8">17YKO=O &B=OW#TO
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M59$DWCOFGN8)*_WD@J?9KO>51RA,J=<>X0:5>VZ1G:$*$D<\MD?(Y+<GR%S
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MM;64<[*E42J+?7WP%95"J6&O5$I=Z=Y4FGXSS=C>Y"BF6<RM07]EJ/@V23'
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M'<C_2NWIEBEA1@ KQYBB@O1\PM%F[UZ>02_9S^D8_F[)QG%JL[J]*7DLF_B
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MM%'$\>@5#6]DP&7U>,-E.!_Q@->RP'I%@QD[:9TOZ[DUZ#8:W?8Q7(858BB
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MR&^D2A(-L)2<3CU);AA?7I$9]APPH^=^][!#9Y38X!0=HCQ:HH)1+#&?$_F
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MFAA"W@"N!?V78??CVV$W.>AV6-X/EK%8W#CL9<OQ-X=,&;)^;H8LZ CIGCI
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ML,;#I<A3K7RC_,Z57/*%^J=^!O77_P%02P,$%     @ &X*K4B"_!/,,*
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MD.3Y07R(JU9N(,II([*/Q",>P?<GKP"!XH3]TCF,(6V8*#\-9-+JLPFL 5:
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M7(30>E!V-=#[=*!YH6BKD:\.Q2/.Z-TK([=VS]QC+T%387Q4(SDO.D/'_#H
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M M#2\3+N8O-TVN7O],&LE,:\G6DGB1$[H^TD?;3'X8PJ-,+PG"%8L*:N H4
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M@5/]@ST&Q"RK*CK$O92Y!..>:QB<>0BE+R,XL;%FK0[L"_)724R/P'R T.3
MV!"%<<9T3-&K!2'.#FP)OP"MI@<AK*>W,?;17DJQ-)4!8N.LII>X5P.*&X6Y
MO:P"A6=,>G!B8\T&/WO4;J,/3!WC2_73C0O5A]1]7<3!R<TI8G0;3FJ #GX
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MU\HVU81JLE=D0M6^2*_/Q7=*E@C>("-\P]BML0 6VZMV.2 *;Z1L0<472,:
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M\;A'!#(BB>M ]GF/TYH:SF!&7]DYA]LDA9LC933?I]<,:-9LQAFV)5N_ >Y
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MH<,$Q[6T!9GZ%)>F8($>[JJE/#FMD?"M,_X!*TN"+1D#>**#".$LRF2F//I
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M%'VVV'@_C,6]"1;T'IKYOK@G*6;HXC(HE<<P2*^4TJ.&])9W((V\)[ Q%TV
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MR.M'"M[7WFQ5 ?#RWL X4F9;87646MG+9XK?M]XHM3J'0A8P]1::*0)7&MG
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M\=A)T@"([V(B.N80U21#?B#!^<&G.OG=@2J+(3#E6(Q>^<P.]3[[R1^749W
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M7#@)9LR?*X^F.EK$Y!XBFHQ+.Y[=6><1JR]1:F)2V/SS)V]B,N!='&;ZU>R
M;]G#=AM!P1L>*$]OB0^0:[<SP=[U#]Q]U$;JW6)'BEIUW%2#A>E-,55$ NIX
M[77E=RQ38*S>ME^4>V?-V+;B,;H<RH9V\SZ4QQU+OU/#O5.!]>6<F1IE7S!K
ME0&%K)*_LLH\]091%BBYUX6Y!O-[E(8PM"$,;0A#&P)8A@"6(8"EH:?.'H!4
M^ZG3\*B5)IXZ#0]BJ?G4:7QO2ZG'E#WCEZ/59T>^@GL.![)7R?V6O[QQR&MC
MY<.+!S@&]\ A\[H2M>(WTQ',D,U^)W6_'#O1$!1W9=X'"$DM]\SX^32JND.7
M-&0-&.*N\;.+,+@GP3]0P!Y:0;=/89J:2A[;5' GWH/E!<E_C.WX79@NPPU^
M0[.Q[Z/ CW[J <5,BKR4-#YXK%02O=RX,Z;2HPJ7M^[8MIF#V7^P-LRL8-4<
M;=NC0@^I*ER/OM1L\BMVWF$[+CH&D3L8/8TR=TLM7Y^5MJ),);T]W$5T6DN6
MVQ8EJD=S^$OV_TQ67BR''1%T#0(/V_1@8+^@_.W^(/.75!\X(7M/NL+^FOB6
M\ZM'PG547<BWB4NG1R6,=ZN :1]]?.DLGC#@[>I*<J\SHSC$B,[+0Y:/KE#\
MSW2>UV]V5+7RD9I5U_3N E,!NCG35!2$,4I/GQ=,#=F+S0]J@MZZJ6H;VP%^
MB9I_@Y0E@*J>Y.:UM4GLZ$?D6'$S:O:(]@R2@'(Z>IJH$ANAF7]#+Z1U9E).
M1_=,^,VXT%\E.SDATMW::5+FB03U%F?-S2B5^B67JA993K3"E"37C*TU_^!8
M;I UZ4%B#*#:K;54*,&EU%N<=5IC7:D$YU+5U/ICSS"Y"M&49(X&X 0%"4K=
M7@]I[]Z*Z=:8!$OD;;TY@JS+TVYGA?:< _56YX!8.W.B)_/:PK.KY'S> SUV
MY=2;J-@([<P^W?Z)$T^R X\P52TQ$DDEZ-W<$) ON8!">RVJF!11$Q-61K&2
MU-!$3V1%KM#:0S8&2]'N=]J+6+*T)VJ).V@GOV=*!*T &4W0S/B:[H9S'$#K
ME&:_ZI9EJ- >;GUM,J%?Z9-DS5"W'#K=>>,OFR:IMUQ]:8Q68Z.0_.W=E_;T
M:I!KYB#0VN2^Q35H]!@G108*;SQFMFYH&MTN]2KK9NLH7?)=>?_I2V\S78 7
MW9N;Z(K69YPA'I<F^ZIU"7L)WU8IHF)>NR8JMW13::O&]\#]J[6_V-$!*?]4
MP'$U6_FJ%M#<UR->.<AL;:KF&@AY<^3(FMW=4I&;I_25FI=P,CLMID9\0-;-
M XAZX,@:W]]7";:0N!E>4,OL#L"*-$!II!7'TFQG3HT8MUU'+RQ\CU<Q,]M6
M50_O8>@GQ])L^U0-EN4!P;Q2G#H5>E3'$Q!-2-@XQW8P4'?*(FA.4N!E_-0;
MM[U=!W!B#E\%Y2=@EXLI=G M#NH*JG\=[6Z)1E$36CR7,H7QD^$>'G#.*H&F
MWJ90*GS1- M*Z1QL#JWA%Q 9:/<^AN7J<V0-OX[405:\Y$,*I^'/C_(Z %(B
MA*-IN%NGCG#N5H+AY98U'$(-5S9B!J!#?+K=)M["<O%?\9JP<]BW/;R.A>@B
M]+&+?/\PO[^TJE%=XJU5-))F7$/L<I8C7F<I9N\A \MDGLBWY? 23'QB4XK2
MA0-,2E8_MHYH[UI<RX2%*QJP=9VI%CC2I!SQ$I FZ>2G<+6RO,UD_H07+IYC
MF[T>QJ8\:_U$8;,S>:&"NAA&M ,Z6)!A'7DC90Q(:511BEIRO0X8D,K8*J'2
MND83F"*!+XZ9RN?"<MBKY=,2H8#WX 8JFW(B'5 N!0SJ4";AFDZ;'6F6D^6"
M\R:I4D!T=2B6+!?)"V.&&1DE(TJQ=84#G#J1748S5=#6+WQ)'"H Q-O:B(EG
M>+SP4&P3 K42F&X'%)4XSSH*W'$F7M#8\]B+*AN\YOT21+96T=!*%"%:299R
M:]JI)A1$<L7,5%*%?:W*FF$55;00O<.I'+,#RDW-?'35$M]A])X$J*;: Q#5
M8:[)M_[I7(\?D68^PM@;K+X*:QM!]%%%@:3V%<PA@SIJ_?"WA/EN9_'H-A"U
M'>%9KFGF@(P>J3V4EMI'HDP^9YF4T49U1VI=>RF"BBB4$#-UX#V*:K(\("]I
M.,X@ *K 4AH=T(#Y_.DP)RS/Q>Z"C1R-*:7:2HAH,8GVAI<RC@IIM*YH*J='
MA%;"3.60S8E@5PZ? B,1 E%%I@,JHI!%+44J\\>N>;4"D=53C#.?(1F-4DVK
M=<TB/%TBN69FZIRXNLO4>@._[N=\V0'-DN5*3U7B>+B:VJ.<CJ;ZROL<2!94
M+B;3NI(0F201714S%0*SV7%<!VKLLOZ*+!0!N1+A/P*4.J PRKC4\KY5.'SM
M)RX892WMJD1XDE$[0,*M*R(Y((C\ZIJIK,0"]AH-7SS:,$:=X8SWZ#7#@$>Y
M#ET[?O.-V-C$_RNEY^"T=6BZ'SZ:S*_] *_H#0-4F'W_2SUZ.1,:76,MRNGH
MB0#SL3^9[XE['?D2I3@$SK80."NZ.%J/OZ-!KWR[<LS,3G^$8;:OGCE*9F<S
MPU""'\H<1PWIH2V'MD]9:KR: /==4ATP/DO9E FD?+*7:!8Z*-+R.05C+UGJ
MMLO*K21E8Z.Q0$>]FG$T]?K)+^\H9=J(4-/3I2K>S5%40)*?C_]"LZ2.]6[A
MZIIND?IC#8D,'4UDJ+^T?3$3Y3$641E],1SA**HY:+2:G"V'ATJ92B*D.F J
ME;*I(\0\%<1KB@+9(/2$O!?,)#JO%TJVV MK$+)P(^4:U5>+5*Y<2'IS3&AI
M:TBB.B\H4Q(O6M:(>S^IP;F!FZ3UZ&MI;9@N7!&//UP<*("@YD!ZL2B06H4@
MP$9H:_9)1._XU?+B-9I$)Y+/&HK%#/M^N(I_IA:5.B-K;0E*SQ84%82"9? <
M?JTE+G6KG#FBW]'J&7D0YDN(M-=<.Y-+Z%]L\N4H^I\IG2$K&T.-OGMKA:[(
MRL(*6G/7'5_+NT,Z_AL&B>O>AUKWUS3NS22QMY(OAR05PY-4]A><7ZS.C+ZX
M%FP14KAO^W*CS]=SE5TBZZIP#N\7H^%M]  F0G8&A_JKV5!7;O$\2Y)WJ>Z)
M CRTP4ESMPN.KME:5!Y=D1LM[_5MMH\>BJ*4<X2#:?C)(P2FG+.-=X@^'S!L
MTI^KM15WNRGA4L\> I0Z\.I1QJ569^78#? ,.R$K*/6$[-"+'MNNWU@'&S1C
M#=^8H(;; L%*LLN;&%VOBW>?$1:!:4<-?NA<T$R%+Q<XQ)"6KS4M7WJ=^A)<
M(0>F.GV@U5G3T:X1X]D,QU.\=>?$6T4_O4*!A9UF.TJ(#-R!0UCAI'2DIUC^
M$I2&$OV]IGA,6/==4' FC+06.\"*+NQLP/N0>=22V[L?]ZRY=3-E%$"'/XBN
MGO(95+Q=--LJVK%MAZLP#O***T9"YB="3:K,;&)#1VV#W&T'TDD8^('ELCZ,
M,8K"0="BY/0\Y*6]D*[H<>@NXEMAS$*\#_Q(867V!#\Y80]_]4:26KDI6JV)
M9WF;N!@D'R8>MF2K3TEFF8275MEX6O1J\GIW0[P?],SS7AG4K*=N%"D)4J,5
ME-H\)4"+"""F+9@B4<\/'K;1UA(%1T3D$VE=P]RCU^A7ZC1)AF(GPEV*'MMV
M3^!Q&"SI]>$O;G@JB76!#ZY-(@Z*],9.X+6SK1+-M.8CF] (+!L@VM4S]K=3
M]I']84%>/LX0CF=+_V5_DO1'?US3:V:P885MO'52B?V*6B&3^<Z/1*8%H29U
M0,+N*(=.Z:H#49J^EG),#Q-X?%WZT;:OMA3N3U1E(?^BT!P0YPM$K@:O8[6\
M5I/34I/!L:C\Q7<B>*QAWM=:H^^R#$"C!DN(:&GC2!>?O4M%Y75D8UU+B'1?
M?^AW)E@K^J^92[Y$=*T -2VS"I]]/,/THI7A"+P#BHG(739?R71)0I_>XJ>O
M5""32R ]INE_X!?$8JJ NA)"4LLE2SHNNXV(ZNV84,'8_4Y7S;;D9@G7*#D?
MZVLLDI8?@(M$ 0&M)^@>#[[T*9I/2(--+AR!+T][:.O<I[;.\G)B>FA_[=V9
M%QF<KSCZD@P@IHA)Y:'1E^C^\D.7E!H%IH?EJ]R>NR;@[FX\,PZY4H,Y!Y6#
M73<R4^%77'N(Q"V-0Z8\D/D%><^D?="4GI+%5_3=/7ENK.Q5NSH(S#_#)=#,
M8T#"\T5RW7,\E>C4T*U:#ZH2[RN'SLQTC49N H>.^%T=]\4X&,4?-$CYJPO/
M6E&^53L%5,E[%0$^KW'(S+;=A"&K?CWM31):O9-S^S">PO79S$VIXA"H%R21
M(OQE0+@P1(7 PF@XIF9FT*C"5#[BBB-LIJ]..<+JP_SX$BB_ W;D:M.(F L$
MG:;(_J3<<;\F/F;NI*FQ0IX?I<PAU="UP  H!8+74TB_FME00SFD%0D.'$\-
M51..&$^U23(IZM^4&Q)]/,4$DK"VB(].376)*I5TT4P_#JOR$VYK-)B"*R39
M,X55_?.D8=(JER+,\1T,LSJ&66&V>0KPF7)?A*$"'%<EX+AI>.)LN<\9KVZ2
MM.!)C%)_K]5)TI$G*BBQ1:Y65[0Z W>@.H?"26G);LYRL]ME*6$)%.$N0DY+
MV&^M:<"Y+@BY3O"XI'^);<N9>MAR1!@I^;@.'Q?$#<5S+'<_TI-K'XUXZ]*-
MQ#:1A.AEOJV#U"/5%O2464;'Q@MR2-0GB[5J9V'-8 PKR0U]Z;K8[4MT]?H2
M)5RG]=S^[N3A8F:^,:H1O43Y-AC=:1!8>R=E7P(2Y7=EGIW3ES+RM759N9'+
M851_))# <KIZ52SH,-K0_5!HM*.X%);/I,WNU/<(> 4LHZ.EX57694N7V,9)
MS4NZ_HDK:+PB7I!XA@H9ALQ:W9BM=B+_U2,^+*6]@E*KLSGTZ-6948::GM1]
MEQY!8>02OV4"LZ#*RI?)XB^C(W5'IF</"VLC\4MK! ZP_D0)!4UE$=8AM48D
MV*\DT:K$LRY+$C4T1,BU.J^+C4P#0R%R>BOP%T,-;G@H3'/P+77T(B&^A-S!
M9/;]'[Q1"'"W<R#-#%"3T:0B&&9/ M/S_65.62)@&?3%XPG$K<H@[$TQ %EQ
M*[/O^^(X;N3@N,O)B!J9_<(#N$N+()AX 3AZ9@9TU4-/G>^(=X14ER3R+<;9
M10O&X'$C7>Z;Y.BIE]*NN>P5]EB2'Z"SCOFV>R9EU0#DSKS[W7#O[^B]?W>9
MM+;6Z\Q+(3WTO! 5A4'>8>L9.U%RB$JE5'_XSJJL&E/3\R3'>,H,OF4K\R/@
M>YL(07VAI@?\2(>=%E.2>JQ)Z.5?$P%, HAI>N3UHI1>,J=#1]KQ!DFA7D5)
M2\WKI-UV<H[4$R,!8G4DZ0[;3+$ T:ZB4(>C@OA,.>8JB U&5<>,*L#:<4O+
M;#=$/1#S=B=WX)A9O*:^32^@=#F(9K\]R8-8=11S!,TLAZ!F U=89SPRU>P2
M\'7#HHOM<([@<(Z4;N2JZQGWN*H_5MKSN&ZMD$OB./&S9NS$3P[6,=V.29<,
M=4Y8I6-VP,FA9CY23;F=.(GD$2W8FPSQ-G185G #>:S'R7?L(#\@+O*GY(*R
M:2/\(M9=M0YUJ=O1CS7=SFZ0U!@29G'_,[G>CI:S-87XG![8]H_6CQWQ,WI"
MT<D_DHWE,'4P<>]1P+[S)_.]/_,I,Z!V1$T-+X4%7^L#EB;/#E[$KWK &<*(
MRJ7"QA(PF4]<-,4KE @&OQ\(,RM 2>[^GV[^=/;;BEKBU_XR&G+AT8F.<F>W
M[@NE0]?H(:2ZS,KHK4C0#B44N%45C-38#$L$M(EIB@RGPW>3[X)("[J)NVPJ
M",GMZ 2UR7Q[#GVG4+%L26:?/2*\>@ZI_<D&NG5M9N[N)CS[D,QW%6/5TUMU
M-%5MW;1OJ>0=\K(;08BF$J[YME+'=2G-.BM.C::Q_<\0>R@9\A$OEN)\5E"1
M//OC7?RK9U&IXA7:;L(HJ"<$P"A"2H>&NT+/=,<R#T.\=^FFIHOX:+'BS$SQ
M4C.+]2>R%B!U!Z&J8"6BLJ4XH(1KKT0^*3DY3B>Y4U<U+I5VS0J-.V@V)<F]
M@%LN28%+]R9TG,T5=D+*S(7EBV7+-#5R;02R- ]XRFP J4F*$]?<IS=;%P^R
M@0I)2*W#=WIDK\+5WD5H2I(C>O+,JB1F+K'KM4=>+.>&>#OW6?R7^-&K<DC9
MTC]V8JJ,[0"_1$ZJN)!I5)SW:<W:H'J99Z;4"R$N@G7&T".)J<.%[G->"YX9
M;??$M0M^G:G?F%-(3TA\58XK^9I,3WT?Q_4!?R>>,WO%L_CT9P6:IT]_'X_.
M3MF_><B*FU/-?\4LDO2-J<)[%'ID;07+#3 95OFX<K-_1I3:=(D\:XW" -L^
M-<NA,RFC48.K1Q0$Z4:0XBF7@I8XE0-1MO*E%YZ"#":M8[XL664RS[ &3=HM
M(%!#>B[O[D=<C4J)3SZ)UOT)<)D1(J=C7JP[S@JE#=KN&-?XH V4P(PJ"+4X
M%ZCDEY*1F(?O!9DYT/_:YY_^:&MUB4M2SD>-\6:]2?"V^U%3O#TR]03C;.>3
M1OD2E;R]#Z1T['^&B.H.V=.YX&NY]Z[I$PF#Y2OR ^2YLAQ54&ELW=!ZWZ5]
MR3P)R%M;7K#)Z1)=M:[B!)N:T_YX$+',_U9OL0X%=Y(:93W4C5[+7U;] @^(
M1Y6EW&X=>7DH<HM]J%M8'M!J=FI\@UN2E*F;W3[)YN%;J:0)^"PQO12RW%E-
MQ(P+TRNKU .OP%;L2\':YI5@YBJPJ_G.C ,U_ZI$<BYJ/$;53/$JNLR2W.LT
M1\/,>C)5:.PZ/C@:9NIK/:I'R/^UJY#.C85:Q)=8C=F!-79NIO*">9,)T _.
MT3-8V4F;8V4O(RERGTWMYZE7-18\BNTJQ2_&":C8HR*I\23*>X";N<7K/D.3
MZE=T#N%PXR_2D@4A$;R]M]G'<VWI4QTATV"_Z4X!K^=T4AN[Q=?&[$M5(Y%V
M1$6<(5\!L]/L&UT!E>&LO"&VV>4WFEJ0RAAI#K"9-HP>G2,57L][:IM]%&N#
M7E'Z!E\7LV]&C:Z+2*90"O0GL\L"-:W<(1ED'//!PE$DW/D)B2G0YV9&4.C1
M[N6)J2G&ZIVM_<$8E*3,$1_.1F6(ER:S<\0'IT!=/;);W"!%]LM@?L@CJZ+8
M!5^)P2BI8PA65$Y)8?YI,$EJ*^^Z)7GX8IA=2K'UQ:@H Y6NP]?!PRB]#J6E
MQ#C"PSE;WX(I+B27XOS-[#?5AJ_VD.J"'/+A.B0->5,E*_GB#$\;THNS7Q-U
M"^J9H5DN6D"5K(7+L=?@"M!6-#IZKUD2A\[-9VT)@\T5FF,;T\LAM>F\ -/-
M_+"=3/3'%"R&L[U$VYK:&X4%I;7QTX%BT\W/5:H0]9)MIUOWQL+>;Y831KUM
MLTSL<R"<@"M!6;:@E@IV&^&M<&GWZ=]A*A%T:3=3Y*W$(98DW^Q<OB.+R7OL
MAEJ'XBG;-49H=D:3.?TE=A</'K5_U$]GC[R6\@,'RNB>!+&*>EH[6YW$FJ,\
M,A4S$IFT/&UM,XXC<:["".TH3BV.3> LL>?S=-F>D$W_%-HUL.Y(.M"@!KR-
MT,R_H8888Y5UX-AA:%=B(=,'D]8]7VYN$@^TL"5$6I?@Z)>3R"+UK]^8;>O#
M*GO*4->R<HEO:S)/.602)5PF7(R.I.61+^EI9%32F%[8 A$CIT76,H&+T;%$
MI2'Z&4BDBHFTOE_NT6OT*W6:/4-1CT;+:E&I<L7"I-J:#[P^<1F5MF8Q#H,E
M\?!?]6>2I:2ES"9:K>D1YVUB,Z[.="I)M5( 6VXNI62TS,.Q_.U!=NCY$IE!
M/@&Y(MY[ES%ZC#VG%YNQO<3HA2J1-&(A];<Q[P9>T5\!2^<I&T_'2ATR2X_!
MWXA#+S[Q119:6E608!MS>\3^GS<>0MF@V/H3+*/:QBQ9EC"\?FP9E;9F :T<
M6TQ#L^Z&"U7.QUH:KD=G'1U\3160&\#%IH" 'NLY*7.QQX,/%9L*0G*-_ZC=
MC?R+@_@3X%%214:*MWNJC-U+:XU9:U!ZX&3Z-$>3MUQHZ7X 1;E[[,7WZ:_3
MOQ.'6?N^&IY!-(=RMT=6[G8H^CT4_598]%O5W1N_T*/FP;%LX&%01:'&&37^
M04^[^%:"XJ"R2^2QI&SV^.NBV>$]1>H,DQ^FSMQV!GQ:(QO/L7TPU/25R,T)
M3+[YN4Q<P,ZL1;[.7 X,FEL7!]AR+AWBPR_<,*)*^5;$Z="*IT$?82NM>-3P
M/GE!WMAQ2%S,)WK>@J]*"1$M;6$>)G">,Q]IN4M:K#A0=/UF9N=DGA%6^*58
MA)J6687//IYAR]MD. +?CHN)U+D9%SZWR]V0*\G5T?IJ>:TFI]M##Y?PO*^U
M^GRR#$C[>PZ)Z&VL$@U\L8G8J-$A)8>,/M\AI.U)T9>MQW<73"6W;4D.VOWK
M/U(LN41HGYG>441<7Y%RI6IZ'Q&!XX@ 3T_3NX> (:LVCE+(1F:73H$JL&+3
MU_3&(.)7" *[]W!1,SM)$G"C)+G77@Z4<LW?M=KQ4E"5>#5X*Z3^E-T74FA"
M]?/-;2JBH7Z^X54BZU8PK_)_<QS--G>;PC'_Q8/W9S+;O%.$*O@ES/3>:*W@
MFWDU-;W;FF)\I5_:.<YF:U\Y@[,H]J(OS<4$;<W2#IKF]6:2Z*!Y;N;NDNR@
M>6ZFETZR@Z;AM8L!.D2D%?E7XX!JLA7Y%X/UCG1C,E 8.(?28*4E#24@"X W
MRS-;WZFQZ(OS/U(<#:]J)_ORG)_1LW.(C Q&32A#*H-;03977]H$EF?#Y3?0
M.FRE.-P",T@5IV3N;D)S7U K$ULKT#K8A(;W9A-(9RY!K"P9FR-HIO6F!L&"
M?/V^]*<3 T]MG0>.[7!V%,3#W>4TQC7\K;6\ADI9.\]LM1>.EO)Z^QV+A1#&
MJ[+2#\=,>0>:8\6LJM@3;W"GO'&&29 =--H]'W9E"5SY'7+/AUV97O#%ROWQ
MMG&FQQ**0U=<^I$W(#/;'*O$"E3TDZ-F]NU*7*&5UG/E';\&*[9:EQ64]^5-
M70:92P[1P@+0O%^(<JUVK&< N!!XBN$GP]O#*=FT I7D.:"#89*%%-2<@(/8
M<RU8JZE%BJ+I+=K5HGC8Z80#:7@O4[5 [G7 25'\;'B?3,%+2'GOHQ0M0V.<
M@#(';VS% 32NF]R%1>\*[%$?N7Z\5HK;PTD-T)5^;S#F=37V..2*ATU=;/B?
M)'?L\:OES6)CZ=;U R^,+][!$GE3NA>2B^.OE$3@W[JQC?H[PHME@&9CJIZM
M!8I^>64%*-TTNRLET$BD&TQK:[XB,]WH?QX1G;2/J5&+O)?8\T:G!NO@U0P#
M6LKFT!U/-F@[=OY,[IG5X+.%9OSZ4Q)83O;WS(E$KP7_0,$CLLG"98\PG%+\
MT;XD0?!MD4EM\OM<+3[/N>+S&YTTO3<\LJW(6A/;3%LOX/I"/0.=WOM 5==%
M]7OD&B*>Q WQDA^QOP.I7=V<'37:69]U)T#>9:C3NJ+#%IN1=MF#8[G?R8PE
M8D>?W+IV[-,YE"HM((/XD2OMV=B1\8C6VQ3A'U2321QK+3.H%\_<_22WMS4Q
MTNF=G#40M5^L]L?M!%)^'4V^?6P6;JS="ENM-RM-;1;V1]ML-:;$U74O+1NB
M$W(&U"N"C7<;';[3N+%W$'\RC_Y="U*[ \HUJDHOXY1.&!#F/;4CXX4.=DWW
M[N8?R/)NW8.0[4?D4W,?L2O031B$'MK&(PB?>TT,W6GYN'Y;8R_V3M/S68^[
M8&](O9826SGDQH:;Z)15C]AI[QQ?'DD7DII!-3>;3#+N%>B1&L0[K2GN0Y9G
M-9D?IBUHT!G%@W<:L\/7Y29!NA-M\:P&%2K( ;6< W ;CPH"<C8#%0L\8TBX
ML\LE1G-JW-MA@%_H03ZGYKT';6PI2D_EZ1793W%4P0T)H2S#B+:X;S(<3>EP
M$MVC@80[,E=(@SPILMV8)ZAYGA19'?-,O##PKCY['VKD%=K"9^<SK:]$_ T%
M+BDE1*1T<5+7<TN6)99?TJM^Z 3LK@_4P6+$FFK=.L4!RPN_=6?X!<]"R_D=
M!\M'Y$1[R5_B]91<NP$.-K!VR&"RVN8':5-;\'$+EE+T7O#X]*.VQ;1/2$[^
MV=W#<=#6QP65^(+/AW;3HKP-[::;:3==(.^%+G"@X%?2Z<3-M/"!)#:M6!DE
M-WHHSBE)V.@#3=GX6AKXIN,#K::]#Z5DD-KLTR4)?<N=35\I(IOXT<9EOF=Z
MQ9201@!%S9XU^"F7\[&^5HQ%A>N$.S(>$-#:TK.T2"&DK6<^(372O@VN4"CN
M)21UX"^O0=O0?=LQH<*Q^YWF-J_2)TV=IK!U!]6!$<]%B2I*I&Q&-S3&N1_X
M!Z\NODS+V;HCM9[YI0BJ_):V=66EAPUP%>UI4J2B^M(A-U>AYZ#2MX:X!<<R
MD; B^M(0M]'="2DI;G(_6,4EQ4]'9I\8*DJ*F]XJ%ZKJBOT##39^[11BC6JZ
M/2]17YK#YGO5]BL&*G<8\IY[AA_.3;I[B:ACFW<=&Q0$6$$,G?WV<#CLWF;F
M'I;L[/?%S#TFV=G/\&*R6O1[T8M]"O)7LYT"38,L&*S!NXZ9?3%I[!0M".CI
M0W/+\D"H(GRJPK9,[U!6)T2.@ +\>M/'3),J+8GY[$M+I4:]%3N1P'UI[)@7
M-7V(R8%R-+S4?'[<>[4')S]2GZ-FMDVI +5,'@='S<RKL$K4LGD^*6Y?S3X+
M"G&3R /CF)EIJJ@P^H23 7DK#;/574M7Z'V8ST[-/HN;?8M7D&:<+H3ACZL*
M$\!5K$!Q-CQ?$+,+WC>S(!(E&U+ 3>\ZV]P.4%,OA/=O,=OV4[L0JBO;\%48
M#@2-!\)^2:6^-#-J8#,T40&,-_,9#@F-NV*W%!U?A)[?S?0N0EGEQ'1)?C*]
MFV)#BR);ZI,#/^R%!O:"RJJTZ5)]5=X(KA][1)9J;BWF=#6^F=V[M$NW#.&2
MXGQQ!N>'KL6I72>?+]JW0;_IU&^@[A#;5?IT:G8[THZMD6R;E'2Y1L/]'[Y<
MFGH'I8OTR>SDY"-;I((N6GRU!N-"IV<3VELN72?UR4G]L2=DGF3*FRKR91D>
M!CJD[#BEHDZBZ<)]&19.M_>AL,5NNB@_*;\T#8NBL\]TNI#J_4EYIU7+/>-Y
M/-/8]\-5C-D/^D=3<DW/C546F\D\:RVSP+N]M#65O>:;9*RS/>H;F707:IX6
M;=]T-IGY7K^M$8LO_(VP:%"'[KQ'77V0(.QTNF-0V438&RR\=V)#7'2B(J^,
M.%RQN&6J#CHAF[O,'!VFC]C_\\9#Z-:EI@ZUEUO%-)^93F-Z:%H9U-.HW0X5
M0TWP/M0$'RKC#I5QA\JX$%D9*N,V79'.7$S;KDAG>(7=1HT-6 6(H3)O1[(!
M3T<]EWF]7FGQ>R5?H"&*I^4%RG>F\ 4:WG4T/ET+N YY4>0A\+<C6V??1\Z7
M2(-%VYF7M(Q!-+8#JDV"33,O8]4#'<%+5\DDNOS",ME*?I0:PFPX>K![V/6Q
M'>T./2\L EQTPK]9$4W[6QPDX\Y2%4_8CR9AX >6.V,EP18+#RVH4MF=GQ:'
M=WTFCV$-,O-H#^-")OYP\*ES)MGMKBY7_&7=NR'>'&&Z^-N($CA6VEEJ!;/=
MN)N64"IG8MB5]9GH=!3$X>FX%__UB)ASBT[KDKB1USRT''WA$778.P;<JP_,
M+BZ'2JZ/897@$SO3N1Q2[!V#9B_>]GOIYOKTO#!+QX!OP3[N(.QU.3V&U2C>
MQJW!+LB2V,VC[3BA9$[)72#TD& M"QTQ1+*\'07BD,(A&L&&L-4)G(W5'\>!
M;_49%%<X[=:YN.7IB!'.2%%G$,[AZ1@0;A7*@\$[93? CV:=V.4.?PRXY9;0
MTX=;[O#'@%NW=FK',3M\QA^R.X;LCB&[8\CN&+([ANR.(;NCJ_';0W;'D-TQ
M9'<<,]1'D]WQQ?"%Z%8$=/$]DB^(\F2!=5Q'/K"\8%@6L%,D79BA.E<+2Y+K
MWTN7Y*NZ)?D6+XD;!>'.AD61<EBG"Z.^_'>LQ*[=86D4/<OPKO:#7NO,.N4\
M4*;K-&01MJOJQ#J[C#XI]WL,]EN3K7A&0QNW-I8*'-*5KM?G8;TZJP?W#<'1
MEX:TX6 (-AP9G*Z@^FY^PW93%TZ?+M/789DDETEWADFZ9$-CLQ:63&6.5MKM
M;#2LI/Z5E$I^3)?L;%BR5JW(_6S@!IN<&W]_UI#PSOMM#^^%FA<&4J\A7:;/
MPS)U2+WM7XO/U+^Z#]?BIBOQ\#;KP]YJU=H[J%/%NZIK6)G.U(I[I'+K82;#
MT5]&_9B;+1H'&/$(JL>)S*8+*0#2_<O2%H("K<LTI(<HY/<H$N0JYQN?18#^
M<EU8)##3Q[U&X!Z 75@C,-/'O4;FZCEC5D9CJB:4*1//DFX O<_3<2.\WYJ\
M"PCO\W3<"!^#MN@XQH=7<(,2OO,N;(]//^!)WQ6$.K'"0^+WD/@])'X/B=]#
MXG?7W.-#XK=R3(?$;R,2OROLJB'YNVO)WT-K/YU/T/"[9H,M_HP/BM+O?=':
MLFQ8)VD_)%^G(:.R2^M4X)A/E^N3\I#=(6A*XU-6NH[GY\-AUKF5!+\9I\OY
M^730HAU:2'" !E_(X3;0I86$AT/Q&E*:LFZ[&@L9 :PW&+)TR..+ALR?3A<>
MQH8PH2$<LCN+-(1#=G^-AG#(3B_/$ [9#?B'<,@A''((A^P.PL>@+3J.\>'-
MW=QPR-IAD$/XXQ#^.(0_#N&/0_CC$/XXA#\.X8_&P-M2^.,0]CB$/793WKOZ
MT#F$/1[#<@UAC\>Q3D/8XW&LTQ#V>+Q+-H0]'OE*#F&/ABSD$/9HR$(.88_B
M07M3$EA._A^Q^J:NCVZ(EVG#ZS_ZEC]V9X]^Z#<3%:F0HR,(FE0Q6QUO1D[T
M,H!F^;LV817TF"1(4<<+2MIN&GDOV$8%FBEFF/X;"W6UR<+%?U'%%&WOZ.%
MZJE8^= Z\/H5N52A.E0,Q[,5=C%['@GP"TH6#?Z.+$A0TYLXHD?CDO)RA5Z0
M0];LC)&>F1 Y'?.Z=:F^HNJ(;CG&P5TB4/"'[PI"+<X%^IY=2D;OZ[8:-5#C
MI5LI \.K=V]>O97*3?]>P)O8]T10P_7E;5SDM*C&K&]/WF+V @%:.GUYR0:C
M)V@!\W=-PWV'NC2D\OL77R&SS["F[LP$[B+@D"L_R-;$QVP;MN.\NT=4<_@^
MQ8O.>T7<" >^-2XMQPZ=!%X*#[:9[L5.R%X"\SZ5<]@US$4'G'1-S5"'Z\KR
M6)M*QL!VEV39 [FBJDCIN-;MN>SC!^TD'BS38JO&-&5'T#%[*DVQY<!D:OQ"
MA8B=6U.2R!9S R^)0[6='[$'F3:8M!;'ZY[(R5S/BVFT?T9638_46!]N2H_,
M-C0 (,KN;8ZEV3U](5A6'@<<- W18)VQN?AV9._0+Y83O4!SV;I^LYV0VB4W
M%'AFK89!8C@<& SQ"@2!AY_I'Q5L]F9,MG8G<0067TL Z7C)=0,\8TS26\T3
MLD.Z83'R"^=SH#%6)'1!Y[.B ;5D1M9C5>H!6-V8Y0@=ZHRXM32]BR-_?,E"
M9KP 4_E\V&IJ8$XPB)S65WT>/0%_ORTA,F1H@W@_ZF8[^;M4+G.\FM81Z+J+
M33X!<$YYDVSH?<.O.94:C_=J1AXN_%KO5ZJ7KW^/YTHW'-&DD_KRZJ[C?*E<
MLS[FJ@N;*IUHNT.O"<_$*/ T/-4; %K)O:K!%_0C!@YTO>80*L\8[)2NZ[PM
M<->_VA'*G6CJ5F/K2VRP.D2++Q=)..^#Y06;J6>Y/KUXL(RA\6R&X\G<NG/B
MK>)(-*EWA3I#=,#K+\6^C%>5$Z2JVL=4VB*24Y+EX >=EC=91[]S%^.%AZ)8
M06%?:[U!I+S%DU>7RO<2K^F.LMF2+="M2[<?\GT6)K/&VV0VX4D *.KQ6>9*
M2!)JYC,-DQ6<WW&PS'X"\VK6'$H/'NLD'6 ROT+/(#_-X;=:\D+H2#PW^-:E
M"IG:YX\4MR@:=\;E#)0# J"J?Y8WEBWQ,%=,0THWI,$6[%RFB%#YQ;Y/O,T]
M"9"03UB(3(M:0.I]KYJ6Q(Q\+\C,AO[7_DSHC^BQ[2&;,B;^X)+WE>RK(@L*
M]M/S!OZ,F/]]BZL/?^BI(-3B7*"O-*5DI"3DX>+[]-?IWXG#HBG\N[M+H(04
M?B_+36)K_.J1<"W%3@$!W:M<3TP[()O^Q2;[&T6BFDM53E;HR4^-;3<8N[/+
M)4;SZS=Z5+$;Z60^ITH+H&]A])HZ)Z8X8!Z46W>&7_ LM)S4U&2X4=-\2J[I
MO1LB6E)DM<U/5*1*/I8\%?-,&O#16$9$Q[Z](^Z"VK\K9C^RRK9PC5-$H0WN
MH?HE_WN]D09B.JY&0 %H@#;/"IGX@6I:K?M0A:>;&T\ 6KW^A0W([!Y2I0#Z
M\JQ?JCY+4.K;*WS%(4F$3O.^9,O7WILEEMKNQCPS#L-J"[<(GRI[W/0'RSIW
M'P*]O'$PAZTL=,Q"[O&[>_S<6' E/"8%B![L\3.SQ;+$0T8J77B\CKK915?$
M0,IWNW*,AFM$'?V6I]"^&(NFR/-$-68'RNR3F08+[(&*5+VE<;C,U/TU[;N\
MQU#>B4&YA'4L-+5I/7>7$QAY;J8<@J,*B& H! ?.['8\$."J@UMXUP:SZZ;4
M1ZT\S(GC:+;'4P;'P] WCI;9%6;DT*H9"<G;=_3G@B9T@@"B:SF&9J>,@#&L
M%V;-8=5@W&A+-8@KE4VM-Z0RNP!(M0,)!:(<:^N)0%E)U.8%<M$<@Q[&"TGH
MZ^E !^?HRCSNEY)I7?F(3/*@%'G.@FBM_:=-J["Z6#B(FP^X,ZIMF2Y%KHV5
M:IF:HW1 Z\C.0$=T%;)\IA4I;_B%RH2-\ LT#*F8AI;X,&H;(90>Y1$S=]AZ
MQ@[=7MO>&%<A<$:B-*7B"K];;W@5KIAY0F]NL0?5<<BK13%\\,@+M5EF%YL[
MRYTY5'%04_"1B2E%].F?(559-X2()YTI&4M+M%R<'KJY0E$-;U <W/ZG=5;E
MV@_PBMF)W^D^73H;5L;\,;I<VQZ3@['KAI;C;*[HD.YBBKS59!X)"'1):@PD
MEPOX[.!%I%]NB)<(,?.T4OUC.=O!Z:_BA_"GM66+3TF*=EO:X?H-^U2YVV@R
MCPL93,EUI.WKJH@2PFW-5>T$8;,JDL,=DGXB)+'G/NHQ("YUU93:PIW*.WJU
M'+9KZX*^0ZJM^<3JAYDN4 -?A)J.624<T'.0F6-LE\Y8:]D19"[%-'3,@![7
M=/Q@\Q0^_S>5\"F9>&G=<:9;=R#>OD5$I8$@<ZPSBIY\ -_?,:$//4%"60'%
M5/3L,8K>=@.$\>Z6R,LHH=+6+,#Y&84TY+*]T,+R0__!\OZ4R K,_;BI/*='
MM X]>\E,O:W_\9(]>2%OS5R4L&*E0()-S6E_/$CJ5OZW4E)P10UGRX]$"R@"
M.5_*<1!Z2VLEQ<'AEUKJR_)&[LQ+<4]<B_\D^YP#KP<,)JUCOBS(?S+/L 95
M7 4$6CD#P:EC111T<%_B#JOG2P82;MV[+ <$J5[%ON2(5>P#4KE9^Y(%5J[L
M2 U5W9?\,-GCD12?ZGW)%JL-W:%)QM,@S):Z:@57;#CW(9&N]+I!P+<BTQ-'
MY&Z=I/1VW)=$$G%;H]BCT9>\MTJ_4 5:!_OQJ]DGI( W4.0P_&:FUI+8@27>
M78Y6S_35H9^<J/'Z<T3-OD3!$"U^*^)XF1U:#L-+Y)V0(Z>A#OA1([?S:,QA
M,SOO2 PVT="!+6JC4[,#[.L+VWY82(J<X;4SZB-7$C&4@GC6,ZNN9-/*1)EQ
M'(=MK"P D8/:,_];Z0X_B$/E, V*4&4\<HJKH7XZ=0=,?M0ZQV_0B2)Y#!PO
M#09T<?I.\AOV/\^4U7___U!+ 0(4 Q0    ( !N"JU)L<V?/AK<  *XN#0 1
M              "  0    !T<VAA+3(P,C$P,S,Q+GAM;%!+ 0(4 Q0    (
M !N"JU(%8-V\FQ,  "+'   1              "  ;6W  !T<VAA+3(P,C$P
M,S,Q+GAS9%!+ 0(4 Q0    ( !N"JU(:P0V9<0D  (EW   5
M  "  7_+  !T<VAA+3(P,C$P,S,Q7V-A;"YX;6Q02P$"% ,4    "  ;@JM2
M(+\$\PPH   SX ( %0              @ $CU0  ='-H82TR,#(Q,#,S,5]D
M968N>&UL4$L! A0#%     @ &X*K4N!J)Y&_8   N]@% !4
M ( !8OT  '1S:&$M,C R,3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !N"JU)Z
MH,?!=3L  #6G!  5              "  51> 0!T<VAA+3(P,C$P,S,Q7W!R
;92YX;6Q02P4&      8 !@"* 0  _)D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
